



(51) International Patent Classification:

A61K 31/125 (2006.01) C12N 15/113 (2010.01)

A61K 31/712 (2006.01)

(21) International Application Number:

PCT/US2020/035811

(22) International Filing Date:

03 June 2020 (03.06.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/856,264 03 June 2019 (03.06.2019) US

62/914,252 11 October 2019 (11.10.2019) US

62/949,817 18 December 2019 (18.12.2019) US

(71) Applicant: QURALIS CORPORATION [US/US]; 700 Main Street, North, Cambridge, MA 02139 (US).

(72) Inventors: HINCKLEY, Sandra; 4 Homestead Street, Sudbury, MA 01776 (US). BROWN, Duncan; 1490 Arch Street, Berkeley CA 94708 (GB). AGRAWAL, Sudhir; 61 Lamplighter Drive, Shrewsbury, MA 01545 (US).

(74) Agent: ASHRAF, Shovon et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept./7th FL, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

14 January 2021 (14.01.2021)

(54) Title: OLIGONUCLEOTIDES AND METHODS OF USE FOR TREATING NEUROLOGICAL DISEASES




FIG. 1A

(57) Abstract: Disclosed herein are antisense oligonucleotide sequences, and methods of use for treating neurological diseases. Described herein are oligonucleotide inhibitors. In various embodiments, the oligonucleotide targets a transcript for the treatment of neurological diseases, including motor neuron diseases, and/or neuropathies. For example, inhibitors of the transcript can be used to treat PD, ALS, FTD, and ALS with FTD.



OLIGONUCLEOTIDES AND METHODS OF USE FOR TREATING NEUROLOGICAL DISEASES

CROSS REFERENCE

[0001] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62/856,264 filed June 3, 2019; U.S. Provisional Patent Application No. 62/914,252 filed on October 11, 2019; and U.S. Provisional Patent Application No. 62/949,817 filed on December 18, 2019, the entire disclosure of each of which is hereby incorporated by reference in its entirety for all purposes.

SEQUENCE LISTING

10 [0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 29, 2020, is named QRL-002WO_SL.txt and is 378,978 bytes in size.

FIELD OF THE INVENTION

15 [0003] The present application relates to inhibitors of STMN2 transcripts that include a cryptic exon, including STMN2 antisense oligonucleotide sequences, and methods for treating neurological diseases.

BACKGROUND

[0004] Motor neuron diseases are a class of neurological diseases that result in the degeneration and death of motor neurons – those neurons which coordinate voluntary movement of muscles by the brain. Motor neuron diseases may be sporadic or inherited, and may affect upper motor neurons and/or lower motor neurons. Motor neuron diseases include amyotrophic lateral sclerosis, progressive bulbar palsy, pseudobulbar palsy, primary lateral sclerosis, progressive muscular atrophy, spinal muscular atrophy, and post-polio syndrome.

25 [0005] Amyotrophic lateral sclerosis (ALS) is a group of motor neuron diseases affecting about 15,000 individuals in the United States of America. ALS is characterized by degeneration and death of upper and lower motor neurons, resulting in loss of voluntary muscle control. Motor neuron death is accompanied by muscle fasciculation and atrophy. Early symptoms of ALS

include muscle cramps, muscle spasticity, muscle weakness (for example, affecting an arm, a leg, neck, or diaphragm), slurred and nasal speech, and difficulty chewing or swallowing. Loss of strength and control over movements, including those necessary for speech, eating, and breathing, eventually occur. Disease progression may be accompanied by weight loss, malnourishment, anxiety, depression, increased risk of pneumonia, muscle cramps, neuropathy, and possibly dementia. Most individuals diagnosed with ALS die of respiratory failure within five years of the first appearance of symptoms. Currently, there is no effective treatment for ALS.

[0006] ALS occurs in individuals of all ages, but is most common in individuals between 55 to 75 years of age, with a slightly higher incidence in males. ALS can be characterized as sporadic or familial. Sporadic ALS appears to occur at random and accounts for more than 90% of all incidences of ALS. Familial ALS accounts for 5-10% of all incidences of ALS.

[0007] FTD refers to a spectrum of progressive neurodegenerative diseases caused by loss of neurons in frontal and temporal lobes of the brain. FTD is characterized by changes in behavior and personality, and language dysfunction. Forms of FTD include behavioral variant FTD (bvFTD), semantic variant primary progressive aphasia (svPPA), and nonfluent variant primary progressive aphasia (nfvPPA). ALS with FTD is characterized by symptoms associated with FTD, along with symptoms of ALS such as muscle weakness, atrophy, fasciculation, spasticity, speech impairment (dysarthria), and inability to swallow (dysphagia). Individuals usually succumb to FTD within 5 to 10 years, while ALS with FTD often results in death within 2 to 3 years of the first disease symptoms appearing.

[0008] Like ALS, there is no known cure for FTD, or ALS with FTD, nor a therapeutic known to prevent or retard either disease's progression.

[0009] Thus, there is a pressing need to identify compounds capable of preventing, ameliorating, and treating neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, corticobasal degeneration (CBD) and/or neuropathies such a chemotherapy induced neuropathy.

[0010] RNA-binding protein transactive response DNA-binding protein 43 (TDP-43) is involved in fundamental RNA processing activities including RNA transcription, splicing, and

transport. TDP-43 binds to thousands of pre-messenger RNA/mRNA targets, with high affinity for GU-rich sequences, including autoregulation of its own mRNA via binding to 3' untranslated region. Reduction in TDP-43 from an otherwise normal adult nervous system alters the splicing or expression levels of more than 1,500 RNAs, including long intron-containing transcripts. *See* Melamed et al., *Nat Neurosci.* (2019), 22(2):180-190.

[0011] In affected neurons in most instances of ALS and approximately 45% of patients with FTD, cytoplasmic accumulation and nuclear loss of TDP-43 have been reported. *See* Melamed et al., *Nat Neurosci.* (2019), 22(2):180-190. Moreover, TDP-43 has been shown to regulate expression of the neuronal growth-associated factor stathmin-2. *See* Melamed (2019); *see also* Klim et al., *Nat Neurosci.* (2019), 22(2):167-179. TDP-43 disruption is shown to drive premature polyadenylation and aberrant splicing in intron 1 of stathmin-2 pre-mRNA, producing truncated mRNA and loss of functional STMN2 protein. *See* Melamed (2019). STMN2 encodes a protein necessary for normal motor neuron outgrowth and repair. *See* Melamed (2019); *see also* Klim (2019).

[0012] The stathmin-2 gene is annotated to contain five constitutive exons (Refseq ID: NM_001199214.1) plus a proposed alternative exon between exons 4 and 5. *See* Melamed (2019); *see also* Klim (2019). Reduction or mutation in TDP-43 induces a new spliced exon, mapping within intron 1. *See* Melamed (2019); *see also* Klim (2019). This new exon (denoted as "exon 2a" or "cryptic exon") appears in STMN2 pre-mRNA when TDP-43 is depleted or endogenous TDP-43 has a N352 mutation. *See* Melamed (2019); *see also* Klim (2019). The cryptic exon in STMN2 pre-mRNA contains a cryptic polyadenylation sequence, which results in premature polyadenylation of the pre-mRNA. *See* Melamed (2019); *see also* Klim (2019). This prematurely polyadenylated RNA includes 227 nucleotides originating from the cryptic exon with its predicted 16 amino acid translation product initiating at the normal AUG codon in exon 1 and ending 11 codons into the cryptic exon. *See* Melamed (2019); *see also* Klim (2019).

[0013] Present invention provides inhibitors of STMN2 transcripts that include a cryptic exon, for treatment of neurological diseases or disorders.

SUMMARY

[0014] Described herein are oligonucleotide inhibitors. In various embodiments, the oligonucleotide targets a transcript for the treatment of neurological diseases, including motor

neuron diseases, and/or neuropathies. For example, inhibitors of the transcript can be used to treat PD, ALS, FTD, and ALS with FTD. In various embodiments, the oligonucleotide inhibitors are antisense oligonucleotides. In various embodiments, the oligonucleotide inhibitors target a Stathmin-2 (STMN2) transcript. In some embodiments, the STMN2 transcript includes a cryptic
5 exon, such as the cryptic exon with a sequence identified below in SEQ ID NO: 447.

[0015] Additionally disclosed herein is a compound comprising an oligonucleotide comprising linked nucleosides with at least a 19 contiguous nucleobase sequence that is at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) complementary to an equal length portion of a transcript with at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%,
10 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 944, or to a contiguous 19 to 50 nucleobase portion of SEQ ID NO: 944, wherein at least one nucleoside linkage of the linked nucleosides is a non-natural linkage. Additionally disclosed herein is an oligonucleotide comprising linked nucleosides with at least a 19 contiguous nucleobase sequence that is at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) complementary to
15 an equal length portion of a transcript with at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 944, or to a contiguous 19 to 50 nucleobase portion of SEQ ID NO: 944, wherein at least one nucleoside linkage of the linked nucleosides is a non-natural linkage.

[0016] In various embodiments, the nucleobase sequence comprises a portion of at least 10
20 contiguous nucleobases that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity with an equal length portion of any one of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432. In various embodiments, the nucleobase sequence comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that shares at least 90% (*e.g.*, 90%, 91%,
25 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity with an equal length portion of any one of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432.

[0017] In various embodiments, the nucleobase sequence comprises a portion of at least 10
contiguous nucleobases that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
30 97%, 98%, 99% or 100%) identity with an equal length portion of any one of SEQ ID NOs: 31, 36, 41, 46, 55, 144, 146, 150, 169, 170, 171, 172, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 249, 252, 380, 385, 390, 395, 400, 975, 980, 985, 999, 1088, 1090, 1094, 1113, 1114, 1115,

1116, 1117, 1121, 1125, 1129, 1141, 1147, 1153, 1159, 1181, 1188, 1193, 1196, 1324, 1329, 1334, 1339, or 1344, wherein at least one nucleoside linkage of the linked nucleosides is a non-natural linkage. In various embodiments, the nucleobase sequence comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity with an equal length portion of any one of SEQ ID NOs: 31, 36, 41, 46, 55, 144, 146, 150, 169, 170, 171, 172, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 249, 252, 380, 385, 390, 395, 400, 975, 980, 985, 999, 1088, 1090, 1094, 1113, 1114, 1115, 1116, 1117, 1121, 1125, 1129, 1141, 1147, 1153, 1159, 1181, 1188, 1193, 1196, 1324, 1329, 1334, 1339, or 1344.

[0018] Additionally disclosed herein is a compound comprising an oligonucleotide comprising linked nucleosides with at least a 19 contiguous nucleobase sequence, wherein the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to an equal length portion of any one of SEQ ID NOs: 894-918 or SEQ ID NOs: 1392-1432. Additionally disclosed herein is an oligonucleotide comprising linked nucleosides with at least a 19 contiguous nucleobase sequence, wherein the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to an equal length portion of any one of SEQ ID NOs: 894-918 or SEQ ID NOs: 1392-1432. In various embodiments, the nucleobase sequence comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that shares at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to of any one of SEQ ID NOs: 894-918 or SEQ ID NOs: 1392-1432.

[0019] Additionally disclosed herein is a compound comprising an oligonucleotide comprising linked nucleosides with at least a 19 contiguous nucleobase sequence, wherein the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that is at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) complementary to an equal length portion of nucleobases within any one of positions 121-144, 144-168, 146-170, 150-170, 150-172, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192, 171-191, 171-193, 172-192, 172-194, 170-194, 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944. Additionally disclosed herein is an oligonucleotide comprising linked nucleosides with a nucleobase sequence with at least a 19 contiguous nucleobase sequence, wherein the nucleobase sequence comprises a portion of at least

10 contiguous nucleobases that is at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) complementary to an equal length portion of nucleobases within any one of positions 121-144, 144-168, 146-170, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192, 171-191, 171-193, 172-192, 172-194, 170-194, 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944.

[0020] In various embodiments, the portion of the nucleobase sequence is 100% complementary to an equal length portion of nucleobases within any one of positions 121-144, 144-168, 146-170, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192, 171-191, 171-193, 172-192, 172-194, 170-194, 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944. In various embodiments, the portion of the nucleobase sequence is 100% complementary to an equal length portion of nucleobases within any one of positions 144-164, 144-166, 145-167, 146-166, 146-168, 147-165, or 148-168 of SEQ ID NO: 944. In various embodiments, the portion of the nucleobase sequence is 100% complementary to an equal length portion of nucleobases within any one of positions 173-191, 173-193, 173-195, 173-197, 175-195, 175-197, 177-197, or 179-197 of SEQ ID NO: 944.

[0021] In various embodiments, the portion of the nucleobase sequence is 100% complementary to an equal length portion of nucleobases within any one of positions 185-205, 187-209, 189-209, 185-207, 197-217, 197-219, or 191-209 of SEQ ID NO: 944. In various embodiments, the portion of the nucleobase sequence is 100% complementary to an equal length portion of nucleobases within any one of positions 237-255, 237-257, 237-259, 239-259, 239-261, 241-261, 237-257, 249-269, 249-271, 252-272, 252-274, or 243-261 of SEQ ID NO: 944. In various embodiments, the nucleobase sequence comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that is complementary to an equal length portion of nucleobases within any one of positions 121-144, 144-168, 146-170, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192, 171-191, 171-193, 172-192, 172-194, 170-194, 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944. In various embodiments, the nucleobase sequence comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that is complementary to an equal length portion of nucleobases within any one of positions 144-164, 144-166, 145-167, 146-166, 146-168, 147-165, 148-168, 173-191, 173-193, 173-195, 173-197, 175-195, 175-197, 177-197, 179-197, 185-205, 185-207, 197-217, 197-219,

187-209, 189-209, 191-209, 237-255, 237-257, 237-259, 239-259, 239-261, 241-261, 237-257, 249-269, 249-271, 252-272, 252-274, or 243-261 of SEQ ID NO: 944.

[0022] In various embodiments, the oligonucleotide is 19 and 40 nucleosides in length. In various embodiments, the oligonucleotide comprises at least one nucleoside linkage selected from the group consisting of a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a phosphorodithioate linkage, a phosphotriester linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothiate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage, or any combination(s) thereof. In various embodiments, at least two, three, or four internucleoside linkages of the oligonucleotide are phosphodiester internucleoside linkages. In various embodiments, the oligonucleotide comprises at least two, three, or four modified internucleoside linkages.

[0023] In various embodiments, each of the modified internucleoside linkage of the oligonucleotide is independently selected from a phosphorothioate linkage, a phosphoramidate linkage, a phosphoramidothiate linkage, a phosphorodiamidate. In various embodiments, all internucleoside linkages of the oligonucleotide are phosphorothioate linkages. In various embodiments, the phosphorothioate internucleoside linkage is in one of a *Rp* configuration or a *Sp* configuration. In various embodiments, the oligonucleotide comprises at least one modified nucleobase. In various embodiments, the at least one modified nucleobase is 5-methyl cytosine, pseudouridine, or 5-methoxyuridine.

[0024] In various embodiments, the oligonucleotide comprises at least one modified sugar moiety. In various embodiments, the modified sugar moiety is one of a 2'-OMe (2'-OCH₃ or 2'-O-methyl) modified sugar moiety, bicyclic sugar moiety, 2'-O-(2-methoxyethyl) (2'-O(CH₂)₂OCH₃ (2'MOE)), 2'-deoxy-2'-fluoro nucleoside, 2'-fluoro-β-D-arabinonucleoside, locked nucleic acid (LNA), constrained ethyl 2'-4'-bridged nucleic acid (cEt), *S*-cEt, hexitol nucleic acids (HNA), and tricyclic analog (*e.g.*, tcDNA).

[0025] In various embodiments, wherein the oligonucleotide comprises three linked nucleosides that are linked through phosphodiester internucleoside linkages at the 5' end and three linked nucleosides that are linked through phosphodiester internucleoside linkages at the 3' end.

In various embodiments, the oligonucleotide comprises one or more 2'-O-(2-methoxyethyl)

5 nucleosides that are linked through phosphorothioate internucleoside linkages. In some embodiments, all cytosine nucleosides in a STMN2 antisense oligonucleotide of the present invention comprise modified sugar moiety comprising 2'-MOE, all nucleosides comprise modified nucleobase 5-methyl cytosine, and all internucleoside linkages are phosphorothioate linkage. In various embodiments, the oligonucleotide comprises three linked nucleosides that are

10 linked through phosphorothioate internucleoside linkages at the 5' end and three linked nucleosides that are linked through phosphorothioate internucleoside linkages at the 3' end. In various embodiments, the oligonucleotide comprises five linked nucleosides that are linked through phosphodiester internucleoside linkages. In various embodiments, the each of the five linked nucleosides are 2'-O-(2-methoxyethyl) (2'MOE) nucleosides. In various embodiments, 15 each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'MOE) nucleosides.

[0026] In various embodiments, the oligonucleotide exhibits at least a 30%, 40%, 50%, 60%, 70%, 80%, or 90% increase of full length STMN2 transcript or STMN2 protein. In various embodiments, the oligonucleotide exhibits at least a 100% increase of full length STMN2

20 transcript or STMN2 protein. In various embodiments, the oligonucleotide exhibits at least a 200% increase of full length STMN2 transcript or STMN2 protein. In various embodiments, the oligonucleotide exhibits at least a 300% increase of full length STMN2 transcript or STMN2 protein. In various embodiments, the oligonucleotide exhibits at least a 400% increase of full length STMN2 transcript or STMN2 protein. In various embodiments, increase of the full length 25 STMN2 protein is measured in comparison to a reduced level of full length STMN2 protein achieved using a TDP43 antisense oligonucleotide. In various embodiments, the oligonucleotide exhibits at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% rescue of full length STMN2 transcript or STMN2 protein. In various embodiments, the oligonucleotide exhibits at least a 50%, 60%, 70%, 80%, or 90% reduction of the STMN2 transcript with the 30 cryptic exon.

[0027] Additionally disclosed herein is a pharmaceutical composition comprising one or more of the oligonucleotides described above, or a pharmaceutically acceptable salt thereof, and a

pharmaceutically acceptable excipient. Additionally disclosed herein is a method of treating a neurological disease and/or a neuropathy in a patient in need thereof, the method comprising administering to the patient an oligonucleotide of any of the oligonucleotides described above or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described above.

5 [0028] In various embodiments, the neurological disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, and corticobasal degeneration (CBD). In various embodiments, the neuropathy is chemotherapy induced
10 neuropathy.

[0029] Additionally disclosed herein is a method of restoring axonal outgrowth and/or regeneration of a neuron, the method comprising exposing the motor neuron to an oligonucleotide of any of the oligonucleotides described above or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described above. Additionally disclosed herein is a method of
15 increasing, promoting, stabilizing, or maintaining STMN2 expression and/or function in a neuron, the method comprising exposing the cell to an oligonucleotide of any of the oligonucleotides described above or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described above. In various embodiments, the neuron is a neuron of a patient in need of treatment of a neurological disease and/or a neuropathy. In various embodiments, the neurological disease
20 is selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, and corticobasal degeneration (CBD). In various embodiments, the neuropathy is chemotherapy induced neuropathy.

25 [0030] In various embodiments, the exposing is performed *in vivo* or *ex vivo*. In various embodiments, the exposing comprises administering a STMN2 oligonucleotide (STMN2 AON) disclosed herein or a pharmaceutical composition thereof to a patient in need thereof. In various embodiments, a STMN2 oligonucleotide or a pharmaceutical composition thereof is administered topically, parenterally (*e.g.*, subcutaneous, intramuscular, intradermal, intraduodenal, or
30 intravenous), intralesionally, intrathecally, intracisternally, orally, rectally, buccally, sublingually, vaginally, pulmonarily, intratracheally, intranasally, transdermally, or intraduodenally. In various embodiments, a STMN2 oligonucleotide or a pharmaceutical composition thereof is administered

orally. In various embodiments, a therapeutically effective amount of a STMN2 oligonucleotide or a pharmaceutical composition thereof is administered intrathecally or intracisternally.

[0031] In various embodiments, the patient is a human. In various embodiments, the pharmaceutical composition is suitable for topical, intrathecal, intracisternal, parenteral (*e.g.*, subcutaneous, intramuscular, intradermal, intraduodenal, or intravenous), intralesional, oral, pulmonary, intratracheal, intranasal, transdermal, rectal, buccal, sublingual, vaginal, or intraduodenal administration.

[0032] Additionally disclosed herein is a use of a STMN2 oligonucleotide or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described above in the manufacture of a medicament for the treatment of neurological disease or a neuropathy. In various embodiments, the neurological disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, and corticobasal degeneration (CBD). In various embodiments, the neuropathy is chemotherapy induced neuropathy.

[0033] Additionally disclosed herein is a method of treating a neurological disease or a neuropathy in a patient in need thereof, the method comprising administering to a patient in need thereof a therapeutically effective amount of a STMN2 oligonucleotide or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described above. In various embodiments, the neurological disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, and corticobasal degeneration (CBD). In various embodiments, the neuropathy is chemotherapy induced neuropathy. In various embodiments, the pharmaceutical composition is administered topically, parenterally (*e.g.*, subcutaneous, intramuscular, intradermal, intraduodenal, or intravenous), intralesionally, orally, pulmonarily, rectally, buccally, sublingually, vaginally, intratracheally, intranasally, intracisternally, intrathecally, transdermally, or intraduodenally. In various embodiments, the pharmaceutical composition is administered intrathecally or intracisternally. In various embodiments, a therapeutically effective amount of a STMN2 oligonucleotide or a pharmaceutical composition thereof is administered intrathecally or intracisternally. In various embodiments, the patient is human.

[0034] Additionally disclosed herein is a STMN2 oligonucleotide or a pharmaceutically acceptable salt thereof, for use as a medicament in the treatment of a neurological disease or a neuropathy. In certain embodiments, the present disclosure provides a STMN2 oligonucleotide or a pharmaceutically acceptable salt thereof, for use in the treatment of a neurological disease or a neuropathy. In various embodiments, the neurological disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, and corticobasal degeneration (CBD). In various embodiments, the neuropathy is chemotherapy induced neuropathy.

[0035] Additionally disclosed herein is a STMN2 oligonucleotide comprising linked nucleosides with a nucleobase sequence of any one of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432, or a pharmaceutically acceptable salt thereof; wherein the oligonucleotide comprises at least one nucleoside linkage selected from the group consisting of: a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a phosphorodithioate linkage, a phosphotriester linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothiate linkage, a phosphorodiamidate linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage, and/or wherein at least one nucleoside of the linked nucleosides is substituted with a component selected from the group consisting of a 2'-O-(2-methoxyethyl) nucleoside (2'-O-methoxyethylribonucleosides (2'-MOE)), a 2'-O-methyl nucleoside, a 2'-deoxy-2'-fluoro nucleoside, a 2'-fluoro-β-D-arabinonucleoside, a locked nucleic acid (LNA), constrained methoxyethyl (cMOE), constrained ethyl (cET), and a peptide nucleic acid (PNA).

[0036] In various embodiments, at least one internucleoside linkage of the oligonucleotide is a phosphorothioate linkage. In various embodiments, the oligonucleotide comprises three linked nucleosides that are linked through phosphodiester internucleoside linkages at the 5' end and three linked nucleosides that are linked through phosphodiester internucleoside linkages at the 3' end. In various embodiments, the oligonucleotide comprises one or more 2'-O-(2-methoxyethyl) nucleosides that are linked through phosphorothioate internucleoside linkages. In various

embodiments, the oligonucleotide comprises five linked nucleosides that are linked through phosphodiester internucleoside linkages. In various embodiments, each of the five linked nucleosides are 2'-O-(2-methoxyethyl) (2'MOE) nucleosides. In various embodiments, each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'MOE) nucleosides. In various embodiments, all internucleoside linkages of the oligonucleotide are phosphorothioate linkages, optionally wherein each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[0037] Additionally disclosed herein is a pharmaceutical composition comprising the oligonucleotide of any oligonucleotide described above, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. Additionally disclosed herein is STMN2 oligonucleotide or a pharmaceutically acceptable salt thereof capable of increasing, restoring, or stabilizing expression of the STMN2 mRNA capable of translation of a functional STMN2 and/or activity and/or function of STMN2 protein in a cell or a human patient of a neurological disease or disorder, wherein the level of increase, restoration, or stabilization of expression and/or activity and/or function is sufficient for use of the oligonucleotide as a medicament for the treatment of neurological disease or disorder. In various embodiments, wherein the oligonucleotide comprises one or more chiral centers and/or double bonds. In various embodiments, the oligonucleotide exist as stereoisomers selected from geometric isomers, enantiomers, and diastereomers.

[0038] Additionally disclosed herein is a method of treating a neurological disease and/or a neuropathy in a patient in need thereof, the method comprising administering to a patient in need thereof a therapeutically effective amount of a STMN2 oligonucleotide or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition described above, in combination with a second therapeutic agent selected from Riluzole (Rilutek), Edaravone (Radicava), rivastigmine, donepezil, galantamine, selective serotonin reuptake inhibitor, antipsychotic agents, cholinesterase inhibitors, memantine, benzodiazepine antianxiety drugs, AMX0035 (ELYBRIO), ZILUCOPLAN (RA101495), dual AON intrathecal administration (*e.g.*, BIIB067, BIIB078), BIIB100, levodopa/carbidopa, dopaminergic agents (*e.g.*, ropinirole, pramipexole, rotigotine), medroxyprogesterone, KCNQ2/KCNQ3 openers, anticonvulsants and psychostimulant agents, and/or a therapy (*e.g.*, selected from breathing care, physical therapy, occupational therapy, speech therapy, nutritional support), for treating said neurologic disease.

[0039] In various embodiments, the neurological disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease

(AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, and corticobasal degeneration (CBD). In various embodiments, the neuropathy is chemotherapy induced neuropathy.

5

BRIEF DESCRIPTION OF THE DRAWINGS

[0040] FIG. 1A is a schematic depiction of portions of the STMN2 transcript and STMN2 antisense oligonucleotides that are designed to target certain portions of the STMN2 transcript. FIG. 1B is another schematic depiction of portions of the STMN2 transcript and STMN2 antisense oligonucleotides that are designed to target certain portions of the STMN2 transcript in SY5Y cells. FIG. 1C is yet another schematic depiction of portions of the STMN2 transcript and STMN2 antisense oligonucleotides that are designed to target certain portions of the STMN2 transcript in human motor neurons. In each of FIG. 1A, 1B, and 1C the solid line represents tested STMN2 AON that increased STMN2-FL mRNA expression by greater than 50% over TDP43 AON treated alone. The dotted line represents tested STMN2 AON that increased STMN2-FL (full length) mRNA less than 50% over TDP43 AON treated alone.

[0041] FIG. 2 is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript in the presence of 6 different STMN2 antisense oligonucleotides (QSN-36, QSN-55, QSN-177, QSN-203, QSN-244, and QSN-395).

[0042] FIG. 3 is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels in the presence of 6 different STMN2 antisense oligonucleotides (QSN-173, QSN-181, QSN-197, QSN-215, QSN-385, and QSN-400).

[0043] FIG. 4 is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript in the presence of 6 different STMN2 antisense oligonucleotides (QSN-173, QSN-181, QSN-197, QSN-215, QSN-385, and QSN-400).

[0044] FIG. 5A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2

transcript with cryptic exon mRNA levels in the presence of 6 different STMN2 antisense oligonucleotides (QSN-185, QSN-209, QSN-237, QSN-252, QSN-380, and QSN-390).

[0045] FIG. 5B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript in the presence of 6 different STMN2 antisense oligonucleotides (QSN-185, QSN-209, QSN-237, QSN-252, QSN-380, and QSN-390).

[0046] FIG. 6A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels in the presence of 2 different STMN2 antisense oligonucleotides (QSN-144 and QSN-237) over two duplicate experiments.

[0047] FIG. 6B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript in the presence of 2 different STMN2 antisense oligonucleotides (QSN-144 and QSN-237) over two duplicate experiments.

[0048] FIG. 7A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels in the presence of 5 different STMN2 antisense oligonucleotides (QSN-36, QSN-173, QSN-177, QSN-181, and QSN-185).

[0049] FIG. 7B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2 transcript in the presence of 5 different STMN2 antisense oligonucleotides (QSN-36, QSN-173, QSN-177, QSN-181, and QSN-185).

[0050] FIG. 8A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels in the presence of 5 different STMN2 antisense oligonucleotides (QSN-197, QSN-203, QSN-237, QSN-380, and QSN-395).

[0051] FIG. 8B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in the presence of TDP43 antisense, and restoration of the full-length STMN2

transcript in the presence of 5 different STMN2 antisense oligonucleotides (QSN-197, QSN-203, QSN-237, QSN-380, and QSN-395).

[0052] FIG. 9A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and
5 reduction of the STMN2 transcript with cryptic exon mRNA levels in the presence of 3 different STMN2 antisense oligonucleotides (QSN-144, QSN-173, and QSN-237).

[0053] FIG. 9B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript in the presence of 3 different STMN2 antisense
10 oligonucleotides (QSN-144, QSN-173, and QSN-237).

[0054] FIG. 10A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of a QSN-181 STMN2 antisense oligonucleotide.

15 [0055] FIG. 10B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of a QSN-181 STMN2 antisense oligonucleotide.

[0056] FIG. 11A is a bar graph showing the results of RT-qPCR analysis of STMN2
20 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of a QSN-185 STMN2 antisense oligonucleotide.

[0057] FIG. 11B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and
25 restoration of the full-length STMN2 transcript across different dosages of a QSN-185 STMN2 antisense oligonucleotide.

[0058] FIG. 12A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense,

and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of a QSN-197 STMN2 antisense oligonucleotide.

[0059] FIG. 12B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of a QSN-197 STMN2 antisense oligonucleotide.

[0060] FIG. 13A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of a QSN-144 STMN2 antisense oligonucleotide.

[0061] FIG. 13B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of a QSN-144 STMN2 antisense oligonucleotide.

[0062] FIG. 14A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of a QSN-173 STMN2 antisense oligonucleotide.

[0063] FIG. 14B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript across different dosages of a QSN-173 STMN2 antisense oligonucleotide.

[0064] FIG. 15A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels across different dosages of a QSN-237 STMN2 antisense oligonucleotide.

[0065] FIG. 15B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and

restoration of the full-length STMN2 transcript across different dosages of a QSN-237 STMN2 antisense oligonucleotide.

[0066] FIG. 16 is a protein blot and quantified bar graph showing the normalized quantity of STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and
5 restoration of the full-length STMN2 transcript for 2 different STMN2 antisense oligonucleotides (QSN-173 and QSN237).

[0067] FIG. 17A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different variants of
10 a QSN-237 STMN2 antisense oligonucleotide.

[0068] FIG. 17B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different variants of a QSN-237 STMN2 antisense oligonucleotide.

15 [0069] FIG. 18A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different variants of a QSN-185 STMN2 antisense oligonucleotide.

[0070] FIG. 18B is a bar graph showing the results of RT-qPCR analysis of TDP43 and
20 STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different variants of a QSN-185 STMN2 antisense oligonucleotide.

[0071] FIG. 19A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense,
25 and reduction of the STMN2 transcript with cryptic exon mRNA levels using different variants of a QSN-173 STMN2 antisense oligonucleotide.

[0072] FIG. 19B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and

restoration of the full-length STMN2 transcript using different variants of a QSN-173 STMN2 antisense oligonucleotide.

[0073] FIG. 20A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different variants of a QSN-237 STMN2 antisense oligonucleotide.

[0074] FIG. 20B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different variants of a QSN-237 STMN2 antisense oligonucleotide.

[0075] FIG. 21A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different variants of a QSN-173 STMN2 antisense oligonucleotide.

[0076] FIG. 21B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different variants of a QSN-173 STMN2 antisense oligonucleotide.

[0077] FIG. 22A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different variants of a QSN-144 STMN2 antisense oligonucleotide.

[0078] FIG. 22B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different variants of a QSN-144 STMN2 antisense oligonucleotide.

[0079] FIG. 23 shows the dose response curve illustrating increasing restoration of full length STMN2 transcript with increasing concentrations of STMN2 AON.

[0080] FIG. 24A shows a Western blot assay demonstrating the qualitative increase of full length STMN2 protein in response to higher concentrations of STMN2 AON.

[0081] FIG. 24B shows the quantitated levels of full length STMN2 protein normalized to GAPDH in response to different concentrations of STMN2 AON.

5 **[0082]** FIG. 25A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different QSN-144 STMN2 AONs and AON variants.

10 **[0083]** FIG. 25B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different QSN-144 STMN2 AONs and AON variants.

15 **[0084]** FIG. 26A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different QSN-173 STMN2 AONs and AON variants.

20 **[0085]** FIG. 26B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different QSN-173 STMN2 AONs and AON variants.

[0086] FIG. 27A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different QSN-185 STMN2 AONs and AON variants.

25 **[0087]** FIG. 27B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different QSN-185 STMN2 AONs and AON variants.

[0088] FIG. 28A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different QSN-237 STMN2 AONs and AON variants.

5 **[0089]** FIG. 28B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different QSN-237 STMN2 AONs and AON variants.

10 **[0090]** FIG. 29A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different STMN2 AONs (QSN-31, QSN-41, and QSN-46).

15 **[0091]** FIG. 29B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different STMN2 AONs (QSN-31, QSN-41, and QSN-46).

[0092] FIG. 30 is a bar graph showing reversal of cryptic exon induction in human motor neurons using QSN-237 STMN2 antisense oligonucleotide even in view of increasing proteasome inhibition.

20 **[0093]** FIGs. 31A and 31B show bar graphs showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels and STMN2 full-length mRNA levels, which demonstrate reduction of the STMN2 transcript with cryptic exon mRNA levels and restoration of the full-length STMN2 transcript using different STMN2 AONs and AON variants.

25 **[0094]** FIG 32 is a bar graph showing the results of a western blot analysis of STMN2 protein levels, which demonstrates restoration of the full-length STMN2 protein using different STMN2 AONs and AON variants.

[0095] FIG. 33A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA expression in human motor neurons, which demonstrates

reduction of the STMN2 transcript with cryptic exon mRNA levels using different STMN2 AONs (QSN-31, QSN-41, and QSN-46).

[0096] FIG. 33B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels, which demonstrates restoration of the full-length STMN2 transcript using different STMN2 AONs (QSN-31, QSN-41, and QSN-46).

[0097] FIG. 34A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA expression in human motor neurons, which demonstrates reduction of the STMN2 transcript with cryptic exon mRNA levels using different STMN2 AONs (QSN-146, QSN-150, and QSN-169).

[0098] FIG. 34B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels, which demonstrates the restoration of the full-length STMN2 transcript using different STMN2 AONs (QSN-146, QSN-150, and QSN-169).

[0099] FIG. 34C is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA expression in human motor neurons, which demonstrates reduction of the STMN2 transcript with cryptic exon mRNA levels using different STMN2 AONs (QSN-170, QSN-171, and QSN-172).

[00100] FIG. 34D is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels, which demonstrates the restoration of the full-length STMN2 transcript using different STMN2 AONs (QSN-170, QSN-171, and QSN-172).

[00101] FIG. 34E is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA expression in human motor neurons, which demonstrates reduction of the STMN2 transcript with cryptic exon mRNA levels using different STMN2 AONs (QSN-249).

[00102] FIG. 34F is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels, which demonstrates the restoration of the full-length STMN2 transcript using different STMN2 AONs (QSN-249).

DETAILED DESCRIPTION

[00103] The features and other details of the disclosure will now be more particularly described. Certain terms employed in the specification, examples and appended claims are

collected here. These definitions should be read in light of the remainder of the disclosure and understood as by a person of skill in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art.

5 **[00104]** The terms “treat,” “treatment,” “treating,” and the like are used herein to generally mean obtaining a desired pharmacological and/or physiological effect. The effect may be therapeutic in terms of partially or completely curing a disease and/or adverse effect attributed to the disease. The term “treatment” as used herein covers any treatment of a disease in a mammal, particularly a human, and includes: (a) inhibiting the disease, *i.e.*, preventing the disease from
10 increasing in severity or scope; (b) relieving the disease, *i.e.*, causing partial or complete amelioration of the disease; or (c) preventing relapse of the disease, *i.e.*, preventing the disease from returning to an active state following previous successful treatment of symptoms of the disease or treatment of the disease.

[00105] “Preventing” includes delaying the onset of clinical symptoms, complications, or
15 biochemical indicia of the state, disorder, disease, or condition developing in a subject that may be afflicted with or predisposed to the state, disorder, disease, or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder, disease, or condition. “Preventing” includes prophylactically treating a state, disorder, disease, or condition in or developing in a subject, including prophylactically treating clinical symptoms, complications, or
20 biochemical indicia of the state, disorder, disease, or condition in or developing in a subject.

[00106] The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” as used herein interchangeably refers to any and all solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active
25 substances is well known in the art. The compositions may also contain other active compounds providing supplemental, additional, or enhanced therapeutic functions.

[00107] The term “pharmaceutical composition” as used herein refers to a composition comprising at least one biologically active compound, for example, a STMN2 antisense oligonucleotide (AON), as disclosed herein formulated together with one or more
30 pharmaceutically acceptable excipients.

[00108] “Individual,” “patient,” or “subject” are used interchangeably and include any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or non-human primates, and most preferably humans. The compounds of the invention can be administered to a mammal, such as a human, but can also be other mammals such as an animal in need of veterinary treatment, *e.g.*, domestic animals (*e.g.*, dogs, cats, and the like), farm animals (*e.g.*, cows, sheep, pigs, horses, and the like) and laboratory animals (*e.g.*, rats, mice, guinea pigs, non-human primates, and the like). In some embodiments, the mammal treated in the methods of the invention is desirably a mammal in whom modulation of STMN2 expression and/or activity is desired.

[00109] The term “STMN2 oligonucleotide,” “STMN2 antisense oligonucleotide,” or “STMN2 AON” refers to an oligonucleotide that is capable of increasing, restoring, or stabilizing full-length STMN2 activity *e.g.*, full length STMN2 expression, for example, full length STMN2 mRNA and/or full length STMN2 protein expression. Generally, a STMN2 oligonucleotide reduces the level of mature STMN2 transcripts with a cryptic exon by targeting a STMN2 transcript comprising a cryptic exon. A patient suffering from ALS, FTD, ALS with FTD, or another neurological or motor neuron disease can be a patient that is diagnosed with the disease or that displays symptoms of the disease. A patient suffering from ALS, FTD, ALS with FTD, or another neurological or motor neuron disease can be a patient that previously suffered from the disease and, after recovering or experiencing complete or partial amelioration of the disease and/or disease symptoms, experiences a complete or partial relapse of the disease or disease symptoms. A patient suffering from ALS, FTD, ALS with FTD, or another neurological or motor neuron disease or condition can be a patient that harbors a genetic mutation associated with manifestation of the disease or condition. For example, a patient suffering from ALS can be a patient that harbors a genetic mutation in any of SOD1, C9orf72, Ataxin 2 (ATXN2), Charged Multivesicular Body Protein 2B (CHMP2B), Dynactin 1 (DCTN1), Human Epidermal Growth Factor Receptor 4 (ERBB4), FIG4 phosphoinositide 5-phosphatase (FIG4), NIMA related kinase 1 (NEK1), Heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1), Neurofilament Heavy (NEFH), Peripherin (PRPH), TAR DNA binding protein 43 (TDP43 or TARDBP), Fused in Sarcoma (FUS), Ubiquilin-2 (UBQLN2), Kinesin Family Member 5A (KIF5A), Valosin-Containing Protein (VCP), Alsln (ALS2), Senataxin (SETX), Sigma Non-Opioid Intracellular Receptor 1 (SIGMAR1), Survival of Motor Neuron 1, Telomeric (SMN1), Spastic Paraplegia 11, Autosomal Recessive (SPG11), Transient Receptor Potential Cation Channel Subfamily M Member 7 (TRPM7), Vesicle-Associated Membrane Protein-Associated Protein B/C (VAPB),

Angiogenin (ANG), Profilin-1 (PFN1), Matrin-3 (MATR3), Coiled-coil-helix-coiled-coil-helix domain Containing 10 (CHCHD10), Tubulin, Alpha 4A (TUBA4A), TBK1, C21orf2, Sequestosome-1 (SQSTM1, also known as Ubiquitin-binding protein p62), and/or optineurin (OPTN), in particular, where the mutation is associated with ALS or a high risk of developing ALS.

[00110] A patient at risk of ALS, FTD, ALS with FTD, or another neurological or motor neuron disease can include those patients with a familial history of the disease or a genetic predisposition to the disease (*e.g.*, a patient that harbors a genetic mutation associated with high disease risk, for example), or patients exposed to environmental factors that increase disease risk. For example, a patient may be at risk of ALS if the patient harbors a mutation in any of genes encoding SOD1, C9orf72, ATXN2, CHMP2B, DCTN1, ERBB4, FIG4, HNRNPA1, NEFH, PRPH, NEK1, TDP43, FUS, UBQLN2, KIF5A, VCP, ALS2, SETX, SIGMAR1, SMN1, SPG11, TRPM7, VAPB, ANG, PFN1, MATR3, CHCHD10, TUBA4A, TBK1, SQSTM1, C21orf2, and/or OPTN, in particular, where the mutation is associated with ALS or high risk of developing ALS. A patient at risk may also include those patients diagnosed with a disease or condition that has a high comorbidity with ALS, FTD, ALS with FTD, or another neurological or motor neuron disease (for example, a patient suffering from dementia, which is significantly associated with higher odds of a family history of ALS, FTD, and of bulbar onset ALS (*see* Trojsi, F., *et al.* (2017) “Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohort” *J Neurol* 264: 2224-31)).

[00111] As used herein, “STMN2” (also known as Superior Cervical Ganglion-10 Protein, Stathmin-Like 2, SCGN10, SCG10, Neuronal Growth-Associated Protein, Neuron-Specific Growth-Associated Protein, or Protein SCG10 (Superior Cervical Ganglia NEAR Neural Specific 10) refers to the gene or gene products (*e.g.*, protein or mRNA transcript (including pre-mRNA) encoded by the gene) identified by Entrez Gene ID No. 11075 and allelic variants thereof, as well as orthologs found in non-human species (*e.g.*, non-human primates or mice).

[00112] In the present specification, the term “therapeutically effective amount” means the amount of the subject inhibitor of STMN2 transcripts that include a cryptic exon that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor, or other clinician. The inhibitor of STMN2 transcripts that include a cryptic exons of the invention are administered in therapeutically effective amounts to treat and/or prevent a disease, condition, disorder, or state, for example, ALS, FTD, ALS with

FTD, or another motor neuron disease or neurological disease or condition. Alternatively, a therapeutically effective amount of an inhibitor of STMN2 transcripts that include a cryptic exon is the quantity required to achieve a desired therapeutic and/or prophylactic effect, such as an amount which results in the prevention of or a decrease in the symptoms associated with a disease associated with reduced STMN2 activity in the motor neurons.

[00113] The phrase “oligonucleotide that targets a STMN2 transcript” refers to an oligonucleotide that binds to a STMN2 transcript. In various embodiments, the oligonucleotide binds to a region of a STMN2 transcript. Example regions of a STMN2 transcript are shown in Table 1, which show sequences corresponding to regions of branch points (*e.g.*, branch point 1, 2, and 3) a 3' splice acceptor region, an ESE binding region, TDP43 binding sites, a cryptic exon, and a Poly A region. In various embodiments, the oligonucleotide binds to a region of a STMN2 transcript with a cryptic exon, the region being located less than 75 nucleobases upstream or downstream to any of the branch points (*e.g.*, branch point 1, 2, and 3) a 3' splice acceptor region, an ESE binding region, TDP43 binding sites, a cryptic exon, and a Poly A region.

[00114] The term “pharmaceutically acceptable salt(s)” as used herein refers to salts of acidic or basic groups that may be present in inhibitors of STMN2 transcripts that include a cryptic exon used in the present compositions. Inhibitors of STMN2 transcripts that include a cryptic exon included in the present compositions that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, *i.e.*, salts containing pharmacologically acceptable anions, including but not limited to malate, oxalate, chloride, bromide, iodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, *p*-toluenesulfonate and pamoate (*i.e.*, 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Inhibitors of STMN2 transcripts that include a cryptic exon included in the present compositions that include an amino moiety may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above. Compounds included in the present compositions that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts and, particularly, calcium, magnesium, sodium, and lithium salts. Pharmaceutically acceptable salts of the disclosure include, for example, pharmaceutically acceptable salts of STMN2 AONs that include

a nucleobase sequence of any of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432.

[00115] Inhibitors of STMN2 transcripts that include a cryptic exon of the disclosure may contain one or more chiral centers, groups, linkages, and/or double bonds and, therefore, exist as stereoisomers, such as geometric isomers, enantiomers or diastereomers. The term “stereoisomers” when used herein consist of all geometric isomers, enantiomers or diastereomers. These compounds may be designated by the symbols “*R*” or “*S*” (or “*R*_p” or “*S*_p”) depending on the configuration of substituents around the stereogenic atom, for example, a stereogenic carbon, phosphorus, or sulfur atom. In some embodiments, one or more linkages of the compound may have a *R*_p or *S*_p configuration (e.g., one or more phosphorothioate linkages have either a *R*_p or *S*_p configuration). The configuration of each phosphorothioate linkage may be independent of another phosphorothioate linkage (e.g., one phosphorothioate linkage has a *R*_p configuration and a second phosphorothioate linkage has a *S*_p configuration). The present invention encompasses various stereoisomers of these compounds and mixtures thereof. Stereoisomers include enantiomers and diastereomers. Mixtures of enantiomers or diastereomers may be designated “(±)” in nomenclature, but the skilled artisan will recognize that a structure may denote a chiral center implicitly. Individual stereoisomers of inhibitors of STMN2 transcripts that include a cryptic exon of the present invention can be prepared synthetically from commercially available starting materials that contain asymmetric or stereogenic centers, or by preparation of racemic mixtures followed by resolution methods well known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) salt formation employing an optically active resolving agent, or (3) direct separation of the mixture of optical enantiomers on chiral chromatographic columns. Stereoisomeric mixtures can also be resolved into their component stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase super critical fluid chromatography, chiral-phase simulated moving bed chromatography, chiral-phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent. Stereoisomers can also be obtained from stereomerically-pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.

[00116] The inhibitors of STMN2 transcripts that include a cryptic exon disclosed herein can exist in solvated as well as unsolvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.

5 [00117] The disclosure also embraces isotopically labeled compounds of the invention (*i.e.*, isotopically labeled inhibitors of STMN2 transcripts that include a cryptic exon) which are identical to those recited herein, except that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number abundantly found in nature. Examples of isotopes that can be incorporated into compounds of the invention include
10 isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{31}P , ^{32}P , ^{33}P , ^{35}S , ^{18}F , and ^{36}Cl , respectively.

[00118] Certain isotopically labeled disclosed compounds (*e.g.*, those labeled with ^3H and ^{14}C) are useful in compound and/or substrate tissue distribution assays. Tritiated (*i.e.*, ^3H) and carbon-14 (*i.e.*, ^{14}C) isotopes are particularly preferred for their ease of preparation and detectability.

15 Further, substitution with heavier isotopes such as deuterium (*i.e.*, ^2H) may afford certain therapeutic advantages resulting from greater metabolic stability (*e.g.*, increased *in vivo* half-life or reduced dosage requirements) and hence may be preferred in some circumstances.

[00119] As used herein, “2’-O-(2-methoxyethyl)” (also 2'-MOE and 2'-O(CH₂)₂OCH₃ and MOE) refers to an *O*-methoxyethyl modification of the 2' position of a furanose ring. A 2’-O-(2-methoxyethyl) is used interchangeably as “2'-*O*-methoxyethyl” in the present disclosure. A sugar
20 moiety in a nucleoside modified with 2'-MOE is a modified sugar.

[00120] As used herein, “2'-MOE nucleoside” (also 2’-O-(2-methoxyethyl) nucleoside) means a nucleoside comprising a 2'-MOE modified sugar moiety.

[00121] As used herein, “2'-substituted nucleoside” means a nucleoside comprising a
25 substituent at the 2'-position of the furanose ring other than H or OH. In certain embodiments, 2' substituted nucleosides include nucleosides with bicyclic sugar modifications.

[00122] As used herein, “5-methyl cytosine” (5-MeC) means a cytosine modified with a methyl group attached to the 5 position. A 5-methyl cytosine (5-MeC) is a modified nucleobase.

[00123] As used herein, “bicyclic sugar” means a furanose ring modified by the bridging of two atoms. A bicyclic sugar is a modified sugar.

[00124] As used herein, “bicyclic nucleoside” (also BNA) means a nucleoside having a sugar moiety comprising a bridge connecting two carbon atoms of the sugar ring, thereby forming a bicyclic ring system. In certain embodiments, the bridge connects the 4'-carbon and the 2'-carbon of the sugar ring.

[00125] As used herein, “cap structure” or “terminal cap moiety” means chemical modifications, which have been incorporated at either terminus of an antisense compound.

[00126] As used herein, “cEt” or “constrained ethyl” means a bicyclic nucleoside having a sugar moiety comprising a bridge connecting the 4'-carbon and the 2'-carbon, wherein the bridge has the formula: 4'-CH(CH₃)—O-2'.

[00127] As used herein, “constrained ethyl nucleoside” (also cEt nucleoside) means a nucleoside comprising a bicyclic sugar moiety comprising a 4'-CH(CH₃)—O-2' bridge.

[00128] As used herein, “internucleoside linkage” refers to the covalent linkage between adjacent nucleosides in an oligonucleotide. In some embodiments, as used herein, “non-natural linkage” refers to a “modified internucleoside linkage.”

[00129] As used herein, “contiguous” in the context of an oligonucleotide refers to nucleosides, nucleobases, sugar moieties, or internucleoside linkages that are immediately adjacent to each other. For example, “contiguous nucleobases” means nucleobases that are immediately adjacent to each other in a sequence.

[00130] As used herein, “locked nucleic acid” or “LNA” or “LNA nucleosides” means nucleic acid monomers having a bridge (*e.g.*, methylene, ethylene, aminooxy, or oxyimino bridge) connecting two carbon atoms between the 4' and 2' position of the nucleoside sugar unit, thereby forming a bicyclic sugar. Examples of such bicyclic sugar include, but are not limited to A) α -L-Methyleneoxy (4'-CH₂—O-2') LNA, (B) β -D-Methyleneoxy (4'-CH₂—O-2') LNA, (C) Ethyleneoxy (4'-(CH₂)₂—O-2') LNA, (D) Aminooxy (4'-CH₂—O—N(R)-2') LNA and (E) Oxyamino (4'-CH₂—N(R)—O-2') LNA.

[00131] As used herein, LNA compounds include, but are not limited to, compounds having at least one bridge between the 4' and the 2' position of the sugar wherein each of the bridges

independently comprises 1 or from 2 to 4 linked groups independently selected from —
 $[C(R_1)(R_2)]_n$ —, — $C(R_1)=C(R_2)$ —, — $C(R_1)=N$ —, — $C(=NR_1)$ —, — $C(=O)$ —, — $C(=S)$ —, —
O—, — $Si(R_1)_2$ —, — $S(=O)_x$ — and — $N(R_1)$ —; wherein: x is 0, 1, or 2; n is 1, 2, 3, or 4; each R_1
and R_2 is, independently, H, a protecting group, hydroxyl, C_1 - C_{12} alkyl, substituted C_1 - C_{12} alkyl,
5 C_2 - C_{12} alkenyl, substituted C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, substituted C_2 - C_{12} alkynyl, C_5 - C_{20} aryl,
substituted C_5 - C_{20} aryl, a heterocycle radical, a substituted heterocycle radical, heteroaryl,
substituted heteroaryl, C_5 - C_7 alicyclic radical, substituted C_5 - C_7 alicyclic radical, halogen, OJ_1 ,
 NJ_1J_2 , SJ_1 , N_3 , $COOJ_1$, acyl ($C(=O)$ —H), substituted acyl, CN, sulfonyl ($S(=O)_2$ - J_1), or sulfoxyl
($S(=O)$ - J_1); and each J_1 and J_2 is, independently, H, C_1 - C_{12} alkyl, substituted C_1 - C_{12} alkyl, C_2 - C_{12}
10 alkenyl, substituted C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, substituted C_2 - C_{12} alkynyl, C_5 - C_{20} aryl,
substituted C_5 - C_{20} aryl, acyl ($C(=O)$ —H), substituted acyl, a heterocycle radical, a substituted
heterocycle radical, C_1 - C_{12} aminoalkyl, substituted C_1 - C_{12} aminoalkyl or a protecting group.

[00132] Examples of 4'-2' bridging groups encompassed within the definition of LNA include,
but are not limited to one of formulae: — $[C(R_1)(R_2)]_n$ —, — $[C(R_1)(R_2)]_n$ —O—, — $C(R_1R_2)$ —
15 $N(R_1)$ —O— or — $C(R_1R_2)$ —O— $N(R_1)$ —. Furthermore, other bridging groups encompassed with
the definition of LNA are 4'- CH_2 -2', 4'-(CH_2)₂-2', 4'-(CH_2)₃-2', 4'- CH_2 —O-2', 4'-(CH_2)₂—O-2', 4'-
 CH_2 —O— $N(R_1)$ -2' and 4'- CH_2 — $N(R_1)$ —O-2'- bridges, wherein each R_1 and R_2 is,
independently, H, a protecting group or C_1 - C_{12} alkyl.

[00133] Also included within the definition of LNA according to the invention are LNAs in
20 which the 2'-hydroxyl group of the ribosyl sugar ring is connected to the 4' carbon atom of the
sugar ring, thereby forming a bridge to form the bicyclic sugar moiety. The bridge can also be a
methylene (— CH_2 —) group connecting the 2' oxygen atom and the 4' carbon atom, for which the
term methyleneoxy (4'- CH_2 —O-2') LNA is used. Furthermore, in the case of the bicyclic sugar
moiety having an ethylene bridging group in this position, the term ethyleneoxy (4'- CH_2CH_2 —O-
25 2') LNA is used. α -L-methyleneoxy (4'- CH_2 -O-2'), an isomer of methyleneoxy (4'- CH_2 —O-2')
LNA is also encompassed within the definition of LNA, as used herein.

[00134] As used herein, “hotspot region” is a range of nucleobases on a target nucleic acid
amenable to oligomeric compound-mediated modulation of the splicing of the target nucleic acid.

[00135] As used herein, “hybridization” means the pairing or annealing of complementary
30 oligonucleotides and/or nucleic acids. While not limited to a particular mechanism, the most

common mechanism of hybridization involves hydrogen bonding, which may be Watson-Crick, Hoosteen or reversed Hoosteen hydrogen bonding between complementary nucleobases.

[00136] As used herein, “increasing the amount of activity” refers to more transcriptional expression, more accurate splicing resulting in full length mature mRNA and/or protein expression, and/or more activity relative to the transcriptional expression or activity in an untreated or control sample.

[00137] As used herein, “mismatch” or “non-complementary nucleobase” refers to the case when a nucleobase of a first nucleic acid is not capable of pairing with the corresponding nucleobase of a second or target nucleic acid.

[00138] As used herein, “linked nucleosides” are nucleosides that are connected through internucleoside linkages in a contiguous sequence (*i.e.*, no additional nucleosides are presented between those that are linked).

[00139] As used herein, “modified internucleoside linkage” refers to a substitution or any change from a naturally occurring internucleoside linkage (*e.g.*, a phosphodiester internucleoside bond). “Phosphorothioate linkage” is a modified internucleoside linkage in which one of the non-bridging oxygen atoms of a phosphodiester internucleoside linkage is replaced with a sulfur atom.

[00140] As used herein, “modified nucleobase” means any nucleobase other than adenine, cytosine, guanine, thymidine, or uracil. Examples of a modified nucleobase include 5-methyl cytosine, pseudouridine, or 5-methoxyuridine. An “unmodified nucleobase” means the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C), and uracil (U).

[00141] As used herein, a “modified nucleoside” means a nucleoside having, independently, a modified sugar moiety and/or modified nucleobase. A universal base is a modified nucleobase that can pair with any one of the five unmodified nucleobases. Modified nucleosides include abasic nucleosides, which lack a nucleobase.

[00142] As used herein, “modified oligonucleotide” means an oligonucleotide comprising at least one modified internucleoside linkage, modified sugar, and/or modified nucleobase.

[00143] As used herein, “modified sugar” or “modified sugar moiety” means a modified furanosyl sugar moiety or a modified sugar moiety having other than a furanosyl moiety that can

link a nucleobase to another group, such as an internucleoside linkage, conjugate group, or terminal group in an oligonucleotide.

[00144] As used herein, “monomer” means a single unit of an oligomer. Monomers include, but are not limited to, nucleosides and nucleotides, whether naturally occurring or modified.

5 **[00145]** As used herein, “motif” means the pattern of unmodified and modified nucleosides in an antisense compound.

[00146] As used herein, “natural sugar moiety” means a sugar moiety found in DNA (2'-H) or RNA (2'-OH).

10 **[00147]** As used herein, “naturally occurring internucleoside linkage” means a 3' to 5' phosphodiester linkage.

[00148] As used herein, “non-complementary nucleobase” refers to a pair of nucleobases that do not form hydrogen bonds with one another or otherwise support hybridization.

15 **[00149]** As used herein, “nucleic acid” refers to molecules composed of monomeric nucleotides. A nucleic acid includes, but is not limited to, ribonucleic acids (RNA), deoxyribonucleic acids (DNA), single-stranded nucleic acids, double-stranded nucleic acids, small interfering ribonucleic acids (siRNA), short-hairpin RNA (shRNA), and microRNAs (miRNA).

[00150] As used herein, “nucleobase” means a heterocyclic moiety capable of pairing with a base of another nucleic acid.

20 **[00151]** As used herein, “nucleobase complementarity” refers to a nucleobase that is capable of base pairing with another nucleobase. For example, in DNA, adenine (A) is complementary to thymine (T). For example, in RNA, adenine (A) is complementary to uracil (U). In certain embodiments, complementary nucleobase refers to a nucleobase of an antisense compound that is capable of base pairing with a nucleobase of its target nucleic acid. For example, if a nucleobase
25 at a certain position of an antisense compound is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be complementary at that nucleobase pair.

[00152] As used herein, “nucleobase sequence” means the order of contiguous nucleobases independent of any sugar, linkage, and/or nucleobase modification.

[00153] As used herein, “nucleoside” means a nucleobase linked to a sugar. The term “nucleoside” also includes a “modified nucleoside” which has independently, a modified sugar moiety and/or modified nucleobase.

[00154] As used herein, “nucleoside mimetic” includes those structures used to replace the sugar or the sugar and the base and not necessarily the linkage at one or more positions of an oligomeric compound such as for example nucleoside mimetics having morpholino, cyclohexenyl, cyclohexyl, tetrahydropyranyl, bicyclo, or tricyclo sugar mimetics, *e.g.*, non-furanose sugar units. Nucleotide mimetic includes those structures used to replace the nucleoside and the linkage at one or more positions of an oligomeric compound such as for example peptide nucleic acids or morpholinos (morpholinos linked by —N(H)—C(=O)—O— or other non-phosphodiester linkage). Sugar surrogate overlaps with the slightly broader term nucleoside mimetic but is intended to indicate replacement of the sugar unit (furanose ring) only. The tetrahydropyranyl rings provided herein are illustrative of an example of a sugar surrogate wherein the furanose sugar group has been replaced with a tetrahydropyranyl ring system. “Mimetic” refers to groups that are substituted for a sugar, a nucleobase, and/or internucleoside linkage. Generally, a mimetic is used in place of the sugar or sugar-internucleoside linkage combination, and the nucleobase is maintained for hybridization to a selected target.

[00155] As used herein, “nucleotide” means a nucleoside having a phosphate group covalently linked to the sugar portion of the nucleoside.

[00156] As used herein, “oligomeric compound” or “oligomer” means a polymer of linked monomeric subunits which is capable of hybridizing to at least a region of a nucleic acid molecule.

[00157] As used herein, “oligonucleotide” means a polymer of linked nucleosides each of which can be modified or unmodified, independent one from another.

Modifications

[00158] A nucleoside is a base-sugar combination. The nucleobase (also known as base) portion of the nucleoside is normally a heterocyclic base moiety. Nucleotides are nucleosides that

further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to the 2', 3' or 5' hydroxyl moiety of the sugar. Oligonucleotides are formed through the covalent linkage of adjacent nucleosides to one another, to form a linear polymeric oligonucleotide. Within the
5 oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside linkages of the oligonucleotide.

[00159] Modifications to antisense compounds encompass substitutions or changes to internucleoside linkages, sugar moieties, or nucleobases. Modified antisense compounds are often preferred over native forms because of desirable properties such as, for example, enhanced
10 cellular uptake, enhanced affinity for nucleic acid target, increased stability in the presence of nucleases, or increased inhibitory activity.

[00160] Chemically modified nucleosides may also be employed to increase the binding affinity of a shortened or truncated antisense oligonucleotide for its target nucleic acid. Consequently, comparable results can often be obtained with shorter antisense compounds that
15 have such chemically modified nucleosides.

Modified Internucleoside Linkages

[00161] The naturally occurring internucleoside linkage of RNA and DNA is a 3' to 5' phosphodiester linkage. Antisense compounds having one or more modified, i.e. non-naturally occurring, internucleoside linkages are often selected over antisense compounds having naturally
20 occurring internucleoside linkages because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence of nucleases.

[00162] Oligonucleotides having modified internucleoside linkages include internucleoside linkages that retain a phosphorus atom as well as internucleoside linkages that do not have a
25 phosphorus atom. Representative phosphorus containing internucleoside linkages include, but are not limited to, phosphodiesters, phosphotriesters, methylphosphonates, phosphoramidate, and phosphorothioates. Methods of preparation of phosphorus-containing and non-phosphorus-containing linkages are well known.

[00163] In certain embodiments, antisense compounds targeted to a STMN2 nucleic acid
30 comprise one or more modified internucleoside linkages. In certain embodiments, the modified

internucleoside linkages are interspersed throughout the antisense compound. In certain embodiments, the modified internucleoside linkages are phosphorothioate linkages. In certain embodiments, each internucleoside linkage of an antisense compound is a phosphorothioate internucleoside linkage. In certain embodiments, the antisense compounds targeted to a STMN2 nucleic acid comprise at least one phosphodiester linkage and at least one phosphorothioate linkage.

Modified Sugar Moieties

[00164] Antisense compounds can optionally contain one or more nucleosides wherein the sugar group has been modified. Such sugar modified nucleosides may impart enhanced nuclease stability, increased binding affinity, or some other beneficial biological property to the antisense compounds. In certain embodiments, nucleosides comprise chemically modified ribofuranose ring moieties. Examples of chemically modified ribofuranose rings include without limitation, addition of substituent groups (including 5' and 2' substituent groups, bridging of non-geminal ring atoms to form bicyclic nucleic acids (BNA), replacement of the ribosyl ring oxygen atom with S, N(R), or C(R₁)(R₂) (R, R₁ and R₂ are each independently H, C₁-C₁₂ alkyl or a protecting group) and combinations thereof. Examples of chemically modified sugars include 2'-F-5'-methyl substituted nucleoside (*see* PCT International Application WO 2008/101157 Published on Aug. 21, 2008 for other disclosed 5',2'-bis substituted nucleosides) or replacement of the ribosyl ring oxygen atom with S or CF₂ with further substitution at the 2'-position (*see* published U.S. Patent Application US2005-0130923, published on Jun. 16, 2005) or alternatively 5'-substitution of a BNA (*see* PCT International Application WO 2007/134181 Published on Nov. 22, 2007 wherein LNA is substituted with for example a 5'-methyl or a 5'-vinyl group).

[00165] Examples of nucleosides having modified sugar moieties include without limitation nucleosides comprising 5'-vinyl, 5'-methyl (R or 5), 4'-S, 2'-F, 2'-OCH₃, 2'-OCH₂CH₃, 2'-OCH₂CH₂F and 2'-O(CH₂)₂OCH₃ substituent groups. The substituent at the 2' position can also be selected from allyl, amino, azido, thio, O-allyl, O—C₁-C₁₀ alkyl, OCF₃, OCH₂F, O(CH₂)₂SCH₃, O(CH₂)₂—O—N(R_m)(R_n), O—CH₂—C(=O)—N(R_m)(R_n), and O—CH₂—C(=O)—N(R₁)—(CH₂)₂—N(R_m)(R_n)-, where each R₁, R_m and R_n is, independently, H or substituted or unsubstituted C₁-C₁₀ alkyl.

[00166] Additional examples of modified sugar moieties include a 2'-OMe modified sugar moiety, bicyclic sugar moiety, 2'-O-(2-methoxyethyl) (2'MOE), 2'-deoxy-2'-fluoro nucleoside,

2'-fluoro-β-D-arabinonucleoside, locked nucleic acid (LNA), constrained ethyl 2'-4'-bridged nucleic acid (cEt) (4'-CH(CH₃)-O-2'), *S*-constrained ethyl (*S*-cEt) 2'-4'-bridged nucleic acid, 4' - CH₂-O-CH₂-2', 4' -CH₂-N(R)-2', 4'-CH(CH₂OCH₃)-O-2' ("constrained MOE" or "cMOE"), hexitol nucleic acids (HNA), and tricyclic analog (*e.g.*, tcDNA).

5 [00167] As used herein, "bicyclic nucleosides" refer to modified nucleosides comprising a bicyclic sugar moiety. Examples of bicyclic nucleosides include without limitation nucleosides comprising a bridge between the 4' and the 2' ribosyl ring atoms. In certain embodiments, antisense compounds provided herein include one or more bicyclic nucleosides comprising a 4' to 2' bridge. Examples of such 4' to 2' bridged bicyclic nucleosides, include but are not limited to one
10 of the formulae: 4'-(CH₂)—O-2' (LNA); 4'-(CH₂)—S-2'; 4'-(CH₂)₂—O-2' (ENA); 4'-CH(CH₃)—O-2' and 4'-CH(CH₂OCH₃)—O-2' (and analogs thereof see U.S. Pat. No. 7,399,845, issued on Jul. 15, 2008); 4'-C(CH₃)(CH₃)—O-2' (and analogs thereof see published International Application WO/2009/006478, published Jan. 8, 2009); 4'-CH₂—N(OCH₃)-2' (and analogs thereof see published International Application WO/2008/150729, published Dec. 11, 2008); 4'-CH₂—O—
15 N(CH₃)-2' (see published U.S. Patent Application US2004-0171570, published Sep. 2, 2004); 4'-CH₂—N(R)—O-2', wherein R is H, C₁-C₁₂ alkyl, or a protecting group (see U.S. Pat. No. 7,427,672, issued on Sep. 23, 2008); 4'-CH₂—C(H)(CH₃)-2' (see Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134); and 4'-CH₂—C—(=CH₂)-2' (and analogs thereof see published International Application WO 2008/154401, published on Dec. 8, 2008).

20 [00168] Further reports related to bicyclic nucleosides can also be found in published literature (*see* for example: Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et al., Tetrahedron, 1998, 54, 3607-3630; Wahlestedt et al., Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 5633-5638; Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222; Singh et al., J. Org. Chem., 1998, 63, 10035-10039; Srivastava et al., J. Am. Chem. Soc., 2007, 129(26) 8362-8379; Elayadi et al.,
25 Curr. Opinion Invest. Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol., 2001, 8, 1-7; and Orum et al., Curr. Opinion Mol. Ther., 2001, 3, 239-243; U.S. Pat. Nos. 6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 7,034,133; 7,053,207; 7,399,845; 7,547,684; and 7,696,345; U.S. Patent Publication No. US2008-0039618; US2009-0012281; U.S. Patent Ser. No. 60/989,574; 61/026,995; 61/026,998; 61/056,564; 61/086,231; 61/097,787; and 61/099,844;
30 Published PCT International applications WO 1994/014226; WO 2004/106356; WO 2005/021570; WO 2007/134181; WO 2008/150729; WO 2008/154401; and WO 2009/006478. Each of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical

sugar configurations including for example α -L-ribofuranose and β -D-ribofuranose (see PCT international application PCT/DK98/00393, published on Mar. 25, 1999 as WO 99/14226).

[00169] In certain embodiments, bicyclic sugar moieties of BNA nucleosides include, but are not limited to, compounds having at least one bridge between the 4' and the 2' position of the pentofuranosyl sugar moiety wherein such bridges independently comprises 1 or from 2 to 4 linked groups independently selected from $—[C(R_a)(R_b)]_n—$, $—C(R_a)=C(R_b)—$, $—C(R_a)=N—$, $—C(=O)—$, $—C(=NR_a)—$, $—C(=S)—$, $—O—$, $—Si(R_a)_2—$, $—S(=O)_x—$, and $—N(R_a)—$; wherein:

x is 0, 1, or 2;

n is 1, 2, 3, or 4;

each R_a and R_b is, independently, H, a protecting group, hydroxyl, C_1 - C_{12} alkyl, substituted C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, substituted C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, substituted C_2 - C_{12} alkynyl, C_5 - C_{20} aryl, substituted C_5 - C_{20} aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C_5 - C_7 alicyclic radical, substituted C_5 - C_7 alicyclic radical, halogen, OJ_1 , NJ_1J_2 , SJ_1 , N_3 , $COOJ_1$, acyl ($C(=O)—H$), substituted acyl, CN, sulfonyl ($S(=O)_2-J_1$), or sulfoxyl ($S(=O)-J_1$); and

each J_1 and J_2 is, independently, H, C_1 - C_{12} alkyl, substituted C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, substituted C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, substituted C_2 - C_{12} alkynyl, C_5 - C_{20} aryl, substituted C_5 - C_{20} aryl, acyl ($C(=O)—H$), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C_1 - C_{12} aminoalkyl, substituted C_1 - C_{12} aminoalkyl or a protecting group.

[00170] In certain embodiments, the bridge of a bicyclic sugar moiety is $—[C(R_a)(R_b)]_n—$, $—[—[C(R_a)(R_b)]_n—O—$, $—C(R_aR_b)—N(R)—O—$ or $—C(R_aR_b)—O—N(R)—$. In certain embodiments, the bridge is 4'-CH₂-2', 4'-(CH₂)₂-2', 4'-(CH₂)₃-2', 4'-CH₂-O-2', 4'-(CH₂)₂-O-2', 4'-CH₂-O-N(R)-2' and 4'-CH₂-N(R)-O-2'- wherein each R is, independently, H, a protecting group or C_1 - C_{12} alkyl, each R_a and R_b is, independently, H, a protecting group, hydroxyl, C_1 - C_{12} alkyl, substituted C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, substituted C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, substituted C_2 - C_{12} alkynyl, C_5 - C_{20} aryl, substituted C_5 - C_{20} aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C_5 - C_7 alicyclic radical, substituted C_5 - C_7 alicyclic radical, halogen, OJ_1 , NJ_1J_2 , SJ_1 , N_3 , $COOJ_1$, acyl ($C(=O)—H$), substituted acyl, CN, sulfonyl ($S(=O)_2-J_1$), or sulfoxyl ($S(=O)-J_1$).

[00171] In certain embodiments, bicyclic nucleosides are further defined by isomeric configuration. For example, a nucleoside comprising a 4'-2' methylene-oxy bridge, may be in the

α -L configuration or in the β -D configuration. Previously, α -L-methyleneoxy (4'-CH₂—O-2') BNA's have been incorporated into antisense oligonucleotides that showed antisense activity (Frieden et al., Nucleic Acids Research, 2003, 21, 6365-6372).

[00172] In certain embodiments, bicyclic nucleosides include, but are not limited to, α -L-methyleneoxy (4'-CH₂—O-2') BNA, β -D-methyleneoxy (4'-CH₂—O-2') BNA, ethyleneoxy (4'-(CH₂)₂—O-2') BNA, aminoxy (4'-CH₂—O—N(R)-2') BNA, oxyamino (4'-CH₂—N(R)—O-2') BNA, methyl(methyleneoxy) (4'-CH(CH₃)—O-2') BNA, methylene-thio (4'-CH₂—S-2') BNA, methylene-amino (4'-CH₂—N(R)-2') BNA, methyl carbocyclic (4'-CH₂—CH(CH₃)-2') BNA, and propylene carbocyclic (4'-(CH₂)₃-2') BNA.

[00173] The present disclosure provide, in some embodiments, methods for treating, ameliorating, or preventing a neurological disease such as, but not limited to, ALS, FTD, or ALS with FTD, or treating, ameliorating, or preventing a neurological disease, condition, or a disorder characterized symptoms associated with a neurological disease such as, but not limited to, ALS, FTD, or ALS with FTD, include methods of administering a pharmaceutically acceptable composition, for example, a pharmaceutically acceptable formulation, that includes one or more inhibitors of STMN2 transcripts that include a cryptic exon, to a patient. Inhibitors of STMN2 transcripts that include a cryptic exon can increase, restore, or stabilize STMN2 activity, for example, STMN2 activity, and/or levels of STMN2 expression, for example, STMN2 mRNA and/or protein expression.

[00174] The present disclosure also provides pharmaceutical compositions comprising inhibitor of STMN2 transcripts that include a cryptic exon as disclosed herein formulated together with one or more pharmaceutically or cosmetically acceptable excipients. These formulations include those suitable for oral, sublingual, intratracheal, intranasal, transdermal, pulmonary, intrathecal, intracisternal, parenteral (*e.g.*, subcutaneous, intramuscular, intradermal, intraduodenal, or intravenous) or intralesional, administration, transmucosal (*e.g.*, buccal, vaginal, and rectal), or for topical use, *e.g.*, as part of a composition suitable for applying topically to skin and/or mucous membrane, for example, a composition in the form of a gel, a paste, a wax, a cream, a spray, a liquid, a foam, a lotion, an ointment, a topical solution, a transdermal patch, a powder, a vapor, or a tincture. Although the most suitable form of administration in any given case will depend on the degree and severity of the condition being treated and on the nature of the particular inhibitor of STMN2 transcripts that include a cryptic exon being used.

[00175] The present disclosure also provides a pharmaceutical composition comprising an inhibitor of STMN2 transcripts that include a cryptic exon, or a pharmaceutically acceptable salt thereof (for example, a STMN2 AON that includes a nucleobase sequence of any of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432).

5 [00176] The present disclosure also provides methods that include the use of pharmaceutical compositions comprising inhibitor of STMN2 transcripts that include a cryptic exon as disclosed herein (*e.g.*, a STMN2 AON of any one of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432) formulated together with one or more pharmaceutically acceptable excipients. Exemplary compositions provided herein include
 10 compositions comprising an inhibitor of STMN2 transcripts that include a cryptic exon, as described above, and one or more pharmaceutically acceptable excipients. Formulations include those suitable for oral, sublingual, intratracheal, intranasal, transdermal, pulmonary, intrathecal, intracisternal, parenteral (*e.g.*, subcutaneous, intramuscular, intradermal, intraduodenal, or intravenous) or intralesional, administration, transmucosal (*e.g.*, buccal, vaginal, and rectal), or for
 15 topical use. The most suitable form of administration in any given case will depend on the clinical symptoms, complications, or biochemical indicia of the state, disorder, disease, or condition that one is trying to prevent in a subject; the state, disorder, disease, or condition one is trying to prevent in a subject; and/or on the nature of the particular compound and/or the composition being used.

20 **Inhibitors of STMN2 transcripts that include a cryptic exon**

[00177] In certain embodiments, STMN2 levels (*e.g.*, STMN2 mRNA or full length STMN2 protein levels) and/or activity (*e.g.*, biological activity, for example, STMN2 activity) can be increased, restored, or stabilized using compounds or compositions that target a STMN2 gene product that includes a cryptic exon (for example, a STMN2 pre-mRNA).

25 [00178] In some embodiments, an inhibitor of STMN2 transcripts that include a cryptic exon can be, but is not limited to, nucleotide-based inhibitors of STMN2 (for example, STMN2 shRNAs, STMN2 siRNAs, STMN2 PNAs, STMN2 LNAs, 2'-*O*-methyl (2'OMe) STMN2 antisense oligonucleotide (AON), 2'-*O*-(2-methoxyethyl) (2'MOE) STMN2 AON, or STMN2 morpholino oligomers (*e.g.*, phosphorodiamidate morpholino (PMO))), or compositions that
 30 include such compounds. In some embodiments an inhibitor of STMN2 is an antisense oligonucleotide (AON) comprising 2'OMe (*e.g.*, an STMN2 AON comprising one or more 2'OMe

modified sugar), MOE (*e.g.*, an STMN2 AON comprising one or more MOE modified sugar (*e.g.*, 2'-MOE)), PNA (*e.g.*, a STMN2 AON comprising one or more *N*-(2-aminoethyl)-glycine units linked by amide bonds or carbonyl methylene linkage as repeating units in place of a sugar-phosphate backbone), LNA (*e.g.*, a STMN2 AON comprising one or more locked ribose, and can be a mixture of 2'-deoxy nucleotides or 2'OMe nucleotides), c-ET (*e.g.*, a STMN2 AON comprising one or more cET sugar), cMOE (*e.g.*, a STMN2 AON comprising one or more cMOE sugar), morpholino oligomer (*e.g.*, a STMN2 AON comprising a backbone comprising one or more PMO), deoxy-2'-fluoro nucleoside (*e.g.*, a STMN2 AON comprising one or more 2'-fluoro- β -D-arabinonucleoside), ENA (*e.g.*, a STMN2 AON comprising one or more ENA modified sugar), HNA (*e.g.*, a STMN2 AON comprising one or more HNA modified sugar), or tcDNA (*e.g.*, a STMN2 AON comprising one or more tcDNA modified sugar). In some embodiments, a STMN2 AON comprises one or more phosphorothioate linkage, phosphodiester linkage, phosphotriester linkage, methylphosphonate linkage, phosphoramidate linkage, phosphorodiamidate morpholino (PMO) linkage ("morpholino linkage"), peptide nucleic acid (PNA) linkage, or any combination of phosphorothioate linkage, phosphodiester linkage, a phosphotriester linkage, methylphosphonate linkage, phosphoramidate linkage, phosphorodiamidate morpholino (PMO) (morpholino) linkage, and PNA linkage. In some embodiments, a STMN2 AON comprises one or more phosphorothioate linkage, phosphodiester linkage, or a combination of phosphorothioate and phosphodiester linkages.

STMN2 Antisense Therapeutics

[00179] Antisense therapeutics are a class of nucleic acid-based compounds that can be used to modulate a STMN2 mRNA or STMN2 transcript (for example, a STMN2 pre-mRNA comprising a cryptic exon). Antisense therapeutics may be single- or double-stranded deoxyribonucleic acid (DNA)-based, ribonucleic acid (RNA)-based, or DNA/RNA chemical analogue compounds. In general, antisense therapeutics are designed to include a nucleobase sequence that is complementary or nearly complementary to an mRNA or pre-mRNA sequence transcribed from a given gene in order to promote binding between the antisense therapeutic and the pre-mRNA or mRNA. In certain embodiments, antisense therapeutics act by binding to an mRNA or pre-mRNA, thereby inhibiting protein translation, altering pre-mRNA splicing into mature mRNA (*e.g.*, by preventing appropriate proteins such as splicing activator proteins from binding), and/or causing destruction of mRNA. In certain embodiments, the antisense therapeutic nucleobase sequence is complementary to a portion of a targeted gene's or mRNA's sense sequence. In

certain embodiments, STMN2 antisense therapeutics described herein are oligonucleotide-based compounds that include an oligonucleotide sequence complementary to a pre-mRNA sense, or a portion thereof. In certain embodiments, STMN2 antisense therapeutics described herein can also be nucleotide chemical analog-based compounds. Synthetic oligonucleotides as therapeutic agents has evolved into broad applications involving multiple modalities. These applications include ribozymes, small interfering RNA (siRNA), microRNA, aptamers, non-coding RNA, splicing modulation, targeting toxic repeats, gene editing, and immune modulations. The STMN2 oligonucleotides (STMN2 AONs) of the present disclosure prevent aberrant or mis-splicing by targeting a STMN2 transcript (*e.g.*, STMN2 pre-mRNA (*e.g.*, SEQ ID NO: 944)).

[00180] Antisense oligonucleotides (AONs) are short oligonucleotide-based sequences that include an oligonucleotide sequence complementary to a target RNA sequence. In certain embodiments, AONs are between 8 to 50 nucleotides in length, for example, 8, 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides in length. In certain embodiments, the AONs are 25 nucleotides in length. In certain embodiments, AONs may include chemically modified nucleosides (for example, 2'-*O*-methylated nucleosides or 2'-*O*-(2-methoxyethyl) nucleosides (2'-*O*-methoxyethylribonucleosides (2'-MOE))) as well as modified internucleoside linkages (for example, phosphorothioate linkages). In certain embodiments, STMN2 AONs described herein include oligonucleotide sequences that are complementary to STMN2 RNA sequences. In certain embodiments, STMN2 AONs described herein can include chemically modified nucleosides and modified internucleoside linkages (for example, phosphorothioate linkages).

[00181] Peptide nucleic acids (PNAs) are short, artificially synthesized polymers with a structure that mimics DNA or RNA. PNAs include a backbone composed of repeating N-(2-aminoethyl)-glycine units linked by peptide bonds. In certain embodiments, STMN2 PNAs described herein can be used as antisense therapeutics that bind to STMN2 RNA sequences with high specificity and increase, restore, and/or stabilize STMN2 levels (*e.g.*, STMN2 mRNA or protein levels) and/or activity (*e.g.*, biological activity, for example, STMN2 activity).

[00182] Locked nucleic acids (LNAs) are oligonucleotide sequences that include one or more modified RNA nucleotides in which the ribose moiety is modified with an extra bridge connecting the 2' oxygen and 4' carbon. LNAs are believed to have higher *T_m*'s than analogous oligonucleotide sequences. In certain embodiments, STMN2 LNAs described herein can be used as antisense therapeutics that bind to STMN2 RNA sequences with high specificity and repress premature polyadenylation of STMN2 pre-mRNA, and increase, restore, and/or stabilize STMN2

levels (*e.g.*, STMN2 mRNA or protein levels) and/or activity (*e.g.*, biological activity, for example, STMN2 activity).

[00183] Morpholino oligomers are oligonucleotide compounds that include DNA bases attached to a backbone of methylenemorpholine rings linked through phosphorodiamidate groups.

5 In certain embodiments, morpholino oligomers of the present invention can be designed to bind to specific STMN2 pre-mRNA sequence of interest, thereby repressing premature polyadenylation of the pre-mRNA, and increase, restore, and/or stabilize STMN2 levels (*e.g.*, STMN2 mRNA or protein levels) and/or activity (*e.g.*, biological activity, for example, STMN2 activity). In certain
10 embodiments, STMN2 morpholino oligomers described herein can be used as antisense therapeutics that bind to STMN2 pre-mRNA sequences with high specificity and repress premature polyadenylation of STMN2 pre-mRNA, and increase, restore, and/or stabilize STMN2 levels (*e.g.*, STMN2 mRNA or protein levels) and/or activity (*e.g.*, biological activity, for example, STMN2 activity). In certain embodiments, STMN2 morpholino oligomers described
15 herein can also be used to bind STMN2 pre-mRNA sequences, altering STMN2 pre-mRNA splicing and STMN2 gene expression, and increase, restore, and/or stabilize STMN2 levels (*e.g.*, STMN2 mRNA or protein levels) and/or activity (*e.g.*, biological activity, for example, STMN2 activity).

[00184] In some embodiments, STMN2 antisense therapeutics include a STMN2 AON comprising 2'OMe (*e.g.*, an STMN2 AON comprising one or more 2'OMe modified sugar), MOE
20 (*e.g.*, an STMN2 AON comprising one or more MOE modified sugar (*e.g.*, 2'-MOE)), PNA (*e.g.*, a STMN2 AON comprising one or more *N*-(2-aminoethyl)-glycine units linked by amide bonds or carbonyl methylene linkage as repeating units in place of a sugar-phosphate backbone), LNA (*e.g.*, a STMN2 AON comprising one or more locked ribose, and can be a mixture of 2'-deoxy nucleotides or 2'OMe nucleotides), c-ET (*e.g.*, a STMN2 AON comprising one or more cET
25 sugar), cMOE (*e.g.*, a STMN2 AON comprising one or more cMOE sugar), morpholino oligomer (*e.g.*, a STMN2 AON comprising a backbone comprising one or more PMO), deoxy-2'-fluoro nucleoside (*e.g.*, a STMN2 AON comprising one or more 2'-fluoro- β -D-arabinonucleoside), ENA (*e.g.*, a STMN2 AON comprising one or more ENA modified sugar), HNA (*e.g.*, a STMN2 AON comprising one or more HNA modified sugar), or tcDNA (*e.g.*, a STMN2 AON comprising one
30 or more tcDNA modified sugar). In some embodiments, a STMN2 AON comprises one or more phosphorothioate linkage, phosphodiester linkage, phosphotriester linkage, methylphosphonate linkage, phosphoramidate linkage, morpholino linkage, PNA linkage, or any combination of

phosphorothioate linkage, phosphodiester linkage, a phosphotriester linkage, methylphosphonate linkage, phosphoramidate linkage, morpholino linkage, and PNA linkage. In some embodiments, a STMN2 AON comprises one or more phosphorothioate linkage, phosphodiester linkage, or a combination of phosphorothioate and phosphodiester linkages.

5 STMN2 Antisense Oligonucleotides

[00185] In certain embodiments, a STMN2 antisense oligonucleotide, such as disclosed herein, may be an oligonucleotide sequence of 5 to 100 nucleotides in length, for example, 10 to 40 nucleotides in length, for example, 14 to 40 nucleotides in length, 10 to 30 nucleotides in length, for example, 14 to 30 nucleotides in length, for example, 14 to 25 or 15 to 22 nucleotides in length, or 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length. In certain embodiments, the AONs are 25 nucleotides in length. In certain embodiments, STMN2 antisense oligonucleotides (AONs) described herein are short synthetic oligonucleotide sequence complementary to a STMN2 transcript (*e.g.*, pre-mRNA), a portion of a STMN2 transcript, or a STMN2 gene sequence.

15 [00186] In some embodiments, a STMN2 AON includes a nucleobase sequence that is 80%, 85%, 90%, 95%, or 100% complementary to the STMN2 transcript (*e.g.*, STMN2 pre-mRNA) that includes a cryptic exon. In some embodiments, the nucleobase sequence of the STMN2 antisense oligonucleotide is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that are 80%, 85%, 90%, 95%, or 100% complementary to an equal length portion of nucleobases in a portion of the STMN2 transcript that includes a cryptic exon. AON binding specificity can be assessed via measurement of parameters such as dissociation constant, melting temperature (T_m), or other criteria such as changes in protein or RNA expression levels or other assays that measure STMN2 activity or expression.

[00187] In some embodiments, a STMN2 AON can include a non-duplexed oligonucleotide. In some embodiments, a STMN2 AON can include a duplex of two oligonucleotides where the first oligonucleotide includes a nucleobase sequence that is completely or almost completely complementary to a STMN2 pre-mRNA sequence and the second oligonucleotide includes a nucleobase sequence that is complementary to the nucleobase sequence of the first oligonucleotide.

[00188] In some embodiments, a STMN2 AON can target STMN2 pre-mRNAs that include a cryptic exon produced from STMN2 genes of one or more species. For example, a STMN2 AON can target a STMN2 pre-mRNA, which includes a cryptic exon, of a mammalian STMN2 gene, for example, a human (*i.e.*, *Homo sapiens*) STMN2 gene. In particular embodiments, the STMN2 AON targets a human STMN2 pre-mRNA, which includes a cryptic exon. In some embodiments, the STMN2 AON includes a nucleobase sequence that is complementary to a nucleobase sequence of a STMN2 gene or a STMN2 pre-mRNA, which includes a cryptic exon, or a portion thereof.

[00189] STMN2 AONs described herein include antisense oligonucleotides comprising the oligonucleotide sequences listed in Table 1 below:

Table 1. STMN2 AON Sequences

SEQ ID NO:	AON Sequence* (5' → 3')	Region	Target Sequence (5' → 3')
1	GGAGGGATACCTGTATATTACAAGT		ACTTGTAATATACAGGTATCCCTCC SEQ ID NO: 448
2	AGGAGGGATACCTGTATATTACAAG		CTTGTAATATACAGGTATCCCTCCT SEQ ID NO: 449
3	CAGGAGGGATACCTGTATATTACAA		TTGTAATATACAGGTATCCCTCCTG SEQ ID NO: 450
4	CCAGGAGGGATACCTGTATATTACA		TGTAATATACAGGTATCCCTCCTGG SEQ ID NO: 451
5	ACCAGGAGGGATACCTGTATATTAC		GTAATATACAGGTATCCCTCCTGGT SEQ ID NO: 452
6	TACCAGGAGGGATACCTGTATATTA		TAATATACAGGTATCCCTCCTGGTA SEQ ID NO: 453
7	TTACCAGGAGGGATACCTGTATATT		AATATACAGGTATCCCTCCTGGTAA SEQ ID NO: 454
8	CTTACCAGGAGGGATACCTGTATAT		ATATACAGGTATCCCTCCTGGTAAG SEQ ID NO: 455
9	GCTTACCAGGAGGGATACCTGTATA		TATACAGGTATCCCTCCTGGTAAGC SEQ ID NO: 456
10	AGCTTACCAGGAGGGATACCTGTAT		ATACAGGTATCCCTCCTGGTAAGCT SEQ ID NO: 457
11	GAGCTTACCAGGAGGGATACCTGTA		TACAGGTATCCCTCCTGGTAAGCTC SEQ ID NO: 458
12	AGAGCTTACCAGGAGGGATACCTGT		ACAGGTATCCCTCCTGGTAAGCTCT SEQ ID NO: 459
13	CAGAGCTTACCAGGAGGGATACCTG		CAGGTATCCCTCCTGGTAAGCTCTG SEQ ID NO: 460
14	CCAGAGCTTACCAGGAGGGATACCT		AGGTATCCCTCCTGGTAAGCTCTGG SEQ ID NO: 461
15	ACCAGAGCTTACCAGGAGGGATACC		GGTATCCCTCCTGGTAAGCTCTGGT SEQ ID NO: 462

16	TACCAGAGCTTACCAGGAGGGATAC		GTATCCCTCCTGGTAAGCTCTGGTA SEQ ID NO: 463
17	ATACCAGAGCTTACCAGGAGGGATA		TATCCCTCCTGGTAAGCTCTGGTAT SEQ ID NO: 464
18	AATACCAGAGCTTACCAGGAGGGAT		ATCCCTCCTGGTAAGCTCTGGTATT SEQ ID NO: 465
19	TAATACCAGAGCTTACCAGGAGGGA		TCCCTCCTGGTAAGCTCTGGTATTA SEQ ID NO: 466
20	ATAATACCAGAGCTTACCAGGAGGG		CCCTCCTGGTAAGCTCTGGTATTAT SEQ ID NO: 467
21	CATAATACCAGAGCTTACCAGGAGG		CCTCCTGGTAAGCTCTGGTATTATG SEQ ID NO: 468
22	ACATAATACCAGAGCTTACCAGGAG		CTCCTGGTAAGCTCTGGTATTATGT SEQ ID NO: 469
23	GACATAATACCAGAGCTTACCAGGA		TCCTGGTAAGCTCTGGTATTATGTC SEQ ID NO: 470
24	AGACATAATACCAGAGCTTACCAGG		CCTGGTAAGCTCTGGTATTATGTCT SEQ ID NO: 471
25	AAGACATAATACCAGAGCTTACCAG		CTGGTAAGCTCTGGTATTATGTCTT SEQ ID NO: 472
26	TAAGACATAATACCAGAGCTTACCA		TGGTAAGCTCTGGTATTATGTCTTA SEQ ID NO: 473
27	TTAAGACATAATACCAGAGCTTACC		GGTAAGCTCTGGTATTATGTCTTAA SEQ ID NO: 474
28	GTTAAGACATAATACCAGAGCTTAC		GTAAGCTCTGGTATTATGTCTTAAC SEQ ID NO: 475
29	TGTTAAGACATAATACCAGAGCTTA		TAAGCTCTGGTATTATGTCTTAACA SEQ ID NO: 476
30	ATGTTAAGACATAATACCAGAGCTT	branch point 1	AAGCTCTGGTATTATGTCTTAACAT SEQ ID NO: 477
31	AATGTTAAGACATAATACCAGAGCT	branch point 1	AGCTCTGGTATTATGTCTTAACATT SEQ ID NO: 478
32	AAATGTTAAGACATAATACCAGAGC	branch point 1	GCTCTGGTATTATGTCTTAACATTT SEQ ID NO: 479
33	AAAATGTTAAGACATAATACCAGAG	branch point 1	CTCTGGTATTATGTCTTAACATTTT SEQ ID NO: 480
34	AAAAATGTTAAGACATAATACCAGA	branch point 1	TCTGGTATTATGTCTTAACATTTTT SEQ ID NO: 481
35	TAAAAATGTTAAGACATAATACCAG	branch point 1	CTGGTATTATGTCTTAACATTTTTTA SEQ ID NO: 482
36	TTAAAAATGTTAAGACATAATACCA	branch point 1	TGGTATTATGTCTTAACATTTTTTAA SEQ ID NO: 483
37	TTTAAAAATGTTAAGACATAATACC	branch point 1	GGTATTATGTCTTAACATTTTTTAAA SEQ ID NO: 484
38	ATTTAAAAATGTTAAGACATAATAC	branch point 1	GTATTATGTCTTAACATTTTTTAAAT SEQ ID NO: 485
39	GATTTAAAAATGTTAAGACATAATA	branch point 1	TATTATGTCTTAACATTTTTTAAATC SEQ ID NO: 486
40	AGATTTAAAAATGTTAAGACATAAT	branch point 1	ATTATGTCTTAACATTTTTTAAATCT SEQ ID NO: 487

41	TAGATTTAAAAATGTTAAGACATAA	branch point 1	TTATGTCTTAACATTTTTAAATCTA SEQ ID NO: 488
42	ATAGATTTAAAAATGTTAAGACATA	branch point 1	TATGTCTTAACATTTTTAAATCTAT SEQ ID NO: 489
43	CATAGATTTAAAAATGTTAAGACAT	branch point 1	ATGTCTTAACATTTTTAAATCTATG SEQ ID NO: 490
44	CCATAGATTTAAAAATGTTAAGACA	branch point 1	TGTCTTAACATTTTTAAATCTATGG SEQ ID NO: 491
45	ACCATAGATTTAAAAATGTTAAGAC	branch point 1	GTCTTAACATTTTTAAATCTATGGT SEQ ID NO: 492
46	TACCATAGATTTAAAAATGTTAAGA	branch point 1	TCTTAACATTTTTAAATCTATGGTA SEQ ID NO: 493
47	TTACCATAGATTTAAAAATGTTAAG		CTTAACATTTTTAAATCTATGGTAA SEQ ID NO: 494
48	ATTACCATAGATTTAAAAATGTTAA		TTAACATTTTTAAATCTATGGTAAT SEQ ID NO: 495
49	GATTACCATAGATTTAAAAATGTTA		TAACATTTTTAAATCTATGGTAATC SEQ ID NO: 496
50	AGATTACCATAGATTTAAAAATGTT	Branch point 2	AACATTTTTAAATCTATGGTAATCT SEQ ID NO: 497
51	AAGATTACCATAGATTTAAAAATGT	Branch point 2	ACATTTTTAAATCTATGGTAATCTT SEQ ID NO: 498
52	AAAGATTACCATAGATTTAAAAATG	Branch point 2	CATTTTTAAATCTATGGTAATCTTT SEQ ID NO: 499
53	TAAAGATTACCATAGATTTAAAAAT	Branch point 2	ATTTTTAAATCTATGGTAATCTTTA SEQ ID NO: 500
54	GTAAAGATTACCATAGATTTAAAAA	Branch point 2	TTTTAAATCTATGGTAATCTTTAC SEQ ID NO: 501
55	TGTAAAGATTACCATAGATTTAAAA	Branch point 2	TTTAAATCTATGGTAATCTTTACA SEQ ID NO: 502
56	TTGTAAAGATTACCATAGATTTAAA	Branch point 2	TTTAAATCTATGGTAATCTTTACAA SEQ ID NO: 503
57	TTTGTAAAGATTACCATAGATTTAA	Branch point 2	TTAAATCTATGGTAATCTTTACAAA SEQ ID NO: 504
58	TTTTGTAAAGATTACCATAGATTTA	Branch point 2	TAAATCTATGGTAATCTTTACAAAA SEQ ID NO: 505
59	ATTTTGTAAAGATTACCATAGATTT	Branch point 2	AAATCTATGGTAATCTTTACAAAAT SEQ ID NO: 506
60	TATTTTGTAAAGATTACCATAGATT	Branch point 2	AATCTATGGTAATCTTTACAAAATA SEQ ID NO: 507
61	ATATTTTGTAAAGATTACCATAGAT	Branch point 2	ATCTATGGTAATCTTTACAAAATAT SEQ ID NO: 508
62	AATATTTTGTAAAGATTACCATAGA	Branch point 2	TCTATGGTAATCTTTACAAAATATT SEQ ID NO: 509
63	AAATATTTTGTAAAGATTACCATAG	Branch point 2	CTATGGTAATCTTTACAAAATATTT SEQ ID NO: 510
64	AAAATATTTTGTAAAGATTACCATA	Branch point 2	TATGGTAATCTTTACAAAATATTTT SEQ ID NO: 511
65	TAAAATATTTTGTAAAGATTACCAT	Branch point 2	ATGGTAATCTTTACAAAATATTTTA SEQ ID NO: 512

66	GTAAAATATTTTGTAAGATTACCA	Branch point 2	TGGTAATCTTTACAAAATATTTTAC SEQ ID NO: 513
67	AGTAAAATATTTTGTAAGATTACC		GGTAATCTTTACAAAATATTTTACT SEQ ID NO: 514
68	AAGTAAAATATTTTGTAAGATTAC		GTAATCTTTACAAAATATTTTACTT SEQ ID NO: 515
69	GAAGTAAAATATTTTGTAAGATTA		TAATCTTTACAAAATATTTTACTTC SEQ ID NO: 516
70	GGAAGTAAAATATTTTGTAAGATT		AATCTTTACAAAATATTTTACTTCC SEQ ID NO: 517
71	CGGAAGTAAAATATTTTGTAAGAT		ATCTTTACAAAATATTTTACTTCCG SEQ ID NO: 518
72	TCGGAAGTAAAATATTTTGTAAGA		TCTTTACAAAATATTTTACTTCCGA SEQ ID NO: 519
73	TTCGGAAGTAAAATATTTTGTAAG		CTTACAAAATATTTTACTTCCGAA SEQ ID NO: 520
74	GTTTCGGAAGTAAAATATTTTGTA		TTACAAAATATTTTACTTCCGAAC SEQ ID NO: 521
75	AGTTCGGAAGTAAAATATTTTGTA		TTACAAAATATTTTACTTCCGAAC SEQ ID NO: 522
76	GAGTTCGGAAGTAAAATATTTTGTA		TACAAAATATTTTACTTCCGAAC SEQ ID NO: 523
77	TGAGTTCGGAAGTAAAATATTTTGT		ACAAAATATTTTACTTCCGAAC SEQ ID NO: 524
78	ATGAGTTCGGAAGTAAAATATTTTG		CAAAAATATTTTACTTCCGAAC SEQ ID NO: 525
79	TATGAGTTCGGAAGTAAAATATTTT		AAAATATTTTACTTCCGAAC SEQ ID NO: 526
80	ATATGAGTTCGGAAGTAAAATATTT		AAATATTTTACTTCCGAAC SEQ ID NO: 527
81	TATATGAGTTCGGAAGTAAAATATT		AATATTTTACTTCCGAAC SEQ ID NO: 528
82	GTATATGAGTTCGGAAGTAAAATAT		ATATTTTACTTCCGAAC SEQ ID NO: 529
83	GGTATATGAGTTCGGAAGTAAAATA		TATTTTACTTCCGAAC SEQ ID NO: 530
84	AGGTATATGAGTTCGGAAGTAAAAT		ATTTTACTTCCGAAC SEQ ID NO: 531
85	CAGGTATATGAGTTCGGAAGTAAAA		TTTACTTCCGAAC SEQ ID NO: 532
86	CCAGGTATATGAGTTCGGAAGTAAA		TTACTTCCGAAC SEQ ID NO: 533
87	CCCAGGTATATGAGTTCGGAAGTAA		TTACTTCCGAAC SEQ ID NO: 534
88	CCCCAGGTATATGAGTTCGGAAGTA		TACTTCCGAAC SEQ ID NO: 535
89	TCCCCAGGTATATGAGTTCGGAAGT		ACTTCCGAAC SEQ ID NO: 536
90	ATCCCCAGGTATATGAGTTCGGAAG		CTTCCGAAC SEQ ID NO: 537
91	AATCCCCAGGTATATGAGTTCGGA		TTCCGAAC SEQ ID NO: 538

			SEQ ID NO: 538
92	AAATCCCCAGGTATATGAGTTCGGA		TCCGAACATCATATACCTGGGGATT SEQ ID NO: 539
93	AAAATCCCCAGGTATATGAGTTCGG		CCGAACATCATATACCTGGGGATTTT SEQ ID NO: 540
94	TAAAATCCCCAGGTATATGAGTTCG		CGAACATCATATACCTGGGGATTTTA SEQ ID NO: 541
95	ATAAAATCCCCAGGTATATGAGTTC		GAACATCATATACCTGGGGATTTTAT SEQ ID NO: 542
96	AATAAAATCCCCAGGTATATGAGTT		AACATCATATACCTGGGGATTTTATT SEQ ID NO: 543
97	TAATAAAATCCCCAGGTATATGAGT		ACTCATATACCTGGGGATTTTATTA SEQ ID NO: 544
98	GTAATAAAATCCCCAGGTATATGAG		CTCATATACCTGGGGATTTTATTAC SEQ ID NO: 545
99	AGTAATAAAATCCCCAGGTATATGA		TCATATACCTGGGGATTTTATTACT SEQ ID NO: 546
100	GAGTAATAAAATCCCCAGGTATATG		CATATACCTGGGGATTTTATTACTC SEQ ID NO: 547
101	AGAGTAATAAAATCCCCAGGTATAT		ATATACCTGGGGATTTTATTACTCT SEQ ID NO: 548
102	CAGAGTAATAAAATCCCCAGGTATA		TATACCTGGGGATTTTATTACTCTG SEQ ID NO: 549
103	CCAGAGTAATAAAATCCCCAGGTAT		ATACCTGGGGATTTTATTACTCTGG SEQ ID NO: 550
104	CCCAGAGTAATAAAATCCCCAGGTA		TACCTGGGGATTTTATTACTCTGGG SEQ ID NO: 551
105	TCCCAGAGTAATAAAATCCCCAGGT		ACCTGGGGATTTTATTACTCTGGGA SEQ ID NO: 552
106	TTCCCAGAGTAATAAAATCCCCAGG		CCTGGGGATTTTATTACTCTGGGAA SEQ ID NO: 553
107	ATTCCCAGAGTAATAAAATCCCCAG		CTGGGGATTTTATTACTCTGGGAAT SEQ ID NO: 554
108	AATTCCCAGAGTAATAAAATCCCCA		TGGGGATTTTATTACTCTGGGAATT SEQ ID NO: 555
109	TAATTCCCAGAGTAATAAAATCCCC		GGGGATTTTATTACTCTGGGAATTA SEQ ID NO: 556
110	ATAATTCCCAGAGTAATAAAATCCC		GGGATTTTATTACTCTGGGAATTAT SEQ ID NO: 557
111	CATAATTCCCAGAGTAATAAAATCC		GGATTTTATTACTCTGGGAATTATG SEQ ID NO: 558
112	ACATAATTCCCAGAGTAATAAAATC		GATTTTATTACTCTGGGAATTATGT SEQ ID NO: 559
113	CACATAATTCCCAGAGTAATAAAAT		ATTTTATTACTCTGGGAATTATGTG SEQ ID NO: 560
114	ACACATAATTCCCAGAGTAATAAAA		TTTATTACTCTGGGAATTATGTGT SEQ ID NO: 561
115	AACACATAATTCCCAGAGTAATAAA		TTTATTACTCTGGGAATTATGTGTT SEQ ID NO: 562
116	GAACACATAATTCCCAGAGTAATAA		TTATTACTCTGGGAATTATGTGTTC SEQ ID NO: 563

117	AGAACACATAATTCCCAGAGTAATA		TATTACTCTGGGAATTATGTGTTCT SEQ ID NO: 564
118	CAGAACACATAATTCCCAGAGTAAT		ATTACTCTGGGAATTATGTGTTCTG SEQ ID NO: 565
119	GCAGAACACATAATTCCCAGAGTAA		TTACTCTGGGAATTATGTGTTCTGC SEQ ID NO: 566
120	GGCAGAACACATAATTCCCAGAGTA		TACTCTGGGAATTATGTGTTCTGCC SEQ ID NO: 567
121	GGGCAGAACACATAATTCCCAGAGT		ACTCTGGGAATTATGTGTTCTGCCC SEQ ID NO: 568
122	GGGGCAGAACACATAATTCCCAGAG		CTCTGGGAATTATGTGTTCTGCCCC SEQ ID NO: 569
123	TGGGGCAGAACACATAATTCCCAGA		TCTGGGAATTATGTGTTCTGCCCCA SEQ ID NO: 570
124	ATGGGGCAGAACACATAATTCCCAG		CTGGGAATTATGTGTTCTGCCCCAT SEQ ID NO: 571
125	GATGGGGCAGAACACATAATTCCCA		TGGGAATTATGTGTTCTGCCCCATC SEQ ID NO: 572
126	TGATGGGGCAGAACACATAATTCCC		GGAATTATGTGTTCTGCCCCATCA SEQ ID NO: 573
127	GTGATGGGGCAGAACACATAATTCC		GGAATTATGTGTTCTGCCCCATCAC SEQ ID NO: 574
128	AGTGATGGGGCAGAACACATAATTC		GAATTATGTGTTCTGCCCCATCACT SEQ ID NO: 575
129	GAGTGATGGGGCAGAACACATAATT	Branch point 3	AATTATGTGTTCTGCCCCATCACTC SEQ ID NO: 576
130	AGAGTGATGGGGCAGAACACATAAT	Branch point 3	ATTATGTGTTCTGCCCCATCACTCT SEQ ID NO: 577
131	GAGAGTGATGGGGCAGAACACATAA	Branch point 3	TTATGTGTTCTGCCCCATCACTCTC SEQ ID NO: 578
132	AGAGAGTGATGGGGCAGAACACATA	Branch point 3	TATGTGTTCTGCCCCATCACTCTCT SEQ ID NO: 579
133	GAGAGAGTGATGGGGCAGAACACAT	Branch point 3	ATGTGTTCTGCCCCATCACTCTCTC SEQ ID NO: 580
134	AGAGAGAGTGATGGGGCAGAACACA	Branch point 3	TGTGTTCTGCCCCATCACTCTCTCT SEQ ID NO: 581
135	AAGAGAGAGTGATGGGGCAGAACAC	Branch point 3	GTGTTCTGCCCCATCACTCTCTCTT SEQ ID NO: 582
136	TAAGAGAGAGTGATGGGGCAGAACA	Branch point 3	TGTTCTGCCCCATCACTCTCTCTTA SEQ ID NO: 583
137	TTAAGAGAGAGTGATGGGGCAGAAC	Branch point 3	GTTCTGCCCCATCACTCTCTCTTAA SEQ ID NO: 584
138	ATTAAGAGAGAGTGATGGGGCAGAA	Branch point 3	TTCTGCCCCATCACTCTCTCTTAAT SEQ ID NO: 585
139	AATTAAGAGAGAGTGATGGGGCAGA	Branch point 3	TCTGCCCCATCACTCTCTCTTAATT SEQ ID NO: 586
140	CAATTAAGAGAGAGTGATGGGGCAG	Branch point 3	CTGCCCCATCACTCTCTCTTAATTG SEQ ID NO: 587
141	CCAATTAAGAGAGAGTGATGGGGCA	Branch point 3	TGCCCCATCACTCTCTCTTAATTGG SEQ ID NO: 588

142	TCCAATTAAGAGAGAGTGATGGGGC	Branch point 3	GCCCCATCACTCTCTCTTAATTGGA SEQ ID NO: 589
143	ATCCAATTAAGAGAGAGTGATGGGG	Branch point 3	CCCCATCACTCTCTCTTAATTGGAT SEQ ID NO: 590
144	AATCCAATTAAGAGAGAGTGATGGG	Branch point 3	CCCATCACTCTCTCTTAATTGGATT SEQ ID NO: 591
145	AAATCCAATTAAGAGAGAGTGATGG	Branch point 3	CCATCACTCTCTCTTAATTGGATTT SEQ ID NO: 592
146	AAAATCCAATTAAGAGAGAGTGATG		CATCACTCTCTCTTAATTGGATTTT SEQ ID NO: 593
147	AAAAATCCAATTAAGAGAGAGTGAT		ATCACTCTCTCTTAATTGGATTTTT SEQ ID NO: 594
148	TAAAAATCCAATTAAGAGAGAGTGA		TCACTCTCTCTTAATTGGATTTTTA SEQ ID NO: 595
149	TTAAAAATCCAATTAAGAGAGAGTG		CACTCTCTCTTAATTGGATTTTTAA SEQ ID NO: 596
150	TTTAAAAATCCAATTAAGAGAGAGT		ACTCTCTCTTAATTGGATTTTTAAA SEQ ID NO: 597
151	TTTTAAAAATCCAATTAAGAGAGAG		CTCTCTCTTAATTGGATTTTTAAAA SEQ ID NO: 598
152	ATTTTAAAAATCCAATTAAGAGAGA		TCTCTCTTAATTGGATTTTTAAAAT SEQ ID NO: 599
153	AATTTTAAAAATCCAATTAAGAGAG		CTCTCTTAATTGGATTTTTAAAATT SEQ ID NO: 600
154	TAATTTTAAAAATCCAATTAAGAGA		TCTCTTAATTGGATTTTTAAAATTA SEQ ID NO: 601
155	ATAATTTTAAAAATCCAATTAAGAG		CTCTTAATTGGATTTTTAAAATTAT SEQ ID NO: 602
156	TATAATTTTAAAAATCCAATTAAGA		TCTTAATTGGATTTTTAAAATTATA SEQ ID NO: 603
157	ATATAATTTTAAAAATCCAATTAAG		CTTAATTGGATTTTTAAAATTATAT SEQ ID NO: 604
158	AATATAATTTTAAAAATCCAATTAA		TTAATTGGATTTTTAAAATTATATT SEQ ID NO: 605
159	GAATATAATTTTAAAAATCCAATTA		TAATTGGATTTTTAAAATTATATTC SEQ ID NO: 606
160	TGAATATAATTTTAAAAATCCAATT		AATTGGATTTTTAAAATTATATTCA SEQ ID NO: 607
161	ATGAATATAATTTTAAAAATCCAAT		ATTGGATTTTTAAAATTATATTCAT SEQ ID NO: 608
162	TATGAATATAATTTTAAAAATCCAA		TTGGATTTTTAAAATTATATTCATA SEQ ID NO: 609
163	ATATGAATATAATTTTAAAAATCCA		TGGATTTTTAAAATTATATTCATAT SEQ ID NO: 610
164	AATATGAATATAATTTTAAAAATCC		GGATTTTTAAAATTATATTCATATT SEQ ID NO: 611
165	CAATATGAATATAATTTTAAAAATC		GATTTTTAAAATTATATTCATATTG SEQ ID NO: 612
166	GCAATATGAATATAATTTTAAAAAT		ATTTTTAAAATTATATTCATATTGC SEQ ID NO: 613
167	TGCAATATGAATATAATTTTAAAAA		TTTTTAAAATTATATTCATATTGCA

			SEQ ID NO: 614
168	CTGCAATATGAATATAATTTTAAAA		TTTTAAAATTATATTCATATTGCAG SEQ ID NO: 615
169	CCTGCAATATGAATATAATTTTAAAA		TTTAAAATTATATTCATATTGCAGG SEQ ID NO: 616
170	TCCTGCAATATGAATATAATTTTAA		TTAAAATTATATTCATATTGCAGGA SEQ ID NO: 617
171	GTCCTGCAATATGAATATAATTTTA	Acceptor site	TAAAATTATATTCATATTGCAGGAC SEQ ID NO: 618
172	AGTCCTGCAATATGAATATAATTTT	Acceptor site	AAAATTATATTCATATTGCAGGACT SEQ ID NO: 619
173	GAGTCCTGCAATATGAATATAATTT	Acceptor site	AAATTATATTCATATTGCAGGACTC SEQ ID NO: 620
174	CGAGTCCTGCAATATGAATATAATT	Acceptor site	AATTATATTCATATTGCAGGACTCG SEQ ID NO: 621
175	CCGAGTCCTGCAATATGAATATAAT	Acceptor site	ATTATATTCATATTGCAGGACTCGG SEQ ID NO: 622
176	GCCGAGTCCTGCAATATGAATATAA	Acceptor site	TTATATTCATATTGCAGGACTCGGC SEQ ID NO: 623
177	TGCCGAGTCCTGCAATATGAATATA	Acceptor site	TATATTCATATTGCAGGACTCGGCA SEQ ID NO: 624
178	CTGCCGAGTCCTGCAATATGAATAT	Acceptor site	ATATTCATATTGCAGGACTCGGCAG SEQ ID NO: 625
179	TCTGCCGAGTCCTGCAATATGAATA	Acceptor site	TATTCATATTGCAGGACTCGGCAGA SEQ ID NO: 626
180	TTCTGCCGAGTCCTGCAATATGAAT	Acceptor site	ATTCATATTGCAGGACTCGGCAGAA SEQ ID NO: 627
181	CTTCTGCCGAGTCCTGCAATATGAA	Acceptor site	TTCATATTGCAGGACTCGGCAGAAG SEQ ID NO: 628
182	TCTTCTGCCGAGTCCTGCAATATGA	Acceptor site	TCATATTGCAGGACTCGGCAGAAGA SEQ ID NO: 629
183	GTCTTCTGCCGAGTCCTGCAATATG	Acceptor site	CATATTGCAGGACTCGGCAGAAGAC SEQ ID NO: 630
184	GGTCTTCTGCCGAGTCCTGCAATAT	Acceptor site	ATATTGCAGGACTCGGCAGAAGACC SEQ ID NO: 631
185	AGGTCTTCTGCCGAGTCCTGCAATA	Acceptor site	TATTGCAGGACTCGGCAGAAGACCT SEQ ID NO: 632
186	AAGGTCTTCTGCCGAGTCCTGCAAT	Acceptor site	ATTGCAGGACTCGGCAGAAGACCTT SEQ ID NO: 633
187	GAAGGTCTTCTGCCGAGTCCTGCAA	Acceptor site	TTGCAGGACTCGGCAGAAGACCTTC SEQ ID NO: 634
188	CGAAGGTCTTCTGCCGAGTCCTGCA	Acceptor site	TGCAGGACTCGGCAGAAGACCTTCG SEQ ID NO: 635
189	TCGAAGGTCTTCTGCCGAGTCCTGC	Acceptor site	GCAGGACTCGGCAGAAGACCTTCGA SEQ ID NO: 636
190	CTCGAAGGTCTTCTGCCGAGTCCTG	Acceptor site	CAGGACTCGGCAGAAGACCTTCGAG SEQ ID NO: 637
191	TCTCGAAGGTCTTCTGCCGAGTCCT	ESE Binding	AGGACTCGGCAGAAGACCTTCGAGA SEQ ID NO: 638
192	CTCTCGAAGGTCTTCTGCCGAGTCC	ESE Binding	GGACTCGGCAGAAGACCTTCGAGAG SEQ ID NO: 639

193	TCTCTCGAAGGTCTTCTGCCGAGTC	ESE Binding	GACTCGGCAGAAGACCTTCGAGAGA SEQ ID NO: 640
194	TTCTCTCGAAGGTCTTCTGCCGAGT	ESE Binding	ACTCGGCAGAAGACCTTCGAGAGAA SEQ ID NO: 641
195	TTTCTCTCGAAGGTCTTCTGCCGAG	ESE Binding	CTCGGCAGAAGACCTTCGAGAGAAA SEQ ID NO: 642
196	CTTTCTCTCGAAGGTCTTCTGCCGA	ESE Binding	TCGGCAGAAGACCTTCGAGAGAAAG SEQ ID NO: 643
197	CCTTTCTCTCGAAGGTCTTCTGCCG	ESE Binding	CGGCAGAAGACCTTCGAGAGAAAGG SEQ ID NO: 644
198	ACCTTTCTCTCGAAGGTCTTCTGCC	ESE Binding	GGCAGAAGACCTTCGAGAGAAAGGT SEQ ID NO: 645
199	TACCTTTCTCTCGAAGGTCTTCTGC	ESE Binding	GCAGAAGACCTTCGAGAGAAAGGTA SEQ ID NO: 646
200	CTACCTTTCTCTCGAAGGTCTTCTG	ESE Binding	CAGAAGACCTTCGAGAGAAAGGTAG SEQ ID NO: 647
201	TCTACCTTTCTCTCGAAGGTCTTCT	ESE Binding	AGAAGACCTTCGAGAGAAAGGTAGA SEQ ID NO: 648
202	TTCTACCTTTCTCTCGAAGGTCTTC	ESE Binding	GAAGACCTTCGAGAGAAAGGTAGAA SEQ ID NO: 649
203	TTTCTACCTTTCTCTCGAAGGTCTT	ESE Binding	AAGACCTTCGAGAGAAAGGTAGAAA SEQ ID NO: 650
204	TTTTCTACCTTTCTCTCGAAGGTCT	ESE Binding	AGACCTTCGAGAGAAAGGTAGAAAA SEQ ID NO: 651
205	ATTTTCTACCTTTCTCTCGAAGGTC	ESE Binding	GACCTTCGAGAGAAAGGTAGAAAAT SEQ ID NO: 652
206	TATTTTCTACCTTTCTCTCGAAGGT	ESE Binding	ACCTTCGAGAGAAAGGTAGAAAATA SEQ ID NO: 653
207	TTATTTTCTACCTTTCTCTCGAAGG	ESE Binding	CCTTCGAGAGAAAGGTAGAAAATAA SEQ ID NO: 654
208	CTTATTTTCTACCTTTCTCTCGAAG	ESE Binding	CTTCGAGAGAAAGGTAGAAAATAAG SEQ ID NO: 655
209	TCTTATTTTCTACCTTTCTCTCGAA	ESE Binding	TTCGAGAGAAAGGTAGAAAATAAGA SEQ ID NO: 656
210	TTCTTATTTTCTACCTTTCTCTCGA	ESE Binding	TCGAGAGAAAGGTAGAAAATAAGAA SEQ ID NO: 657
211	ATTCTTATTTTCTACCTTTCTCTCG	ESE Binding	CGAGAGAAAGGTAGAAAATAAGAAT SEQ ID NO: 658
212	AATTCTTATTTTCTACCTTTCTCTC	ESE Binding	GAGAGAAAGGTAGAAAATAAGAATT SEQ ID NO: 659
213	AAATTCTTATTTTCTACCTTTCTCT	ESE Binding	AGAGAAAGGTAGAAAATAAGAATTT SEQ ID NO: 660
214	CAAATTCTTATTTTCTACCTTTCTC	ESE Binding	GAGAAAGGTAGAAAATAAGAATTTG SEQ ID NO: 661
215	CCAAATTCTTATTTTCTACCTTTCT	ESE Binding	AGAAAGGTAGAAAATAAGAATTTGG SEQ ID NO: 662
216	GCCAAATTCTTATTTTCTACCTTTC	ESE Binding	GAAAGGTAGAAAATAAGAATTTGGC SEQ ID NO: 663
217	AGCCAAATTCTTATTTTCTACCTTT	ESE Binding	AAAGGTAGAAAATAAGAATTTGGCT SEQ ID NO: 664

218	GAGCCAAATTCTTATTTTCTACCTT	ESE Binding	AAGGTAGAAAATAAGAATTTGGCTC SEQ ID NO: 665
219	AGAGCCAAATTCTTATTTTCTACCT	ESE Binding	AGGTAGAAAATAAGAATTTGGCTCT SEQ ID NO: 666
220	GAGAGCCAAATTCTTATTTTCTACC	ESE Binding	GGTAGAAAATAAGAATTTGGCTCTC SEQ ID NO: 667
221	AGAGAGCCAAATTCTTATTTTCTAC	ESE Binding	GTAGAAAATAAGAATTTGGCTCTCT SEQ ID NO: 668
222	CAGAGAGCCAAATTCTTATTTTCTA		TAGAAAATAAGAATTTGGCTCTCTG SEQ ID NO: 669
223	ACAGAGAGCCAAATTCTTATTTTCT		AGAAAATAAGAATTTGGCTCTCTGT SEQ ID NO: 670
224	CACAGAGAGCCAAATTCTTATTTTC		GAAAATAAGAATTTGGCTCTCTGTG SEQ ID NO: 671
225	ACACAGAGAGCCAAATTCTTATTTT		AAAATAAGAATTTGGCTCTCTGTGT SEQ ID NO: 672
226	CACACAGAGAGCCAAATTCTTATTT	Overlaps TDP-43 site 1	AAATAAGAATTTGGCTCTCTGTGTG SEQ ID NO: 673
227	TCACACAGAGAGCCAAATTCTTATT	Overlaps TDP-43 site 1	AATAAGAATTTGGCTCTCTGTGTGA SEQ ID NO: 674
228	CTCACACAGAGAGCCAAATTCTTAT	Overlaps TDP-43 site 1	ATAAGAATTTGGCTCTCTGTGTGAG SEQ ID NO: 675
229	GCTCACACAGAGAGCCAAATTCTTA	Overlaps TDP-43 site 1	TAAGAATTTGGCTCTCTGTGTGAGC SEQ ID NO: 676
230	TGCTCACACAGAGAGCCAAATTCTT	Overlaps TDP-43 site 1	AAGAATTTGGCTCTCTGTGTGAGCA SEQ ID NO: 677
231	ATGCTCACACAGAGAGCCAAATTCT	Overlaps TDP-43 site 1	AGAATTTGGCTCTCTGTGTGAGCAT SEQ ID NO: 678
232	CATGCTCACACAGAGAGCCAAATTC	Overlaps TDP-43 site 1	GAATTTGGCTCTCTGTGTGAGCATG SEQ ID NO: 679
233	ACATGCTCACACAGAGAGCCAAATT	Overlaps TDP-43 site 1	AATTTGGCTCTCTGTGTGAGCATGT SEQ ID NO: 680
234	CACATGCTCACACAGAGAGCCAAAT	Overlaps TDP-43 site 1	ATTTGGCTCTCTGTGTGAGCATGTG SEQ ID NO: 681
235	ACACATGCTCACACAGAGAGCCAAA	Overlaps TDP-43 site 1	TTTGGCTCTCTGTGTGAGCATGTGT SEQ ID NO: 682
236	CACACATGCTCACACAGAGAGCCAA	Overlaps TDP-43 site 1 & 2	TTGGCTCTCTGTGTGAGCATGTGTG SEQ ID NO: 683

237	GCACACATGCTCACACAGAGAGCCA	Overlaps TDP-43 site 1 & 2	TGGCTCTCTGTGTGAGCATGTGTGC SEQ ID NO: 684
238	CGCACACATGCTCACACAGAGAGCC	Overlaps TDP-43 site 1 & 2	GGCTCTCTGTGTGAGCATGTGTGCG SEQ ID NO: 685
239	ACGCACACATGCTCACACAGAGAGC	Overlaps TDP-43 site 1 & 2	GCTCTCTGTGTGAGCATGTGTGCGT SEQ ID NO: 686
240	CACGCACACATGCTCACACAGAGAG	Overlaps TDP-43 site 1 & 2	CTCTCTGTGTGAGCATGTGTGCGTG SEQ ID NO: 687
241	ACACGCACACATGCTCACACAGAGA	Overlaps TDP-43 site 1 & 2	TCTCTGTGTGAGCATGTGTGCGTGT SEQ ID NO: 688
242	CACACGCACACATGCTCACACAGAG	Overlaps TDP-43 site 1 & 2	CTCTGTGTGAGCATGTGTGCGTGTG SEQ ID NO: 689
243	ACACACGCACACATGCTCACACAGA	Overlaps TDP-43 site 1 & 2	TCTGTGTGAGCATGTGTGCGTGTGT SEQ ID NO: 690
244	CACACACGCACACATGCTCACACAG	Overlaps TDP-43 site 1 & 2 & 3	CTGTGTGAGCATGTGTGCGTGTGTG SEQ ID NO: 691
245	GCACACACGCACACATGCTCACACA	Overlaps TDP-43 site 1 & 2 & 3	TGTGTGAGCATGTGTGCGTGTGTGC SEQ ID NO: 692
246	CGCACACACGCACACATGCTCACAC	Overlaps TDP-43 site 2 & 3	GTGTGAGCATGTGTGCGTGTGTGCG SEQ ID NO: 693
247	TCGCACACACGCACACATGCTCACA	Overlaps TDP-43 site 2 & 3	TGTGAGCATGTGTGCGTGTGTGCGA SEQ ID NO: 694
248	CTCGCACACACGCACACATGCTCAC	Overlaps TDP-43 site 2 & 3	GTGAGCATGTGTGCGTGTGTGCGAG SEQ ID NO: 695
249	TCTCGCACACACGCACACATGCTCA	Overlaps TDP-43	TGAGCATGTGTGCGTGTGTGCGAGA SEQ ID NO: 696

		site 2 & 3	
250	CTCTCGCACACACGCACACATGCTC	Overlaps TDP-43 site 2 & 3	GAGCATGTGTGCGTGTGTGCGAGAG SEQ ID NO: 697
251	TCTCTCGCACACACGCACACATGCT	Overlaps TDP-43 site 2 & 3	AGCATGTGTGCGTGTGTGCGAGAGA SEQ ID NO: 698
252	CTCTCTCGCACACACGCACACATGC	Overlaps TDP-43 site 2 & 3	GCAATGTGTGCGTGTGTGCGAGAGAG SEQ ID NO: 699
253	TCTCTCTCGCACACACGCACACATG	Overlaps TDP-43 site 2 & 3	CATGTGTGCGTGTGTGCGAGAGAGA SEQ ID NO: 700
254	CTCTCTCTCGCACACACGCACACAT	Overlaps TDP-43 site 2 & 3	ATGTGTGCGTGTGTGCGAGAGAGAG SEQ ID NO: 701
255	TCTCTCTCTCGCACACACGCACACA	Overlaps TDP-43 site 2 & 3	TGTGTGCGTGTGTGCGAGAGAGAGA SEQ ID NO: 702
256	CTCTCTCTCTCGCACACACGCACAC	Overlaps TDP-43 site 3	GTGTGCGTGTGTGCGAGAGAGAGAG SEQ ID NO: 703
257	TCTCTCTCTCTCGCACACACGCACA	Overlaps TDP-43 site 3	TGTGCGTGTGTGCGAGAGAGAGAGA SEQ ID NO: 704
258	GTCTCTCTCTCTCGCACACACGCAC	Overlaps TDP-43 site 3	GTGCGTGTGTGCGAGAGAGAGAGAC SEQ ID NO: 705
259	TGTCTCTCTCTCTCGCACACACGCA	Overlaps TDP-43 site 3	TGCGTGTGTGCGAGAGAGAGAGACA SEQ ID NO: 706
260	CTGTCTCTCTCTCTCGCACACACGC	Overlaps TDP-43 site 3	GCGTGTGTGCGAGAGAGAGAGACAG SEQ ID NO: 707
261	TCTGTCTCTCTCTCTCGCACACACG	Overlaps TDP-43 site 3	CGTGTGTGCGAGAGAGAGAGACAGA SEQ ID NO: 708
262	GTCTGTCTCTCTCTCTCGCACACAC	Overlaps TDP-43 site 3	GTGTGTGCGAGAGAGAGAGACAGAC SEQ ID NO: 709
263	TGTCTGTCTCTCTCTCTCGCACACA	Overlaps TDP-43 site 3	TGTGTGCGAGAGAGAGAGACAGACA SEQ ID NO: 710
264	CTGTCTGTCTCTCTCTCTCGCACAC		GTGTGCGAGAGAGAGAGACAGACAG

			SEQ ID NO: 711
265	GCTGTCTGTCTCTCTCTCGCACA		TGTGCGAGAGAGAGACAGACAGC SEQ ID NO: 712
266	GGCTGTCTGTCTCTCTCTCGCAC		GTGCGAGAGAGAGACAGACAGCC SEQ ID NO: 713
267	AGGCTGTCTGTCTCTCTCTCGCA		TGCGAGAGAGAGAGACAGACAGCCT SEQ ID NO: 714
268	CAGGCTGTCTGTCTCTCTCTCGC		GCGAGAGAGAGAGACAGACAGCCTG SEQ ID NO: 715
269	GCAGGCTGTCTGTCTCTCTCTCG		CGAGAGAGAGAGACAGACAGCCTGC SEQ ID NO: 716
270	GGCAGGCTGTCTGTCTCTCTCTC		GAGAGAGAGAGACAGACAGCCTGCC SEQ ID NO: 717
271	AGGCAGGCTGTCTGTCTCTCTCT		AGAGAGAGAGACAGACAGCCTGCCT SEQ ID NO: 718
272	TAGGCAGGCTGTCTGTCTCTCTC		GAGAGAGAGACAGACAGCCTGCCTA SEQ ID NO: 719
273	TTAGGCAGGCTGTCTGTCTCTCT		AGAGAGAGACAGACAGCCTGCCTAA SEQ ID NO: 720
274	CTTAGGCAGGCTGTCTGTCTCTC		GAGAGAGACAGACAGCCTGCCTAAG SEQ ID NO: 721
275	TCTTAGGCAGGCTGTCTGTCTCT		AGAGAGACAGACAGCCTGCCTAAGA SEQ ID NO: 722
276	TTCTTAGGCAGGCTGTCTGTCTC		GAGAGACAGACAGCCTGCCTAAGAA SEQ ID NO: 723
277	CTTCTTAGGCAGGCTGTCTGTCT		AGAGACAGACAGCCTGCCTAAGAAG SEQ ID NO: 724
278	TCTTCTTAGGCAGGCTGTCTGTCTC		GAGACAGACAGCCTGCCTAAGAAGA SEQ ID NO: 725
279	TTCTTCTTAGGCAGGCTGTCTGTCT		AGACAGACAGCCTGCCTAAGAAGAA SEQ ID NO: 726
280	TTTCTTCTTAGGCAGGCTGTCTGTC		GACAGACAGCCTGCCTAAGAAGAAA SEQ ID NO: 727
281	ATTTCTTCTTAGGCAGGCTGTCTGT		ACAGACAGCCTGCCTAAGAAGAAAT SEQ ID NO: 728
282	CATTTCTTCTTAGGCAGGCTGTCTG		CAGACAGCCTGCCTAAGAAGAAATG SEQ ID NO: 729
283	TCATTTCTTCTTAGGCAGGCTGTCT		AGACAGCCTGCCTAAGAAGAAATGA SEQ ID NO: 730
284	TTCATTTCTTCTTAGGCAGGCTGTC		GACAGCCTGCCTAAGAAGAAATGAA SEQ ID NO: 731
285	ATTCATTTCTTCTTAGGCAGGCTGT		ACAGCCTGCCTAAGAAGAAATGAAT SEQ ID NO: 732
286	CATTCATTTCTTCTTAGGCAGGCTG		CAGCCTGCCTAAGAAGAAATGAATG SEQ ID NO: 733
287	ACATTCATTTCTTCTTAGGCAGGCT		AGCCTGCCTAAGAAGAAATGAATGT SEQ ID NO: 734
288	CACATTCATTTCTTCTTAGGCAGGC		GCCTGCCTAAGAAGAAATGAATGTG SEQ ID NO: 735
289	TCACATTCATTTCTTCTTAGGCAGG		CCTGCCTAAGAAGAAATGAATGTGA SEQ ID NO: 736

290	TTCACATTCATTTCTTCTTAGGCAG		CTGCCTAAGAAGAAATGAATGTGAA SEQ ID NO: 737
291	ATTCACATTCATTTCTTCTTAGGCA		TGCCTAAGAAGAAATGAATGTGAAT SEQ ID NO: 738
292	CATTCACATTCATTTCTTCTTAGGC		GCCTAAGAAGAAATGAATGTGAATG SEQ ID NO: 739
293	GCATTCACATTCATTTCTTCTTAGG		CCTAAGAAGAAATGAATGTGAATGC SEQ ID NO: 740
294	CGCATTCACATTCATTTCTTCTTAG		CTAAGAAGAAATGAATGTGAATGCG SEQ ID NO: 741
295	CCGCATTCACATTCATTTCTTCTTA		TAAGAAGAAATGAATGTGAATGCGG SEQ ID NO: 742
296	GCCGCATTCACATTCATTTCTTCTT		AAGAAGAAATGAATGTGAATGCGGC SEQ ID NO: 743
297	AGCCGCATTCACATTCATTTCTTCT		AGAAGAAATGAATGTGAATGCGGCT SEQ ID NO: 744
298	AAGCCGCATTCACATTCATTTCTTC		GAAGAAATGAATGTGAATGCGGCTT SEQ ID NO: 745
299	CAAGCCGCATTCACATTCATTTCTT		AAGAAATGAATGTGAATGCGGCTTG SEQ ID NO: 746
300	ACAAGCCGCATTCACATTCATTTCT		AGAAATGAATGTGAATGCGGCTTGT SEQ ID NO: 747
301	CACAAGCCGCATTCACATTCATTTCT		GAAATGAATGTGAATGCGGCTTGTG SEQ ID NO: 748
302	CCACAAGCCGCATTCACATTCATTT		AAATGAATGTGAATGCGGCTTGTGG SEQ ID NO: 749
303	GCCACAAGCCGCATTCACATTCATT		AATGAATGTGAATGCGGCTTGTGGC SEQ ID NO: 750
304	TGCCACAAGCCGCATTCACATTCAT		ATGAATGTGAATGCGGCTTGTGGCA SEQ ID NO: 751
305	GTGCCACAAGCCGCATTCACATTCA		TGAATGTGAATGCGGCTTGTGGCAC SEQ ID NO: 752
306	TGTGCCACAAGCCGCATTCACATTC		GAATGTGAATGCGGCTTGTGGCACA SEQ ID NO: 753
307	CTGTGCCACAAGCCGCATTCACATT		AATGTGAATGCGGCTTGTGGCACAG SEQ ID NO: 754
308	ACTGTGCCACAAGCCGCATTCACAT		ATGTGAATGCGGCTTGTGGCACAGT SEQ ID NO: 755
309	AACTGTGCCACAAGCCGCATTCACA		TGTGAATGCGGCTTGTGGCACAGTT SEQ ID NO: 756
310	CAACTGTGCCACAAGCCGCATTCAC		GTGAATGCGGCTTGTGGCACAGTTG SEQ ID NO: 757
311	TCAACTGTGCCACAAGCCGCATTCA		TGAATGCGGCTTGTGGCACAGTTGA SEQ ID NO: 758
312	GTCAACTGTGCCACAAGCCGCATTC		GAATGCGGCTTGTGGCACAGTTGAC SEQ ID NO: 759
313	TGTCAACTGTGCCACAAGCCGCATT		AATGCGGCTTGTGGCACAGTTGACA SEQ ID NO: 760
314	TTGTCAACTGTGCCACAAGCCGCAT		ATGCGGCTTGTGGCACAGTTGACAA SEQ ID NO: 761
315	CTTGTCAACTGTGCCACAAGCCGCA		TGCGGCTTGTGGCACAGTTGACAAG

			SEQ ID NO: 762
316	CCTTGTCAACTGTGCCACAAGCCGC		GCGGCTTGTGGCACAGTTGACAAGG SEQ ID NO: 763
317	TCCTTGTCAACTGTGCCACAAGCCG		CGGCTTGTGGCACAGTTGACAAGGA SEQ ID NO: 764
318	ATCCTTGTCAACTGTGCCACAAGCC		GGCTTGTGGCACAGTTGACAAGGAT SEQ ID NO: 765
319	CATCCTTGTCAACTGTGCCACAAGC		GCTTGTGGCACAGTTGACAAGGATG SEQ ID NO: 766
320	TCATCCTTGTCAACTGTGCCACAAG		CTTGTGGCACAGTTGACAAGGATGA SEQ ID NO: 767
321	ATCATCCTTGTCAACTGTGCCACAA		TTGTGGCACAGTTGACAAGGATGAT SEQ ID NO: 768
322	TATCATCCTTGTCAACTGTGCCACA		TGTGGCACAGTTGACAAGGATGATA SEQ ID NO: 769
323	TTATCATCCTTGTCAACTGTGCCAC		GTGGCACAGTTGACAAGGATGATAA SEQ ID NO: 770
324	TTTATCATCCTTGTCAACTGTGCCA		TGGCACAGTTGACAAGGATGATAAA SEQ ID NO: 771
325	ATTTATCATCCTTGTCAACTGTGCC		GGCACAGTTGACAAGGATGATAAAT SEQ ID NO: 772
326	GATTTATCATCCTTGTCAACTGTGC		GCACAGTTGACAAGGATGATAAATC SEQ ID NO: 773
327	TGATTTATCATCCTTGTCAACTGTG		CACAGTTGACAAGGATGATAAATCA SEQ ID NO: 774
328	TTGATTTATCATCCTTGTCAACTGT		ACAGTTGACAAGGATGATAAATCAA SEQ ID NO: 775
329	ATTGATTTATCATCCTTGTCAACTG		CAGTTGACAAGGATGATAAATCAAT SEQ ID NO: 776
330	TATTGATTTATCATCCTTGTCAACT		AGTTGACAAGGATGATAAATCAATA SEQ ID NO: 777
331	TTATTGATTTATCATCCTTGTCAAC		GTTGACAAGGATGATAAATCAATAA SEQ ID NO: 778
332	ATTATTGATTTATCATCCTTGTCAA		TTGACAAGGATGATAAATCAATAAT SEQ ID NO: 779
333	CATTATTGATTTATCATCCTTGTCA		TGACAAGGATGATAAATCAATAATG SEQ ID NO: 780
334	GCATTATTGATTTATCATCCTTGTG		GACAAGGATGATAAATCAATAATGC SEQ ID NO: 781
335	TGCATTATTGATTTATCATCCTTGT		ACAAGGATGATAAATCAATAATGCA SEQ ID NO: 782
336	TTGCATTATTGATTTATCATCCTTG		CAAGGATGATAAATCAATAATGCAA SEQ ID NO: 783
337	CTTGCATTATTGATTTATCATCCTT		AAGGATGATAAATCAATAATGCAAG SEQ ID NO: 784
338	GCTTGCATTATTGATTTATCATCCT		AGGATGATAAATCAATAATGCAAGC SEQ ID NO: 785
339	AGCTTGCATTATTGATTTATCATCC		GGATGATAAATCAATAATGCAAGCT SEQ ID NO: 786
340	AAGCTTGCATTATTGATTTATCATC		GATGATAAATCAATAATGCAAGCTT SEQ ID NO: 787

341	TAAGCTTGCATTATTGATTTATCAT		ATGATAAATCAATAATGCAAGCTTA SEQ ID NO: 788
342	GTAAGCTTGCATTATTGATTTATCA		TGATAAATCAATAATGCAAGCTTAC SEQ ID NO: 789
343	AGTAAGCTTGCATTATTGATTTATC		GATAAATCAATAATGCAAGCTTACT SEQ ID NO: 790
344	TAGTAAGCTTGCATTATTGATTTAT		ATAAATCAATAATGCAAGCTTACTA SEQ ID NO: 791
345	ATAGTAAGCTTGCATTATTGATTTA		TAAATCAATAATGCAAGCTTACTAT SEQ ID NO: 792
346	GATAGTAAGCTTGCATTATTGATTT		AAATCAATAATGCAAGCTTACTATC SEQ ID NO: 793
347	TGATAGTAAGCTTGCATTATTGATT		AATCAATAATGCAAGCTTACTATCA SEQ ID NO: 794
348	ATGATAGTAAGCTTGCATTATTGAT		ATCAATAATGCAAGCTTACTATCAT SEQ ID NO: 795
349	AATGATAGTAAGCTTGCATTATTGA		TCAATAATGCAAGCTTACTATCATT SEQ ID NO: 796
350	AAATGATAGTAAGCTTGCATTATTG		CAATAATGCAAGCTTACTATCATTT SEQ ID NO: 797
351	TAAATGATAGTAAGCTTGCATTATT		AATAATGCAAGCTTACTATCATTTA SEQ ID NO: 798
352	ATAAATGATAGTAAGCTTGCATTAT		ATAATGCAAGCTTACTATCATTTAT SEQ ID NO: 799
353	CATAAATGATAGTAAGCTTGCATTA		TAATGCAAGCTTACTATCATTTATG SEQ ID NO: 800
354	TCATAAATGATAGTAAGCTTGCATT		AATGCAAGCTTACTATCATTTATGA SEQ ID NO: 801
355	TTCATAAATGATAGTAAGCTTGCAT		ATGCAAGCTTACTATCATTTATGAA SEQ ID NO: 802
356	ATTCATAAATGATAGTAAGCTTGCA		TGCAAGCTTACTATCATTTATGAAT SEQ ID NO: 803
357	TATTCATAAATGATAGTAAGCTTGC		GCAAGCTTACTATCATTTATGAATA SEQ ID NO: 804
358	CTATTCATAAATGATAGTAAGCTTG		CAAGCTTACTATCATTTATGAATAG SEQ ID NO: 805
359	GCTATTCATAAATGATAGTAAGCTT		AAGCTTACTATCATTTATGAATAGC SEQ ID NO: 806
360	TGCTATTCATAAATGATAGTAAGCT		AGCTTACTATCATTTATGAATAGCA SEQ ID NO: 807
361	TTGCTATTCATAAATGATAGTAAGC		GCTTACTATCATTTATGAATAGCAA SEQ ID NO: 808
362	ATTGCTATTCATAAATGATAGTAAG		CTTACTATCATTTATGAATAGCAAT SEQ ID NO: 809
363	TATTGCTATTCATAAATGATAGTAA		TTACTATCATTTATGAATAGCAATA SEQ ID NO: 810
364	GTATTGCTATTCATAAATGATAGTA		TACTATCATTTATGAATAGCAATAC SEQ ID NO: 811
365	AGTATTGCTATTCATAAATGATAGT		ACTATCATTTATGAATAGCAATACT SEQ ID NO: 812
366	CAGTATTGCTATTCATAAATGATAG		CTATCATTTATGAATAGCAATACTG

			SEQ ID NO: 813
367	TCAGTATTGCTATTCATAAATGATA		TATCATTTATGAATAGCAATACTGA SEQ ID NO: 814
368	TTCAGTATTGCTATTCATAAATGAT		ATCATTTATGAATAGCAATACTGAA SEQ ID NO: 815
369	CTTCAGTATTGCTATTCATAAATGA		TCATTTATGAATAGCAATACTGAAG SEQ ID NO: 816
370	TCTTCAGTATTGCTATTCATAAATG		CATTTATGAATAGCAATACTGAAGA SEQ ID NO: 817
371	TTCTTCAGTATTGCTATTCATAAAT		ATTTATGAATAGCAATACTGAAGAA SEQ ID NO: 818
372	TTTCTTCAGTATTGCTATTCATAAA		TTTATGAATAGCAATACTGAAGAAA SEQ ID NO: 819
373	ATTTCTTCAGTATTGCTATTCATAA		TTATGAATAGCAATACTGAAGAAAT SEQ ID NO: 820
374	AATTTCTTCAGTATTGCTATTCATA		TATGAATAGCAATACTGAAGAAATT SEQ ID NO: 821
375	TAATTTCTTCAGTATTGCTATTCAT		ATGAATAGCAATACTGAAGAAATTA SEQ ID NO: 822
376	TTAATTTCTTCAGTATTGCTATTCA		TGAATAGCAATACTGAAGAAATTAA SEQ ID NO: 823
377	TTTAATTTCTTCAGTATTGCTATTC	poly A signal	GAATAGCAATACTGAAGAAATTAAA SEQ ID NO: 824
378	TTTTAATTTCTTCAGTATTGCTATT	poly A signal	AATAGCAATACTGAAGAAATTAAAA SEQ ID NO: 825
379	GTTTTAATTTCTTCAGTATTGCTAT	poly A signal	ATAGCAATACTGAAGAAATTAAAC SEQ ID NO: 826
380	TGTTTTAATTTCTTCAGTATTGCTA	poly A signal	TAGCAATACTGAAGAAATTAAACA SEQ ID NO: 827
381	TTGTTTTAATTTCTTCAGTATTGCT	poly A signal	AGCAATACTGAAGAAATTAAACAA SEQ ID NO: 828
382	TTTGTTTTAATTTCTTCAGTATTGC	poly A signal	GCAATACTGAAGAAATTAAACAAA SEQ ID NO: 829
383	TTTTGTTTTAATTTCTTCAGTATTG	poly A signal	CAATACTGAAGAAATTAAACAAAA SEQ ID NO: 830
384	CTTTTGTTTTAATTTCTTCAGTATT	poly A signal	AATACTGAAGAAATTAAACAAAAG SEQ ID NO: 831
385	TCTTTTGTTTTAATTTCTTCAGTAT	poly A signal	ATACTGAAGAAATTAAACAAAAGA SEQ ID NO: 832
386	ATCTTTTGTTTTAATTTCTTCAGTA	poly A signal	TACTGAAGAAATTAAACAAAAGAT SEQ ID NO: 833
387	AATCTTTTGTTTTAATTTCTTCAGT	poly A signal	ACTGAAGAAATTAAACAAAAGATT SEQ ID NO: 834
388	CAATCTTTTGTTTTAATTTCTTCAG	poly A signal	CTGAAGAAATTAAACAAAAGATTG SEQ ID NO: 835
389	GCAATCTTTTGTTTTAATTTCTTCA	poly A signal	TGAAGAAATTAAACAAAAGATTGC SEQ ID NO: 836
390	AGCAATCTTTTGTTTTAATTTCTTC	poly A signal	GAAGAAATTAAACAAAAGATTGCT SEQ ID NO: 837
391	CAGCAATCTTTTGTTTTAATTTCTT	poly A signal	AAGAAATTAAACAAAAGATTGCTG SEQ ID NO: 838

392	ACAGCAATCTTTTGTTTTAATTTCT	poly A signal	AGAAATTAAAACAAAAGATTGCTGT SEQ ID NO: 839
393	GACAGCAATCTTTTGTTTTAATTC	poly A signal	GAAATTAAAACAAAAGATTGCTGTC SEQ ID NO: 840
394	AGACAGCAATCTTTTGTTTTAATTT	poly A signal	AAATTAAAACAAAAGATTGCTGTCT SEQ ID NO: 841
395	GAGACAGCAATCTTTTGTTTTAATT	poly A signal and site	AATTAAAACAAAAGATTGCTGTCTC SEQ ID NO: 842
396	TGAGACAGCAATCTTTTGTTTTAAT	poly A signal and site	ATTAAAACAAAAGATTGCTGTCTCA SEQ ID NO: 843
397	TTGAGACAGCAATCTTTTGTTTTAA	poly A site	TTAAAACAAAAGATTGCTGTCTCAA SEQ ID NO: 844
398	ATTGAGACAGCAATCTTTTGTTTTA	poly A site	TAAAACAAAAGATTGCTGTCTCAAT SEQ ID NO: 845
399	TATTGAGACAGCAATCTTTTGTTTT	poly A site	AAAACAAAAGATTGCTGTCTCAATA SEQ ID NO: 846
400	ATATTGAGACAGCAATCTTTTGTTT	poly A site	AAACAAAAGATTGCTGTCTCAATAT SEQ ID NO: 847
401	TATATTGAGACAGCAATCTTTTGTT	poly A site	AACAAAAGATTGCTGTCTCAATATA SEQ ID NO: 848
402	ATATATTGAGACAGCAATCTTTTGT	poly A site	ACAAAAGATTGCTGTCTCAATATAT SEQ ID NO: 849
403	GATATATTGAGACAGCAATCTTTTG	poly A site	CAAAAGATTGCTGTCTCAATATATC SEQ ID NO: 850
404	AGATATATTGAGACAGCAATCTTTT	poly A site	AAAAGATTGCTGTCTCAATATATCT SEQ ID NO: 851
405	AAGATATATTGAGACAGCAATCTTT	poly A site	AAAGATTGCTGTCTCAATATATCTT SEQ ID NO: 852
406	TAAGATATATTGAGACAGCAATCTT	poly A site	AAGATTGCTGTCTCAATATATCTTA SEQ ID NO: 853
407	ATAAGATATATTGAGACAGCAATCT	poly A site	AGATTGCTGTCTCAATATATCTTAT SEQ ID NO: 854
408	TATAAGATATATTGAGACAGCAATC	poly A site	GATTGCTGTCTCAATATATCTTATA SEQ ID NO: 855
409	ATATAAGATATATTGAGACAGCAAT	poly A site	ATTGCTGTCTCAATATATCTTATAT SEQ ID NO: 856
410	AATATAAGATATATTGAGACAGCAA	poly A site	TTGCTGTCTCAATATATCTTATATT SEQ ID NO: 857
411	AAATATAAGATATATTGAGACAGCA	poly A site	TGCTGTCTCAATATATCTTATATTT SEQ ID NO: 858
412	TAAATATAAGATATATTGAGACAGC	poly A site	GCTGTCTCAATATATCTTATATTTA SEQ ID NO: 859
413	ATAAATATAAGATATATTGAGACAG		CTGTCTCAATATATCTTATATTTAT SEQ ID NO: 860
414	AATAAATATAAGATATATTGAGACA		TGTCTCAATATATCTTATATTTATT SEQ ID NO: 861
415	TAATAAATATAAGATATATTGAGAC		GTCTCAATATATCTTATATTTATTA SEQ ID NO: 862
416	ATAATAAATATAAGATATATTGAGA		TCTCAATATATCTTATATTTATTAT

			SEQ ID NO: 863
417	AATAATAAATATAAGATATATTGAG		CTCAATATATCTTATATTTATTATT SEQ ID NO: 864
418	AAATAATAAATATAAGATATATTGA		TCAATATATCTTATATTTATTATTT SEQ ID NO: 865
419	TAAATAATAAATATAAGATATATTG		CAATATATCTTATATTTATTATTTA SEQ ID NO: 866
420	GTAAATAATAAATATAAGATATATT		AATATATCTTATATTTATTATTTAC SEQ ID NO: 867
421	GGTAAATAATAAATATAAGATATAT		ATATATCTTATATTTATTATTTACC SEQ ID NO: 868
422	TGGTAAATAATAAATATAAGATATA		TATATCTTATATTTATTATTTACCA SEQ ID NO: 869
423	TTGGTAAATAATAAATATAAGATAT		ATATCTTATATTTATTATTTACCAA SEQ ID NO: 870
424	TTTGGTAAATAATAAATATAAGATA		TATCTTATATTTATTATTTACCAAA SEQ ID NO: 871
425	ATTTGGTAAATAATAAATATAAGAT		ATCTTATATTTATTATTTACCAAAT SEQ ID NO: 872
426	AATTTGGTAAATAATAAATATAAGA		TCTTATATTTATTATTTACCAAATT SEQ ID NO: 873
427	TAATTTGGTAAATAATAAATATAAG		CTTATATTTATTATTTACCAAATTA SEQ ID NO: 874
428	ATAATTTGGTAAATAATAAATATAA		TTATATTTATTATTTACCAAATTAT SEQ ID NO: 875
429	AATAATTTGGTAAATAATAAATATA		TATATTTATTATTTACCAAATTATT SEQ ID NO: 876
430	GAATAATTTGGTAAATAATAAATAT		ATATTTATTATTTACCAAATTATTC SEQ ID NO: 877
431	AGAATAATTTGGTAAATAATAAATA		TATTTATTATTTACCAAATTATTCT SEQ ID NO: 878
432	TAGAATAATTTGGTAAATAATAAAT		ATTTATTATTTACCAAATTATTCTA SEQ ID NO: 879
433	TTAGAATAATTTGGTAAATAATAAA		TTATTATTTACCAAATTATTCTAA SEQ ID NO: 880
434	CTTAGAATAATTTGGTAAATAATAA		TTATTATTTACCAAATTATTCTAAG SEQ ID NO: 881
435	TCTTAGAATAATTTGGTAAATAATA		TATTATTTACCAAATTATTCTAAGA SEQ ID NO: 882
436	CTCTTAGAATAATTTGGTAAATAAT		ATTATTTACCAAATTATTCTAAGAG SEQ ID NO: 883
437	ACTCTTAGAATAATTTGGTAAATAA		TTATTTACCAAATTATTCTAAGAGT SEQ ID NO: 884
438	TACTCTTAGAATAATTTGGTAAATA		TATTTACCAAATTATTCTAAGAGTA SEQ ID NO: 885
439	ATACTCTTAGAATAATTTGGTAAAT		ATTTACCAAATTATTCTAAGAGTAT SEQ ID NO: 886
440	AATACTCTTAGAATAATTTGGTAAA		TTTACCAAATTATTCTAAGAGTATT SEQ ID NO: 887
441	AAATACTCTTAGAATAATTTGGTAA		TTACCAAATTATTCTAAGAGTATTT SEQ ID NO: 888

442	GAAATACTCTTAGAATAATTTGGTA		TACCAAATTATTCTAAGAGTATTTC SEQ ID NO: 889
443	AGAAATACTCTTAGAATAATTTGGT		ACCAAATTATTCTAAGAGTATTCT SEQ ID NO: 890
444	AAGAAATACTCTTAGAATAATTTGG		CCAAATTATTCTAAGAGTATTCTT SEQ ID NO: 891
445	GAAGAAATACTCTTAGAATAATTTG		CAAATTATTCTAAGAGTATTCTTC SEQ ID NO: 892
446	GGAAGAAATACTCTTAGAATAATTT		AAATTATTCTAAGAGTATTCTTCC SEQ ID NO: 893

* At least one nucleoside linkage of the nucleobase sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothiate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

10 [00190] Table 2 below identifies additional STMN2 AON sequences:

Table 2. Additional STMN2 AON Sequences

SEQ ID NO:	AON Sequence* (5' → 3')
945	GGAGGGGAUACCUGUAUAUUACAAGU
946	AGGAGGGGAUACCUGUAUAUUACAAG
947	CAGGAGGGGAUACCUGUAUAUUACAA
948	CCAGGAGGGGAUACCUGUAUAUUACA
949	ACCAGGAGGGGAUACCUGUAUAUUAC
950	UACCAGGAGGGGAUACCUGUAUAUUA
951	UUACCAGGAGGGGAUACCUGUAUAUU
952	CUUACCAGGAGGGGAUACCUGUAUAU
953	GCUUACCAGGAGGGGAUACCUGUAUA
954	AGCUUACCAGGAGGGGAUACCUGUAU
955	GAGCUUACCAGGAGGGGAUACCUGUA
956	AGAGCUUACCAGGAGGGGAUACCUGU
957	CAGAGCUUACCAGGAGGGGAUACCUG
958	CCAGAGCUUACCAGGAGGGGAUACCU
959	ACCAGAGCUUACCAGGAGGGGAUACC
960	UACCAGAGCUUACCAGGAGGGGAUAC
961	AUACCAGAGCUUACCAGGAGGGGAUA

962	AAUACCAGAGCUUACCAGGAGGGAU
963	UAAUACCAGAGCUUACCAGGAGGGA
964	AUAAUACCAGAGCUUACCAGGAGGG
965	CAUAAUACCAGAGCUUACCAGGAGG
966	ACAUAAUACCAGAGCUUACCAGGAG
967	GACAUAAUACCAGAGCUUACCAGGA
968	AGACAUAAUACCAGAGCUUACCAGG
969	AAGACAUAAUACCAGAGCUUACCAG
970	UAAGACAUAAUACCAGAGCUUACCA
971	UUAAGACAUAAUACCAGAGCUUACC
972	GUUAAGACAUAAUACCAGAGCUUAC
973	UGUUAAGACAUAAUACCAGAGCUUA
974	AUGUUAAGACAUAAUACCAGAGCUU
975	AAUGUUAAGACAUAAUACCAGAGCU
976	AAAUGUUAAGACAUAAUACCAGAGC
977	AAAAUGUUAAGACAUAAUACCAGAG
978	AAAAAUGUUAAGACAUAAUACCAGA
979	UAAAAAUGUUAAGACAUAAUACCAG
980	UUAAAAAUGUUAAGACAUAAUACCA
981	UUUAAAAAUGUUAAGACAUAAUACC
982	AUUUAAAAAUGUUAAGACAUAAUAC
983	GAUUUAAAAAUGUUAAGACAUAAUA
984	AGAUUUAAAAAUGUUAAGACAUAAU
985	UAGAUUUAAAAAUGUUAAGACAUAA
986	AUAGAUUUAAAAAUGUUAAGACAUAA
987	CAUAGAUUUAAAAAUGUUAAGACAU
988	CCAUAGAUUUAAAAAUGUUAAGACA
989	ACCAUAGAUUUAAAAAUGUUAAGAC
990	UACCAUAGAUUUAAAAAUGUUAAGA
991	UUACCAUAGAUUUAAAAAUGUUAAG
992	AUUACCAUAGAUUUAAAAAUGUUA
993	GAUUACCAUAGAUUUAAAAAUGUUA
994	AGAUUACCAUAGAUUUAAAAAUGUU
995	AAGAUUACCAUAGAUUUAAAAAUGU
996	AAAGAUUACCAUAGAUUUAAAAAUG
997	UAAAGAUUACCAUAGAUUUAAAAAU
998	GUAAAGAUUACCAUAGAUUUAAAAA
999	UGUAAAGAUUACCAUAGAUUUAAAA
1000	UUGUAAAGAUUACCAUAGAUUUAAA
1001	UUUGUAAAGAUUACCAUAGAUUUAA
1002	UUUUGUAAAGAUUACCAUAGAUUUA
1003	AUUUUGUAAAGAUUACCAUAGAUUU

1004	UAUUUUGUAAAAGAUUACCAUAGAUU
1005	AUAUUUUGUAAAAGAUUACCAUAGAU
1006	AAUAUUUUGUAAAAGAUUACCAUAGA
1007	AAAUAUUUUGUAAAAGAUUACCAUAG
1008	AAAAUAUUUUGUAAAAGAUUACCAUA
1009	UAAAAUAUUUUGUAAAAGAUUACCAU
1010	GUAAAAUAUUUUGUAAAAGAUUACCA
1011	AGUAAAAUAUUUUGUAAAAGAUUACC
1012	AAGUAAAAUAUUUUGUAAAAGAUUAC
1013	GAAGUAAAAUAUUUUGUAAAAGAUUA
1014	GGAAGUAAAAUAUUUUGUAAAAGAUU
1015	CGGAAGUAAAAUAUUUUGUAAAAGAU
1016	UCGGAAGUAAAAUAUUUUGUAAAAGA
1017	UUCGGAAGUAAAAUAUUUUGUAAAAG
1018	GUUCGGAAGUAAAAUAUUUUGUAAA
1019	AGUUCGGAAGUAAAAUAUUUUGUAA
1020	GAGUUCGGAAGUAAAAUAUUUUGUA
1021	UGAGUUCGGAAGUAAAAUAUUUUGU
1022	AUGAGUUCGGAAGUAAAAUAUUUUG
1023	UAUGAGUUCGGAAGUAAAAUAUUUU
1024	AUAUGAGUUCGGAAGUAAAAUAUUU
1025	UAUAUGAGUUCGGAAGUAAAAUAUU
1026	GUUAUGAGUUCGGAAGUAAAAUAU
1027	GGUAUAUGAGUUCGGAAGUAAAAUA
1028	AGGUUAUAUGAGUUCGGAAGUAAAAU
1029	CAGGUUAUAUGAGUUCGGAAGUAAAA
1030	CCAGGUUAUAUGAGUUCGGAAGUAAA
1031	CCCAGGUUAUAUGAGUUCGGAAGUAA
1032	CCCCAGGUUAUAUGAGUUCGGAAGUA
1033	UCCCCAGGUUAUAUGAGUUCGGAAGU
1034	AUCCCCAGGUUAUAUGAGUUCGGAAG
1035	AAUCCCCAGGUUAUAUGAGUUCGGAA
1036	AAAUCCCCAGGUUAUAUGAGUUCGGA
1037	AAAAUCCCCAGGUUAUAUGAGUUCGG
1038	UAAAAUCCCCAGGUUAUAUGAGUUCG
1039	AUAAAAUCCCCAGGUUAUAUGAGUUC
1040	AAUAAAAUCCCCAGGUUAUAUGAGUU
1041	UAAUAAAAUCCCCAGGUUAUAUGAGU
1042	GUAAUAAAAUCCCCAGGUUAUAUGAG
1043	AGUAAUAAAAUCCCCAGGUUAUAUGA
1044	GAGUAAUAAAAUCCCCAGGUUAUAUG
1045	AGAGUAAUAAAAUCCCCAGGUUAUAU

1046	CAGAGUAAUAAAAUCCCCAGGUUAU
1047	CCAGAGUAAUAAAAUCCCCAGGUAU
1048	CCCAGAGUAAUAAAAUCCCCAGGUA
1049	UCCCAGAGUAAUAAAAUCCCCAGGU
1050	UUCCCAGAGUAAUAAAAUCCCCAGG
1051	AUUCCCAGAGUAAUAAAAUCCCCAG
1052	AAUUCCCAGAGUAAUAAAAUCCCCA
1053	UAAUUCCCAGAGUAAUAAAAUCCCC
1054	AUAAUUCCCAGAGUAAUAAAAUCCC
1055	CAUAAUUCCCAGAGUAAUAAAAUCC
1056	ACAUAAUUCCCAGAGUAAUAAAAUC
1057	CACAUAAUUCCCAGAGUAAUAAAAU
1058	ACACAUAAUUCCCAGAGUAAUAAAA
1059	AACACAUAAUUCCCAGAGUAAUAAA
1060	GAACACAUAAUUCCCAGAGUAAUAA
1061	AGAACACAUAAUUCCCAGAGUAAUA
1062	CAGAACACAUAAUUCCCAGAGUAAU
1063	GCAGAACACAUAAUUCCCAGAGUAA
1064	GGCAGAACACAUAAUUCCCAGAGUA
1065	GGGCAGAACACAUAAUUCCCAGAGU
1066	GGGGCAGAACACAUAAUUCCCAGAG
1067	UGGGGCAGAACACAUAAUUCCCAGA
1068	AUGGGGCAGAACACAUAAUUCCCAG
1069	GAUGGGGCAGAACACAUAAUUCCCA
1070	UGAUGGGGCAGAACACAUAAUUCCC
1071	GUGAUGGGGCAGAACACAUAAUUCC
1072	AGUGAUGGGGCAGAACACAUAAUUC
1073	GAGUGAUGGGGCAGAACACAUAAUU
1074	AGAGUGAUGGGGCAGAACACAUAAU
1075	GAGAGUGAUGGGGCAGAACACAUAA
1076	AGAGAGUGAUGGGGCAGAACACAU
1077	GAGAGAGUGAUGGGGCAGAACACAU
1078	AGAGAGAGUGAUGGGGCAGAACACA
1079	AAGAGAGAGUGAUGGGGCAGAACAC
1080	UAAGAGAGAGUGAUGGGGCAGAAC
1081	UUAAGAGAGAGUGAUGGGGCAGAAC
1082	AUUAAGAGAGAGUGAUGGGGCAGAA
1083	AAUUAAGAGAGAGUGAUGGGGCAGA
1084	CAAUUAAGAGAGAGUGAUGGGGCAG
1085	CCAAUUAAGAGAGAGUGAUGGGGCA
1086	UCCAAUUAAGAGAGAGUGAUGGGGC
1087	AUCCAAUUAAGAGAGAGUGAUGGGG

1088	AAUCCAAUUAAGAGAGAGUGAUGGG
1089	AAAUCCAAUUAAGAGAGAGUGAUGG
1090	AAAAUCCAAUUAAGAGAGAGUGAUG
1091	AAAAAUCCAAUUAAGAGAGAGUGAU
1092	UAAAAAUCCAAUUAAGAGAGAGUGA
1093	UUAAAAAUCCAAUUAAGAGAGAGUG
1094	UUUAAAAAUCCAAUUAAGAGAGAGU
1095	UUUUAAAAAUCCAAUUAAGAGAGAG
1096	AUUUUAAAAAUCCAAUUAAGAGAGA
1097	AAUUUUAAAAAUCCAAUUAAGAGAG
1098	UAAUUUUAAAAAUCCAAUUAAGAGA
1099	AUAAUUUUAAAAAUCCAAUUAAGAG
1100	UAUAAUUUUAAAAAUCCAAUUAAGA
1101	AUAUAAUUUUAAAAAUCCAAUUAAG
1102	AAUAUAAUUUUAAAAAUCCAAUUA
1103	GAAUAUAAUUUUAAAAAUCCAAUUA
1104	UGAAUAUAAUUUUAAAAAUCCAAUU
1105	AUGAAUAUAAUUUUAAAAAUCCAAU
1106	UAUGAAUAUAAUUUUAAAAAUCCAA
1107	AUAUGAAUAUAAUUUUAAAAAUCCA
1108	AAUAUGAAUAUAAUUUUAAAAAUCC
1109	CAUAUGAAUAUAAUUUUAAAAAUCC
1110	GCAUAUGAAUAUAAUUUUAAAAAU
1111	UGCAUAUGAAUAUAAUUUUAAAA
1112	CUGCAUAUGAAUAUAAUUUUAAAA
1113	CCUGCAUAUGAAUAUAAUUUUAAA
1114	UCCUGCAUAUGAAUAUAAUUUUAA
1115	GUCCUGCAUAUGAAUAUAAUUUUAA
1116	AGUCCUGCAUAUGAAUAUAAUUUU
1117	GAGUCCUGCAUAUGAAUAUAAUUU
1118	CGAGUCCUGCAUAUGAAUAUAAUU
1119	CCGAGUCCUGCAUAUGAAUAUAAU
1120	GCCGAGUCCUGCAUAUGAAUAUAA
1121	UGCCGAGUCCUGCAUAUGAAUAUA
1122	CUGCCGAGUCCUGCAUAUGAAUAU
1123	UCUGCCGAGUCCUGCAUAUGAAUA
1124	UUCUGCCGAGUCCUGCAUAUGAAU
1125	CUUCUGCCGAGUCCUGCAUAUGAA
1126	UCUUCUGCCGAGUCCUGCAUAUGA
1127	GUCUUCUGCCGAGUCCUGCAUAUG
1128	GGUCUUCUGCCGAGUCCUGCAUAU
1129	AGGUCUUCUGCCGAGUCCUGCAUA

1130	AAGGUCUUCUGCCGAGUCCUGCAAU
1131	GAAGGUCUUCUGCCGAGUCCUGCAA
1132	CGAAGGUCUUCUGCCGAGUCCUGCA
1133	UCGAAGGUCUUCUGCCGAGUCCUGC
1134	CUCGAAGGUCUUCUGCCGAGUCCUG
1135	UCUCGAAGGUCUUCUGCCGAGUCCU
1136	CUCUCGAAGGUCUUCUGCCGAGUCC
1137	UCUCUCGAAGGUCUUCUGCCGAGUC
1138	UUCUCUCGAAGGUCUUCUGCCGAGU
1139	UUUCUCUCGAAGGUCUUCUGCCGAG
1140	CUUUCUCUCGAAGGUCUUCUGCCGA
1141	CCUUUCUCUCGAAGGUCUUCUGCCG
1142	ACCUUUCUCUCGAAGGUCUUCUGCC
1143	UACCUUUCUCUCGAAGGUCUUCUGC
1144	CUACCUUUCUCUCGAAGGUCUUCUG
1145	UCUACCUUUCUCUCGAAGGUCUUCU
1146	UUCUACCUUUCUCUCGAAGGUCUUC
1147	UUUCUACCUUUCUCUCGAAGGUCUU
1148	UUUUCUACCUUUCUCUCGAAGGUCU
1149	AUUUUCUACCUUUCUCUCGAAGGUC
1150	UAUUUUCUACCUUUCUCUCGAAGGU
1151	UUAUUUUCUACCUUUCUCUCGAAGG
1152	CUUAUUUUCUACCUUUCUCUCGAAG
1153	UCUUAUUUUCUACCUUUCUCUCGAA
1154	UUCUUAUUUUCUACCUUUCUCUCGA
1155	AUUCUUAUUUUCUACCUUUCUCUCG
1156	AAUUCUUAUUUUCUACCUUUCUCUC
1157	AAAUUCUUAUUUUCUACCUUUCUCU
1158	CAAAUUCUUAUUUUCUACCUUUCUC
1159	CCAAAUUCUUAUUUUCUACCUUUCU
1160	GCCAAAUUCUUAUUUUCUACCUUUC
1161	AGCCAAAUUCUUAUUUUCUACCUUU
1162	GAGCCAAAUUCUUAUUUUCUACCUU
1163	AGAGCCAAAUUCUUAUUUUCUACCU
1164	GAGAGCCAAAUUCUUAUUUUCUACC
1165	AGAGAGCCAAAUUCUUAUUUUCUAC
1166	CAGAGAGCCAAAUUCUUAUUUUCUA
1167	ACAGAGAGCCAAAUUCUUAUUUUCU
1168	CACAGAGAGCCAAAUUCUUAUUUUC
1169	ACACAGAGAGCCAAAUUCUUAUUUU
1170	CACACAGAGAGCCAAAUUCUUAUUU
1171	UCACACAGAGAGCCAAAUUCUUAUU

1172	CUCACACAGAGAGCCAAAUUCUUAU
1173	GCUCACACAGAGAGCCAAAUUCUUA
1174	UGCUCACACAGAGAGCCAAAUUCUU
1175	AUGCUCACACAGAGAGCCAAAUUCU
1176	CAUGCUCACACAGAGAGCCAAAUUC
1177	ACAUGCUCACACAGAGAGCCAAAU
1178	CACAUGCUCACACAGAGAGCCAAA
1179	ACACAUGCUCACACAGAGAGCCAAA
1180	CACACAUGCUCACACAGAGAGCCAA
1181	GCACACAUGCUCACACAGAGAGCCA
1182	CGCACACAUGCUCACACAGAGAGCC
1183	ACGCACACAUGCUCACACAGAGAGC
1184	CACGCACACAUGCUCACACAGAGAG
1185	ACACGCACACAUGCUCACACAGAGA
1186	CACACGCACACAUGCUCACACAGAG
1187	ACACACGCACACAUGCUCACACAGA
1188	CACACACGCACACAUGCUCACACAG
1189	GCACACACGCACACAUGCUCACACA
1190	CGCACACACGCACACAUGCUCACAC
1191	UCGCACACACGCACACAUGCUCACA
1192	CUCGCACACACGCACACAUGCUCAC
1193	UCUCGCACACACGCACACAUGCUC
1194	CUCUCGCACACACGCACACAUGCUC
1195	UCUCUCGCACACACGCACACAUGC
1196	CUCUCUCGCACACACGCACACAUGC
1197	UCUCUCUCGCACACACGCACACAUG
1198	CUCUCUCUCGCACACACGCACACAU
1199	UCUCUCUCUCGCACACACGCACACA
1200	CUCUCUCUCUCGCACACACGCACAC
1201	UCUCUCUCUCUCGCACACACGCACA
1202	GUCUCUCUCUCUCGCACACACGCAC
1203	UGUCUCUCUCUCUCGCACACACGCA
1204	CUGUCUCUCUCUCUCGCACACACGC
1205	UCUGUCUCUCUCUCUCGCACACACG
1206	GUCUGUCUCUCUCUCUCGCACACAC
1207	UGUCUGUCUCUCUCUCUCGCACACA
1208	CUGUCUGUCUCUCUCUCUCGCACAC
1209	GCUGUCUGUCUCUCUCUCUCGCACA
1210	GGCUGUCUGUCUCUCUCUCUCGCAC
1211	AGGCUGUCUGUCUCUCUCUCUCGCA
1212	CAGGCUGUCUGUCUCUCUCUCUCGC
1213	GCAGGCUGUCUGUCUCUCUCUCUCG

1214	GGCAGGCUGUCUGUCUCUCUCUCUC
1215	AGGCAGGCUGUCUGUCUCUCUCUCU
1216	UAGGCAGGCUGUCUGUCUCUCUCUC
1217	UUAGGCAGGCUGUCUGUCUCUCUCU
1218	CUUAGGCAGGCUGUCUGUCUCUCUC
1219	UCUUAGGCAGGCUGUCUGUCUCUCU
1220	UUCUUAGGCAGGCUGUCUGUCUCUC
1221	CUUCUUAGGCAGGCUGUCUGUCUCU
1222	UCUUCUUAGGCAGGCUGUCUGUCUC
1223	UUCUUCUUAGGCAGGCUGUCUGUCU
1224	UUUCUUCUUAGGCAGGCUGUCUGUC
1225	AUUUCUUCUUAGGCAGGCUGUCUGU
1226	CAUUUCUUCUUAGGCAGGCUGUCUG
1227	UCAUUUCUUCUUAGGCAGGCUGUCU
1228	UUCAUUUCUUCUUAGGCAGGCUGUC
1229	AUUCAUUUCUUCUUAGGCAGGCUGU
1230	CAUUCAUUUCUUCUUAGGCAGGCUG
1231	ACAUUCAUUUCUUCUUAGGCAGGCU
1232	CACAUUCAUUUCUUCUUAGGCAGGC
1233	UCACAUUCAUUUCUUCUUAGGCAGG
1234	UUCACAUUCAUUUCUUCUUAGGCAG
1235	AUUCACAUUCAUUUCUUCUUAGGCA
1236	CAUUCACAUUCAUUUCUUCUUAGGC
1237	GCAUUCACAUUCAUUUCUUCUUAGG
1238	CGCAUUCACAUUCAUUUCUUCUUAG
1239	CCGCAUUCACAUUCAUUUCUUCUUA
1240	GCCGCAUUCACAUUCAUUUCUUCUU
1241	AGCCGCAUUCACAUUCAUUUCUUCU
1242	AAGCCGCAUUCACAUUCAUUUCUUC
1243	CAAGCCGCAUUCACAUUCAUUUCUU
1244	ACAAGCCGCAUUCACAUUCAUUUCU
1245	CACAAGCCGCAUUCACAUUCAUUUC
1246	CCACAAGCCGCAUUCACAUUCAUUU
1247	GCCACAAGCCGCAUUCACAUUCAUU
1248	UGCCACAAGCCGCAUUCACAUUCAU
1249	GUGCCACAAGCCGCAUUCACAUUCA
1250	UGUGCCACAAGCCGCAUUCACAUUC
1251	CUGUGCCACAAGCCGCAUUCACAUU
1252	ACUGUGCCACAAGCCGCAUUCACAU
1253	AACUGUGCCACAAGCCGCAUUCACA
1254	CAACUGUGCCACAAGCCGCAUUCAC
1255	UCAACUGUGCCACAAGCCGCAUUCA

1256	GUCAACUGUGCCACAAGCCGCAUUC
1257	UGUCAACUGUGCCACAAGCCGCAUU
1258	UUGUCAACUGUGCCACAAGCCGCAU
1259	CUUGUCAACUGUGCCACAAGCCGCA
1260	CCUUGUCAACUGUGCCACAAGCCGC
1261	UCCUUGUCAACUGUGCCACAAGCCG
1262	AUCCUUGUCAACUGUGCCACAAGCC
1263	CAUCCUUGUCAACUGUGCCACAAGC
1264	UCAUCCUUGUCAACUGUGCCACAAG
1265	AUCAUCCUUGUCAACUGUGCCACAA
1266	UAUCAUCCUUGUCAACUGUGCCACA
1267	UUAUCAUCCUUGUCAACUGUGCCAC
1268	UUUAUCAUCCUUGUCAACUGUGCCA
1269	AUUUAUCAUCCUUGUCAACUGUGCC
1270	GAUUUAUCAUCCUUGUCAACUGUGC
1271	UGAUUUUAUCAUCCUUGUCAACUGUG
1272	UUGAUUUUAUCAUCCUUGUCAACUGU
1273	AUUGAUUUUAUCAUCCUUGUCAACUG
1274	UAUUGAUUUUAUCAUCCUUGUCAACU
1275	UUAUUGAUUUUAUCAUCCUUGUCAAC
1276	AUUAUUGAUUUUAUCAUCCUUGUCA
1277	CAUUAUUGAUUUUAUCAUCCUUGUCA
1278	GCAUUAUUGAUUUUAUCAUCCUUGUC
1279	UGCAUUAUUGAUUUUAUCAUCCUUGU
1280	UUGCAUUAUUGAUUUUAUCAUCCUUG
1281	CUUGCAUUAUUGAUUUUAUCAUCCUU
1282	GCUUGCAUUAUUGAUUUUAUCAUCCU
1283	AGCUUGCAUUAUUGAUUUUAUCAUCC
1284	AAGCUUGCAUUAUUGAUUUUAUCAUC
1285	UAAGCUUGCAUUAUUGAUUUUAUCAU
1286	GUAAGCUUGCAUUAUUGAUUUUAUCA
1287	AGUAAGCUUGCAUUAUUGAUUUUAUC
1288	UAGUAAGCUUGCAUUAUUGAUUUUAU
1289	AUAGUAAGCUUGCAUUAUUGAUUUUA
1290	GAUAGUAAGCUUGCAUUAUUGAUUU
1291	UGAUAGUAAGCUUGCAUUAUUGAUU
1292	AUGAUAGUAAGCUUGCAUUAUUGAU
1293	AAUGAUAGUAAGCUUGCAUUAUUGA
1294	AAAUGAUAGUAAGCUUGCAUUAUUG
1295	UAAAUGAUAGUAAGCUUGCAUUAU
1296	AUAAAUGAUAGUAAGCUUGCAUUAU
1297	CAUAAAUGAUAGUAAGCUUGCAUUA

1298	UCAUAAAUGAUAGUAAGCUUGCAUU
1299	UUCAUAAAUGAUAGUAAGCUUGCAU
1300	AUUCAUAAAUGAUAGUAAGCUUGCA
1301	UAUUCAUAAAUGAUAGUAAGCUUGC
1302	CUAUUCAUAAAUGAUAGUAAGCUUG
1303	GCUAUUCAUAAAUGAUAGUAAGCUU
1304	UGCUAUUCAUAAAUGAUAGUAAGCU
1305	UUGCUAUUCAUAAAUGAUAGUAAGC
1306	AUUGCUAUUCAUAAAUGAUAGUAAG
1307	UAUUGCUAUUCAUAAAUGAUAGUAA
1308	GUAUUGCUAUUCAUAAAUGAUAGUA
1309	AGUAUUGCUAUUCAUAAAUGAUAGU
1310	CAGUAUUGCUAUUCAUAAAUGAUAG
1311	UCAGUAUUGCUAUUCAUAAAUGAUA
1312	UUCAGUAUUGCUAUUCAUAAAUGAU
1313	CUUCAGUAUUGCUAUUCAUAAAUGA
1314	UCUUCAGUAUUGCUAUUCAUAAAUG
1315	UUCUUCAGUAUUGCUAUUCAUAAAU
1316	UUUCUUCAGUAUUGCUAUUCAUAAA
1317	AUUUCUUCAGUAUUGCUAUUCAUAA
1318	AAUUUCUUCAGUAUUGCUAUUCAUA
1319	UAAUUUCUUCAGUAUUGCUAUUCAU
1320	UUAUUUCUUCAGUAUUGCUAUUCA
1321	UUUAAUUUCUUCAGUAUUGCUAUUC
1322	UUUUAAUUUCUUCAGUAUUGCUAUU
1323	GUUUUAAUUUCUUCAGUAUUGCUAU
1324	UGUUUUAAUUUCUUCAGUAUUGCUA
1325	UUGUUUUAAUUUCUUCAGUAUUGC
1326	UUUGUUUUAAUUUCUUCAGUAUUGC
1327	UUUUGUUUUAAUUUCUUCAGUAUUG
1328	CUUUUGUUUUAAUUUCUUCAGUAUU
1329	UCUUUUGUUUUAAUUUCUUCAGUAU
1330	AUCUUUUGUUUUAAUUUCUUCAGUA
1331	AAUCUUUUGUUUUAAUUUCUUCAGU
1332	CAAUCUUUUGUUUUAAUUUCUUCAG
1333	GCAAUCUUUUGUUUUAAUUUCUUCA
1334	AGCAAUCUUUUGUUUUAAUUUCUUC
1335	CAGCAAUCUUUUGUUUUAAUUUCUU
1336	ACAGCAAUCUUUUGUUUUAAUUUCU
1337	GACAGCAAUCUUUUGUUUUAAUUUC
1338	AGACAGCAAUCUUUUGUUUUAAUUU
1339	GAGACAGCAAUCUUUUGUUUUAAUU

1340	UGAGACAGCAAUCUUUUGUUUUAAU
1341	UUGAGACAGCAAUCUUUUGUUUUAA
1342	AUUGAGACAGCAAUCUUUUGUUUUA
1343	UAUUGAGACAGCAAUCUUUUGUUUU
1344	AUAUUGAGACAGCAAUCUUUUGUUU
1345	UAUAUUGAGACAGCAAUCUUUUGUU
1346	AUAUAUUGAGACAGCAAUCUUUUGU
1347	GAUAUAUUGAGACAGCAAUCUUUUG
1348	AGAUUAUUGAGACAGCAAUCUUUU
1349	AAGAUUAUUGAGACAGCAAUCUUU
1350	UAAGAUUAUUGAGACAGCAAUCUU
1351	AUAAGAUUAUUGAGACAGCAAUCU
1352	UAUAAGAUUAUUGAGACAGCAAUC
1353	AUAUAAGAUUAUUGAGACAGCAAU
1354	AAUAUAAGAUUAUUGAGACAGCAA
1355	AAAUUAAGAUUAUUGAGACAGCA
1356	UAAAUUAAGAUUAUUGAGACAGC
1357	AUAAAUUAAGAUUAUUGAGACAG
1358	AAUAAAUUAAGAUUAUUGAGACA
1359	UAAUAAAUUAAGAUUAUUGAGAC
1360	AUAUAAAUUAAGAUUAUUGAGA
1361	AAUAAUAAAUUAAGAUUAUUGAG
1362	AAAUAAUAAAUUAAGAUUAUUGA
1363	UAAAUAAUAAAUUAAGAUUAUUG
1364	GUAAAUAAUAAAUUAAGAUUAUU
1365	GGUAAAUAAUAAAUUAAGAUUAU
1366	UGGUAAAUAAUAAAUUAAGAUUA
1367	UUGGUAAAUAAUAAAUUAAGAUU
1368	UUUGGUAAAUAAUAAAUUAAGAU
1369	AUUUGGUAAAUAAUAAAUUAAGAU
1370	AAUUUGGUAAAUAAUAAAUUAAGA
1371	UAAUUUGGUAAAUAAUAAAUUAAG
1372	AUAUUUGGUAAAUAAUAAAUUA
1373	AAUAAUUUGGUAAAUAAUAAAUUA
1374	GAAUAAUUUGGUAAAUAAUAAAUU
1375	AGAAUAAUUUGGUAAAUAAUAAUA
1376	UAGAAUAAUUUGGUAAAUAAUAAU
1377	UUAGAAUAAUUUGGUAAAUAAUAA
1378	CUUAGAAUAAUUUGGUAAAUAAUA
1379	UCUUAGAAUAAUUUGGUAAAUAAU
1380	CUCUUAGAAUAAUUUGGUAAAUAAU
1381	ACUCUUAGAAUAAUUUGGUAAAUAA

1382	UACUCUUAGAAUAAUUUGGUAAAUA
1383	AUACUCUUAGAAUAAUUUGGUAAAU
1384	AAUACUCUUAGAAUAAUUUGGUAAA
1385	AAAUACUCUUAGAAUAAUUUGGUAA
1386	GAAAUACUCUUAGAAUAAUUUGGUA
1387	AGAAAUACUCUUAGAAUAAUUUGGU
1388	AAGAAAUACUCUUAGAAUAAUUUGG
1389	GAAGAAAUACUCUUAGAAUAAUUUG
1390	GGAAGAAAUACUCUUAGAAUAAUUU

* At least one nucleoside linkage of the nucleobase sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothiate linkage, a phosphorodiamidate linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

[00191] Table 3 below identifies exemplary STMN2 AON sequences:

10 Table 3. Exemplary STMN2 AON Sequences

SEQ ID NO: (legacy ID*)	Oligonucleotide sequence (5'→3')
SEQ ID NO: 31 (QSN-31)	AATGTTAAGACATAATACCAGAGCT
SEQ ID NO: 36 (QSN-36)	TTAAAAATGTTAAGACATAATACCA
SEQ ID NO: 41 (QSN-41)	TAGATTTAAAAATGTTAAGACATAA
SEQ ID NO: 46 (QSN-46)	TACCATAGATTTAAAAATGTTAAGA
SEQ ID NO: 55 (QSN-55)	TGTAAAGATTACCATAGATTTAAAA
SEQ ID NO: 144 (QSN-144)	AATCCAATTAAGAGAGAGTGATGGG
SEQ ID NO: 146 (QSN-146)	AAAATCCAATTAAGAGAGAGTGATG
SEQ ID NO: 150 (QSN-150)	TTAAAAATCCAATTAAGAGAGAGT

SEQ ID NO: 169 (QSN-169)	CCTGCAATATGAATATAATTTTAAA
SEQ ID NO: 170 (QSN-170)	TCCTGCAATATGAATATAATTTTAA
SEQ ID NO: 171 (QSN-171)	GTCCTGCAATATGAATATAATTTTA
SEQ ID NO: 172 (QSN-172)	AGTCCTGCAATATGAATATAATTTT
SEQ ID NO: 173 (QSN-173)	GAGTCCTGCAATATGAATATAATTT
SEQ ID NO: 177 (QSN-177)	TGCCGAGTCCTGCAATATGAATATA
SEQ ID NO: 181 (QSN-181)	CTTCTGCCGAGTCCTGCAATATGAA
SEQ ID NO: 185 (QSN-185)	AGGTCTTCTGCCGAGTCCTGCAATA
SEQ ID NO: 197 (QSN-197)	CCTTTCTCTCGAAGGTCTTCTGCCG
SEQ ID NO: 203 (QSN-203)	TTTCTACCTTTCTCTCGAAGGTCTT
SEQ ID NO: 209 (QSN-209)	TCTTATTTTCTACCTTTCTCTCGAA
SEQ ID NO: 215 (QSN-215)	CCAAATTCTTATTTTCTACCTTTCT
SEQ ID NO: 237 (QSN-237)	GCACACATGCTCACACAGAGAGCCA
SEQ ID NO: 244 (QSN-244)	CACACACGCACACATGCTCACACAG
SEQ ID NO: 249 (QSN-249)	TCTCGCACACACGCACACATGCTCA
SEQ ID NO: 252 (QSN-252)	CTCTCTCGCACACACGCACACATGC
SEQ ID NO: 380 (QSN-380)	TGTTTTAATTTCTTCAGTATTGCTA
SEQ ID NO: 385 (QSN-385)	TCTTTTGTTTTAATTTCTTCAGTAT
SEQ ID NO: 390 (QSN-390)	AGCAATCTTTTGTTTTAATTTCTTC
SEQ ID NO: 395 (QSN-395)	GAGACAGCAATCTTTTGTTTTAATT
SEQ ID NO: 400 (QSN-400)	ATATTGAGACAGCAATCTTTTGTTT

* At least one nucleoside linkage of the nucleobase sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothiate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

[00192] In some embodiments, all internucleoside linkages of the STMN2 AON oligonucleotides listed in Table 3 are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides, and each "C" is replaced with a 5-MeC. For example, in some embodiments, all internucleoside linkages of the QSN-31 STMN2 AON (SEQ ID NO: 31) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-36 STMN2 AON (SEQ ID NO: 36) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-55 STMN2 AON (SEQ ID NO: 55) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-144 STMN2 AON (SEQ ID NO: 144) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-173 STMN2 AON (SEQ ID NO: 173) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-177 STMN2 AON (SEQ ID NO: 177) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-181 STMN2 AON (SEQ ID NO: 181) oligonucleotide are phosphorothioate linkages, and each of the

linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-185 STMN2 AON (SEQ ID NO: 185) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-197 STMN2 AON (SEQ ID NO: 197) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-203 STMN2 AON (SEQ ID NO: 203) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-209 STMN2 AON (SEQ ID NO: 209) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-215 STMN2 AON (SEQ ID NO: 215) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-237 STMN2 AON (SEQ ID NO: 237) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-244 STMN2 AON (SEQ ID NO: 244) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-252 STMN2 AON (SEQ ID NO: 252) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-380 STMN2 AON (SEQ ID NO: 380) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-385 STMN2 AON (SEQ ID NO: 385) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some

embodiments, all internucleoside linkages of the QSN-390 STMN2 AON (SEQ ID NO: 390) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-395 STMN2 AON (SEQ ID NO: 395) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-400 STMN2 AON (SEQ ID NO: 400) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-169 STMN2 AON (SEQ ID NO: 169) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-170 STMN2 AON (SEQ ID NO: 170) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-171 STMN2 AON (SEQ ID NO: 171) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-172 STMN2 AON (SEQ ID NO: 172) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-249 STMN2 AON (SEQ ID NO: 249) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC.

[00193] In some embodiments, all internucleoside linkages of the STMN2 AON oligonucleotides listed in Table 3 are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. For example, in some embodiments, all internucleoside linkages of the QSN-31 STMN2 AON (SEQ ID NO: 31) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In

some embodiments, all internucleoside linkages of the QSN-36 STMN2 AON (SEQ ID NO: 36) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some embodiments, all internucleoside linkages of the QSN-55 STMN2 AON (SEQ ID NO: 55) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-144 STMN2 AON (SEQ ID NO: 144) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-173 STMN2 AON (SEQ ID NO: 173) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-177 STMN2 AON (SEQ ID NO: 177) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-181 STMN2 AON (SEQ ID NO: 181) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-185 STMN2 AON (SEQ ID NO: 185) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-197 STMN2 AON (SEQ ID NO: 197) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-203 STMN2 AON (SEQ ID NO: 203) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-209 STMN2 AON (SEQ ID NO: 209) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-215 STMN2 AON (SEQ ID NO:

215) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-237 STMN2 AON (SEQ ID NO: 237) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-244 STMN2 AON (SEQ ID NO: 244) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-252 STMN2 AON (SEQ ID NO: 252) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-380 STMN2 AON (SEQ ID NO: 380) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-385 STMN2 AON (SEQ ID NO: 385) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-390 STMN2 AON (SEQ ID NO: 390) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-395 STMN2 AON (SEQ ID NO: 395) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-400 STMN2 AON (SEQ ID NO: 400) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-169 STMN2 AON (SEQ ID NO: 169) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-170 STMN2 AON (SEQ ID NO: 170) oligonucleotide are phosphorothioate

linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-171 STMN2 AON (SEQ ID NO: 171) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-172 STMN2 AON (SEQ ID NO: 172) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides, and none of the 'C' is replaced with 5-MeC. In some embodiments, all internucleoside linkages of the QSN-249 STMN2 AON (SEQ ID NO: 249) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides, and not all or none of the 'C' is replaced with 5-MeC.

[00194] Table 4 below identifies additional exemplary STMN2 AON sequences:

Table 4. Additional Exemplary STMN2 AON Sequences

SEQ ID NO:	Oligonucleotide sequence (5'→3')
SEQ ID NO: 975	AAUGUUAAGACAUAAUACCAGAGCU
SEQ ID NO: 980	UUAAAAAUGUUAAGACAUAAUACCA
SEQ ID NO: 985	UAGAUUUAAAAAUGUUAAGACAUAA
SEQ ID NO: 990	UACCAUAGAUUUAAAAAUGUUAAGA
SEQ ID NO: 999	UGUAAAGAUUACCAUAGAUUUAAAA
SEQ ID NO: 1088	AAUCCAAUUAAGAGAGAGUGAUGGG
SEQ ID NO: 1090	AAAAUCCAAUUAAGAGAGAGUGAUG
SEQ ID NO: 1094	UUUAAAAAUCCAAUUAAGAGAGAGU
SEQ ID NO: 1113	CCUGCAAUAUGAAUAUAAUUUUAAA
SEQ ID NO: 1114	UCCUGCAAUAUGAAUAUAAUUUUAA
SEQ ID NO: 1115	GUCCUGCAAUAUGAAUAUAAUUUUAA
SEQ ID NO: 1116	AGUCCUGCAAUAUGAAUAUAAUUUU
SEQ ID NO: 1117	GAGUCCUGCAAUAUGAAUAUAAUUU
SEQ ID NO: 1121	UGCCGAGUCCUGCAAUAUGAAUAUA
SEQ ID NO: 1125	CUUCUGCCGAGUCCUGCAAUAUGAA
SEQ ID NO: 1129	AGGUCUUCUGCCGAGUCCUGCAAUA
SEQ ID NO: 1141	CCUUUCUCUCGAAGGUCUUCUGCCG
SEQ ID NO: 1147	UUUCUACCUUUCUCUCGAAGGUCUU
SEQ ID NO: 1153	UCUUAUUUUCUACCUUUCUCUCGAA
SEQ ID NO: 1159	CCAAAUUCUUAUUUUCUACCUUUCU
SEQ ID NO: 1181	GCACACAUGCUCACACAGAGAGCCA
SEQ ID NO: 1188	CACACACGCACACAUGCUCACACAG

SEQ ID NO: 1193	UCUCGCACACACGCACACAUGCUCU
SEQ ID NO: 1196	CUCUCUCGCACACACGCACACAUGC
SEQ ID NO: 1324	UGUUUUAAUUUCUUCAGUAUUGCUA
SEQ ID NO: 1329	UCUUUUGUUUUAAUUUCUUCAGUAU
SEQ ID NO: 1334	AGCAAUCUUUUGUUUUAAUUUCUUC
SEQ ID NO: 1339	GAGACAGCAAUCUUUUGUUUUAAUU
SEQ ID NO: 1344	AUAUUGAGACAGCAAUCUUUUGUUU

* At least one nucleoside linkage of the nucleobase sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothiate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage.

10 Full Length STMN2 Transcript

[00195] As described herein, the disclosure provides a method of restoring full length STMN2 transcript expression in a cell, where the method includes exposing the cell to an inhibitor of STMN2 transcripts that include a cryptic exon or contacting the cell with an inhibitor of STMN2 transcripts that include a cryptic exon. Such an inhibitor can sterically block splice machinery, sterically mimic TDP43 binding, and/or repress premature polyadenylation of STMN2 pre-mRNA, and increase, restore, and/or stabilize levels of full length STMN2 transcript.

[00196] In various embodiments, the full length STMN2 transcript comprises a sequence with accession number NM_001199214.2, identified below as SEQ ID NO: 1433.

A TGGCTAAAC AGCAATGGCC TACAAGGAAA AAATGAAGGA GCTGTCCATG
 CTGTCACTGA TCTGCTCTTG CTTTACCCG GAACCTCGCA ACATCAACAT
 CTATACTTAC GATGATATGG AAGTGAAGCA AATCAACAAA CGTGCCTCTG
 GCCAGGCTTT TGAGCTGATC TTGAAGCCAC CATCTCCTAT CTCAGAAGCC
 CCACGAACTT TAGCTTCTCC AAAGAAGAAA GACCTGTCCC TGGAGGAGAT
 CCAGAAGAAA CTGGAGGCTG CAGAGGAAAG AAGAAAGTCT CAGGAGGCCC
 AGGTGCTGAA ACAATTGGCA GAGAAGAGGG AACACGAGCG AGAAGTCCTT

CAGAAGGCTT TGGAGGAGAA CAACAACCTC AGCAAGATGG CGGAGGAAAA
 GCTGATCCTG AAAATGGAAC AAATTAAGGA AAACCGTGAG GCTAATCTAG
 CTGCTATTAT TGAACGTCTG CAGGAAAAGC TGGTCAAGTT TATTTCTTCT
 GAACTAAAAG AATCTATAGA GTCTCAATTT CTGGAGCTTC AGAGGGAAGG

5 AGAGAAGCAA TGA

(SEQ ID NO: 1433)

[00197] In various embodiments, the full length STMN2 protein comprises an amino acid sequence with accession number NP_001186143.1, identified below as SEQ ID NO: 1434.

MAKTAMAYKE KMKELSMLSL ICSCFYPEPR NINIYTYDDM EVKQINKRAS
 10 GQAFELILKP PSPISEAPRT LASPKKKDLS LEEIQKKLEA AEERRKSQEA QVLKQLAEKR
 EHEREVLQKA LEENNNFSKM AEEKLILKME QIKENREANL AAIERLQEK
 LVKFISSELK ESIESQFLEL QREGEKQ

(SEQ ID NO: 1434)

[00198] In various embodiments, the full length STMN2 transcript comprises a sequence with
 15 accession number NM_007029.4, identified below as SEQ ID NO: 1435.

A TGGCTAAAAC AGCAATGGCC TACAAGGAAA AAATGAAGGA GCTGTCCATG
 CTGTCACTGA TCTGCTCTTG CTTTTACCCG GAACCTCGCA ACATCAACAT
 CTATACTTAC GATGATATGG AAGTGAAGCA AATCAACAAA CGTGCCTCTG
 GCCAGGCTTT TGAGCTGATC TTGAAGCCAC CATCTCCTAT CTCAGAAGCC
 20 CCACGAACTT TAGCTTCTCC AAAGAAGAAA GACCTGTCCC TGGAGGAGAT
 CCAGAAGAAA CTGGAGGCTG CAGAGGAAAG AAGAAAGTCT CAGGAGGCCC
 AGGTGCTGAA ACAATTGGCA GAGAAGAGGG AACACGAGCG AGAAGTCCTT
 CAGAAGGCTT TGGAGGAGAA CAACAACCTC AGCAAGATGG CGGAGGAAAA
 GCTGATCCTG AAAATGGAAC AAATTAAGGA AAACCGTGAG GCTAATCTAG
 25 CTGCTATTAT TGAACGTCTG CAGGAAAAGG AGAGGCATGC TGCGGAGGTG
 CGCAGGAACA AGGAACTCCA GGTTGAACTG TCTGGCTGA

(SEQ ID NO: 1435)

[00199] In various embodiments, the full length STMN2 protein comprises an amino acid sequence with accession number NP_008960.2, identified below as SEQ ID NO: 1436.

MAKTAMAYKE KMKELSMLSL ICSCFYPEPR NINIYTYDDM EVKQINKRAS
 GQAFELILKP PSPISEAPRT LASPKKKDLS LEEIQKKLEA AEERRKSQEA QVLKQLAEKR
 EHEREVLQKA LEENNNFSKM AEEKLILKME QIKENREANL AAIERLQEK
 ERHAAEVRRN KELQVELSG

5 **(SEQ ID NO: 1436)**

[00200] In various embodiments, the full length STMN2 transcript comprises a sequence with accession number XM_005251142.2, identified below as SEQ ID NO: 1437.

ATGGCCTAC AAGGAAAAAA TGAAGGAGCT GTCCATGCTG TCACTGATCT
 GCTCTTGCTT TTACCCGGAA CCTCGCAACA TCAACATCTA TACTTACGAT
 10 GATATGGAAG TGAAGCAAAT CAACAAACGT GCCTCTGGCC AGGCTTTTGA
 GCTGATCTTG AAGCCACCAT CTCCTATCTC AGAAGCCCCA CGAACTTTAG
 CTTCTCCAAA GAAGAAAGAC CTGTCCCTGG AGGAGATCCA GAAGAACTG
 GAGGCTGCAG AGGAAAGAAG AAAGTCTCAG GAGGCCCAGG TGCTGAAACA
 ATTGGCAGAG AAGAGGGAAC ACGAGCGAGA AGTCCTTCAG AAGGCTTTGG
 15 AGGAGAACAA CAACTTCAGC AAGATGGCGG AGGAAAAGCT GATCCTGAAA
 ATGGAACAAA TTAAGGAAAA CCGTGAGGCT AATCTAGCTG CTATTATTGA
 ACGTCTGCAG GAAAAGGAGA GGCATGCTGC GGAGGTGCGC AGGAACAAGG
 AACTCCAGGT TGAAGTGTCT GGCTGA

(SEQ ID NO: 1437)

20 **[00201]** In various embodiments, the full length STMN2 protein comprises an amino acid sequence with accession number XP_005251199, identified below as SEQ ID NO: 1438.

MAYKEKMKEL SMLSLICSCF YPEPRNINIY TYDDMEVKQI NKRASGQAFE LILKPPSPIS
 EAPRTLASP KKDLSLEEI QKKLEAAEERR KSQEAQVLKQ LAEKREHERE
 VLQKALEENN NFSKMAEEKL ILKMEQIKEN REANLAAIIE RLQEKERHAA
 25 EVRRNKELQV ELSG

(SEQ ID NO: 1438)

STMN2 Transcript with a Cryptic Exon

[00202] In one embodiment, a STMN2 transcript with a cryptic exon can comprise the sequence provided as SEQ ID NO: 944.

5 ACTTGTAATATACAGGTATCCCTCCTGGTAAGCTCTGGTATTATGTCTTAACATTTTAA
AATCTATGGTAATCTTTACAAAATATTTTACTTCCGAACATCATATACCTGGGGATTTT
ATTACTCTGGGAATTATGTGTTCTGCCCCATCACTCTCTCTTAATTGGATTTTAAAAT
TATATTCATATTGCAGGACTCGGCAGAAAGACCTTCGAGAGAAAGGTAGAAAATAAGA
ATTTGGCTCTCTGTGTGAGCATGTGTGCGTGTGTGCGAGAGAGAGAGACAGACAGCC
TGCCTAAGAAGAAATGAATGTGAATGCGGCTTGTGGCACAGTTGACAAGGATGATAA
10 ATCAATAATGCAAGCTTACTATCATTTATGAATAGCAATACTGAAGAAATTAACA
AAAGATTGCTGTCTCAATATATCTTATATTTATTATTACCAAATTATTCTAAGAGTAT
TTCTTCC

(SEQ ID NO: 944)

15

[00203] In one embodiment, a STMN2 transcript with a cryptic exon can comprise a pre-mRNA STMN2 transcript. In one embodiment, a STMN2 transcript with a cryptic exon can comprise the sequence provided as SEQ ID NO: 1391.

20 AGCTCCTAGGAAGCTTCAGGGCTTAAAGCTCCACTCTACTTGGACTGTACTATCAGGC
CCCCAAAATGGGGGGAGCCGACAGGGAAGGACTGATTTCCATTTCAAACATGCATTCT
GGTACTTTGTACTCCAGCACCATTTGGCCGATCAATATTTAATGCTTGGAGATTCTGAC
TCTGCGGGAGTCATGTCAGGGGACCTTGGGAGCCAATCTGCTTGAGCTTCTGAGTGA
TAATTATTCATGGGCTCCTGCCTCTTGCTCTTTCTCTAGCACGGTCCCCTCTGCAGAC
TCAGTGCCTTATTCAGTCTTCTCTCTCGCTCTCTCCGCTGCTGTAGCCGGACCCTTTGC
25 CTTCGCCACTGCTCAGCGTCTGCACATCCCTACAATGGCTAAAACAGCAATGGTAAG
GCACTGCGCCTCGTTCTCCGTCGGCTCTACCTGGAGCCACCTCTCACCTCCTCTCTTG
AGCTCTAGAAGCATTTCAGAGATATTTTATAAAGAAAAAGATGTTAATGGTAACACAG
GACCAGGAAGGACAGGGCAGTTCTGGGGGAGGTGGGAGGGCAGAGAAGAGGTCTAT
GGAAATCTAAAGCGAAGAATTTCTTTTAAAAGGTAGAAGCGGGTAAGTTGCCCTCCT
30 ATGGGTAGAGAATTTATTCTGTTTCCATATTTAAAATTAGGACTCAATCGTGAGGGGA
GGAAGCTACCTTAACCTGTTTGCCTTAAATGGGCTTAAGGGACATTTTGGAAGTGCTT
TATAACGACCTTTTTTTTTTTTTTTTATTTCTTCTCTAGTTTAAGAAGAAAATAGGAAAGGG
GTAAAGGGAAGGTGGGAGAAAGGAAAAAGAAAATTGCAAAGTCAAAGCGGTCCCAT
CCCGCTGTTTGAAAGATGGGTGGAGACGGGGGGAGGGGATGGAGAGAACTGGGCAC
35 ATTTTACGGTATTGTCTCGTCGAAGAAACCGCTAGTCCTGGGGTGCGGTGCAGGGAG
GTAAGACGGCGGGGGACAGGGTGGGGGTAGGACCTCCGCTCCTTTGTTTTAGGGCAA
GGGAGGGGAAGGAGAGAGGAAGTCGCGGAGGGCGTGGAGGGCGCGGGTGGGCAGC
TGCAGGGGCGGGGAAGCGCGCGGCAGGGAGGGGTGGAGGGACAGCGGCTTCGAAG
GCGCTGGGGTGGGGTTTCTTTGTGTGCGGACCAGCGGTCCCGGGGGGAGGCACCTGC
40 AGCGCTGGGCGCACAAATGCGGACAGCCCCACCCAGTGCGGAACCGCGCAGCCCCGC
CCCCCGCCCGGTGCTGCATCTTCATTTCGAAAGGGGGTTCGGGTGGGGAGCGCAGCGT
GACACCCAGGAGCCCAACCCTGCGGGGACAGCGGCGCCACGCCCCGCGCTCCCCGCT
CCCGACTCCCCGCCGCGGCTTCCAAGAGAGACCTGACCACTGACCCCGCCCTCCCCA

CGCTGGCCTCATTGTTCTGCTTTTAAAGAGAGATGGGAAAAGTGGGTAAACATTTTTCT
TTTCGGAAGCAAATTACATAGAGTGTTTAGACATAGACACAGATAAAGGGTTCTTTG
AAGACCTTTGATCGTTTGCGGGAAAAGCTTCTAGAACCTAGACATGTGTATGTATAAT
AATAGAGATGACATGAAATCGTATATAAAGCAAAAGAGGTCAAAGTCTTAAGTTAA
5 GCCACGCGAAATTTCCGTTTTGTGGGTCAGACAGTGCCAAATATCGGCAATTTTCATAA
GCTCAGAGAGACAAGACAGTGGAGACACAGGATGACCGGAAAAGATTCTGGATTCA
GGGCCTTCATCCGCAATTGGTCTTGTGCCTTGAGTGCCACGGTTCTGGCGCTCAGTG
GCCCCGGGGTGAAAAGGCAGGGTGGGGCCTGGGGTCCTGTGGCAGCTGGAAGCACG
TGTCCTCCCGGGACTTGGTTGCAGGATGCGGAGACAGGGAAAGCTGCCGAAAGGACTC
10 CATCTGCGCGGCTCCGCCCTGCCCTACCCTCCCCGCGGAGCCGGGGAGACCTCAGGC
TCCGAGACTGGCGGGGAAGAGGAATATGGGAGGGGCAGTTGAGCTGTATGCAGTCC
TGGAACCTCTTTTTTCAGCCCCGCAGTCCACAACGGCCCCGAGCACCCCTTGATGTGCG
CAGACCCCCGGCGTGGCTCTCAGCCCCAGCACCGAGCCCCCTCCAGCCAAGCGGGTG
GCTCTGCAGAAAAGCTGGCTCGAGCCCCGCCCGGCCACACAAAGGCGCGGCCCCACC
15 CAGCCCCGGGCGCGAGACCGCAGAGGTGACCCCTTCCAGGGATTACAGGGAGGGCT
GTCTCTTCTCGCCACCCACGGTCCGCGGAGCTCGGGGCTTTTTTTCCCCCAGCCCAA
GCCCCCGCCACCCTCTGTTCTCTATGATTTTCCAGAATGGAGACCCCGCGAGGGGC
TTCTCTAAGGGAGACCCTCGCTCCTCCAGCGGGGCGCGGCTCGGCCCCACCCCTCCCA
GCTGAGGCCCAGAGCCGCCTACCGCTGGCCGGGTGGGGGCGCACGTGGCGACTGGGT
20 GTGTGGAGCGCAGCCAGCCCTGCAGAGCCCCGCGCCGCGCCCTGCGCTCCCTCCCC
GGAGTTGGGCGCTCGCCCCCGCGGTGCAGCCGGGGAGACCGGTTTCTGCGCAGTGTC
CTGAGCTACCCCCGCTTTCCACAATTCGCAGTTCACCTCGCACGTCCAGAAAGGTTCTG
AGAATGGGTGGTGGGGGCGATCTCGCCTCGCTTTCTGCACCCCTCAGAAAGGTTTCC
GCTGCAGGCTAGTGGCTGCAAACTCATCGTCATCATCAGTATTATTATCATTTCAAAT
25 CGTTGTTATTATTTAATGATTCAGTAGCCTTGTTTGTTCTCATTGTTCAAAAGGGACG
TGGATTGCTCTTGGTTAAGGATTAACCCCTGTTGCGTTCGCTTTGCTTCCTCCTAATTG
CCCTCATCCCTTTCCCCCACAATAAGGTAAATTTGTCTCCAGTTGTTCAATTTTAAGTTA
TAAAGCAAATATATTTTTGCTTCCTGCCAGGATTATGTATGTTTCATGTGGCTAAGATA
CATGTGCAAGTGCTTGCTAAGAGCAGGGTTTGTGTGCCAACGATTGCTGGAAAATTC
30 TCTGCAAAGAATTGTTTGTGGCTGCAATGGGTGAGAATACACATATATAATTGAGAT
GATCTTCAACATAAGGTTATATCTATAAATATATAAATATAGTTTATGCACAAAATTT
TAAGTTTTTTCCCTGAACTGTTCTTCCAACCTGCTGATTCTTGATACAGCTCAATCC
TACACAGATACATGGATCGTGAAATGGTAGCCGCCATCCAAATAAAAAATCCCACCCC
AAATATGACAAACGCAAGCATCCTTTCTGGCCATAATTTAACTGCATTTGCAAATCAT
35 GAAAAAAACACTACTTCTGCAGTATTAAAATAATAGATTTTGAAATTAATTCCAATTT
CAAAGATAATTAATTATCAGGGCGAGTGCTTTTTTCTGATTCATTAAACAATTATGT
ATTCAGCATGATTGTAAGAGGTGCATATAATTTCCCATTATCTTTTCTAATGAAGT
GGGCACCTTCTGAATGGATATATAAGTAACTAGAAATGAAAAGCTGAGGATTTGGTC
AGAATTCAGGATAAACTGAAAGAAATGGCAGTAGTTTATCAATTAATCTCATGTA
40 TTTAGTTTATAACCAGGTGAGTAAGCTGAGCCTGCAATAAACACTCTCTGTCCCAGTGT
AACACGTCGCAGGTAGCTAGAATGATAGGATAAATTAATAGACCTTGTGGTGTTTGT
CTATGCACGTTAAAATTTCTCTGAGAGAAAGTATATTTTAAAATGATAATTAAGATTGG
ACATTTGTGCTATTAAAATCTACAACCTTAGTCAAAATTCACAATGGTTTTTTTTTACA
ATAATGTGACTTACAGATTTGTAGTAAATTATTCTATTCTAAAAGAGAAATGAGTGTT
45 TTTATTGTTACAGCTATTACCTCATTAATATTTTTAGCAAACCTTTATTTGTTGCATTG
AAAGCAGTTTTAATTACTTTGGGTTTTTATTTTTCAAATTACTAATGGATAGATGGTG
GAATAAGCATTTAATCATTGTCACAATATGACTTCCATCAAATAGCTCATTCTCAGT
GATTAAAAAATGCTACAAGAGGCTACAATTTACTCAGATTCAGGAAATGTCCTTTCA
GAGTGCCATAAGGCTGATTCATATAATAAATAAGTTTTCTTCCCTATAATTTAAGATC
50 AAATAGTTACTTAGTTCTGTGAATACCTAGCAGTAGCTATCAAACAGAATTTTAAAGT

TAAATCTGTACAACCTAACAATGAAGTGGAGGATGAATCGATACATATTGAATGGAAG
ACTTTGTCATTGATAAATTCAGGCCATCTTTAGGAAAATTCCGGATTATCAATCACC
ATTATTTTTTACTTCAACTGAGTGTGACTGATCACATGCTCAGGCTACCTTGGTAGCT
CATTGCTCACAGGAGGCTGAAAAAAGCTGGCCTCCGAGCAGGAGGAAGCTCAGAGC
5 ACAAACCTAGGCCTGGGCGTGGCCACTGGGAGCTGCTGATAGCGAACCCCAGCTCAC
ACCAGTTTCTTTTTTGGTCGTGGGAAGAAAAACACATATTATCCTGTTGTCACAAGAT
CTGTGACCTTATATGAAAAAATGCTAGAATTTTTTTCATTAAAAAAGAAAATACTGAA
CTAGCCAGTGACCCAGATGTTTTTCAGAACCTAGACTGGTTCTGTCCATTGGAAAACCT
CGGTGTCTGCATTAACTTTTACCACACTAGAGGGCAATCATGTTCTCTAAAAAAGCA
10 GATGATTGATGTAAACCTAGTTCCAAATATTAACCTGTTTAATAAAAATCTTTTCTTTTAC
CAGGAACATTCAAGTGTTTATTCAATAAGCTGATGCCATGCTTTACCCTAGTGGATGA
ACAGAGCTTGTACAATTTTCAAGGAGACAGGATGAAATGAGTGGTCATAATCTGAAA
GTAGATACACGCCCTGGTTAATTATTCCCTGATGGTTTTACTTCTCAGTTTTATTACAT
TGTTATTATAATACCATTATGTTACTTCTGAGATTTTTGTAGTGGATAAATAGTAGAA
15 AAATGTCAGTAGTAATAGCAAAGTTATTTAGCAGCCGAATATTTTAATGCTTAAAAA
TAAAGGAATAAATTAAAGAAAATCATTGTTTACTTCTTCATCGATTGAAATGTGCCCC
CTGTTTCAAGAGCACATCTGAATATCAGAGTCTCCACCTGCAGAGAACATGCAGCTTAG
CGAGTAAAACAGGCAGGTATGTGATACTGAGGAGGTGTACCAAAAACCTGACTGCTGT
TATTTTTCCCATCTTCTAAGTCTGTCTTTCTTTTCCATTTAAAGATACCTTTTTAAATCT
20 AATCCAATGTGATTTCAATCTAGTTTTATCAGATTTCAACAATTATTGAGCATCTCCTT
GTAGTGGTTTTCTGTTTATTAGAAAATCGATGTTAATTTTAACGAAGTAAGAAGAAAT
ATATAAGTATAAACTAATTTTGGGTATCATCAAAAAGTGGATTTTTTAAATATGCATTG
ATAGAATTATTTTTTGTATTACATTTTATGTAATTCTAATCCAGCTATAAAATATTTAAT
AGTGTCAATTAATCTGTGTTCTCAAACCTTTGATGTGCATATGAATTACCTTTGATTTTC
25 ATTAATAATGCAAATTTCTGATTCAATACATCTGGCTTGAGGCAGACATTCTGTCTTCCG
AACAAGCTCCCAGATGATGCTGATTCTGACCACTAAACACATCAGTTTTAGGGATATT
AACTTGTAATATACAGGTATCCCTCCTGGTAAGCTCTGGTATTATGTCTTAACATTTTT
AAATCTATGGTAATCTTTACAAAATATTTTACTTCCGAACCTCATATACCTGGGGATTT
TATTACTCTGGGAATTATGTGTTCTGCCCCATCACTCTCTCTTAATTGGATTTTTTAAAA
30 TTATATTCATATTGCAGGACTCGGCAGAAGACCTTCGAGAGAAAGGTAGAAAATAAG
AATTTGGCTCTCTGTGTGAGCATGTGTGCGTGTGTGCGAGAGAGAGACAGACAGC
CTGCCTAAGAAGAAATGAATGTGAATGCGGCTTGTGGCACAGTTGACAAGGATGATA
AATCAATAATGCAAGCTTACTATCATTTATGAATAGCAATACTGAAGAAATTAAAC
AAAAGATTGCTGTCTCAATATATCTTATATTTATTATTTACCAAATTATTCTAAGAGT
35 ATTTCTTCTGAATACCATGTGAGAAAATTCTTAAGAATTTATTGAGTATGACTGTAT
ATTTGAAAAGAGTGTTTTCTTCTGCTTATCTAAGCCAATAAAGGATCTTCATTATTCA
ATTCTAATTTCTAAGGAAGTCAACCTACAGATCAGAAAGAGGATCTTCAAGGAATA
GCATCAAAGACATAGTCAGGTCTCCCATGCAGTGACTGGCTGACCATGCAGCCATTA
CCACCTTTCTGGAAATATTATGCTGCAAAAATGATACAATACACGAAATATCTCAA
40 TTAATAAATATAACATTTCCCAAATAGGGCACTAAAAACATGATCCCAAATAAACT
AGCTTCAGGGTTTGCAGAATATACTGTTACTCAACACAAAGTTGGACTAAGTCTCAA
AGTTAGCCATTTCAGTTGTTGTTAACAGTTTCATTTTCAGGGTCTCTCAGAAGCTGGGAAA
CTTTCCATTTTTTGCAATTTCTTGTACATTGAAGGAAAGGAAGACACACTTAAGACAGC
ATTACAAAAGTAATTCATGTTTTAAATGTTTAATTCTGGCAGTCGGGCAGGGCTCTCT
45 GTATAACCTCATTTGGAGATGACAAAAATCTAACTTGAGGGCCTCGAGCCAATAAG
TCTTCTATTTCTTTACTCAAACATTTTCCCGCAATGGTGCTTTCTTTCACTGTTTTTC
TGTTGTATTCTATAAATTCAGATTCTCTATGGGAAGTAACTTTTATTGATTGATTAA
CCCTTGTATAGCACATATAACATGCAAGGCATTGTTCTAAGAACTTTCCACATATTAA
CTGTGTTAATCACTTAATAATCCTAAGTAGGTTCTATTACAGATATGGAACTGAGGC
50 ACAGAAAGTTGAAGTATCTTACTCAAGGTCACACAGTTAGTCAGATCCAGAATTTGG

GCCCAGGCCATCTGGCTTCGGAATCCATCTTTACCGATTGCTGCTAGTCTCATATCT
GTTCCATGTTAGAGGTGAGCTCCCATTGCAGAGGTCACACCTGTGATATCACCATTTT
ATTTAAACAGACCAGAGATGGTCTTCTCCTTTCTGATCACAGACTCACCTTGAAGAGA
AAATACTTCCAAATTGATGCCTAGTTTTAATAGCTTACCTGGGGCTTATTCAAATAAT
5 TGCCATGATTTAGGCTTTGGGAGAAAGAGAGCTATGAGGCCGTGTGGGTTGTAACGT
ATGAGACACATGGCGTTCTGCAGGCTCAGCACAGCATCGATTTCTGGTGGGAACACA
CTCTGATGACCAGTTCCAGAAATAACATTGACTTAATCTCCTCAGTCCCATCATGGTT
AGCACATTTCAAAATGCCTCCTTAACTACTTCCATAGGCCAGAGATATTTAGTTTTAA
CATTTTGTGTTGAATAAAATAAATTTACACATTCACATTTAATATAACTATTAGATGTTA
10 TTTCAAGATTCTCTTCATATTACCATCAAAGCAGGCAGGCAGGCAGGAGAGAACTGT
AGGAAGGTTTTGAATCCCTTGTGAAACATTTTTAATTATCTTTTAATAAAGGAATCAG
GCCCTGTCATTTGTCAAGGAGACATTTGCAGTAGTAAAGCTTGTGTTTATAATATCCA
TTTTTATTAGTCATGATTAAAGATAACATTTGTGTACATTTGTTCTCACAAAACACTTT
TATATGAGTGTAAGGTTAATTAATGCATTTTCAGCCATCATTTTGTCTGAGTATGTGGA
15 AATATAGCTTCTTTAGGAATTGTACTTAGAGTAGGAGCCACATATTATACTATAAAAC
CATAACAAAAATATTTTAAGTTTGTCTCACTTGTTGTTGACCTCCAGAGTAAAATAT
TTAATACTCTGGAAAGTTATGGGTTTCAAATTTATTTTATGGCAAGAAATAGATAAT
TACAGTTCTCATAGAGCACATTTAAAATAATTTATTTTTATAGGGCAAAAATATTGCC
TAGGACTGAATGATTTTTTTTTTTTTTACAAAGATTGTAAAGCAACGCCTGCAAGAGTG
20 CCCATTTAGCAGTTATTCTTCTGGAATAATTGTATTTTGGATGTTGGAGTTCGCACATT
AACCATTAGTACAAGTACCCAATATAACAATAGATCATCAGGATAATAAATCTGTCC
ATCTTTTAGTTGTATGTCTTTATATCAGGATAAAGAGAATTGAGTGAAATTTATCTAA
ACCTAGTCCCACAAATACTTTTACAAGAGAGCATGTTAAAGTGTAATTAAATTTTTA
TTAGCATTCTACTCTGTCTTTGGAAGTTTTTTTTTCTTATGAAATGCAGCCATAAAGTT
25 TAACTTCCATTAACAAAGCTGCTCACAGTAAACCTATTATAATAATAGTTTCCCAGTT
TGGGCTTCCTAGTGAGGAGCAACCTAACTCACACGAAACAACCCCAACTTATAATAT
ATTGACTGTTACAAAACCTGAGACCAGAAAATCCCATCAAGATGGTACTGTTATCATTT
CCAGACTCTCGGGAAGAACATTAATCATCTCAGGCACCTTTTAGGATAGACTTATTGCA
GCCTCCCTGGGAACCTCTGCTTCAGAACATAATTATTTTTATTAATGCAGAGTTACTTTT
30 TATTTCCAACAAAAATATCTATTGTTATTATTTAAGTCTTACAGCTTTATCTGAGAAAT
TCCAATTAGCACCTTCTCATAATAAATATTCAAACACATGAAAAATTACCAAAGTTG
TTCTAGTCTTTTAATGACATATTACATGATCCTGCACTCTTGTCACCTTAAAAATTATC
TTTTTATTATATTTCTGATGATTTTTTTCTTATATAGTTTTTTTAAAAGGAGCAGGCAAG
CATAGAAGACTAAAAAATGTTCAAAAGAAAAATTAATCGCATGATCTATCTATATG
35 GGACCTTGTCATTTTTAGAAAACATTCACCTGCTTCATCCTTTTGAATCTTCATATAAT
CCCTCTGAGATGGGCATACTATAACAAGTTGTCTTATTTAAAGATTGGTAAATTTAAGC
TCAAATAATTTATTAGTGGCAAGCCTCAGAGGCAGACTCGGAACACAGGTCTAATA
TATATTATATATATATTATAACATATAATATATATATTACATATAATAAAGTTGTGTA
TATTATTTACCTATCAAAATATTTATATGTAATATATAAATATGTTATATATCATGTAT
40 GTGCCTATTTACATATATATACACATTCATGCAAAATAAGGTTTAGCACTCCCTCCA
CTGTCTCTGTAATAAAACATGCACAGTGAGAATAGTCATACACGAGGCATATTTGTCTT
CAGTTTAAAGTCATTGATAGTCAGTGTCACTAACTAAAGTAAAAATAGATTGGAGCAC
CAACTTTGTTCTGAAGCCTGTGCCAGGTATTATGAGAACAAAAATAAAAAATGTTCTC
ACCCTTGGTGGATTTAGTCTTTTGCAGAAAAAAGATCCTGTACATGTCAGAAAGTTC
45 AATAGTAATAATGGTAATTTATAACTATAAATGGAAGTCACCATCTCACAATTTACC
ATCTTAACAATTTTGTTAAACTGCCCTACAATATTACAAGATAGTACATAATGATACA
CTAGTAACATCAACTAGGAAGTACCAAGATCCACCAAAAGGCTGAAAAATTTAAATA
TTTAATGAGTCCATCAACCAATCTGGCCAGAGAATTCTTTAATTAATAATGCTTCCCAA
ATTTTACTGAGAATCAGCAGCGTTTGAGGAGCTAGCCTCCACCCCCAGAGGTTCTCAC
50 TCTATTAGGTCTGAAGCAGGTCCCATGGATTTGCATTTCTAACAAGCTCCCAGGTGGT

GCTGATGAGGCTGATTCAGAACCACACTTGGAGTAGACCTAAAACAGCAGTGACCTG
TAGGGTCCCCAAGCAGCAGGCCAGGACAGCATGTGAGTTACGTCCTCTGTGGAGCTC
TGCAACAAGGCGTCAAGAGGTCAGAGTCTAAGTCCCCATCAGCTCTGCCCTTCTCCA
CCAGTGCTGCTGGTGCTGCATGGAAGGAAGAGCCCAGAAGGGATTCTGAGTTTCAGT
5 CTTTACTCTTGCTGACGCACCTTGGTCAGGTCAATTTTCTGTTTGTTCCTCTAATTCA
GCATCTGTAAAATAGCCATGTGAACTGCCTTGTCCATATCAGAGGGTCTTTTTTCAGAC
TCAAGGAAAAAAACGTGAAAGTGATTAGTGTCTGTCAAGTAGTATATAAATGCAAGA
AGTTGAGTTTTTAAATTGTCATTAGATATAAATACCCATGTGCATGCATTTAGAATGA
GTAAAGAGGGAACAAGGAGCGCAATCAAAAACCTGCGTCATTTGCTTTTTTGAAAAATA
10 CTTTCTATGTAATGAAAAGTGAAATAAAATGTTAATTGAGTCCCTCTGACAACAGCAT
CAGACGTTTTTGCAGTTCTTGTGATTAGAACCCACCTGGCCAGCCCTTCTTCCTCCTAA
AGAAGAGCCTTCTTCTTCTTAAATGAAGGTTGGCTCAGAAGAAGCAATTAATCTCATTC
AACGTTTTTGTACAGTCAATCCACATCCAACTTTTCCCAACTCAATCTGCTTTAAGG
GAAGGATGGTAAGTGGTGGCCCAAGATGGCAACCATCAAGCTTAGAGAATCTCTAGA
15 AGCAGGGGTGTCCCCAGCAAGTAGACACTGAAAATATGAGAGGGCTGATAAGCCAG
AGATAAAACTCAGTACTTACTTTGCTTCTAGTCCATGTCTACCCCTTTCTTGGCACCAC
CTTGACACTACCCTCTGAGTCCACCTTCTGAGATGGTACAACTCTGCTTAGACAAA
GCAGCCCATGTCCAAAGGTGTTAGGGCTCAGTTTAAAGCTGCCTTCAAAGTTAAAA
CAGAAGTGTAAGTTCTGTGCAATTAATAATAATCAGCTTGTCTTGGAACCTCAAACG
20 AATGTAAAATCCTATGAAAATTAATAAGCAGTACCACAAGTTACCCCAAAGTCCTT
AGGTCAGTAACTGTTTCTGTTACAGGTAAAGAGAGAGCATGGATTAGAGGTGGGCGTG
GGTATCCAGTGGACATGGTTTTGAACCATGCTCCACTACTACTACTATCTGAGAATT
CTTAAATTTATTAATCATTTCTATATTATAATTTTCTCAGTTATGAAATGGGAAAACA
ATACCTAAATCACATGGTTGTTAAGTAAGCAATTGATTGTTAAGCATTTGGTCATCAA
25 AAATATTAATCCCCTTCCCTGATTCCCTAGATAAATGATGAAAATACTAAATAAAAT
AATAAAAATTTAAAGTGAACATCTCAATTCTTATACTTTGTTAATTTCTACATGTATT
ACAAATCTACTAGAAATTACTTGGAATTGAGGAAATGATTACTGCTTAATAATTCTTT
GTGGTAGAGGGAGAGTTGGTATCATATTTATGAGACAGCAGCCAATATAGTATATCT
CAAAGGAAAAAATCCATTCTACATAATGCCAGAATTTAATAGTTAAGCATTTTATCTA
30 GGTACAGCACAATAAGCAAGATGGATAATTAATAATAAAGTATATTTCTCTTGCAT
ATATTTCTCATTTTCATGTTTCCCTATCATATTTTATATCTTACCTTACTTCAAATACATA
TATACCTTCAATAAAACTGAGCCTTCTTGCTTACCCAGGAAGTTTCATCATTACAGTAG
AAATAAAAGATGACTTTAGAAATATTAATAACAAAAATCTACACTGAGGTCTTTTG
AATGCAGGAAAAAGAATTATATCACACACACACGTACACGCACGCATGCATACACAC
35 ACACAGAACCTCTCGTTCTTTCTTAAACATCTTATCAATCCATCAGTTTCACTCCCACTC
CGTATCACCTGACTGTGCACAATATCTCATTGCCACCTCCCAGTCTTCTCCCTGCCTG
GCACCCTCCTGCTCTCCTGCTTCCACTTTAAACACCCTTCCCTTCAGCTAGGTCTTTTCT
TTCAGGGATCCTCCCGTTGCTTTCTTATCTGGATCAATTTAGCCTTCCCTCTTCTCCACC
CATTAGTGATAAGCACGACAAAGACACTAGAGTCAAATAATACAAACAGAAATATA
40 CCTTAGATGAGTATGGTGATGAAAAGGATATGGATACTTAGAGTTTAGCACTATTCTC
TCAGCCACTCAGGAAAGCAACGCCTTTACAATCAATAGTGTTTCAGGTACCAATCAA
TAATCTGTTATTGCTATTTTTTAAATCTATAAGGTATCAGTAAAATGTAATTACTAGA
GCAACAAAGATATCTTGTGAAATCAAATTAGTATTCATCCAGCAACTGAGTACAAAG
GTTTAAGGGAGGATAACTACCAATACCAAAACATTTTAAGCATTTTGTGTTTGCCTCCT
45 AAATATCAAATCATGTAAATGTGTGGTACATAAATTAGGAATTATTTTATGACATA
GCTGCAGACATATTAAGAGAAATATGTGCTTATATTTACAAGTATAGTACAGTTCTTT
TTCATATTAGATACTGTTGATGATAATCTGCATATAAAAATGCTCAATATTTTTTCAC
ATTTATAAGCCATAAAATACAGCTAATAAAATGTGTTTCTACTTTCTCATAAACATGG
AATAGTGACAAACAAGGAGCTTTATATGAAAGCACCATTACAATTTAACTCTCACA
50 AGGTCATAATATATTGCACTAAGCAGGAGAGTTCAGCTTATTTAAAAAATAA

ACTCTAATGAGGTTCTGGAATGCAGAGCCAAAGCATAAAGATGGAAATAAAAGAAT
TGCATGTCTTCTGAACTGACTTGTTGATGATTTTTTTTAAAAAAGGTTTTGTGTCTTCT
GACTTGGTTGATGATTTTTTTTAAAAAAACGTTTTGTGGTAGAACAAATAAGGTAAATG
AAATTCAGTATTTAGGATGAAAAGTTTTTCTAATTTTCAGGAACAACATTGAAGAAAT
5 ATTGAACTAAGCAGCTTTGAAAGAATCAGATTCCATTTGTTGAAATTTTTCTGAGAAT
GAATTTTTTTTAAAGACAGTGTACACAGTTGCAGTGTGTATTGGTTATGGATTGTGGCAA
GCTATATTACAACCTTACCCAAGAAATAAGGAGGCTGGGCGTGGTGGCTCACACCTGT
AATCCCAGCACTTTGGGTGGCCGAGGCGGGCGGATCACGAGGTCAGGAGATCGAGA
10 CCATCCTGGCTAACACGGTGAAACCCCGTCTCTACTAAAAGTACAAAAAATTAGCCG
GGTGTGGTGGCGGGTGCCTGTAGTCCCAGCTACTCGGGAGGCTGAGGCAGGAGAATG
GCGTGAATCCGGGAGGGGGAGTTTGCAGTGAGCCGAGATTGTACCACTGCACTCCAG
CCTGGGCGACAGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAGA
AAGAAAGAAAGAAGGAAAAAAGTCACTTGAAAAGAATACTGGACTTTGTGTCCAGC
TTGCATAGCTGAAAAGAATAAAAAACCTGTCCACTTAACTCATTGCAAAAAGAAGAT
15 GTCACTCCTACAAATAGCAAAGAGTCATGAAATTATTCTATCCAGAAAAGTATACAT
TTCATCCCTTTGGATAAATTTTAGAAGTGAACCTATGAATACATACGGTGAGGATAGCC
AGCTAAGAAGTCAAGAAGGATTTCTCAAATTTGCTGCTCAGAAAGATCATACTCTCC
ACAAAACAAATAATAGCAGGCTTTCCAAGTCAACCTTGAATCCAGCTTTCCTTTATCT
TTCCTTCTTGTGAACTTTCCTAGTTTACTATCTAACAATGAATTTGACGATAGCCAC
20 ATACCATCTTATAGCAATATTTGTTATCATATCCCTTGTTATTTATCATTACCTGCTC
TGCTTGAGCCAGCTACAAGTCACATGTCCACGCACTTTTTCTGTTTGATTTTTTACA
GCACTTTGAGACATGTCTCATTATTCCTACTTGACAGGAAAGAAGCCATGGAAAGTT
GAGTGACTTGCTCCTGATCACAAATGCTGGCCAAGGAAGAGTCGAGTTTCAAATCTA
ATGATCTTTCCACTGCACTCTAGATTCCCTCATTTTGAACCTATTTTTTTTATTTTTTGCAT
25 ATAGACTTTTTTCCACATTTTGAACCTGTTTTTTATTTTTTGCATATAGACTTTTCTCTT
ATACCCAACCTATATTGATGACTTCTTTTAGGCTAGAACTTGTTTCACTTACTTTCCCT
TTCTTCAGATTGCTGCAATATTGGCCAACATGTATTGGGTACTTACTGAGTCAAGTAC
TGTGATTGTGCCAAGTATCTTATAGGAGGATTATCATCCTCATTTTTTACAGGTGAGAA
AGGAAAGGAGGTAAAGTCACACACAGCCAACAAAAATGGTAGCACCAGGATTTGAA
30 ACAAATCAGTCTGACCCAAGTTGACTTTGTTAACCCTGTATGCACAGTCTTCTTAGA
CATAGTAAGAGCTCTAATTGTGTTTGGTGATTTGATTATTATGACAAAGTAAGTAAGG
GAAGCAGGGAGAATTATAAGAAATAAGGCTCCACAACACTTGGCTATAGCAAAGCC
CCTTAAAACCTTCAAAGGTACCCAAAGAATAAAGATCAGGCTGGGAGCAGTGGCTC
ACGCCTGTAATCCCAGCACTTTGGGAGGCGGAGGTGGGTGGATCACCTGAGTTCAGG
35 AGTTCGAGACCAGCCTGGACAACATGGTGAAACCCTGTCTCTACTAAAAATACAAAA
ATTAGCTGGATGTGGTGGTTGCCGCCTGTAATCCCAGCTACTTGGGAGGCTGAGGCA
GGGAGAATCGCTTGAACCCAGGAGGTGGAGGTGTCAGTGAGCCGAGATCATGCCACT
GCACTCCAGCCTGGGCAACAAGAGCAAAAAACTCTGACTCAAAAAAATAAATAAAT
CAATCAATAAAATAAAGATCAATTTGGAGAAATTAATGCTTATTAATAAGCAATGTC
40 TTGCACAGCACTTCAGTTTCTCAATACATTACCTAACTCAATCCTTACAACAACACCC
TATCCCCATTTTGTGGATAAATAAACTCATGTTTCAAGAGGTGAATAAATTATCTAAG
GTTAATAGTTCCCTGACCTAGAGCTCAAATCTTCAGTTTCTATCATATTCTTGCCCTTAC
CCTGGGGTAGCTAACATTCCTCACTAGTATTGGAGCTAAAATAAGGGAGAGAACAT
ATAAATGAATACAAAGGAGACATTCACCTGCCTTCTCTTTCTCCTTACATAGAGAAGG
45 TTGATTATCTGCTATTGTGAAGTTTGCCTTTTGAAGGATAGAAATGAGAAGACTTTCT
TAAATTTTGCCTCTACGCCAAGAAATTAGAGTGGTACCACCAGTAGTTCCATTTTCAA
ACTATCACTGTAGCTAAAGCTATGTGGTAAGGGCCAAGGAAAAGAAGTATTCTTGCA
CTTCAAATGCACTGAAATACCAGTCAGTAGCATAATATAAAGGAATTTAGTGGAGA
GAAGAGTTGACCTCAATCTGGCTCCAACATCTCGGCTCTTAACCCCTACCCTACACTT
50 GTTCTTCATGGGGAAGCTAATTGGGCCACTGGAAGATTGAGCAGCTACCATTTGCAG

CTGAGGGACAGCCCCTCCCTGCTTAGCAACCAATGGATATGCATTTATGGAACACCT
GCTAACTGCGACACACACTCCTATGTATGAGGGGAAAATACAAAAAATGTTAAAGGAG
ATGCCTTCCCTTGCCCTCAGGAACTTAAGTATAGTTGCAAAGAAATGATTAGCAGC
AAACGAAACCATGGAGAAGTAAGGGCTAAGGTCTGTGAAACAAGCCTAGAAAATAA
5 CCTTGTCTTGAAAAACAAAAAGAAAGAAAGAAAGAAAGAAACTCCAAGGCC
TTGTGAAGGAAACCATTAAGTTTGCTTCACTTCTGTGTTTAGGAAGACACAAACCCAG
TCTTAATGAACCTCAAGGCCACAACACTACTGGAGACATTTAGGAATTGTCACCACATTC
TAATGTATATATCCTCTGTTTGGCCCTTCCTATTAATATTTTGTAAAATTTTGAAGAT
ATGAGCAATGTTTAAAACCATGAATCCCCCTTTTTTATAAGTAATATTTAGGCTGAA
10 TAAACAAGAGAAAATAGGACATAAAGGGGAGCCAACGTGTGCCTTCATTTATAATGT
ATTCCCAAGTTGTGAGTTTGGTTTATCAGCAATTTATCATGCCAAATTCOAAGTCATA
TTTATCTATGCAGATCAAACACTTGATTCTATTTTGCCTTAATTTTTTTATTGGGTAT
GTTTATGACCAAGTCATATGGTATTTTCTGTGACAGATAAAATGCACAGGTTATTCCA
ATCTGGCTCAGCCAGTCATAGCAACATGTAGTCCTTCTCATGTCTTAAGAATGAGTAT
15 CAAGAATTCAAAGGGAGTTCCAGATGGCATCCAAAAAGCTTACAGTTTATGCATCAC
TTATTCTAACAGTAGAAAAAGAATATTTGAAGCCAAAAATAGACCTTGCATGTAGCA
TGTGGAAGAGTAGAAATTGCCCTGATAGTTAAACAATTTGAAATTCAAGACATTAAT
TTCTTTATGAAGCATTTGTACATCATAGGTAATATTTTATGCCTATCATATATACT
TATTATGAAATACAAAGAAATTATTCATTCTATCTAAGACTTTGTATCCTTTACCAAT
20 ATCTCTCCATTCTCCACCTCCACCCTAGCCCCTGGAAACCACCCTTCTACTCTCTGCT
TCTATGAGTTCTTTTTTAGTGAGATCATGCAGTATTTGTCTTTCTGTTCTCTTATTT
CACTTGACATAATGTCCTTCAGGCTTATCCATGTTGTCACAAATGACAGAATTCCTT
CTTAAGGCTGAATAGTATTCCATTGTGTGTATGTAGCACATTTTCTTTATTAATTCATT
TGTTGATGGATACTCATATTGATTCCATATCTTGGGTCTTGTGAATAATGATGCAGTG
25 AACATAGGAGTGCAGATATCTTTTGACATACTGATTCCACTTTGATGGGATATATAC
CCAGTAGTGGGACTGCTGGATCATCTAGTAGTTTTATTTTTTTTTATTTTTTATTTTTT
TATTTTGAGACAGAGCCTTGCTATGTCGCCCAGGCTGGAGTACAGTGGTGCCATCTAG
GCTCACTGCAATCTCTGCCTCCTGGGTTCAAGCAATTTTCTGCCTCAGCCTCCTGAG
TAGCTGGGATTACAGGCACGCACCACCATGCCCGGCTAATTTTTGTATGTTTAGTAGA
30 GACGGGGTTTCACCATGTCTCGAACTCCTGTCTTCAAGTGATCCGTCCACCTCAGACT
CCCAAAGTGCTGCGATTACAGGTGTGAGCCACCACGCCTGGCCTAGTAGTTCTGTTTT
TAATTTTTTGAGGAGCCTCCATACTGCTTTCCATAATGGCTCTAGGAATTTACATTCC
ACCAGCAGTGCACAAGGATTGCTTTTCTCCACATTCTGGCTAACCAGTCTCCTGTCTT
TTTGAGAACAGACATTTCAACACGTGTGAGATAATATCTCATTGTGGTTTTGATTTGC
35 ATTTCCCTGATGATTAGTGATCTTGTGCCTTTTTTTCATATAACTGCTGGACATTAATAT
GCCTTCCTTTGAGAACTGTGTATACAGGAGAAAAATAATCACTTCTCAGAGGAGCTTTC
ATTTCAAAATATCCGGGAAAAAAATAGAAAAAATGGAAAATTTATCCTAGAGTAAGT
TGCTTTTTATATTTTGACCCTGTTTGTGACATAAACTGGATGATACAAAACCTGGAATG
CAAAGGCTTTAGGAGGATTACTTACTTACTTGTATATTGCTTTAGGTTGTTTGCAGAA
40 AATTATACTAATTGAAGTTCAGGCTATGATGTGATAAAATCTATGTCAGGAGATGAG
TCTACATGCAAAGTTTGAGGAAGTGACATTTGAGTTTCAAACAAAAAAGCAATTTT
CAATGTATATCTAGGTTAACCCTAAAGATTCTTTTACCCTATTTAGCTGCCTCTAA
GATGGATGCTGAGGATAATTACACTGTAGAACAATAGGACGATGCTTCACACTCACC
TCACAGGCTCTGTTATTCCACATACTGCCAGAGATACTCCAAAATAAAATCACTGCA
45 ACATCAGGCAGTTATAAACCTCAACGGTATTATTTTCTATTTATATACAGTATATTTT
ATATTTTACAAGTATAAAATAGAATATATTTATTCTATTCTTTGACACAAAGTGAC
CATAAGACATATTACTTAAGTATGACTAGCAAAGTCATGGGGCTTGTCAATTCAGGAG
GAAACTCTTAACCTAAGTTCAGTTTTTGTTCCTGACACCATTTACATAAGCCAACT
AATGCTTCACACTGTGCAAAACAATGCACAGTGTGTGAATGAATGGCTAAAATAAA
50 ACTCTAATGAGTGGGGTTTGAAAAATGCAACTTTAGAAAACCTGTTGAGAAAATGTTG

CACACTGCGCATTTTTACAAAATTTTCGTTGAAGGACACTGGATATTCTTTTTAGGATTA
 TGGAGGGAAGCAAAATTTTGGCTCCTACATGCAGTTTTTGTGGCCTTTGCCTGAAATA
 GTCATCTCCCATTAATTATTTAGATATCATTCAATTCCTAAGACAACATTTAGGGAGA
 CTGCCTTAAGTACAATTTGTACACTACCCAGATAAGAATTTCTTTTTGGTGAAACATCG
 5 ATAAATATTACTTGGCAGTAACACCAAGTTAAATATTTGTTTCACAGTCGACGTTAA
 TAACTATTATAGATAAAGTGAATTTTATAAGACATACTCAGATCTAAAACAGCAATA
 TGGAGCTCTTCAAATCCATTGAACTTCATACCAGCCTACGGAAGTAGAGGTTTTTAT
 GCAAACCTCTTCAAGAAATATGCTCTGAACTTTTAATTCTTAGATTGATAGAGGAATT
 10 AAATCATGATATAACTAATAGGTTTGTGGTACAAATTGCTGCTGCTTAATCTGACTCT
 GTGTCTTCCCAGTGTTCTATATGAATTAGATATTCCATTATCTAAAGACAATCAACCC
 CATCCCACGGTGATAGCTCTAGGACTCCCTTTGAGTTCATTAAATCTGTATTCTCAGT
 CTCCAAACTTCTGGTTAATTCAAACAGAAAAGTCAACTGGCCCATGAACTAAAATAA
 AGTCATCTGAATTTTTTTTTTTATTTTGCAGTGTGATAAAAGTCTCGCACTTTTTATTTC
 TGAAAGTTTCTGCTTTCACTGAGAGCATAATAGGCTATCCACCCTTATGCAATCTTAC
 15 ATACAAAGTCATAGTCAGGCTAAATTCAAAAACACATGTGAGATAGAAGTCAACGTT
 TATTTTCTGGAGAAAAGCCACACATTACAACAAAGTGAACAATGAAGCTGGCATCCT
 TATCACTGGTGACCAAAACATTTGTGACTCTGGACATTGGCCCCACAAATGCGATAA
 ACATTCTGCATAGGAAGTGAGTTTTGCTAATTAATAATGGATCCAAAATACTTTCTAC
 TCTTCAGCCAAGAATTAATAAAGTAATAGGGAGGAATTGAAATCACTTGGGTGCTACA
 20 TTGAGCCATTCTGGAGAAGCAATTCAGAGAATGTCATGGCAGCCTCAAATTGCTGCT
 CAGGAGCATCCCAGCTTAGAAGATTGCAGGAAAGGAAGAGCAAAGTCATTCTTACAT
 GAGAACTGTCCTTAACCAGATGAATAGACTCTCCATTTTTTACCCTGGCTTTGTCTCA
 TTTAAGTCCCAACCAATCTAGCTATCATTTTAGGTTTTACTACCTGCTAGTATTTAGGA
 GCTTAGGGGGATAAAAAAATCCCTCAATACTCAGAATTAGACTTGGTGATAAAAAATC
 25 TTGACACATAAACAGAATAAAGCGCTTTCATTACTCCTCTAAACCACAGTGTCATTG
 GTCTCTATCAAGGACTGTAAGAATTTCTTTCATCAGGGGAAAGAAAAAAGGACAAG
 AGCCTGCAAGATGTAGCGGAAGTCTCATTAACACAGCAGGAGCTTTAACTGGAATC
 CAGAGTAAGGTGAGGTACCAGGTTACAACAATTTACTGCTTTTATTACAATTTTGATC
 ACAAGGACTGATTTCATGTCATCTAGTTTCTTTTCTTGTCACTATCACTGGTGCTAAG
 30 AATACATCAAATTGAAATTTAAGAGCCTCATATGTTTCTGTATAACCCAGTGATGGGT
 TGTACTGCTTTGACCTTCTTAAATGTCCCTTTATTTTCATTTGATATCCATTCCCATAGA
 AAAACTATAATGCTTTGGTTGGTCAAAATATTAATCTTTCAAAACCTCCCTGGCTTAG
 AAAACCAAATTTTTGTAGAGAGAGATGGGTAGAATCTAATTTTATTCTAAAGCAATT
 AGCATTACATCATCACAGCAGAAATATCTAGAATATTACCTCATGTCAGTGATCTTCT
 35 GATATGTTAAAAAGGGTATTTTAAAATCTGAGTTATTTCTTTTTCTTTTTAAAGTTACA
 TCATTAATTACATACTCATCAACCAAAATATTTTATGCTCCAAATTTGAACCGATATA
 GTATGTAAGAAGTGTTCAAAATGAAATTATTTTGGTCTATTTTGTCTTTGAAGAAGAT
 CACAGGGATGGACCTCCCAAAAGGATTTTAAATGGGATTACATATCTGACTTTTAA
 AAAAAATTATCTGACCTTGAGTTATAGTGCCCCAAAGTAAGCAAAGTTCCAAACACA
 40 CAGTATCATCAGAATTGAGTTAAAATTATCACCAGGGGCTTAATTTCTGAAATTAAA
 AAGGAAATGTTATTTCTTATGAAAAGAAAAGGAACCAAAAATGAACTTCAAGGTAG
 CTGATTTCTGTCTATGTAAAGACTTAGGTAATGGGAGAAAGGGAAAAGGAAGGACAG
 AATTAGGAGAGGAGCAGTGTTTAAACAATTGCGGGTGCAAGACTCAAGTTTTTTAGAA
 TCCATTAGCAGAGAACCCTATTTCTCCCATTAATGCTGTCTTTTAAATCCTGGCAC
 45 CAGCTCTGAGGACTGCAGGGTCCATAGCTAGTGCCCCACTCTACCCAGTTTAAAGAC
 ACCACTGCCTGGAAATGACAGGGGTTTTTTTTCTTAAGGAAAGAGGTGCTTTCTGCCAC
 GTATATATAAATTGGTAAGCTTCAAATAAAGTGCTTTTGTCTTTCTGTCTATCAGAA
 ACTGTGCAAATCGAATTGCTGTAAAACCAAGGGCAAGAGACATCAATCCTGCATTCT
 ATAGCATCTGATTTTATCCTTTATCCCCAGGCACATTTCAAAAGGAAAAAATGAGGT
 50 TGCATTTAAATTGAGTATTTGGGACTTGCCAGGAAAACCTCCCGCTAGACTAATATGA

TTGCAGGGAAAAACAAGAGAAAGGAAAAGTGGAGAGGGAGTGTGCTAACAGATCCTG
GGCCTCGTCAGCAGAGCCGTCCTGAGCACAAGGCCATGGTCAGACATCTGGTCCCCG
GAATGACGTTTTCTTTATGGTCATTAAGAACACCAGTGTGTCTGGGACACAAACAAGT
ATTCCTTTCAGGGATTATGACACATTTTCTCCCAAAGTAGTATATTAATGACATTTCC
5 AGAGCATTCTTTACTATCTTTTATATGTGATCAGGAAGACTAATACATATCACTACTT
CTTTTACACACAGCATTAGCCAAAACATAAAGTGTCAAATACAATTTTGCCTAGGATG
AATAAACAGAAGAAATTTTTATGATACTGCACTATCAATTCCAAATTAAATAACAAC
AAAATGATAAGTGTTAAATTCATATTAATGATTGTTCCACACAAGCCGGAACAAAA
TCTTTCTAAGAAGTCTTTCATGAGTTAATCCCATCTTTCAAAGTGTTCAGTGGCTCCG
10 AATTCAGTTACTGTTTCCTATCAGTTCTTCTTTCATTAAGTCTCTTCCCTTTTTTTTCTC
TTTGCATATTTCCCTTAGCCGGGTACATAATCTGCTGTGCTTTATTCATTTGTGTCTT
AAGTTTGTTCCTCGATGACATACCTTTCAGCAACGCCATCTGGGGAGTTTGGGCAAC
TGTACCACGTTAGGAGGAAACCTTCTTCACAGGAGAGTGTGCCTTTGCTGCAGGGA
AGGAATTAGGATTTGCTTGGACTGTGGTTGCAGCTGGCTTTTAAGGATCTCCTTAGAA
15 TGCAAGCAACTCATCAATGAGAATCTCTGCAATGGTTGTCAGTGGGTAGAGTCATGC
TATGTGGGGTCATAGCCTTTGAAACAAATAACAGTAAAGATAAAAATGCTATTAAAG
GAATCACCACCCACAGAGGTTAACTGGGTTTTGTCCCCAGACCACCTCGAACAAGAA
AGAACATTTTTATCAGTCATTTTCTTAGTTTTAGCTGATAAAACAAAGTACCATAGAC
TAGGTGGCTTATAAACAACAGAAATTTATTTTTCACAGCTTTGGAACTGGAAGTCTG
20 AGATCAGGCCGCCAGAATGATCAGATTCTAGTTAGGGCCTACTTTGCTTTTGCAGACT
GCCAACTTCTAGCTGCATTTTTCATGTGGCAAAAGGAGATTGAGCTAGCTCTCTGGTCT
CTTCTTATAAGGACACTAATCCCATTCATGAAGGCTTCACCTTCATCATCTAATTACT
CTCCAAAGACCCACCTCCAAATACTATCACATTGGGAATTAGATTTCAAATACAAA
TTTTGCGGGGACACAAATATTCAGTCCATAATAGTAATGATTACTCATTATACATAGG
25 GCTCTAAATGTGCTAGCTTCTGATAGTTTTTACACTCACTTCTCTTTATTAGCTTGTC
AGCATAATTAGGGCAGTGGCCTTACTGAAAATTATTGAATTTAGTTTCCTAAGGACA
GATATTGAGGAGTTTTTCTTCACTAAAAATTCACGTTCCGATACAGCTTTCATCTGTT
ACTACTTTGTGAGATGGAAAATCTTTTATTTTATTTTATGTTTGGATTGACCCTTCTT
AATAAAGTCGGCATGTAATATGCTTCATGTGTTTCTAATATGTGCTTAATTTTGCAA
30 ATGTTTTGCATACCAGAATGCATTTCTCTTCCAAAAAAGGTACCAGCCTACAAAACCT
TGCTGTTACTGTTTTCAATTAGTTCATGGAATTAAATGTATTAAATGTTTTATGCTCTG
GCAGAAATTATGATTCTCACTTAACCTCCATATAAATCTGGATCTGCCTGGGCCTTTAT
AAGTGACACAATTTCACTAATGAATAAACAATGATACAAAGAAATTTGGTTTAGC
CTTCTAAAATTTCAAAGGCGTTCAACAAAATATCTCAGAATGGATGTTCCAGGACTTT
35 TATGGCACAGGACAACATGTATTGCTTATTTTAAGAAAATAAGCTAAATAGTGAGGG
GATTCTTTTAGCAGATCCTCAGGATGTGTTAGGTTGAATCATAGGCAAATGATATTTG
ATCATTGCACCTGTAAACACATTGAACCTCATCCTAAAATTGTAGAGCTAGAAGAAA
GCCTTCTGGCAGTTTTTAAATAGATTGATTTACTGCAATTTATCCAGAAGCTTCACCG
TTGTCAGTGGCTACATGTGACTTTGGCCTCTGTGGGGCTATATCCTCATTGTGAAAATT
40 GGTGGTGAGGTAGGTGGACAGTTGACTAAATAATCTCTTAGAATAATTCTAGTATCT
GTGGATCTAAAGCATCCAGGGGTTGAATATGTTTCTTCTGGCCAAGAAAAGATGCA
CCTGTCAATAATGCCCAAACCTCATCTTCTGAGAATCCTCTTTCCCAAGATACCCACTC
TCCCTTGGGTTATATTATAGTAATGATCAGAAGCCCCTGCCAAGAAGAACTGTAA
CCTGGGAGGTCTATATTTTATTTACAGCCATCTGTTTATACTTTCTCACAAGTTAGTG
45 CACAGTATACCCATCATTTTCTACCATTTTCCTTAATTTATTAATTTTACTAATTGCAT
AATTAACAAAAGTAAGAAGATTTTACCTCCTTATCCCCATCTGGTAGTTTGCAGATAC
TTGGCCTGATGACAACTGACAGTGATGAGATACTACCAAGTTTACCAGGGCAGGAG
GCTTCCTAGAGAAAAAATGAGAAAATGAAATGGGGAAGGGGAGTGAAGGATTGAGG
AGGTGACAATCTGGACTCTTGCAACTGCATGGCAAGGTTGGCACACAAGCTGGGTTG
50 CAACGGAGGGAAGGAGATCCTTATCAGATGTAATCAGAGCTCAGATCGAGGGCTTTG

GTGTGTGTAGAAAGAGGGAGAGACAAAGAACTTAAACAGAGCTGCCATTTGACCTT
GCAATCCCATTACTTGGTGTATACCCAAAGGAGAATAAATCATTCTATTA AAAAGAC
ACATGTGCTTGTATGTTTCATGGCAGCACTATTCACAATAGCTAAGACATGGAATCAA
ACTAGGTGTCCATCTATGGCAGATTGGATAAAGAAAAATGGGGTAAATATAAAGCATG
5 CAATACAACATGGCCATAAGAAAAAATGAAATCATGTCCTTTGCTGCAACATGGATG
CAGTTGGGACCCATAATCCTAAGTGAATTAACACAGGAACAGAAAACCAAATACAG
CATGTTCTCACTTATAAGTGGGAGCTAAACACTGAGCACACATGGACATAAATATGA
GAACAATAAACACTGTGGACTACTAGAGGGGGGAAGGAGAGAGGTTTGTAAACTA
CCTATCAGGTGCTATGCTCAATACCTGGGTGATGGGATTTACACCCCAAACATCAGC
10 ATCATTTAATATTCCCATGTAAAAAGACTGCACATATACCCCTTGTATCTAAAATAAA
ACTTGAAATTAAAAAAGAAAGAAAGAAAGAGGCTGGAAATAGAGGCTCACAC
CTGTAATCCCAGCACTTTGGGTGGCCAAGGTGGGTGGATTGCTTGAGCCCGGGAATT
CAAGACCAGCCTGAGAAACCTGGTGAACTCTGTCTGTACAAAAAATACAAAAATTA
TCCAGGCATGGTGGAGCGCACCTGTAGTCCCAGCTAATGGGGAGGCTGAGGGGGGA
15 ACATCACTTGAGCCCAGGAGGTGGAGGTTGCAGTGAGCTGGGATCACACCACTGCAC
TACAGCCTGGGTAACAGAGCAACTCTGTCTCAAAGAGAGAGAGGAAAGAAAAAAGA
AAAGATGGACAGATAAGAAAATGCACTTGGAGATTAAGAGAAAGCAGCAACATAGG
ACCCTGGATAATGTGTTTGCTTAATAACTATCCTGATGAGTTATCTGACTATTCCCAA
ATGAGTACGTGGCAATTCAGGCTGAACCATCAGAGTAGCCCTCCGGAATCTTACTTA
20 TGTACAATAGACCTGCATGCACATTTACTAGAATGAGCCTCTCTCTCTGGTAATCATG
TCTGCTTCCACTAATTCCATCTGTTTCCTCTCTCTCCCTCCTATCCTGCTAGATCTTAAT
TCCTTCGACCTTCCTTTGTTTTTCTAACTCCCTTTCTTTCTCTTGTATTTAACCTGCTA
TACTATGCAATTGATCTCCTCTGCACTAAGGAACATGCACTTCAGAATTCTGTTGACA
TCTTGCATTCTTTATATTTAGTGAAAGAATGCAAAGGAGTCTACCTGGCAATATTCA
25 CTCTGCAGGAGGCAATAATTATTATTCAAATTAAGGAAGCAGTAAAGAGAAATTCA
GAAAAAATGAAATATACTAATCTTCAGCTTTTCATTTACGCCTACAAGGAAAAAATG
AAGGAGCTGTCCATGCTGTCACTGATCTGCTCTTGCTTTTACCCGGAACCTCGCAACA
TCAACATCTATACTTACGATGGTGAGTAACCTAGGATAGACATACCCCTGCTAGCTA
GATCATTTGGAAAGGTTGACATATATTTGTTTCTTACAGCTCCTGATATAATTACATC
30 AATATTTTGTAGCTCTCACTATTGACTTGCCGTGTCTAGCTATTATGTCCAATTGATTA
CCTATTGCTGAAAACAGTTTGAATTTGGTGCTAATAACAACACATCAATGTCTGTAA
GAAATGTGGATGGATTCTTATTAACAGCCACATCCAGCATATCAACATCCACAATAT
GTCTAAGGTCTTTCTTTGCAAATAATTTAATAGGCTAAGCCATAATTGGAGTAGATCA
TAATTTGTAAAGAAAATGCTTTATACTTAGAAAACCTCAAGAGAAAGAATCAACAACCA
35 TAATTGTTTTTGTCTTTATTGTAGTCTTTATAAAGTTTCTATACTTTGTATATACATGTC
AACCAGCTAATGATAATAATAATTGGCTCAATAAATAAACTGACTTACGACTGAGG
CCCTAGATAAAGAGGGTCTGAAAAGAAAAGCCTAAAGAATTAGCATGGCAATTAAC
ATGATTGAGGTGCAACTCTTTAGGTTTGATTTATCCTGATTCAATTTTGCTTACTTTGGC
TCTGCCACAATCCACATGATCTTGGTCAAATAGATACTTGGATTCTCTAAGTCTCATT
40 TAACTCTAGCATCTTCCTCTTGGAGTTGTTGTGAGGTTTAAACGGTTTAATGTAAGTC
AAATATGCAAAACCAAGCCTAGCTCATTATATCACTCTACAATGATAGCTATCATTAT
CAACATCATCCTTACCTAATTCAGTCAATTTAACTAAAATATTTTATACAGTTCTATGT
ATCCTAGATATCCCTAAGGCATATTTTACTAACTCTCAGGCTCACAAATATTTTTCTTT
TCCATATATGTAAAGAAAGACATTAATGACAAAACAACTGACCTTGTGGCAGTTAA
45 CCCCTTCTGCACCTTTAAAGCCTATTCAAGGACTCAAAGGCATTTACCTTCCAAAGTT
ATTCTATCGTAGCACAAAAATCATAAATGCTAATTAACCTGTTCCATAAGGAAATGTCC
TCCATGTGAAAGGAATTCTGTCTCCAAACAAAACATTCATTAGAATGCAGGGCCAAT
GCCTACTTTGTACAAATTCATTCGGTCAGCAAATAAATTAGACAGACCTTTATTATTT
GCTAGATGTAGCTGTGAAGAAGGATCCAGCTATGTTTCTTATGAGACTAATGTCGAA
50 CTATGGGTGTCACTGAGGATCCAGAGTTCCATAGGGCGTAGTCCTCACCTTCAAAG

AATTCAGGGCTTAGTAGAAGAGTCTTACACAAATGACTAGAATGTAGAACACAGAGT
 GGTTAGGACAAAGGAGCCAGGGATGGTTTTTGTCTGGGTAGGGAATGAAAAAAGGG
 GAAGAAAATATGTGAAGTTATGTGTGAGCTGATTCTTGAAATAAGCTGTTTTTATTTG
 CCTGCGTTCTCTTATAATCCTTTTCCATAGGCTTCCATAATTTTTATTGAGCTGTATTT
 5 AAAGTTGAATAGATAATTCAACATTTCTCGTAAACTGTGCTTCCATAAAAGAGTCCGTA
 GAGAATTTCAAATTTCTGCAGTCTTTAACTTGACCTGGTATTTCTATGTTAGATAATA
 ACGTGACTTGTTTATTGCAGGCCAACATTATAACAATAAATTATTATTATTGTTTACA
 TTTGTAAGCACTAAGTATATGGCTTGTGCTTTGCATTTCAGCATCCTTTATCATTTAATC
 TTCACAACCCACCTTAGAAGGAAGGTACTCTTTTTATTTCCATCTTTTAAATGAGGAAA
 10 TAAAAGCATAAAGAAGTTAATTAACCTTACCTAGTGTCACACAGCTATTAAGAGGGGC
 TTAATAATTTGGATGCAAATATAGGCAGTTCTAATTCCAGAGCCTCTAATCTAAGGCAT
 TTAACACCCCATCACCTTATCAAATAAGCTGTTTTTATTTGCCCGTGTCTCTTATAAT
 CCTTATCCATAGGTTTCCATAATTTTTATAAAATTGTATTTAAAATTTAAGTATAATCT
 TGGATGCCATCAGGAAAATGAAAAACATTTTTACATTTGTGAAGGAAAAAGCCCCACA
 15 TCATTTCCAATATAGTTATTGAGTTAGTATTATCTAGACTATCTATTAGCAGCTAAGG
 ATCTGAGGTCAAGGCCTGCCAGCCTGGCATTTTACTTGACCACAACCTCCATGTGCAC
 TAACCAGGCTGCTAAAAGAACATTAACGGGAACATAACCTGCTGGCTTGGTTGCCAC
 AATTTTAAAAAGACGTTAATAAATTAGAGAGCACTTAGAGGTTAGGAAATAATATGG
 TGGTAAAGATCTAGAAACAGTGTCTTCTGGGGCACTTGAAGATGTTTAGCCTGGGG
 20 GAACAACTTGAAATGGAACATAACTGTTTTCAAATACTTGAAAAATGGTGGTGCACC
 ACAGAGAATGGCCTAATCATGGGTAGCTTCAGACTTCAAACAAGGATCAGTGGGCTA
 AAACCAGAGAGATGGAGTTTGGGACTCAAAGAATGCTCATCTGAAATTGAGGGCTGA
 CCAGCGAGGTTCTTTTAAAAATCATTGCATTTTACTAAATTGTGAGTTCTGTAATTAT
 AAATGTCTTAGCAGGTGCTAGCTGTCTCTTTTCTATTATAAATTATACTATTTTATGT
 25 TATAATTTGTATTATACAGGCTTAAACATAAGGGTCTGATAATCTGCTTATCTTTAA
 TACATAAGCCACTGATAGAAAATAAGTGGCTAACCATTCTTCAGTTCTTTTTTTAATT
 GACAAAAATTGTATATGTTTGCAGGTGTATGGCATATTTTGAAATATGTATACATTAGA
 GAATGGCTAAGTGAAGCAAATTCACATATGCATTACCTCACACACCTGTCATTTATTT
 GTGATGAGAACAATAAATCTACTCTTTCAGTGATTTTCAAGAATACAGTACATTGTTA
 30 TTAACAATAGTCAGCATGGTGTACAATAAGTCTTCTGCGGCCGGGCGTGGTGGCTCA
 CGCCTATAATCCCAGCACTTTGGGAGGCCAAGGCTGGCAGATCACGAGGTCAGGAGT
 TCGAGACCAGCCTGACCAACATGCTGAAACCTTGCTCTACTAAAAATAGAAAAATT
 AGCTGAGTGTGGTGGTAAGCGCCTGTAGTCCCAGCTACTCAGGAGGCTGAGGCAGGA
 GAATTGCTTGAACCTGGGAGGCGGAGGTTGCAGTGAGTCGAGATAGTGCCACTGCAC
 35 TCCAGCCTGGCAAAGAGGGGAACTCCGTCTCAATAATAAGTCTCTTGCATTTGTTCT
 TCCTGTTTAACTGAAATTATGTATTCTTTGATCAACATCTCCCCAGTCTCCACCCCTAA
 CCCCTGGTAACCAACAATTCTACTCTGCTTCCGTGAGTTCAACTTTATGAATAGTCCAC
 ATGTAAGTGAGATCATGTGGTATTTGTCTTTCTGTGCCTAGCTTATTTCACTTAGCATA
 GTGTCCTCCAGGTTACACCATGTTGTCAAAAATGACAGGATTTCCCCCAACTTTTTTA
 40 AGGCTGAACAGTATTCCATGTGTATGTGTATAAATTAGATTAGTAGATGTTGCCACTC
 CCTCCTCCACCACAGTGGCTCTATCCCTGGCTCCTGGCTCCAGCCGAGTACACTAGAG
 GAGGATATTCTAAACAGCAACAACACAGGAGCAAAGACATTACAATGGGGTGTGTGTC
 TTATTGCCCCCATTAGACTGTAAGCATCTTGAAGACAAGGACCCCCATCACAGAGTG
 ATGTTGTCTATCCCTGGAGTGGGCACTGTGCATGATTGATGACTGGAAGCAATGAACA
 45 TACAGAAGGGCAAACAGAAATCAGCAGGATGCTTTGCATTTTCAGCATTGACTTTGC
 CAAATATGCCCAACTGTTTCAGGGAGTTACATTGGTTCTAACGAAGCTCCTGTGATTCC
 TAAGCACAGGAATGGTGATAATATATATAATGGTGCATGCATATATACGCATATCTA
 GATAATGATATCTCATTATATGTGAGAACTGAAGAAGTCCGTTATGTTTCTCGTCTAA
 CCAAAAAGGGCCTACAGCTACGATAATTTCCAAACAATAAATCTGTGCTACTTGAT
 50 TTTCATGCAAAGCTCATATTTGTTCAAAAGGAAAATAAAGCTTAATTTAAAATCAATT

TAGGCTATTTTTATCTAAGTATGCTTACCGTTATTCAACTCCCTGCAGATATTGTCAAA
TTTCTCAATATGGTAAATATTTATTCTGTAAATATATCCATAGTTACACTAAAGAC
AGAGAGGTCTTATATGTTCTAAACAACATAGAGCAAATGCTCATAAACAGCATTTTA
TTCCTATCTCCCGGAATAACAACGCTACTTCCAATTGCTGGAATCTAAATTATTA
5 TAAACCCATGCTGCAAGCTTTGTATGCTTAACATTCTCAAATGTTCACTTTTCAGATA
TGGAAGTGAAGCAAATCAACAAACGTGCCTCTGGCCAGGCTTTTGAGCTGATCTTGA
AGCCACCATCTCCTATCTCAGAAGCCCCACGAACCTTTAGCTTCTCCAAAGAAGAAAG
ACCTGTCCCTGGAGGAGATCCAGAAGAACTGGAGGCTGCAGAGGAAAGAAGAAAG
GTAACCTTTTTCCATAGGTTTTCTTCTCTCTCTCCCTCCCTGCTCCTCCCTCTCACACA
10 CTCGGGCACACATGCACGCACACACACACACACACACACACACACACACACACA
CACACATACAGAGAGCAATGACAGCTGAACCTGTGCCATGCCAACATGTATAGGTTT
TCAGTAGACACAGAGCCAGGCTAGTTGGGGTAAAACTGTAAGATAGATGCTAATTT
TAGGCTAGCCAAACCAGAGCTCTCAGAAATCCAAAGAGCTTCAGTGCTCTAGTGCCC
CTTCCCGTATATTGAATCCCCTTATTATAAAAGCCTCCCTTCCCTAGACCATCAGGCA
15 GAAGCACTGTAGAGAAAACACAGCCCTGGCGAACTCCAGTGGTGGGGAGGGGAAGA
AGTGCTGCTTCCTCCCTCTCAGGATCTGTGTCACCCCCCTTTGTCAGGCGTGTTTTCT
TGGAATTACAAATTACCAGATCTTCCCTCCAAGATCTTTCCTGCCAGGGTAAGGGCC
AAGAGCTTGCCCCCTTCTCTCAGAGTCCCCTGCTGCCCTGGAAGTTGGTCCTTC
CAAGATCAGGACCTTCTCTGAGTTCTTTGAATATGTTCTTTATCTTTTTCTAAGACTTG
20 ATGGGGATTTTTCTTTTTTGCCATTGGTCCCTGCTTATATTAAGAGCTTTCCTTTTG
CCAAATCTTTACTTTTCCATAATCACATGGCTAAGAAGAGCCAAGGGTATTATTTGAG
AACACTTAGAAATCCTAGGGACTGTGTACACAAACAGAAGTTGTTTGAATGTGTCTG
TTCCAACCATGTGGTTATGGTAGTTAATCCCATCAAGGTACTCACGATCATCCAAAAA
TGGAATTCTTTTATGTAATTCATCCCCACATTGTATTTCCCAATATTTTTTATGATATA
25 ATTTTAGAATCAGGTAATCACTAAGAACATGTTCCCTGCACAGTTTTATGATGTTTTCT
TCTAAAAAGTCAGCCAAAACCTTTGGACACTTCTATGTTGGATAATTAACAGAAAT
GAAGATAATCCTCCTCCTAAAGATTGAATTCTCCAAGAGAGAATGCAGGACAAACAC
AGATGTGCTGTGTATAGTATATGTGCATATATACATGCATATATGTACACAAATATGT
GTATTATCAAATAATGAGGCTCAAACATTAGAAATCCTTAGATTAAATTTTCTAAACA
30 AGAAAACACTAATCTTTGTAGTTGAAAAAAATCCTCCTATGATATGTAATATGCTG
ATCTCAATTTTACCTAAGAGTGATGTTCTCCAAATGTCCGATGAGCATGTCATATAT
ATATATATGAATTTTATATATATAATTACAATGGTAATTGGTATATAGAGATATCTA
TATTATAGATATATATAGCTATCTCTATATATTACATATACCAATTATAGATATAAAT
ATAACAATGGTAACTGGTGTATATGTGATGTGTATATATGTATATGTATACCATAATT
35 ATATATTAATATTGTATATATGCCATAATTATATATTAATATTGGTATATATACACCA
TGATTATATATTAATATTGGTGTGTGTATGTGTGTGTGTATATATATATATATATAA
AATACTAGTTATCATTGTTCTAGATTTAAAAAACAGGAACCTGAGCTACTAACTCGAC
TATATATATATATATATACAGGAAGTTGCTTTAAACATTTTTATCAGCTTTTTTAT
TGTTATTTTATAGCTTTATTCTCATAGTAAAGCTAAAATAAATTATTCAACATTATCAA
40 AACTTTGCTGCCAGCAGATGTAAGCAATACCTAAAACAGTGGAGAGCATGTTGCACC
CAAAGCAGTTTAAGCTCTGACCCAAGCACTGGCATCTTATAGGCACTGGGTAGAGAT
AAGAGTCATAGGTGACATATATTGAGATGCTATGACTTGATTAGAATATGGAGTCA
GTGACTGAGGTGAAATTAACACTCAAACCACAATTCAACATCCTGATTTAGGATGTT
GCTGGTGTCTTAGGTACTACACTTAATTTGAAAGAAATTATTGAGGATAAAAAAAG
45 AACTGGGATCAACAAAATTAAGTGGTGTCTTATAAGAGTCCCTGAGGTACTAATT
AATGAACTGATAAAGCTCCTGCACCCTGACAGCAAGAAATTATCAATGATTATACA
TTTAAACAATTGAATTGAACTAGAACTGGCCACATGGTTAAAAGACATTTACAAAT
GTAATCATCCAGTGTTATGATGCCAGAAAAAAATTCCTTAGAATGCTTTAAAAA
GCCGTATTCATCACCTTTCCAGTTATTTGTTAAACATTTTGTAAATGCAAAAATAACC
50 ATATAGATTATGCCCTAGTGGTTCGGGTTTTATTTTATAGTTTTTTATGGTTTTTTTTGT

AATGGTAGAGTTTTAATTAAAAGAAAATACAACCTAATTAGCAGAAAAGTGCCAACTTT
AAAAAATCACTAATTGATTTTATTCTATTGGGTATACTGACTTAATTAGCACTAATT
TAAAGAACTATTAATTATCTTTAAAGAGTCTTTAGCAAGTGCATATATCTCAGTAATT
ATGTTAGTAAGGACATGCCTATAACCAAAACCCAACTCAACTAGTTAAAACAAAAAG
5 CAAATATGTGACTAAAAAGTCTAGGAGTGGCTACAGCATCAGGAACAGCTGGATCCA
GGGATCACAGTATTATCAGAAAACCTTTCTTTTCAGTGCCTGTCATCTCTTCCTGCATTTA
ACTGGTTTTCATTATCAAGAAAGTTTAATTTCAATAGTCAGTTCCAAATTATTTTTCTCA
CAACTTAGCAACTCCAGCAGAAACAGAGCTTCTTTTTCCCAATAGTTTAAACAAAAGTC
CCGAAATTGAGTCTCAATGGCCTGGCCTGGATCACAGGCCCAACCCAGAACCAATCA
10 TTATGGCCAAGAGGATGTAGTAGTTTGATATGCTAGCCTGAATCACATGCCACCCT
GACCTGCAAAGGATTTTAGGTAAGATCCCTGGGGTAAGAATTGTGGAGGGGTAGTTC
CCCAGAAGAAAATCGAGGTGTTCTCACAAAGAGGAAGGGGTAAATGGATCTTAAATAA
ACAAAACCTATAGATGTCCACATTTTCTATCTATAAATGTTTAGTGTTACTATAACAAT
TAGAATAATTATTTAGTTTCATACACTATTCAATTTGTATCTCCCTTCTGTTGCCCTGTT
15 GCCGTATTTTTCTTACAGATAGAATGAAAAATATTAATCTAGGCAGCTCTGTGAAACA
GTACTGTCCAAGGAATATAACGTGAGCCAGGCCGGGTGTGGTGGCTCATGGCTATAA
TCCCAGCACTTTGGGACGCCGAGGCAGGTGGATCACCTGAGATCAGGAGTTCAAGAC
CAGCCTGGCCAACATGGCAAACCCCATCTCTACTAAAAATACAAAATTCGCAGGG
CATAGTGGCGAGTGCCTGTAATCCCAGCTACTGGGGAGGCTGAGGCAGAAGAATTGC
20 TTGAACCCAGGAGGTGGAGGTTGCAGTGAACCAAGATGGTACCATTGCACTCCAGCC
TGGATGACAGAGCAAGACTCCATCTCAAAAAAAAAAAGAAAGAAATGTAATGGGA
GCCATATGTGTATTTTTTAAATGTTCTAGAAGCCACATTTTTTAAATAAAAAGAAATAT
GAAATGAATTTTAGTAAAATATTCTTCACCCAATATATTCAAAACATTATTTCAATAT
GCATGTAATCAATATAGAAGTATTAATGAGCTGTTTCACATTATTTTATTCTACTAA
25 GTGTTTGAAATCCAGTGTGTATTTTACGTTTACAACCTCATTTCAATTCATGTTAGACAT
ATTCCTAGTGCCTAGTAGCCAAAGGCAGCCAGTAGCACAGATACGGATATTTAAACA
GAAAACACCTAGTGAATAATGGGGAAATTTTAGGCCTAAGTTTTTAAATCCATACC
AGATAATTATTCAGATTCAAATTTACTTTGTTTTTTCATATATATTCTTTAAAAATTAC
ATTAATATGGGAACCTCAGAAAGTTCAAAAGAAATTTCCATTCTATGGTTTTAGTCTTT
30 ACATTGTCAGAACTAATGCAAGTGTGAAGTTTAGGATGTACTGTAAGTAATAGGATC
TTCTAAATCTCATGCCTTCTTCAGCTACCTACTCTGTTTCTATTTAGTTCCCTCACTGT
GGGGAGGGGACTTCTCTGAACCTAGGTTTCATCTCTCACTCTCGTTCATGGTAAACAG
GTTTTCTTTGTGGCACCTAGCACAAATTAGTAAGTAATTAGTATTTACTGGCATATTA
GTATATATATGCATATGTATTTATTTAACCCTATGTCTTCTACTAGATTATAAACTCCA
35 TGAAGATAGAACTTGTCTTTTGTTTAATAGTGCTTGGCAATAGTTATTACTGTAAACA
TTTTTTTTCTTTCTTATTCAACTCCTGTTAGTCATTGCCTGAGTACTACAAATGTTTTTA
AGTAAATTAATAAATAAATACTTTTCAGGGCCAAATGTGAAAGCGGCAATATATAGCT
TGTTTTGATTTTTTATTCCACCCTCCCATCCTAAAACAATTATAGTCACTAAGTTTCCA
AATGACATCTGAAATTGCACTAAGGAAATCCTAGTCTGGGCAAAATCACTCAGTCAA
40 CAGATATTTATCAAGCACTTACTATTTGGCAGGCCCTGTTCTAGACACAGGGGATACT
CATCAAACCTTACATTCCAGTGGGGGAGAAAGAGCTAATAAATACATACACAGCATAT
TAGATGATGCAAATTAGCAGGACAAAGAGAACTGGGGGTGTGGGGGTGAAAGAAG
CTAATATTATATGTTATTATTACTATATATAAATAATATAATTATTGGATAGTCAAAAA
AAAACCTCTTGAATAAGACATTTGAAAAGAAGCACAAAGGTAGCAAGGGAGTAGGG
45 CGGGCAGCTCTTCTCTGGGACCTGAACATTCAAATGATGAGAGCAGCAGGTGCGGA
GGCCCTGAAATAGGAATGTATGAGGTGTGTTTGAGAAATAACATGGAGGCCAGCGTG
GCTGAAGCTGAGAGCAGGGGGAGAGTGGTAGCAACTGAAGTCAGAGGTCACAATTA
AGGACTTTGACTTCACATGAAATGGGAGATCATGAAGGATAATAAAGCCATTTCACT
ACTTTATGTGAATCACAGCATCTTTTTAAAGAAGTATCCTTTTTTAAAGGGGGAGATG
50 ACTAGAAAAATAAATAGTGTTAGATAAATAGAGAAAACAGGAAAACATTCTAGACT

AAGACAGTGATTCCAGAACTAAGGATCCACAGAGGCGAGAATGCAGAAAGTGTAGG
TTTCAGAGCAGTGGGTAGACTAAGGGTTTGGACTAGTGGATTGATAGGGAGTTGG
AGAGTAGCGAGGTGGGATTAGGGAGGGCTGTGAATGCCAGGTTAGTGTGCAAACCTCC
ATTATATAAGCAGTAAGGAGTCACTACAGACTTTTCAAAAATACATACATGTTCCAC
5 CTGGCCCACGGGTAGCAACATTTTCGTTGCCCTGGACCCATTTCCTTCCAATAAGT
TACAGGTTTGTGAAGATTCTACCTAGCAAACATATTACTTTTAAATAACTATTAATAA
ATTATCTTACCATGATTATAATCAAAGGAATCTGTAATTGCTAATTATTTCTGATTATT
AAAAGATAAGCAGTATTGCACTAAATTGACATAATTCTAACTCAAAGTAAATATACA
GATAGACATGGCTATAGATGTGAAATATGATTTCTGTAGGGCTTTTTAAATTTAAAA
10 AAACCTACGAGTTCTCCTCCCTCCCCCTACCCTTAATACCTTGAAGGCCTCTTTGTGG
GACTTCAGGGACCCCTTCAGGGAATATGACCTAGGCTGTATTTGGGGGGCTTTCTGG
GTTTATAGCTGGAAGGCTGCCACAGAGGCATCGCCACTTGGGCTCAGATTCACTTTGT
GTTCAATGTTTTGGCAATGTCCCCACCTCCCCATTCCATCTGTTGACACTATTGCAGC
ACTGACCATCTGGTTACTAGGTTGGAGGATACTCCCTCGGGCTCCTTTGAACCAGAAT
15 TAGTGCTCCAGTGATTAGATAATAGAAGAAGCTTGTCAATAAAAAGAATAAGCCCTTT
CCCTGCTTTTTCTCCATTCTTTGATTATCGCTGGTAGTCAGTGATGATCATCTCTATGA
GTCTATATCAATCTCATCAGGTCAGTTTGAACCTCATCTCTTGAAATCAAAGTTTCCA
TAATGCAACTGACCCACAAGGGTGAAATGACATGAATGCTTTAACCATCCATTTATC
ATTTATTCATTCAACCAACATGTATTTAGCAAGAGGCAGCAGAGTTAGCATAAC
20 TATACATCCCAGTTGGCCCAGGACAACCTCCAGCTAACTCTCGTTGTTTTGATACCATT
ATTAATTATTTCTCTTTACTCTCATAAGTGTTCCACTTTGGACAATCAATTACATGAGC
ATCCTTAGCAGGGCACAGTGTTTAAGGGCATCTTTAAAATATTGTCTTTAAGAACATG
TGGTTAAGAGAATGTCTGTGTTCAAATCCTGGTTCACCACTTAAAAGCTGTGTGACC
TCAAGCAAGTGACTTAATCTCCGTATGTCTCCTTTGTCAATCTGTAAAATGAGACTA
25 GTAATAGAACCTTATGGAGTTAGTGTGAGAATTGGAAGGTTACTCTACAATAAAGACA
TATAACCAGCATGGTAAAAGGGTTAGCAATTACTATGTGAAGAAGCATCCAGTTTCT
GACCTCACAGAGATTATCTAGCAAACCTCATGATTTTATAAAGAAAAGAAGTTTCTCA
TCAACAGAGACTGAAATGCTACCATACAATATACGTTGCTTTTTTTTTTTTTTTTTTT
TGAGACGGAGTCTCGCTCTGCCACTCAGGCTCAGGCTGGAGTGCAGTGTTGCCACCTT
30 GGCTAATTGCAACCTCCACCTCCCAGGTTCAAGCAATTCTCCTGCCTCAGTCTCCCAA
GTAGCTGGGATTATAGGCACCCACCACACCCAGCTAATTTTTATATTTTAGTAG
AGACAAGGTTTTGTCATGTTGGCCAGACTGGTCTCAAACCTCCTGACCTCAGGTGATCC
ACCCACCTCAGCCTTCCGAAGTGCTGGCATTACAGGCATGAGCCACCATGCCCGGCC
AATATTTTTAAATATTATAAAATATTCTTTATCAAATTGCATAGAAGAAAAGACAGTT
35 TGATAGGTAATAGATATATAAATAGGTCAGGCCAACTAAAAGTGTCTGAAAAAATT
AATATTGTGAAAACAAAAGGATTTTAATGACATTGATAAAATCTCACCCCTAAAAGAG
ATTAAATTAATAATCACCCCTACTTGAACCAGTTCAGTGAGATTTCAATAGCATGCTCT
CATTACTGGCATAATCAGCTTCAAAGTCACTAAGCCTCTGAAAGGAAGATGTGTTGC
TTATTCTTAATAAAATGGCATAAAAGTAGATCATTAGTCACCAAACATGATAGACTT
40 ACCTTTTCCATTTGTTGGCATCTCACATTGTAGATGGCAATTAAAATGGAATCCAGGG
AAAGAGGGGGTGGTTTGTATAGCAATGGATTATGAAACAAAGTACTGGATTATTCAC
CGCTTGACATTACAGGAAACATTCTGCTCCTTACAGAATATGGCACGTGGGCCACAGA
ATCTTCCGTGTGCTACCTTCTCGGTGAAGAAGAGCACCCCCAAGTTTCTTTTCTAGG
AGCTAACCACAGTAAACCCATTACACACTTTAGCAGAAGGGCTCATTCTAAAGGTCT
45 TAGGATTTTAATCATTTTAAATTTCTGTTATGCTTCAGGCTCTTCAACACAAAGTGA
ATATTGTACTCTTTGGTTTACATAATTATATTCAATTGTCATATTTCAACAGGACATT
ATTTGTGACTTTAGATGGGTCAATAATGATTTTCATTGTCAGCAGTAAAGTCAATAAT
TACAGACACATCACCTACCCTACTTGTGTAAAAGCATTTTTTGGTACTAGGAGATTTA
GTGTCTGATCAACGGTCCTGGATAGCAAGTAATATATCCCCCAAATAATGAAAAGTG
50 ACAAGAAAATAAATATGTTTACTTCAGAAATAAATGGAAAATTAGTGCTATCTAAAA

TGTAGTCTTAAGTCTCATCTGTGTACATAAAAGTAAAATGAGTTTTATGTACTAGTTAC
TCAAATTTATCTTCCACTCCATTTGTATAGTAATTAAGTCTTACACTCAGTAATATAC
AAATTGGTAATTAACCTCTTTGCAAAATGTTAAAGTGTTCTAAATGTACAATAAGTC
TCCTTTCTGTCTCATTTGTTTTTCGCTTCACGTACCTCTCATGTAATTATTTCAATGATT
5 GAGTTCAGTGTGAGGAGGTTTATGCCTAGAAAAGGTGCTCACCAATAACGTGCCTCA
GTTCCCATAATAGCAAGATCGAGAAGGTTCTTTAGTCTCCCGGAACGTACGTTGAA
CATCTCAGTTCTATATTTTGCCTTGACATTTGCATTATATCAGCTGATCATTGTCTTGC
CCTAATTTTCCCTTTTAATATTTTAGTGACCTTCTATGTTAGGTACAGGTTATTTAGAA
GTGTTCCCTCCAAGGCCAGATACTTTTTCTTGAACAATTTATTTTAAACAACCTTTTAGC
10 GATTTTCTCACTTCACCACCCTCCGTTTCATAAGTCCACGCAATCACAATTCCTTTCTG
CTAATCTGCACAGTCAAGATATAAAGTAAGAATACCTATTTGAACATGTAGTGAGAA
CTTTACTTCTCTGCCAAAAATGAAGGAAAATGCTGCCACTTTTGTATGTCACATGTTT
TTTATTCTACAGCCTCACTCACTTCATGTCATGTTTTAGTGCAGTTTTCTGGACTAACT
GCTTATTTTCTCATTGATTAAACTGCCTATTTGCTCATTGGAATTAGAGCCAATTTTTT
15 TCCTTGAGGGTCTGACTAGAAGATTAAACTATGTTTCATGTGAGAATCAATTTCTACCT
AAGAAATGAGTTAGAGGAGTTATGGGCAGCAATATCTATCTGGATGCTACACTGTGA
AAAAGGAAGCGAGGTTATGCCTTTCTACCCCAATGGGGTAGCAGAGACCTCAGGAAC
TGAGGTAGATGCCCCCTGGTTATTAGCGCCCCTGAATAATTTGTTCAAAAATTGACT
GCTGGACAGGTGTCGTGTTGCACGCCTGTAGTCCCAGCTGTGCAGGAGGCTGAGGCA
20 AGAGGATCTCTTGAGCCCAGGAATTTGAGGCTATAGTAAACTAAGGTCACACCACTA
TACTCCAGCCTGAGCAACAAAGCAAGACCCTGTCTCTAAATTTAAAAAAAATATTG
AATGCTTATGAATAGAGACTAATATAGGAAGTCATAAGTATTTCCCTGGGATAGAAT
GCTTTCCACCATAATTGACTTGACATCCTGTATTTTTGTATGTGTGGACTTAAGTTTTA
AATATTTGAAACACAGACAATTATTAAGTCCTGCAAATGTGTGAGTTAATAGTGGAT
25 ATAACATTCCTTCCAGGGTGTAAGAAAAGGTACCACAGAAAGTGAGCAGCCCTGAAG
CACAGCCTGGCCTAGTTTGGCAGGTCTCTGTGAGTTAGCAGCAGACTCACGTGACCA
CACTCTGTACTGCCTTCTGTTTCTGTTTCACCCCATTAATTGTGCTAAAGAAATGCACT
TGACACCTATGCTGTGTAATCTCATTTAGCCCCAATAGCAACAAAAGTACTAACCCCA
TTAAATTGAGTCATTTCAAACCTGAGCCAAATGTTGCACTCCAGTAAATGGAGTAGGC
30 ATTGGTTATAATGGGAATTCTCCATTATTCATAATGGAAACCACAGGAGTTTGTTTAT
GCAGATCAAATGTGTCCCACCAAGGCAAGAAGTATGGAAAAGTGGTGTGCTGTATT
ACCTTGTAATTTCAAAGCCTTCCCGTCTGAATCTTATTTCCCTGCTGTTTCCCTCTTGAC
TTTGGTCTTTTCAAAAGGAAAATTAAGAACACAAATATAAACATTAAGTTAAAACA
CAACTGAACAAAGTGCCAACTTAATTGGAGCATCTGAAAATGAAACATTAGGCAGT
35 TGCAGTGGCCTCTTGATAATAATTCACAGTAACTCTCTGTAAGCTGATCCTGTCTGAA
GAGCAGCAGGCACAAGGCCCTGGCCATGAAGTCCATCTCAAAGGGCCAGGCTCAG
CAAAGCAGGATGCAAACCCAGGCTTTCCAAATACCAGGTTGGGGCTCATGTCACTGT
GCCACAGGAGCTTCTGTAGAAAGGCTACTTGAAAAAAGTGGCCATTAAAAATCCAGG
TGGATCCTATCTAGGGCAGTGTTGGAAACACTGATCTATGGGAGGAGGAGCAGGAAG
40 GAATTGTTTAACCACTGAGCAGAAATGTTACATTGCTACCTGCCTTTAGCAGCTGTGG
CTGATGGGTACCAGTTGCTAAGAAGAGCATTACCTAACAGTGTATTAAGATAGAAAA
ATGATTTTAAAGCACGGCACTTAGAGAATGTTGAAGTTTTACTTTGCTTTATTTTGATT
TGTTTGGTTTGACTTTGTCTCCTGGAGCATCCTCCATGGATTTCTGTTTATTACAAGAG
AAACCTAGGGCTCTAACCCAATTCCTAATTCTTGGACACATTGCACCCTTGTTTTGTG
45 ATAATCCAGCCTTCTTCCCTGAGAAGGTTTGCTGGACTGGAGGTTACATGTATTGAAT
TTTCTAAAATGAAGGTGCAAAGCTGTCTCCTCTTATTTCTTTGTGGTGCTCACTTCACT
GTGAGATTTCTATCAATACAGCCCAAGTCAGTGGGCATGCATGAGGTGGAGATGAG
GGAGTTAGGAAGGACTTGGACTCTCATCAACCATCAGGATCCCTGAATCCACTAACT
GTTCATAATCAAAGAAGTTTGAACAAATACTTCACACACATGAAATTGCCAAAATTT
50 TGCATTTGAGTTGTTATACCAGTAAGTCCAGTTGCCATCATCTCCTTGTCAACAAGTGT

CTTAAATTTTGCTTTTGATAATAATGATTACCACTCATTTCAGTACTAACTTACTTGATA
TTAGACACTGCATTAAATACCTTGCAAACATTATTTTGTGTGATCCTGACAACCATAT
GAGATAGGTACTATTCTTATCCATTACCAAAAAAATTAATTTTCATGAAGACTTTTCCC
AGAGAGAGAACTTTAAATATTTACACACACACCTCTCTCCCTGTAACAATTCGCTAG
5 TCCTGATAACAGCAAATAAGCAAAGTCTGTGTAGGATGCTTTACCAACAGTCCCACC
TAGAGGCAGGAGAGTGAACCAGCTAGAAAATATTTTATTCATATTTCTTCCAGAAAG
GCTCCATTGGAGTTTGAACCTCAATTTATGTTATAATTTTCTTATTATTTTGTATTGGT
TTTCCTGAAACCAATACAAAGTAAGAAAGCATTGGTTCCACTAAAAATGTCCTAAAA
CCAGCCAAGCACAGTGGCTCACACCTATAATCCCAGTACTTTGGGAGGCCGAGGCCG
10 GTGGATCACTTAAGCCAGGAGTTCAAGACTAGCCTGGCCAACATGACGAAACCCCAT
CTCTACTAAAAATACAAAAATTAGCAGGGTGTGGTAGCACACACCTGTAATCTCAGC
TACTCAGGAAGCTGAGACATGAGAATCGCTTGAACCTCAGAGGCAGAGATTACAGTG
AGCAGAGATCACGCCACTGTACTTCTGCCTGGGTGACAGAGCGAGACTCTATCTAAA
AAAAAATAAACACATAAATAGTAAATGTCCTGAAACCATTATGGGGTTAAAGCAA
15 GAGGCAGGGCTGGTTCCCAGGATTTTCTGTCTAATCTCCAGTGAGCCACAGACCTATT
CCTGATCAACTTGAGAATAAACACATCAGTAAAGATGTGTAAGGCTGTCTGACTTTC
CCATTTCTGTAGAATTTTATTTGAAGAGAAGTTTCTCCTTTCTCCAGGCCCATATTGT
TTATACAAAAAGACCTTTCCAGTAAATGTCCACAACCACTACCATCAACTAAAATGTT
TTCCCACTAATGCTTTCAATGGTAATCAGTATTTAACAGGGCACTTAGGATTATTTTTT
20 GATCAACCATTGTTTAGATATTCCCCTTATAATTACTCCTGTGAAGGATTGCCTCGG
GGCATCAGCTGATCCTGAGAAATTATCCAGAAGCCATGAGTGTGTAATAATTTAGTC
TTAAACCTAAATAGGTCAGTATTGGGTGGGACTTTTCTCAGCTGCATAATGGGGAGA
ATAAAAAGAATATGGAAAGAAGTTACGTAACACATCCTGGGTCACAAACAGAGGTA
AGACTTGAACACAGGCCTGACATCAAAGCCCATGCCAGTATGACTTACAAAAGGTAG
25 ACTGGACTACCTGCATTTGAGTCACTAGTGATGCTTATCACTGGGCCTCACCAAAGAA
CCTTGGAATCAGAATCTTTGGAGGTAGATGCCAGGCACCTGCATTGTTATCAAGTGCT
CCAGTGATTACCATTCACTGTACAGAGCCAAACAGACTCCTGATGCTGGAAGAAAAT
TACAGTGCTCAAAGTGCAGGGCAGGGTGTACATCTGGATCTAAATCACTGAGCAACC
ACAGGGTTTCAAGAGAGGGTCAAAACAAGGACTTTCTGCTCTCTGTGGCCAAGGGGA
30 CACTAAGTTTGCCTGTTCTCAGATCTCCAAAGAGACTTTGGTGTATGGGGGATAGG
GAGGGGGGAAGGGGGTGTGAAATAAAAGGAGAAAGTGAATTTGATTATTTGATTGA
TGAAAATTGAAAAGCTTATTGTAGGGCCTAGCCTACAGTTGATGAAAAACAATGGA
TCAGGAAGAAGATCAGAACTTGTCTCAGTCCTCAACTGTTTTCTCAGGCTTTGGTTG
AATATTGCCATCCTGTAATTCATTATAGCATTTTCTGTTGCATAAACGCTTAGCAACA
35 AAGCCTTTTTTTAAAAAAATTTGTAACCTCCTCAATGAGGATTAAATGCTTCTTCTTA
AGACAGTCCGAAATATACTCACAGCTGAAAATTCAGCTAACCGCATTTCCTCACTAG
CCACATTCTATAGAAAATCTAAGCCATGCAGATGAGTACAGACTTGACAATAGTGC
TCAAGGCTGGGAGTACTATTCATCTGAAAAGAATGCTCCCTCCAATTGGTGGGCCGTT
ATTCTGCTAGGTTTGTGTTTGGATAATTATAAGATGGCTATGTTTTCTTCCCCAGTCT
40 CAGGAGGCCAGGTGCTGAAACAATTGGCAGAGAAGAGGGAACACGAGCGAGAAGT
CCTTCAGAAGGCTTTGGAGGAGAACAACAACCTTCAGCAAGATGGCGGAGGAAAAGC
TGATCCTGAAAATGGAACAAATTAAGGAAAACCGTGAGGCTAATCTAGCTGCTATTA
TTGAACGTCTGCAGGAAAAGGTAATCTCAGCAGAGTCCTGAGCAGATGGATATATTC
ATATGCAGCACAGCTGGGTGAACTTCCATATGCCTGAGCACAGAGACGAAGTCAAAA
45 TTTGCTGCAGGTGTGAGGACAACCTAACTCCCATGGGCAGGGTCTCACAGTGTAGCAT
TGAGTTAGCAGGAGGTGCAACATGGTAGAGAAATGGGAATCCATCATGAAAGCTGG
AATTTTGTCAAATTTTCCCATGGTGTGAGTGGATTGAGGGAGGCTGATTCATGCTTTTGA
AATGTGTAAGACTTCTATACAAGCCTCACGAGGCAATCTGTAGGAAAAATGTTACAC
TGGAATATTAATGTCTATATATTATATTGATATAAGTATAAATAACATTTGATTAA
50 TATTTGTTTAATATATGACATTAAATATATATTTAATTAATAATTAATTAGAAAAA

TATATTTGCCAGAAAAGGCCAGGGTATTTATGAACACTGGTAAGCCCATTCTAGGGT
ATAATAGCATCACATGGGACCATAGCAAAGATTAGCTCATAGGGGATGTTTCATCCA
GTTCTGGTATCCTGGTGGCCTTCTCTTCAACAACCTAAACATATATTCATTCCCATGA
GTCAGGAGGAGCTGTGCTGGAGTTCTTCTGAAAAATGCTGTCTTTCACTTTTGTACTC
5 TCTATGCTGTCTCCCACCTATCCCCTCAAAAAACCTTTCTTTGAAAATATACAGTAT
AGCTGTGAGTAGTTTAGCTGTGTCCGTTTCCAGAAATTGGAATAAGCATTGAGAAAT
GGGATGTTTGAGAAAGACGCCTCAATCCTTTTCTGAGCAGTCAGTCACCCTTCCC GCC
AGTAGCAAGTGCCTTTGTGTGATAGGCATTGGAGATGCAGAGCAAAACAGGAGTGTG
CCTGTCATCAGAGCCCTGAGAGTTTAATTAGATGAGCCTCCTGTTTTCTATTTCTCAG
10 AGTTTCATGTCTTCTGTTAGAGATGGCCCTTCTCATCTAAGGTTCAAAAAACCTTATC
CTGAAGTTCTGATGATTCTGTTTTTCACTCTCAGTCTCTGACTGCAAATATCCAAC TAG
AAACAAAGGAAATCAGGCATGAAAACCTTTTAAAGATATAATTGCATGGAGATCTTCA
TTTGTGCTCGTGAGGAATTTTTGAAAGCATTGCTGGGGAAGGGTGTGTGGGCTCTGAT
GCAGCAGTAAGACACTGAGGCTCTCAGAGGTCCGTGGACGAGTACTGCTGACTTGGG
15 CAAGAACC GGAATAGTTACCTGATGCCTTATCCGAAACATGAAAGTTCGGATTAAAT
TTGTATTTATAAGCTAGTGTTTTTATACTCTCAGAACAATGTCATTGCGTTTTACCCAA
GTGAGTCAAGTCACGATTTGGAAGAGGCAACAGAATTTGGCTCTCTCCAGGTGATTT
ATGGCGGTATAGGAACACATGTTTTACTCAGATACAGGGGAGCAAAGTTCCATTTGC
TAAAGTTTACTCCCCTGACCTTCAACCAGTCAGTCTTCTCCATCTGCCACC ACTTTGC
20 ACTTCTCCAGAGAACTAAGGATGTTCCCGCTTGACCAGTGCTCATAACATGGACAGC
AGAGGGCCACTGTGTGATCTCTTTGAGATCACTGTGACTCAACCTTCTTCTCACATCC
TAGGCCCTAAAACAATTAAGTGAAGTTGCTAGGAACGGTACCTGCTGATCTTATTGC
AGCATTCTCAATTAGGCCTCAATGCAAGATTTATATCACTGGCAGTCCTGGAGCATTT
TTGTTTTTCAAATTACACATAACCCAAACACACGGCATAGCCTCCTTTTTTGTGTTG
25 TTTTTTTGAGATAGAGTCTCGCTGTGTGCGCCAGGCTGGAGTGCAGTGGCACGATCTC
AGCTCACTGCAACCTCTGCCTCCTGGGTTCAAGTGATTCTCATGTCTCAGCCTCCCAA
GTAGCTGAGATTACAGGCGTATACCACCACGCCAGCTAATTTTTTGTATTTTTAGTAG
AGACAGGGTTTTGCCGTGTTGGCCAAGCTGGTCTCAAACCTGACCTCAAGTGATCC
ACCCACCTCGGCCTCCCGAAGTGCTGGGATTACAGGTGTGAGCCACCGTGCCAGCC
30 AGGGCATATCCTTCTTGATTTCAATTGTAAAATAGTTCAAAAATTTTCCATATTTTATC
TAATATTTCCAGAAAGTGCTAGCTTTTAAACGGACCATTTTTTCTCTGTGTGTTTTTT
CTCTTCACCTAGCCCAGCCATGCTCAGCTCATTTTTGTACTCTTCCACTCCCAACCAA
ATTTAGTGCCCTCCCCCATACATGCATACATGTACATCTGCACACC ACTTTTCTTGCA
AATAATCAACCCAAAGAGTGCTTAAAATTCCTGACATCAACCCACAGAATCTCCAAG
35 GATGGGACCCAGCATCCATACATTTTAAAAACTCTCCATATAGTTCCAATATGCAGCC
AGATTTGAGAACTAGTGGTTCGTAGCCTGTTCTGATTTAAATCTCAGCTCTCAGCAGT
CTATCCCACGTCACATAATGCAGCCCAGAGAAATTCTAGGACCACATTTTTTTCTGGT
ATTTCATAGCTAATGAGGTGCTTTTCAAATCTAATAGGATCTTTGGCCAGTGTCAGTC
AAGATCTTTTATCTCCTCAATAAAAAGGAAATACCATATTTACTTTGATTTGATGTAT
40 ATCACATAGGTGGATTTAATACAAAATTGTGGTTTACATATTGTGAATGTGTATACTA
AAACTACTTTGCTTTTTTCTAAAATAAGACAAAGTTTTATATTGGAAGTAATATTTAG
CATTTTGTGTTGAATGAAGTTACTCCTATTAAATTAGAAATTTAAAAGAGGGT CAGTAA
TAACAGTAAAGCCAAAAGGCATGACACTGCCAACGTAACATAAGCTGCTCTGAAATC
TACCATATCAAAAAGATAATTATGCTGGGCATGGTGGCTCACACCTGTAATCCCAGCA
45 CTTTGGGAGGCCAAGGCAAGAGAATTGCTTGAAGCCAGGAGTTCGAGACCAGCCTGG
GAAATATAATGATACCTTGCTTCAAACAAAAATTCAAAAATTAGCCAGCAGTGGTGG
CACACTTGTA AAAATGCCTGTAGTCATAGCTACTTCAGAGGCTGAGATGAAAGGATT
GCTTGGGCCAAGGAGTTCGAGACTGCACTCCAACCTGGGAAATATTGTGCCACTGCA
CTCCAACCTGGGAAACAGAACAAAGACCCTGTCTCTAAAATAAAAAGAAAAAAAAG
50 ATGACCACTTCTGAAATGACACCTATCAATGAGTTAATCATTCAATGAATATGTATTG

AGTCCCTACTATATGCTTAGGAACCTTTGTAATATCATTACCAACCATGTCTTTCCCA
ATACAGACAATACAAAATTCAGCAATAAATAATATAGCACCAACAATTAGAGAATA
AGACAACATGTAGTATGGTCCAATATAGACAGTAAATACAAAGACACTGAATAATAT
CAGTAAAAGTAAATTCACATCAAGGTCCTACACCATGCGCCCACCTTATGATAGC
5 CCTCACTGGCCCTATCAATTAAGCAAGAGACATGATACAACCTCTGTGCAAGCTTTTCC
ACAATCTGCCTACCATTCAGCACTCAGTCGCTCTTCCCTTCAATTAAGAGAATTGAGC
ATTCAAGCATATTTTACCATGATGCCATAATGGTATCTTCAATGTCCTGACTGACTGAT
AAATTCCCAGAAACCCCTCAGAGCCCCAGCCATGTTAGCTCAAAGCCTTTAGCTAAA
10 ACTGAAAGCCTAAAGCAAAAGCAGCCCTGGCTGCACTTCGGAATCTACTGGACAGCT
CTTTAAGGGATTCTGATTTAATGTCTGGAATAGGGCCAAGAACCCTTGATTATTTTAA
AGGCTCACTAGTAGGCTCTAATATTTAGCCGTGGTTGAGAACCCTGTGCTAAATGTT
TCTTAAATATGCTTTGTGATGTCATCATAAATTATATTTTAGTATTTTTTGTCTTTGTG
CATAAGTGTTCTTTCTTCCCTCCAAAGAAGAATGTTACACTCATTTCTTATTTTCACTTTT
15 CTGTTTTTCATAGCACCTCATCTTAACACTCCAGGCTATTATATAGAAAAGAATCAAAT
GTGGAGAAGGCTGTGGGAGAAGGGATGCCTGTGCCACAAAGGCCTGCATTAGGCTG
ACCTATTGATGTCATATCCAGGACTCAAAAGACTAGTCTGTGGATTATGACTGGTGA
AGTTCAAAATGTTCTTATTCTTAGAGTGGTATGAGAAGTAGAAAGAGAGAGAAACAG
AGAAGGGGAGGAGAGGGGAAGAGAGGAAGATGAGAGAAAGGAAAGAGAGGGGGGA
AACACCTGTTCTTGACATACAGGAATGATTCAAGACATTTTCTTCCCTCCCCTGATGTG
20 TCCCTTTCTCCCCTAACGCACTATGCAGCATCCTGCAGAAAATTCACCACCTGACCCT
TTTAGAAACCCTGAGTAGTAGGAGCGCCAAATGACCCAATCAAGAATTGCAGTGAGA
CAGTTAGTTTTGAAAAATCAGTTAAAGCATGTATAATCATTTTAAACAACAATACATCT
ATTCATAAACATATAATTTTAATGTCAAATATTTACGTGTAAACATATTGACCAATC
TTTCGATGTAGTTGGGCCCAATACCTTTTCCAAAAATTGATCAGTTAATGGGGGTTCT
25 ATGGGGGTTTCTTTTCTTGCCATTATTCACACTTATGTCACATTAGCTATGATTTGCAG
TTTTAATTTCTTTAAATTTGAGTAGGGACTAAAGACATCTCCAAAAAGCCTGGATATA
GACTTTTTTACAACCTTTTCCATAGCTTTTATAGTTGACTCACCCAGTATCTACTAAATAC
TTCACCTTTCTCACGTATTTCCAAAGGTTTCTCTCCACCCTCACAATTTTCCATTAATGT
AGTACTTAATTAAATTAGATAGTTAAATTTTCAAATGTGAATTGCTAAACAGGTGTGG
30 AAATACCATTGGCTATAATCAAGCATATAACACAACCATTTGAGAAGGAAAGTATGT
GGCAATATTAGGGAAGAGCCCTTTCTCTCAAGCAATTCAGCATTTAGGAACCATCA
GACAGCAGGACGATGGAGGGAACAGAGAGGGTTAACATGGCAAGTTACTGAAGAGG
ACTTCTACTGAATCTTGTTGAATTCCCCACTTAATCCAGATTGTATCATATCTTCTTTC
TTTTGTAATTCTACCATATCATCTTAGTCAATGCCAAGACTTCTGAGCTCATAACATG
35 GTAACAAATACCAAAGGAGCTTTTCACTATCGTTTAGAAAGGAGAGAAGCAAGTAAC
CCAGACAAACTTGACAACCTGCTTTCCCCTATCCAACCATGAAGTACAGTACTTAGGA
AATAAAAGAAATTGCTTCACTATAATTCATCATTTCACTTCTAATATCTAGAAAATGT
CAAATGAAAATATTATAGCCATATTTTAGTGGCAATAGTAGCACATAATATGATGCA
ACTTAAAATGATAAAAATATTTTCAGGGAATAAGATTCTGTGATTCTTTCCCTAAGAG
40 GTAATTTTGATAATATGTACCTGTTTTGTAAATGTCAATAGTCTTGGGGATACAGGTG
GTGTTTGGTTACATGGAAAAGTTCCCTTAGTGGTGATTCTGAGATTTTAGTGCACCCA
ATACCCAAGCAGTGTACACTGTACCCAATATGTAGTCTTTCATCCCTCGCCCCCACTC
CCAACCTTCCCCCACAAGTCTCTAAAGTCCATTATATCACTCTTATATCTTTGCATACT
CATAGCTTAGCTCCCCTTATGAGAACATATGATAGTTAGTGCTCAATTCCTGAGTTA
45 CTTCACTTAGAATAATGGCCTCCAGCTCCACCCAAGTTGCTGCAAAAGACACTATTTA
GTTCCTTTTTATGGCTGAGTAGTATTACATGGTGTATATATACCACATTTTATTTATCC
ACTTGTTGGTCAATGGACACTTAACATTAGTTCCATATCTTTGTAATTTCAAGTTGTGC
TGCTATAAGCATGCATGAGCCTGTGTCTTTTTCATATAATTACTTCTTTTCCCTTTGGGT
AGATACCCAGCAGTGGGATTGCTGGATCAAATGATAGTTCTACTTTCAGTTCTTTATG
50 TTTTCCACAGTGGTCATACTAATTTACATTCCCATCAACAGTGTAAGTGTTCCCTTTT

CATCACACCCATGCCAACACCTATTGTTTTTTGACTTTTTTAATTACGGCCATTCTTGCA
GGAGTAAGGTGGTATTTTCATTGTGGTTTTAATTTGCATTTCCCTGATGTTGACAATATT
TAACTCTTTAGTTATAGATTCCAGCTATTATCAATTTACACCTATTGCATTCTTCTCAT
CTTTTGTCTTCTTGTGATTCTGATGCACAAATATCATTGTGCAACCACTTACTGTTGA
5 ACATGTCTGATGAACACTTACTATTGAACATGTCTGATGAATGAATAATGAAATAGG
AAAAGGGATTAAAACTAGCCTTTATTAATTGTTTGCTATAGGCCAGACATTTTTTGAT
GTACTATCACATTTTCATCCAAACAACAACCTAAAAGAAAATACTGTGATTATCCCCAT
TTCACATCTAAGGAACCTGGTCTTTAGGAAGATTAAAGTCATTTGGCCAAGATCACAA
GTAGACCACAGAGACTAGATTTGAATGCAAGTCTGTTTGACTCCAAACCTTTTTACTA
10 TCTGCCCATGACCCCTGATCACCAACATCTCAATGTATGAACATGTGCTTTCTTAGCT
CACACAACCTCACTCCTGACCCCTTTTTTATATTGCAAGTGCATAGTCATTAGTAAAAA
GAAGGATTTTTGATGATACTGACCTCATCTTGAATTTAATTAGGCTCATATGACAGAA
TTCCATAGATGGAATTGACATCCTAGGTCATATAGTCCAAGTCCTTGTTTATATTTGA
TACCTAGTGAGATTAAAGGGACATTAAAAAGTAAAGAAAGGAAAGACCTCATATTTT
15 TTACCTTCCAGTAGAGAAATCTTTCTATGAAATCAGAGGAAAGAATTAGAGGACCAG
AATTTTTCTTAAAATCAACTTTTCATACATCTTTTTTTCATATAAAAGGCATAGCTGCAT
ACAATGCTAAAATATTGTATTACATTTTCTTTTATATTGATGGGAGGAAGGGGGTAAAT
TGCAGAAAACATTGTAAATTTAGATATGCTTGGGCCTCTGACAGTGCCTAGCAAATA
TCAGGAGATCAATAATGAAATAAATATTATCAAAGAGTAGTCTTCTTGATGAACCTT
20 CTCTGAGTATCACAACCTGCTTTAGGAACCTCTAGATTCAAGGTCTAGTAATTGCAAAC
AGTGAGCTGATAAGAAAAACAGACTGTATGGGAAATTACATGCTTCTGTCATGACTG
CCTTTTGTCTCTCCACATTTTGATATAAAGTCACATTAACAGTTCATGAGTAAATATTC
GATAATGTGAACGTAAAGTGTTCAAATAATAGAGTGACTAAAATGCCTGAAAACAAA
TAATTTTTAATTAGAACTCATAATCATTTATTTTCTCTTTTTTCCACATTATCTCAAGC
25 TCACAAATTATATTTATTCTTTTCTATGGCAAAATCCATTTTGTAAACACTAATTTTGA
GTTTAACAAGAAGTGTACTCCAAAGTAGCCTAATAATACTAATTATAATGTTTCCTGC
TATGTTATCAGTTTGAATTTATATGAATCTTTAGACTTGAGGCTTCTTTTTCTAGCAT
AGTGATGGTCTGGGCTTTTTCTCAATTTTGGCCAGAGCTCAGCTCTCACTAATTAGTTT
CTTCTGCATGAGAAAAAGATTTTGCTTCATCTTTTTCTTATAATAGCAGAACAAAA
30 AGAAGAATCAGCTGCATCCATGCTAATTTCCCCTGTGACATTTCCAAACAGGATTTGA
TTTCTCTATGCATGCCTCTTTCCTTCTCTTCATGGTTTTTGAACATATACAAAAGCTCA
TTTAAACCAATTAAATAAAATTTGTTTTTAATCTCTTTCTCTAGAGTCAACTTCCTGCTT
ACTCCAACCTCTGTATCTTTGAAGGAAGTATAGGGTGGTCTATGCCTTTTTTCTCCCAG
AATCTACACTTGAAAAGACACATTTTTCCATGCAACTATAAAATGTTCTCCTCACTCA
35 ACATTGAAATTGTATAGCAGTGATTAAGAGAGTGAGCTGTAGAGCCAGGTTCCCTGG
GTTTAAATCCCACTTGTTAGTATCATGAAGATGGGCAAGTACTTACCCTTCCTGTGT
TTCAGTTTCTTCATCTGCAAAATGGGGACAATAATAGAATGTCCACTATAAGATTATT
GTGAGGATTAAGGGAATTAATACAGGTAAAACGTGTACTGATGCAGGTCTGGTACAC
ATTAAGTGCCTAATAAATATTCAGTATTATGATATAAAGAACCCTATAAGTGTAGACT
40 CCTTGAGATTAATAGAGTTTAACGATAAGTTTTACTTTATAGCTGGTCAAGTTTATTT
CTTCTGAACTAAAAGAATCTATAGAGTCTCAATTTCTGGAGCTTCAGAGGGAAGGAG
AGAAGCAATGTAAGCAACATTCTACAGAAATATAAATAATACTACTAATAATTAGCA
TCTTAAAATTTCAATTCAATGAACATTTATTTAGCGCCTATGATATATGCAAGACAGT
TTGATTTTAGTCATCTGATGTATAGCCACATACTAAAAAATACTGATTTTAGTCATCT
45 GATGTATAGCCACATACTAAAAAATACTTCCTCCATCAGTTCCCTCCTCAGGAAGTTC
AGTTCCCAATCCCAGGCTAGTACCTTGTTTCTTATGTAAATAAACATCCACCAATTA
CATGCTATCTGCAAAGCACTCTGCTAGGCCCTGCAAATGGAAAAAATAATGATAAAA
CATAGTCCAGGCCCTCAATGAGCTTACAGTCAAATATAATAGAGGAGACAAGAACAG
AGAGGCTCATAATACAACTAGAATAAAATGACTGCCGAATAAAAGGAAAGATTTAT
50 GCAGGTGTTCAAATGGAAAGTGAGATAAGTTTGCAGGTAGTCTTTGCAGTCTCATA

AAAATCTTTATGGAGAAAAGGACAATGGTCATAGGGCTTAAAGAGTAAGTTTATAAT
 CCTGACCAGTGGAGATGAAAGACTAGCATTGAAAATTGCATGACAAGACAATTCCAT
 TAAACTGAAACATCAAGTGTGTGTAGGAAAAGATGGGGGTATGACTGGAAACGTCA
 CTTGGACTGCAATTATGAAGGGCCTTGACAAACAGGTCAAGAGTTTAAGAAGCAGTA
 5 TAGAAAGTCTTCGTCTGGATCTAGCCCTCCCAGAGTGTCCATCAGGATTATAAAGTC
 CTAAAATATTAGTCAAAAGGAACGACATCATTAGAAATGATAGAGAAACAATAATG
 TGATGTTTTATTACCTTTCTCTGGATTTATACTCTGATCCTAATATTCAAAACTATCTT
 AATAACATGAACTTTTGGTCATAGTTTTAAACAAAAACAGTGTTAAATATATTTTTTA
 AAACACAGTAAGTCTTGTAAGATCTTTTCTAACATGACATTTTGCAGGGCCCATATTT
 10 TCCTTCTGAAATGGGAAAAATTCATAAAAGTAGACACCAAACCTGGGTACTTCTAGT
 CAAGCGCATGGTACGCAAAGGACCAGACAAAAAGGGCCTGTGACATTTCTTCTTCT
 TTTGTGTTTTTTAGGAGAGGCATGCTGCGGAGGTGCGCAGGAACAAGGAACCTCCAGG
 TTGAAGTGTCTGGCTGAAGCAAGGGAGGGTCTGGCACGCCCCACCAATAGTAAATCC
 CCCTGCCTATATTATAATGGATCATGCGATATCAGGATGGGGAATGTATGACATGGTT
 15 TAAAAAGAACTCATTATAAAAAAAAAAAAAAAAAACAAAAAAATCAAAAATTAAAAAA
 TCAATGCGGTCTCTTTGCAGAATGTTTTGCTTGATGTTTAAAAAATACCTTGGATCTT
 ATTTTGTAATACTTACATTTTTGTAAATAACAAGTATTGCATTATGCAAGTTAT
 TTCATAATCTTACATGTCCTGTAACAGGCTTTTGATGTTGTGTCTTTCCACTCAAATGA
 ATTTGCTAGGTCTGTTCTTTTTGAAGCTCCCCATGTCTAACTCCATTCCAAAAGAAAA
 20 ATGAGGTCAGTAGACAGTCTATGGTGCTAGAAACCCACCATTGCCTAATGACCTAGA
 AGGCTTTGTTGTCTCTGAGCTTGACTAAGACCATACCTAGATCACAGGTATTATGACT
 CCACATGAACCTTCACATTTGTTCGCTCATAATCTACTTACTGCCTAAAAACTACAAA
 ACCAGGCTAAGAAATACCACCAGTCATAGCATTTACTTCTGCTTCTCCTGGATTATGT
 GCTACAAATGTGCTTTGGCTTTAGAAAGGGATGGATGAGAAGACAGACCTGAGACCA
 25 ATCTGGGTAGAAGCAAAAAGTTGAACCTTTTAAAGTGCTGAACACAAATCCAAATTC
 GAATGGTTCAAGCAGCCGTGAAATCGCTCTTCATAAAGTGGGCTTAATTCTCTAGTTT
 AAGTTCTTTTGATGGAATGAATTAATTAATGTGTCAGGTGGCTTATTTGTGGATGCCA
 TGATTGATGATGTTCAATTTAAGCTCTTACCTATAGTACAAGTACATGATGCTACTGA
 ATATTTTTCCACTTGGAACCTGTGAGCTGGTTGTTGCATTAAAACACACATACAAACA
 30 AAATCAAAAACACTGCGGACTTTCCTCAAGCTGGTCTTTCTTCCCCAGTGTAAGGCA
 ATCCTGCCTACTAACAACACCAACAACAAAACACTCCATCTGTGAAGCTGACGCAGT
 TAAGGGGGCTAGGCAGGGCATTGTGCCAACTAAGAATCACCAGATACCCACCATAA
 GTACCTATCGCAGTTTTGAAGTCGTTTCTCCCAACTCCCAACTCCTGAAGGTTGCTG
 CCTGCATATTTACTCTTCATTAGTGCTATTTTCCTGTATGTCATTGTGAGCAAGCTGTG
 35 ATTAATAAAGAATTGGAGTTCTGTGAACATAATAAAGGTTTGGTCTGTT

(SEQ ID NO: 1391)

[00204] A STMN2 cryptic exon sequence within the STMN2 transcript is provided as SEQ ID NO: 447.

40 GACTCGGCAGAAGACCTTCGAGAGAAAGGTAGAAAATAAGAATTTGGCTCTCTGTGT
 GAGCATGTGTGCGTGTGTGCGAGAGAGAGACAGACAGCCTGCCTAAGAAGAAAT
 GAATGTGAATGCGGCTTGTGGCACAGTTGACAAGGATGATAAATCAATAATGCAAGC
 TTACTATCATTTATGAATAGCAATACTGAAGAAATTAACAAAAGATTGCTGTCTC

(SEQ ID NO: 447) (Source: NCBI Reference Sequence: NC_000008.11).

[00205] In various embodiments, the STMN2 transcript with a cryptic exon shares between 90-100% identity with SEQ ID NO: 944. In various embodiments, the STMN2 transcript with a cryptic exon shares at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with SEQ ID NO: 944.

5 STMN2 Antisense Oligonucleotides Targeting Portions of the STMN2 Transcript

[00206] In various embodiments, STMN2 AON disclosed herein target specific portions of STMN2 transcripts that include a cryptic exon. SEQ ID NO: 944, shown above, describes one example of a STMN2 transcript that includes a cryptic exon. In some embodiments, a STMN2 transcript that includes a cryptic exon may share at least 80%, 85%, 90%, 95%, or 100% identity with the nucleobase sequence of SEQ ID NO: 944.

[00207] In some embodiments, an STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript having a length of 10 nucleobases. In some embodiments, an STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript having a length of 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobases in length.

[00208] In some embodiments, an STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript comprising any one of positions 121-144, 144-168, 146-170, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192, 171-191, 171-193, 172-192, 172-194, 170-194, 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944. In some embodiments, an STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript comprising any one of positions 144-164, 144-166, 145-167, 146-166, 146-168, 147-165, or 148-168 of SEQ ID NO: 944. In some embodiments, an STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript comprising any one of positions 173-191, 173-193, 173-195, 173-197, 175-195, 175-197, 177-197, or 179-197 of SEQ ID NO: 944. In some embodiments, an STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript comprising any one of positions 185-205, 187-209, 189-209, 185-207, 197-217, 197-219, or 191-209 of SEQ ID NO: 944. In some embodiments, an STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript comprising any one of positions 237-255, 237-257, 237-

259, 239-259, 239-261, 241-261, 237-257, 249-269, 249-271, 252-272, 252-274, or 243-261 of SEQ ID NO: 944.

[00209] In some embodiments, an STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript consisting of any one of positions 121-144, 144-168, 146-170, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192, 171-191, 171-193, 172-192, 172-194, 170-194, 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944. In some embodiments, an STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript consisting of any one of positions 144-164, 144-166, 145-167, 146-166, 146-168, 147-165, or 148-168 of SEQ ID NO: 944. In some embodiments, an STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript consisting of any one of positions 173-191, 173-193, 173-195, 173-197, 175-195, 175-197, 177-197, or 179-197 of SEQ ID NO: 944. In some embodiments, an STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript consisting of any one of positions 185-205, 187-209, 189-209, 185-207, 197-217, 197-219, or 191-209 of SEQ ID NO: 944. In some embodiments, an STMN2 AON targets a specific portion of the STMN2 transcript, the specific portion of the STMN2 transcript consisting of any one of positions 237-255, 237-257, 237-259, 239-259, 239-261, 241-261, 237-257, 249-269, 249-271, 252-272, 252-274, or 243-261 of SEQ ID NO: 944.

[00210] In various embodiments, the STMN2 AON comprises a nucleobase sequence that comprises a portion of at least 10 contiguous nucleobases that is complementary to an equal length portion of nucleobases within any one of positions 144-164, 144-166, 145-167, 146-166, 146-168, 147-165, 148-168, 173-191, 173-193, 173-195, 173-197, 175-195, 175-197, 177-197, 179-197, 185-205, 185-207, 197-217, 197-219, 187-209, 189-209, 191-209, 237-255, 237-257, 237-259, 239-259, 239-261, 241-261, 237-257, 249-269, 249-271, 252-272, 252-274, or 243-261 of SEQ ID NO: 944. In various embodiments, the STMN2 AON comprises a nucleobase sequence that comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that is complementary to an equal length portion of nucleobases within any one of positions 144-164, 144-166, 145-167, 146-166, 146-168, 147-165, 148-168, 173-191, 173-193, 173-195, 173-197, 175-195, 175-197, 177-197, 179-197, 185-205, 185-207,

197-217, 197-219, 187-209, 189-209, 191-209, 237-255, 237-257, 237-259, 239-259, 239-261, 241-261, 237-257, 249-269, 249-271, 252-272, 252-274, or 243-261 of SEQ ID NO: 944.

[00211] In various embodiments, the oligonucleotide comprises linked nucleosides with at least a 19 contiguous nucleobase sequence that is at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) complementary to an equal length portion of a transcript with at least 90% identity (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity) to SEQ ID NO: 944, or to a contiguous 19 to 50 nucleobase portion of SEQ ID NO: 944, wherein at least one nucleoside linkage of the linked nucleosides is a non-natural linkage. In various embodiments, the oligonucleotide comprises linked nucleosides with at least a 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobase sequence that is at least 90% complementary (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary) to an equal length portion of a transcript with at least 90% (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identity to SEQ ID NO: 944, or to a contiguous 19 to 50 nucleobase portion of SEQ ID NO: 944, wherein at least one nucleoside linkage of the linked nucleosides is a non-natural linkage.

[00212] In various embodiments, the oligonucleotide comprises linked nucleosides with at least a 19 contiguous nucleobase sequence that comprises a portion of at least 10 contiguous nucleobases that shares at least 90% identity (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity) with an equal length portion of any one of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432. In various embodiments, the oligonucleotide comprises linked nucleosides with at least a 19 contiguous nucleobase sequence that comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that shares at least 90% identity (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity) with an equal length portion of any one of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432.

[00213] In various embodiments, the oligonucleotide comprises linked nucleosides with at least a 19 contiguous nucleobase sequence that comprises a portion of at least 10 contiguous nucleobases that shares at least 90% identity (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity) with an equal length portion of any one of SEQ ID NOs: 31, 36, 41, 46, 55, 144, 146, 150, 169, 170, 171, 172, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 249, 252, 380, 385, 390, 395, 400, 975, 980, 985, 999, 1088, 1090, 1094, 1113, 1114, 1115, 1116,

1117, 1121, 1125, 1129, 1141, 1147, 1153, 1159, 1181, 1188, 1193, 1196, 1324, 1329, 1334, 1339, or 1344, wherein at least one nucleoside linkage of the linked nucleosides is a non-natural linkage. In various embodiments, the oligonucleotide comprises linked nucleosides with at least a 19 contiguous nucleobase sequence that comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that shares at least 90% identity (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity) with an equal length portion of any one of SEQ ID NOs: 31, 36, 41, 46, 55, 144, 146, 150, 169, 170, 171, 172, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 249, 252, 380, 385, 390, 395, 400, 975, 980, 985, 999, 1088, 1090, 1094, 1113, 1114, 1115, 1116, 1117, 1121, 1125, 1129, 1141, 1147, 1153, 1159, 1181, 1188, 1193, 1196, 1324, 1329, 1334, 1339, or 1344, wherein at least one nucleoside linkage of the linked nucleosides is a non-natural linkage.

[00214] In various embodiments, the oligonucleotide comprises linked nucleosides with at least a 19 contiguous nucleobase sequence, wherein the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that shares at least 90% identity (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity) to an equal length portion of any one of SEQ ID NOs: 894-918 or SEQ ID NOs: 1392-1432. In various embodiments, the oligonucleotide comprises linked nucleosides with at least a 20, 21, 22, 23, 24, or 25 contiguous nucleobase sequence, wherein the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that shares at least 90% identity (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity) to an equal length portion of any one of SEQ ID NOs: 894-918 or SEQ ID NOs: 1392-1432.

[00215] In various embodiments, the oligonucleotide comprises linked nucleosides with at least a 19 contiguous nucleobase sequence, wherein the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that shares at least 90% identity (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity) to an equal length portion of any one of SEQ ID NOs: 894-918 or SEQ ID NOs: 1392-1432. In various embodiments, the oligonucleotide comprises linked nucleosides with at least a 20, 21, 22, 23, 24, or 25 contiguous nucleobase sequence, wherein the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that shares at least 90% identity (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,

98%, 99%, or 100% identity) to an equal length portion of any one of SEQ ID NOs: 894-918 or SEQ ID NOs: 1392-1432.

[00216] In various embodiments, the oligonucleotide comprises linked nucleosides with at least a 19 contiguous nucleobase sequence, the nucleobase sequence comprising a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that shares at least 90% identity (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity) to of any one of SEQ ID NOs: 894-918 or SEQ ID NOs: 1392-1432.

[00217] In various embodiments, the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that is at least 90% complementary (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary) to an equal length portion of nucleobases within any one of positions 121-144, 144-168, 146-170, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192, 171-191, 171-193, 172-192, 172-194, 170-194, 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944. In various embodiments, the nucleobase sequence comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that is at least 90% complementary (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary) to an equal length portion of nucleobases within any one of positions 121-144, 144-168, 146-170, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192, 171-191, 171-193, 172-192, 172-194, 170-194, 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944.

[00218] In various embodiments, the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that is at least 90% complementary (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary) to an equal length portion of nucleobases within any one of positions 121-144, 144-168, 146-170, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192, 171-191, 171-193, 172-192, 172-194, 170-194, 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944. In various embodiments, the nucleobase sequence comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that is at least 90% complementary (*e.g.*, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary) to an equal length portion of nucleobases within any one of positions 121-144, 144-168, 146-170, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192,

171-191, 171-193, 172-192, 172-194, 170-194, 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944.

[00219] In various embodiments, the portion of the nucleobase sequence is 100% complementary to an equal length portion of nucleobases within any one of positions 121-144, 144-168, 146-170, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192, 171-191, 171-193, 172-192, 172-194, 170-194, 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944. In various embodiments, the portion of the nucleobase sequence is 100% complementary to an equal length portion of nucleobases within any one of positions 144-164, 144-166, 145-167, 146-166, 146-168, 147-165, or 148-168 of SEQ ID NO: 944. In various embodiments, the portion of the nucleobase sequence is 100% complementary to an equal length portion of nucleobases within any one of positions 173-191, 173-193, 173-195, 173-197, 175-195, 175-197, 177-197, or 179-197 of SEQ ID NO: 944. In various embodiments, the portion of the nucleobase sequence is 100% complementary to an equal length portion of nucleobases within any one of positions 185-205, 187-209, 189-209, 185-207, 197-217, 197-219, or 191-209 of SEQ ID NO: 944. In various embodiments, the portion of the nucleobase sequence is 100% complementary to an equal length portion of nucleobases within any one of positions 237-255, 237-257, 237-259, 239-259, 239-261, 241-261, 237-257, 249-269, 249-271, 252-272, 252-274, or 243-261 of SEQ ID NO: 944.

STMN2 Antisense Oligonucleotide Variants

[00220] In various embodiments, STMN2 AONs include different variants, hereafter referred to as STMN2 AON variants. A STMN2 AON variant may be an oligonucleotide sequence of 5 to 100 nucleotides in length, for example, 10 to 40 nucleotides in length, for example, 14 to 40 nucleotides in length, 10 to 30 nucleotides in length, for example, 14 to 30 nucleotides in length, for example, 16 to 28 nucleotides in length, for example, 19 to 23 nucleotides in length, for example, 21 to 23 nucleotides in length, for example, or 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. A STMN2 AON variant may be an oligonucleotide sequence complementary to a portion of a STMN2 pre-mRNA sequence or a STMN2 gene sequence.

[00221] In various embodiments, a STMN2 AON variant represents a modified version of a corresponding STMN2 AON that includes a nucleobase sequence selected from any one of SEQ ID NOs: 1-446 or SEQ ID NOs: 945-1390. In some embodiments, a STMN2 AON variant includes a nucleobase sequence that represents a shortened version of a nucleobase sequence of a

STMN2 AON selected from any one of SEQ ID NOs: 1-446 OR SEQ ID NOs: 945-1390. As one example, if a STMN2 AON includes a 25mer (*e.g.*, 25 nucleotides in length) a variant (*e.g.*, a STMN2 variant) may include a shorter version (*e.g.*, 15mer, 16mer, 17mer, 18mer, 19mer, 20mer, 21mer, 22mer, 23mer, or 24mer) of the 25mer STMN2 AON. In one embodiment, a nucleobase sequence of a STMN2 AON variant differs from a corresponding nucleobase sequence of a STMN2 AON in that 1, 2, 3, 4, 5, or 6 nucleotides are removed from one or both of the 3' and 5' ends of the nucleobase sequence of the STMN2 AON. In one embodiment, the corresponding STMN2 AON variant may include a 23mer where two nucleotides were removed from one of the 3' or 5' end of a 25mer included in the STMN2 AON. In one embodiment, the corresponding STMN2 AON variant may include a 23mer where one nucleotide is removed from each of the 3' and 5' ends of the 25mer included in the STMN2 AON. In one embodiment, the corresponding STMN2 AON variant may include a 21mer where two nucleotides are removed from each of the 3' and 5' ends of the 25mer included in the STMN2 AON. In one embodiment, the corresponding STMN2 AON variant may include a 21mer where four nucleotides are removed from either the 3' or 5' end of the 25mer included in the STMN2 AON. In one embodiment, the corresponding STMN2 AON variant may include a 19mer where three nucleotides are removed from each of the 3' and 5' ends of the 25mer included in the STMN2 AON. In one embodiment, the corresponding STMN2 AON variant may include a 19mer where six nucleotides are removed from either the 3' or 5' end of the 25mer included in the STMN2 AON.

[00222] Example sequences of STMN2 AON variants are shown below in Table 3. The example STMN2 AON variants are each associated with an identifier that describes the differences between the STMN2 AON variant and the corresponding STMN2 AON. As an example, a STMN2 AON variant includes SEQ ID NO: 894 and is identified using identifier: QSN-144-1/5-1/3. This first portion of the identifier "QSN-144" indicates that the STMN2 AON variant is a modified version of the QSN-144 STMN2 AON which includes SEQ ID NO: 144. Additionally, the second portion of the identifier which includes the numerical indicators of "1/5-1/3" indicate that one nucleotide is removed from each of the 5' end and the 3' end of the nucleobase sequence included in the QSN-144 STMN2 AON (*e.g.*, 1 nucleotide removed from each of 3' and 5' end of SEQ ID NO: 144). To provide another example, a STMN2 AON variant includes SEQ ID NO: 895 and is identified as QSN-144-2/3. This STMN2 AON variant is a modified version of the QSN-144 STMN2 AON. The numerical indicators of "2/3" indicate that two nucleotides are removed from the 3' end of the nucleobase sequence of the QSN-144 STMN2 AON (*e.g.*, 2 bases removed from 3' end of SEQ ID NO: 144).

[00223] In some embodiments, a STMN2 AON variant differs from a corresponding STMN2 AON in that one or more internucleoside linkages of the STMN2 AON variant are phosphodiester bonds. In such embodiments, the length of the STMN2 AON variant may be the same length as the corresponding STMN2 AON (*e.g.*, 25 nucleotides in length). In some embodiments, the phosphodiester internucleoside linkages connect two, three, four, five, six, seven, eight, nine, or ten contiguous nucleotides.

[00224] In some embodiments, the phosphodiester internucleoside linkages connect nucleotides located at one or both of the 3' or 5' ends. For example, two, three, four, five, six, seven, eight, nine, or ten contiguous nucleotides at one or both of the 3' or 5' ends are connected via phosphodiester internucleoside linkages.

[00225] In some embodiments, the phosphodiester internucleoside linkages connect nucleotides located within the nucleobase sequence. For example, within a 25mer STMN2 AON variant, contiguous nucleotides between positions 6-15 may be connected through phosphodiester internucleoside linkages. In some embodiments, contiguous nucleotides between any one of positions 7-15, 8-14, or 9-13 are connected through phosphodiester internucleoside linkages.

[00226] Table 5 below identifies variants of STMN2 AON sequences:

Table 5. STMN2 Antisense Oligonucleotide Variant Sequences

SEQ ID NO:	Identifier	AON Sequence* (5' → 3')	SEQ ID NO:	Target Sequence (5' → 3')
894	QSN-144-1/5-1/3	ATCCAATTAAGAGAGAGTGATGG	919	CCATCACTCTCTCTTAATTGGAT
895	QSN-144-2/3	AATCCAATTAAGAGAGAGTGATG	920	CATCACTCTCTCTTAATTGGATT
896	QSN-144-2/5	TCCAATTAAGAGAGAGTGATGGG	921	CCCATCACTCTCTCTTAATTGGA
897	QSN-144-2/5-2/3	TCCAATTAAGAGAGAGTGATG	922	CATCACTCTCTCTTAATTGGA
898	QSN-144-3/5-3/3	CCAATTAAGAGAGAGTGAT	923	ATCACTCTCTCTTAATTGG
899	QSN-144-4/3	AATCCAATTAAGAGAGAGTGA	924	TCCTCTCTCTTAATTGGATT
900	QSN-144-4/5	CAATTAAGAGAGAGTGATGGG	925	CCCATCACTCTCTCTTAATTG
901	QSN-173-2/3	GAGTCCTGCAATATGAATATAAT	926	ATTATATTCATATTGCAGGACTC

902	QSN-173-2/5	GTCCTGCAATATGAATATAATTT	927	AAATTATATTCATATTGCAGGAC
903	QSN-173-2/5-2/3	GTCCTGCAATATGAATATAAT	928	ATTATATTCATATTGCAGGAC
904	QSN-173-4/3	GAGTCCTGCAATATGAATATA	929	TATATTCATATTGCAGGACTC
905	QSN-173-4/5	CCTGCAATATGAATATAATTT	930	AAATTATATTCATATTGCAGG
906	QSN-173-6/3	GAGTCCTGCAATATGAATA	931	TATTCATATTGCAGGACTC
907	QSN-173-6/5	TGCAATATGAATATAATTT	932	AAATTATATTCATATTGCA
908	QSN-185-2/5	GTCTTCTGCCGAGTCCTGCAATA	933	TATTGCAGGACTCGGCAGAAGAC
909	QSN-185-4/3	AGGTCTTCTGCCGAGTCCTGC	934	GCAGGACTCGGCAGAAGACCT
910	QSN-185-4/5	CTTCTGCCGAGTCCTGCAATA	935	TATTGCAGGACTCGGCAGAAG
911	QSN-185-6/5	TCTGCCGAGTCCTGCAATA	936	TATTGCAGGACTCGGCAGA
912	QSN-237-2/3	GCACACATGCTCACACAGAGAGC	937	GCTCTCTGTGTGAGCATGTGTGC
913	QSN-237-2/5	ACACATGCTCACACAGAGAGCCA	938	TGGCTCTCTGTGTGAGCATGTGT
914	QSN-237-2/5-2/3	ACACATGCTCACACAGAGAGC	939	GCTCTCTGTGTGAGCATGTGT
915	QSN-237-4/3	GCACACATGCTCACACAGAGA	940	TCTCTGTGTGAGCATGTGTGC
916	QSN-237-4/5	ACATGCTCACACAGAGAGCCA	941	TGGCTCTCTGTGTGAGCATGT
917	QSN-237-6/3	GCACACATGCTCACACAGA	942	TCTGTGTGAGCATGTGTGC
918	QSN-237-6/5	ATGCTCACACAGAGAGCCA	943	TGGCTCTCTGTGTGAGCAT
1417	QSN-173-po3	G-A-G-TCCTGCAATATGAATATAA-T-T-T ¹	620	AAATTATATTCATATTGCAGGACTC
1418	QSN-173-po5	GAGTCCTG-C-A-A-T-A-TGAATATAATTT ¹	620	AAATTATATTCATATTGCAGGACTC
1419	QSN-144-po3	A-A-T-CCAATTAAGAGAGAGTGAT-G-G-G ¹	591	CCCATCACTCTCTCTTAATTGGATT
1420	QSN-144-po5	AATCCAAT-T-A-A-G-A-GAGAGTGATGGG ¹	591	CCCATCACTCTCTCTTAATTGGATT
1421	QSN-185-po3	A-G-G-TCTTCTGCCGAGTCCTGCA-A-T-A ¹	633	ATTGCAGGACTCGGCAGAAGACCTT
1422	QSN-185-po5	AGGTCTTC-T-G-C-C-G-AGTCCTGCAATA ¹	633	ATTGCAGGACTCGGCAGAAGACCTT
1423	QSN-237-po3	G-C-A-CACATGCTCACACAGAGAG-C-C-A ¹	684	TGGCTCTCTGTGTGAGCATGTGTGC
1424	QSN-237-po5	GCACACAT-G-C-T-C-A-CACAGAGAGCCA ¹	684	TGGCTCTCTGTGTGAGCATGTGTGC

* Except where noted to the contrary (e.g., in SEQ ID NOs: 1417, 1418, 1419, 1420, 1421, 1422, 1423, and 1424 in Table 5), at least one nucleoside linkage of the nucleobase sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a

5 methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothiate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage. In some embodiments, except where noted to the contrary (*e.g.*, in SEQ ID NOs: 1417, 1418, 1419, 1420, 1421, 1422, 1423, and 1424 in Table 5), every nucleoside linkage is a phosphorothioate linkage.

¹ The notation “-” indicates the presence of a phosphodiester linkage in SEQ ID NOs: 1417, 1418, 1419, 1420, 1421, 1422, 1423, and 1424 in Table 5.

[00227] Table 6 below identifies additional variants of STMN2 AON sequences:

Table 6. Additional STMN2 Antisense Oligonucleotide Variant Sequences

SEQ ID NO:	Identifier	AON Sequence* (5' → 3')
1392	QSN-144-1/5-1/3	AUCCAAUUAAGAGAGAGUGAUGG
1393	QSN-144-2/3	AAUCCAAUUAAGAGAGAGUGAUG
1394	QSN-144-2/5	UCCAAUUAAGAGAGAGUGAUGGG
1395	QSN-144-2/5-2/3	UCCAAUUAAGAGAGAGUGAUG
1396	QSN-144-3/5-3/3	CCAAUUAAGAGAGAGUGAU
1397	QSN-144-4/3	AAUCCAAUUAAGAGAGAGUGA
1398	QSN-144-4/5	CAAUUAAGAGAGAGUGAUGGG
1399	QSN-173-2/3	GAGUCCUGCAAUAUGAAUAUAAU
1400	QSN-173-2/5	GUCCUGCAAUAUGAAUAUAAUUU
1401	QSN-173-2/5-2/3	GUCCUGCAAUAUGAAUAUAAU
1402	QSN-173-4/3	GAGUCCUGCAAUAUGAAUAUA
1403	QSN-173-4/5	CCUGCAAUAUGAAUAUAAUUU
1404	QSN-173-6/3	GAGUCCUGCAAUAUGAAUA
1405	QSN-173-6/5	UGCAAUAUGAAUAUAAUUU
1406	QSN-185-2/5	GUCUUCUGCCGAGUCCUGCAAUA
1407	QSN-185-4/3	AGGUCUUCUGCCGAGUCCUGC
1408	QSN-185-4/5	CUUCUGCCGAGUCCUGCAAUA
1409	QSN-185-6/5	UCUGCCGAGUCCUGCAAUA
1410	QSN-237-2/3	GCACACAUGCUCACACAGAGAGC
1411	QSN-237-2/5	ACACAUGCUCACACAGAGAGCCA
1412	QSN-237-2/5-2/3	ACACAUGCUCACACAGAGAGC

1413	QSN-237-4/3	GCACACAUGCUCACACAGAGA
1414	QSN-237-4/5	ACAUGCUCACACAGAGAGCCA
1415	QSN-237-6/3	GCACACAUGCUCACACAGA
1416	QSN-237-6/5	AUGCUCACACAGAGAGCCA
1425	QSN-173-po3	G-A-G-UCCUGCAAUAUGAAUAUAA-U-U-U ¹
1426	QSN-173-po5	GAGUCCUG-C-A-A-U-A-UGAAUAUAAUUU ¹
1427	QSN-144-po3	A-A-U-CCAAUUAAGAGAGAGUGAU-G-G-G ¹
1428	QSN-144-po5	AAUCCAAU-U-A-A-G-A-GAGAGUGAUGGG ¹
1429	QSN-185-po3	A-G-G-UCUUCUGCCGAGUCCUGCA-A-U-A ¹
1430	QSN-185-po5	AGGUCUUC-U-G-C-C-G-AGUCCUGCAAUA ¹
1431	QSN-237-po3	G-C-A-CACAUGCUCACACAGAGAG-C-C-A ¹
1432	QSN-237-po5	GCACACAU-G-C-U-C-A-CACAGAGAGCCA ¹

* Except where noted to the contrary (*e.g.*, in SEQ ID NOs: 1425, 1426, 1427, 1428, 1429, 1430, 1431, and 1432 in Table 6), at least one nucleoside linkage of the nucleobase sequence is selected from a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothiate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage. In some embodiments, except where noted to the contrary (*e.g.*, in SEQ ID NOs: 1425, 1426, 1427, 1428, 1429, 1430, 1431, and 1432 in Table 6), every nucleoside linkage is a phosphorothioate linkage.

¹ The notation “-” indicates the presence of a phosphodiester linkage in SEQ ID NOs: 1425, 1426, 1427, 1428, 1429, 1430, 1431, and 1432 in Table 6.

Performance of STMN2 Antisense Oligonucleotides and Variants

[00228] Generally, STMN2 AON and STMN2 AON variants can target STMN2 transcripts with a cryptic exon in order to increase, restore, rescue, or stabilize levels of expression of STMN2 mRNA that is capable of translation to produce a functional STMN2 protein (*e.g.*, full length STMN2). In various embodiments, STMN2 AON and STMN2 AON variants can exhibit at least a 60%, 70%, 80%, or 90% increase of full length STMN2 protein. In various embodiments, STMN2 AON and STMN2 AON variants can exhibit at least a 100%, 200%, 300%, or 400% increase of full length STMN2 protein. In some embodiments, the percent

increase of the full length STMN2 protein is an increase in comparison to a reduced level of full length STMN2 protein achieved using a TDP43 antisense oligonucleotide. For example, a TDP43 antisense oligonucleotide can be used to deplete full length STMN2 protein followed by increase of the full length STMN2 protein using a STMN2 AON or STMN2 AON variant.

5 **[00229]** In some embodiments, STMN2 AON and STMN2 AON variants reduce levels of STMN2 transcript with a cryptic exon. In various embodiments, STMN2 AON and STMN2 AON variants can exhibit at least a 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% reduction of the STMN2 transcript with the cryptic exon. In some embodiments, the percent reduction of cryptic exon levels is a decrease in comparison to an increased level of cryptic exon
10 achieved using a TDP43 antisense oligonucleotide. For example, a TDP43 antisense oligonucleotide can be used to increase cryptic exon levels followed by a reduction of cryptic exon levels using a STMN2 AON or STMN2 AON variant.

[00230] In some embodiments, STMN2 AON and STMN2 AON variants can exhibit at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% rescue of full length STMN2
15 protein. In some embodiments, the percent rescue of full length STMN2 refers to the % of full length STMN2 following depletion using a TDP43 antisense oligonucleotide and a treatment using STMN2 AON or STMN2 AON variant in comparison to a negative control (*e.g.*, cells that did not undergo depletion or treatment or cells that were treated with a vehicle solution).

[00231] In some embodiments, STMN2 AON and AON variants exhibit between 50% to 100%
20 rescue of full length STMN2. In some embodiments, STMN2 AON and AON variants exhibit between 60% to 100% rescue of full length STMN2. In some embodiments, STMN2 AON and AON variants exhibit between 70% to 100% rescue of full length STMN2. In some embodiments, STMN2 AON and AON variants exhibit between 80% to 100% rescue of full length STMN2. In some embodiments, STMN2 AON and AON variants exhibit between 90% to 100% rescue of full
25 length STMN2. In some embodiments, STMN2 AON and AON variants exhibit between 60% to 90% rescue of full length STMN2. In some embodiments, STMN2 AON and AON variants exhibit between 50% to 80% rescue of full length STMN2. In some embodiments, STMN2 AON and AON variants exhibit between 60% to 80% rescue of full length STMN2.

[00232] In particular embodiments, QSN-31 STMN2 AON (SEQ ID NO: 31) exhibits between
30 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-31 STMN2 AON (SEQ ID NO: 31) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-31 STMN2 AON (SEQ ID NO: 31) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-31 STMN2

AON (SEQ ID NO: 31) oligonucleotide are phosphorothioate linkages, each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and each "C" is replaced with a 5-MeC.

[00233] In particular embodiments, QSN-36 STMN2 AON (SEQ ID NO: 36) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-36 STMN2 AON (SEQ ID NO: 36) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-36 STMN2 AON (SEQ ID NO: 36) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-36 STMN2 AON (SEQ ID NO: 36) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some embodiments, all internucleoside linkages of the QSN-36 STMN2 AON (SEQ ID NO: 36) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC.

[00234] In particular embodiments, QSN-41 STMN2 AON (SEQ ID NO: 41) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-41 STMN2 AON (SEQ ID NO: 41) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-41 STMN2 AON (SEQ ID NO: 41) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-41 STMN2 AON (SEQ ID NO: 41) oligonucleotide are phosphorothioate linkages, each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and each "C" is replaced with a 5-MeC.

[00235] In particular embodiments, QSN-46 STMN2 AON (SEQ ID NO: 46) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-46 STMN2 AON (SEQ ID NO: 46) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-46 STMN2 AON (SEQ ID NO: 46) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-46 STMN2 AON (SEQ ID NO: 46) oligonucleotide are phosphorothioate linkages, each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and each "C" is replaced with a 5-MeC.

[00236] In particular embodiments, QSN-55 STMN2 AON (SEQ ID NO: 55) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-55 STMN2 AON (SEQ ID NO: 55) exhibits between 60 to 90% rescue of full length STMN2. In particular
5 embodiments, QSN-55 STMN2 AON (SEQ ID NO: 55) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-55 STMN2 AON (SEQ ID NO: 55) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some
10 embodiments, all internucleoside linkages of the QSN-55 STMN2 AON (SEQ ID NO: 55) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC.

[00237] In particular embodiments, QSN-144 STMN2 AON (SEQ ID NO: 144) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-144 STMN2 AON (SEQ ID NO: 144) exhibits between 60 to 90% rescue of full length STMN2. In particular
15 embodiments, QSN-144 STMN2 AON (SEQ ID NO: 144) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-144 STMN2 AON (SEQ ID NO: 144) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some
20 embodiments, all internucleoside linkages of the QSN-144 STMN2 AON (SEQ ID NO: 144) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC.

[00238] In particular embodiments, QSN-146 STMN2 AON (SEQ ID NO: 146) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-146 STMN2
25 AON (SEQ ID NO: 146) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-146 STMN2 AON (SEQ ID NO: 146) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-146 STMN2 AON (SEQ ID NO: 146) oligonucleotide are phosphorothioate linkages, each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and each
30 "C" is replaced with a 5-MeC.

[00239] In particular embodiments, QSN-150 STMN2 AON (SEQ ID NO: 150) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-150 STMN2

AON (SEQ ID NO: 150) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-150 STMN2 AON (SEQ ID NO: 150) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-150 STMN2 AON (SEQ ID NO: 150) oligonucleotide are phosphorothioate linkages, each of the linked
5 nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and each "C" is replaced with a 5-MeC.

[00240] In particular embodiments, QSN-169 STMN2 AON (SEQ ID NO: 169) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-169 STMN2 AON (SEQ ID NO: 169) exhibits between 60 to 90% rescue of full length STMN2. In particular
10 embodiments, QSN-169 STMN2 AON (SEQ ID NO: 169) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-169 STMN2 AON (SEQ ID NO: 169) oligonucleotide are phosphorothioate linkages, each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and each "C" is replaced with a 5-MeC.

[00241] In particular embodiments, QSN-170 STMN2 AON (SEQ ID NO: 170) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-170 STMN2 AON (SEQ ID NO: 170) exhibits between 60 to 90% rescue of full length STMN2. In particular
15 embodiments, QSN-170 STMN2 AON (SEQ ID NO: 170) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-170 STMN2 AON (SEQ ID NO: 170) oligonucleotide are phosphorothioate linkages, each of the linked
20 nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and each "C" is replaced with a 5-MeC.

[00242] In particular embodiments, QSN-171 STMN2 AON (SEQ ID NO: 171) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-171 STMN2
25 AON (SEQ ID NO: 171) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-171 STMN2 AON (SEQ ID NO: 171) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-171 STMN2 AON (SEQ ID NO: 171) oligonucleotide are phosphorothioate linkages, each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and each
30 "C" is replaced with a 5-MeC.

[00243] In particular embodiments, QSN-172 STMN2 AON (SEQ ID NO: 172) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-172 STMN2 AON (SEQ ID NO: 172) exhibits between 60 to 90% rescue of full length STMN2. In particular

embodiments, QSN-172 STMN2 AON (SEQ ID NO: 172) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-172 STMN2 AON (SEQ ID NO: 172) oligonucleotide are phosphorothioate linkages, each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and each

5 "C" is replaced with a 5-MeC.

[00244] In particular embodiments, QSN-173 STMN2 AON (SEQ ID NO: 173) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-173 STMN2 AON (SEQ ID NO: 173) exhibits between 60 to 90% rescue of full length STMN2. In particular
10 embodiments, QSN-173 STMN2 AON (SEQ ID NO: 173) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-173 STMN2 AON (SEQ ID NO: 173) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some
15 embodiments, all internucleoside linkages of the QSN-173 STMN2 AON (SEQ ID NO: 173) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC.

[00245] In particular embodiments, QSN-177 STMN2 AON (SEQ ID NO: 177) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-177 STMN2 AON (SEQ ID NO: 177) exhibits between 60 to 90% rescue of full length STMN2. In particular
20 embodiments, QSN-177 STMN2 AON (SEQ ID NO: 177) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-177 STMN2 AON (SEQ ID NO: 177) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some
25 embodiments, all internucleoside linkages of the QSN-177 STMN2 AON (SEQ ID NO: 177) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In particular embodiments, QSN-181 STMN2 AON (SEQ ID NO: 181) exhibits between
30 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-181 STMN2 AON (SEQ ID NO: 181) exhibits between 60 to 90% rescue of full length STMN2. In particular
embodiments, QSN-181 STMN2 AON (SEQ ID NO: 181) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-181 STMN2 AON (SEQ ID NO: 181) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some

embodiments, all internucleoside linkages of the QSN-181 STMN2 AON (SEQ ID NO: 181) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC.

- 5 **[00246]** In particular embodiments, QSN-185 STMN2 AON (SEQ ID NO: 185) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-185 STMN2 AON (SEQ ID NO: 185) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-185 STMN2 AON (SEQ ID NO: 185) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-185 STMN2 AON (SEQ ID NO: 185) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In some embodiments, all internucleoside linkages of the QSN-185 STMN2 AON (SEQ ID NO: 185) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In particular embodiments, QSN-197 STMN2 AON (SEQ ID NO: 197) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-197 STMN2 AON (SEQ ID NO: 197) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-197 STMN2 AON (SEQ ID NO: 197) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-197 STMN2 AON (SEQ ID NO: 197) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some embodiments, all internucleoside linkages of the QSN-197 STMN2 AON (SEQ ID NO: 197) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC.
- 25 **[00247]** In particular embodiments, QSN-203 STMN2 AON (SEQ ID NO: 203) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-203 STMN2 AON (SEQ ID NO: 203) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-203 STMN2 AON (SEQ ID NO: 203) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-203 STMN2 AON (SEQ ID NO: 203) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some embodiments, all internucleoside linkages of the QSN-203 STMN2 AON (SEQ ID NO: 203) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the

oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In particular embodiments, QSN-209 STMN2 AON (SEQ ID NO: 209) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-209 STMN2 AON (SEQ ID NO: 209) exhibits between 60 to 90% rescue of full length STMN2. In some
5 embodiments, all internucleoside linkages of the QSN-209 STMN2 AON (SEQ ID NO: 209) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In particular embodiments, QSN-209 STMN2 AON (SEQ ID NO: 209) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-209 STMN2 AON (SEQ
10 ID NO: 209) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC.

[00248] In particular embodiments, QSN-215 STMN2 AON (SEQ ID NO: 215) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-215 STMN2
15 AON (SEQ ID NO: 215) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-215 STMN2 AON (SEQ ID NO: 215) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-215 STMN2 AON (SEQ ID NO: 215) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some
20 embodiments, all internucleoside linkages of the QSN-215 STMN2 AON (SEQ ID NO: 215) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In particular embodiments, QSN-237 STMN2 AON (SEQ ID NO: 237) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-237 STMN2 AON
25 (SEQ ID NO: 237) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-237 STMN2 AON (SEQ ID NO: 237) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-237 STMN2 AON (SEQ ID NO: 237) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some
30 embodiments, all internucleoside linkages of the QSN-237 STMN2 AON (SEQ ID NO: 237) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC.

[00249] In particular embodiments, QSN-244 STMN2 AON (SEQ ID NO: 244) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-244 STMN2 AON (SEQ ID NO: 244) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-244 STMN2 AON (SEQ ID NO: 244) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-244 STMN2 AON (SEQ ID NO: 244) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some embodiments, all internucleoside linkages of the QSN-244 STMN2 AON (SEQ ID NO: 244) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC.

[00250] In particular embodiments, QSN-249 STMN2 AON (SEQ ID NO: 249) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-249 STMN2 AON (SEQ ID NO: 249) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-249 STMN2 AON (SEQ ID NO: 249) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-249 STMN2 AON (SEQ ID NO: 249) oligonucleotide are phosphorothioate linkages, each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides, and each "C" is replaced with a 5-MeC.

[00251] In particular embodiments, QSN-252 STMN2 AON (SEQ ID NO: 252) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-252 STMN2 AON (SEQ ID NO: 252) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-252 STMN2 AON (SEQ ID NO: 252) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-252 STMN2 AON (SEQ ID NO: 252) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some embodiments, all internucleoside linkages of the QSN-252 STMN2 AON (SEQ ID NO: 252) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC.

[00252] In particular embodiments, QSN-380 STMN2 AON (SEQ ID NO: 380) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-380 STMN2 AON (SEQ ID NO: 380) exhibits between 60 to 90% rescue of full length STMN2. In particular

embodiments, QSN-380 STMN2 AON (SEQ ID NO: 380) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-380 STMN2 AON (SEQ ID NO: 380) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some
5 embodiments, all internucleoside linkages of the QSN-380 STMN2 AON (SEQ ID NO: 380) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In particular embodiments, QSN-385 STMN2 AON (SEQ ID NO: 385) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-385 STMN2 AON
10 (SEQ ID NO: 385) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-385 STMN2 AON (SEQ ID NO: 385) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-385 STMN2 AON (SEQ ID NO: 385) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some
15 embodiments, all internucleoside linkages of the QSN-385 STMN2 AON (SEQ ID NO: 385) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC.

[00253] In particular embodiments, QSN-390 STMN2 AON (SEQ ID NO: 390) exhibits
20 between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-390 STMN2 AON (SEQ ID NO: 390) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-390 STMN2 AON (SEQ ID NO: 390) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-390 STMN2 AON (SEQ ID NO: 390) oligonucleotide are phosphorothioate linkages, and each of the linked
25 nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides. In some embodiments, all internucleoside linkages of the QSN-390 STMN2 AON (SEQ ID NO: 390) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In particular embodiments, QSN-395 STMN2 AON (SEQ ID NO: 395) exhibits between
30 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-395 STMN2 AON (SEQ ID NO: 395) exhibits between 60 to 90% rescue of full length STMN2. In particular embodiments, QSN-395 STMN2 AON (SEQ ID NO: 395) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-395 STMN2

AON (SEQ ID NO: 395) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides. In some embodiments, all internucleoside linkages of the QSN-395 STMN2 AON (SEQ ID NO: 395) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the

5 oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC. In particular embodiments, QSN-400 STMN2 AON (SEQ ID NO: 400) exhibits between 50 to 80% rescue of full length STMN2. In particular embodiments, QSN-400 STMN2 AON (SEQ ID NO: 400) exhibits between 60 to 90% rescue of full length STMN2. In particular

10 embodiments, QSN-400 STMN2 AON (SEQ ID NO: 400) exhibits between 70 to 100% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-400 STMN2 AON (SEQ ID NO: 400) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides. In some

15 embodiments, all internucleoside linkages of the QSN-400 STMN2 AON (SEQ ID NO: 400) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC.

[00254] In particular embodiments, QSN-144-1/5-1/3 (SEQ ID NO: 894) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-144-1/5-1/3 (SEQ ID NO: 894) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments,

20 QSN-144-1/5-1/3 (SEQ ID NO: 894) exhibits between 50 to 60% rescue of full length STMN2. In particular embodiments, QSN-144-2/3 (SEQ ID NO: 895) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-144-2/3 (SEQ ID NO: 895) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-144-2/3 (SEQ ID NO: 895) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all

25 internucleoside linkages of the QSN-144-2/3 STMN2 AON (SEQ ID NO: 895) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides.

[00255] In particular embodiments, QSN-144-2/5 (SEQ ID NO: 896) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-144-2/5 (SEQ ID NO: 896)

30 exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-144-2/5 (SEQ ID NO: 896) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-144-2/5 (SEQ ID NO: 896) oligonucleotide

are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00256] In particular embodiments, QSN-144-2/5-2/3 (SEQ ID NO: 897) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-144-2/5-2/3 (SEQ ID NO: 897) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-144-2/5-2/3 (SEQ ID NO: 897) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-144-2/5-2/3 STMN2 AON (SEQ ID NO: 897) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00257] In particular embodiments, QSN-144-3/5-3/3 (SEQ ID NO: 898) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-144-3/5-3/3 (SEQ ID NO: 898) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-144-3/5-3/3 (SEQ ID NO: 898) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-144-3/5-3/3 (SEQ ID NO: 898) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00258] In particular embodiments, QSN-144-4/3 (SEQ ID NO: 899) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-144-4/3 (SEQ ID NO: 899) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-144-4/3 (SEQ ID NO: 899) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-144-4/3 STMN2 AON (SEQ ID NO: 899) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00259] In particular embodiments, QSN-144-4/5 (SEQ ID NO: 900) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-144-4/5 (SEQ ID NO: 900) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-144-4/5 (SEQ ID NO: 900) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-144-4/5 (SEQ ID NO: 900) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00260] In particular embodiments, QSN-173-2/3 (SEQ ID NO: 901) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-173-2/3 (SEQ ID NO: 901) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-173-

2/3 (SEQ ID NO: 901) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-173-2/3 STMN2 AON (SEQ ID NO: 901) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

5 **[00261]** In particular embodiments, QSN-173-2/5 (SEQ ID NO: 902) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-173-2/5 (SEQ ID NO: 902) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-173-2/5 (SEQ ID NO: 902) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-173-2/5 (SEQ ID NO: 902) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

10 **[00262]** In particular embodiments, QSN-173-2/5-2/3 (SEQ ID NO: 903) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-173-2/5-2/3 (SEQ ID NO: 903) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-173-2/5-2/3 (SEQ ID NO: 903) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-173-2/5-2/3 (SEQ ID NO: 903) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

15 **[00263]** In particular embodiments, QSN-173-4/3 (SEQ ID NO: 904) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-173-4/3 (SEQ ID NO: 904) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-173-4/3 (SEQ ID NO: 904) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-173-4/3 (SEQ ID NO: 904) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

20 **[00264]** In particular embodiments, QSN-173-4/5 (SEQ ID NO: 905) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-173-4/5 (SEQ ID NO: 905) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-173-4/5 (SEQ ID NO: 905) exhibits between 50 to 60% rescue of full length STMN2. In some
25
30
embodiments, all internucleoside linkages of the QSN-173-4/5 (SEQ ID NO: 905) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00265] In particular embodiments, QSN-173-6/3 (SEQ ID NO: 906) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-173-6/3 (SEQ ID NO: 906) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-173-6/3 (SEQ ID NO: 906) exhibits between 50 to 60% rescue of full length STMN2. In some
5 embodiments, all internucleoside linkages of the QSN-173-6/3 (SEQ ID NO: 906) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00266] In particular embodiments, QSN-173-6/5 (SEQ ID NO: 907) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-173-6/5 (SEQ ID NO: 907)
10 exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-173-6/5 (SEQ ID NO: 907) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-173-6/5 (SEQ ID NO: 907) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00267] In particular embodiments, QSN-185-2/5 (SEQ ID NO: 908) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-185-2/5 (SEQ ID NO: 908) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-185-2/5 (SEQ ID NO: 908) exhibits between 50 to 60% rescue of full length STMN2. In some
15 embodiments, all internucleoside linkages of the QSN-185-2/5 (SEQ ID NO: 908) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00268] In particular embodiments, QSN-185-4/3 (SEQ ID NO: 909) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-185-4/3 (SEQ ID NO: 909) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-185-4/3 (SEQ ID NO: 909) exhibits between 50 to 60% rescue of full length STMN2. In some
25 embodiments, all internucleoside linkages of the QSN-185-4/3 (SEQ ID NO: 909) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00269] In particular embodiments, QSN-185-4/5 (SEQ ID NO: 910) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-185-4/5 (SEQ ID NO: 910)
30 exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-185-4/5 (SEQ ID NO: 910) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-185-4/5 (SEQ ID NO: 910) oligonucleotide

are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00270] In particular embodiments, QSN-185-6/5 (SEQ ID NO: 911) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-185-6/5 (SEQ ID NO: 911) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-185-6/5 (SEQ ID NO: 911) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-185-6/5 (SEQ ID NO: 911) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00271] In particular embodiments, QSN-237-2/3 (SEQ ID NO: 912) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-237-2/3 (SEQ ID NO: 912) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-237-2/3 (SEQ ID NO: 912) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-237-2/3 (SEQ ID NO: 912) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00272] In particular embodiments, QSN-237-2/5 (SEQ ID NO: 913) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-237-2/5 (SEQ ID NO: 913) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-237-2/5 (SEQ ID NO: 913) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-237-2/5 (SEQ ID NO: 913) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00273] In particular embodiments, QSN-237-2/5-2/3 (SEQ ID NO: 914) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-237-2/5-2/3 (SEQ ID NO: 914) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-237-2/5-2/3 (SEQ ID NO: 914) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-237-2/5-2/3 (SEQ ID NO: 914) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

[00274] In particular embodiments, QSN-237-4/3 (SEQ ID NO: 915) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-237-4/3 (SEQ ID NO: 915) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-237-

4/3 (SEQ ID NO: 915) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-237-4/3 (SEQ ID NO: 915) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

5 [00275] In particular embodiments, QSN-237-4/5 (SEQ ID NO: 916) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-237-4/5 (SEQ ID NO: 916) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-237-4/5 (SEQ ID NO: 916) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-237-4/5 (SEQ ID NO: 916) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

10 [00276] In particular embodiments, QSN-237-6/3 (SEQ ID NO: 917) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-237-6/3 (SEQ ID NO: 917) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-237-6/3 (SEQ ID NO: 917) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of the QSN-237-6/3 (SEQ ID NO: 917) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

15 [00277] In particular embodiments, QSN-237-6/5 (SEQ ID NO: 918) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-237-6/5 (SEQ ID NO: 918) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-237-6/5 (SEQ ID NO: 918) exhibits between 50 to 60% rescue of full length STMN2. In some embodiments, all internucleoside linkages of QSN-237-6/5 (SEQ ID NO: 918) oligonucleotide are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

20 [00278] In particular embodiments, QSN-173-po3 (SEQ ID NO: 1417) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-173-po3 (SEQ ID NO: 1417) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-173-po3 (SEQ ID NO: 1417) exhibits between 50 to 60% rescue of full length STMN2. In particular embodiments, QSN-173-po5 (SEQ ID NO: 1418) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-173-po5 (SEQ ID NO: 1418) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-173-po5 (SEQ ID NO: 1418) exhibits between 50 to 60% rescue of full length STMN2.

[00279] In particular embodiments, QSN-144-po3 (SEQ ID NO: 1419) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-144-po3 (SEQ ID NO: 1419) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-144-po3 (SEQ ID NO: 1419) exhibits between 50 to 60% rescue of full length STMN2. In particular embodiments, QSN-144-po5 (SEQ ID NO: 1420) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-144-po5 (SEQ ID NO: 1420) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-144-po5 (SEQ ID NO: 1420) exhibits between 50 to 60% rescue of full length STMN2.

[00280] In particular embodiments, QSN-185-po3 (SEQ ID NO: 1421) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-185-po3 (SEQ ID NO: 1421) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-185-po3 (SEQ ID NO: 1421) exhibits between 50 to 60% rescue of full length STMN2. In particular embodiments, QSN-185-po5 (SEQ ID NO: 1422) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-185-po5 (SEQ ID NO: 1422) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-185-po5 (SEQ ID NO: 1422) exhibits between 50 to 60% rescue of full length STMN2.

[00281] In particular embodiments, QSN-237-po3 (SEQ ID NO: 1423) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-237-po3 (SEQ ID NO: 1423) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-237-po3 (SEQ ID NO: 1423) exhibits between 50 to 60% rescue of full length STMN2. In particular embodiments, QSN-237-po5 (SEQ ID NO: 1424) exhibits between 30 to 100% rescue of full length STMN2. In particular embodiments, QSN-237-po5 (SEQ ID NO: 1424) exhibits between 40 to 80% rescue of full length STMN2. In particular embodiments, QSN-237-po5 (SEQ ID NO: 1424) exhibits between 50 to 60% rescue of full length STMN2.

Additional Chemically Modified STMN2 Antisense Oligonucleotides

[00282] STMN2 AONs described herein, can include chemically modified nucleosides, including modified ribonucleosides and modified deoxyribonucleosides. Chemically modified nucleosides include, but are not limited to, uracil, uracine, uridine, 2'-O-(2-methoxyethyl) modifications, for example, 2'-O-(2-methoxyethyl)guanosine, 2'-O-(2-methoxyethyl)adenosine, 2'-O-(2-methoxyethyl)cytosine, and 2'-O-(2-methoxyethyl)thymidine. In certain embodiments, mixed modalities, *e.g.*, a combination of a STMN2 peptide nucleic acid (PNA) and a STMN2 locked nucleic acid (LNA). Chemically modified nucleosides also include, but are not limited to,

locked nucleic acids (LNAs), 2'-MOE, 2'-O-methyl, 2'-fluoro, and 2'-fluoro- β -D-arabinonucleotide (FANA), and Fluoro Cyclohexenyl nucleic acid (F-CeNA) modifications. Chemically modified nucleosides that can be included in STMN2 AONs described herein are described in Johannes and Lucchino, (2018) "Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs" *Nucleic Acid Ther.* 28(3): 178–93; Rettig and Behlke, (2012) "Progress toward in vivo use of siRNAs-II" *Mol Ther* 20:483–512; and Khvorova and Watts, (2017) "The chemical evolution of oligonucleotide therapies of clinical utility" *Nat Biotechnol.*, 35(3):238-48, the contents of each of which are incorporated by reference herein.

[00283] STMN2 AONs described herein can include chemical modifications that promote stabilization of an oligonucleotide's terminal 5'-phosphate and phosphatase-resistant analogs of 5'-phosphate. Chemical modifications that promote oligonucleotide terminal 5'-phosphate stabilization or which are phosphatase-resistant analogs of 5'-phosphate include, but are not limited to, 5'-methyl phosphonate, 5'-methylenephosphonate, 5'-methylenephosphonate analogs, 5'-E-vinyl phosphonate (5'-E-VP), 5'-phosphorothioate, and 5'-C-methyl analogs. Chemical modifications that promote AON terminal 5'-phosphate stabilization and phosphatase-resistant analogues of 5'-phosphate are described in Khvorova and Watts, (2017) "The chemical evolution of oligonucleotide therapies of clinical utility" *Nat Biotechnol.*, 35(3):238-48, the contents of which are incorporated by reference herein.

[00284] In some embodiments described herein, STMN2 AONs described herein can include chemically modified nucleosides, for example, 2' O-methyl ribonucleosides, for example, 2' O-methyl cytidine, 2' O-methyl guanosine, 2' O-methyl uridine, and/or 2' O-methyl adenosine. STMN2 AONs described herein can include one or more chemically modified bases, including a 5-methylpyrimidine, for example, 5-methyl cytosine, and/or a 5-methylpurine, for example, 5-methylguanine. Chemically modified bases can further include pseudo-uridine or 5-methoxyuridine. STMN2 AONs described herein can include any of the following chemically modified nucleosides: 5-methyl-2'-O-methylcytidine, 5-methyl-2'-O-methylthymidine, 5-methylcytidine, 5-methyluridine, and/or 5-methyl 2'-deoxycytidine.

[00285] STMN2 AONs described herein can include a phosphate backbone where one or more of the oligonucleoside linkages is a phosphate linkage. STMN2 AONs described herein may include a modified oligonucleotide backbone, where one or more of the nucleoside linkages of the nucleobase sequence is selected from the group consisting of a phosphorothioate linkage, an alkyl phosphate linkage, a phosphorodithioate linkage, a phosphotriester linkage, an alkylphosphonate

linkage, a 3-methoxypropyl phosphonate linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothiate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage. In some embodiments of STMN2 AONs described herein, at least one internucleoside linkage of the nucleobase sequence is a phosphorothioate linkage. For example, in some embodiments of STMN2 AONs described herein, one, two, three, or more internucleoside linkages of the nucleobase sequence is a phosphorothioate linkage. In preferred embodiments of STMN2 AONs described herein, all internucleoside linkages of the nucleobase sequence are phosphorothioate linkages. Thus, in some embodiments, all of the nucleotide linkages of a STMN2 AON of any of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432 are phosphorothioate linkages. In some embodiments, one or more of the nucleotide linkages of a STMN2 AON of any of SEQ ID NOs: SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432 are phosphorothioate linkages.

[00286] It is contemplated that in some embodiments, a disclosed STMN2 AON may optionally have at least one modified nucleobase, *e.g.*, 5-methyl cytosine, and/or at least one methylphosphonate nucleotide, which is placed, for example, either at only one of the 5' or 3' ends or at both 5' and 3' ends or along the oligonucleotide sequence. In some embodiments, all internucleoside linkages of a STMN2 AON oligonucleotide of the present disclosure are phosphorothioate linkages, and each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides and each "C" is replaced with a 5-MeC.

[00287] Contemplated STMN2 AONs may optionally include at least one modified sugar. For example, the sugar moiety of at least one nucleotide constituting the oligonucleotide is a ribose in which the 2'-OH group may be replaced by any one selected from the group consisting of OR, R, R'OR, SH, SR, NH₂, NR₂, N₃, CN, F, Cl, Br, and I (wherein R is an alkyl or aryl and R' is an alkylene). Examples of a modified sugar moiety include a 2'-OMe modified sugar moiety, bicyclic sugar moiety, 2'-O-(2-methoxyethyl) (2'MOE), 2'-deoxy-2'-fluoro nucleoside, 2'-fluoro-β-D-arabinonucleoside, locked nucleic acid (LNA), constrained ethyl 2'-4'-bridged nucleic acid (cEt), S-cEt, hexitol nucleic acids (HNA), and tricyclic analog (*e.g.*, tcDNA).

[00288] In some embodiments, STMN2 AONs comprise 2'OMe (*e.g.*, an STMN2 AON comprising one or more 2'OMe modified sugar), MOE (*e.g.*, an STMN2 AON comprising one or more MOE modified sugar (*e.g.*, 2'-MOE)), PNA (*e.g.*, a STMN2 AON comprising one or more *N*-(2-aminoethyl)-glycine units linked by amide bonds or carbonyl methylene linkage as repeating units in place of a sugar-phosphate backbone), LNA (*e.g.*, a STMN2 AON comprising one or more locked ribose, and can be a mixture of 2'-deoxy nucleotides or 2'OMe nucleotides), c-ET (*e.g.*, a STMN2 AON comprising one or more cET sugar), cMOE (*e.g.*, a STMN2 AON comprising one or more cMOE sugar), morpholino oligomer (*e.g.*, a STMN2 AON comprising a backbone comprising one or more PMO), deoxy-2'-fluoro nucleoside (*e.g.*, a STMN2 AON comprising one or more 2'-fluoro- β -D-arabinonucleoside), ENA (*e.g.*, a STMN2 AON comprising one or more ENA modified sugar), HNA (*e.g.*, a STMN2 AON comprising one or more HNA modified sugar), or tcDNA (*e.g.*, a STMN2 AON comprising one or more tcDNA modified sugar). In some embodiments, a STMN2 AON comprises one or more phosphorothioate linkage, phosphodiester linkage, phosphotriester linkage, methylphosphonate linkage, phosphoramidate linkage, morpholino linkage, PNA linkage, or any combination of phosphorothioate linkage, phosphodiester linkage, a phosphotriester linkage, methylphosphonate linkage, phosphoramidate linkage, morpholino linkage, and PNA linkage. In some embodiments, a STMN2 AON comprises one or more phosphorothioate linkage, phosphodiester linkage, or a combination of phosphorothioate and phosphodiester linkages.

Motor Neuron Diseases

[00289] Motor neuron diseases are a group of diseases characterized by loss of function of motor neurons that coordinate voluntary movement of muscles by the brain. Motor neuron diseases may affect upper and/or lower motor neurons, and may have sporadic or familial origins. Motor neuron diseases include amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), progressive bulbar palsy, pseudobulbar palsy, progressive muscular atrophy, primary lateral sclerosis, spinal muscular atrophy, post-polio syndrome, and ALS with frontotemporal dementia.

[00290] Symptoms of motor neuron diseases include muscle decay or weakening, muscle pain, spasms, slurred speech, difficulty swallowing, loss of muscle control, joint pain, stiff limbs, difficulty breathing, drooling, and complete loss of muscle control, including over basic functions such as breathing, swallowing, eating, speaking, and limb movement. These symptoms are also sometimes accompanied by depression, loss of memory, difficulty with planning, language

deficits, altered behavior, and difficulty assessing spatial relationships and/or changes in personality.

[00291] Motor neuron diseases can be assessed and diagnosed by a clinician of skill, for example, a neurologist, using various tools and tests. For example, the presence or risk of developing a motor neuron disease can be assessed or diagnosed using blood and urine tests (for example, tests that assay for the presence of creatinine kinase), magnetic resonance imaging (MRI), electromyography (EMG), nerve conduction study (NCS), spinal tap, lumbar puncture, and/or muscle biopsy. Motor neuron diseases can be diagnosed with the aid of a physical exam and/or a neurological exam to assess motor and sensory skills, nerve function, hearing and speech, vision, coordination and balance, mental status, and changes in mood or behavior.

Amyotrophic Lateral Sclerosis

[00292] ALS is a progressive motor neuron disease that disrupts signals to all voluntary muscles. ALS results in atrophy of both upper and lower motor neurons. Symptoms of ALS include weakening and wasting of the bulbar muscles, general and bilateral loss of strength, spasticity, muscle spasms, muscle cramps, fasciculations, slurred speech, and difficulty breathing or loss of ability to breathe. Some individuals with ALS also suffer from cognitive decline. At the molecular level, ALS is characterized by protein and RNA aggregates in the cytoplasm of motor neurons, including aggregates of the RNA-binding protein TDP43.

[00293] ALS is most common in males above 40 years of age, although it can also occur in women and children. Risk of ALS is also heightened in individuals who smoke, are exposed to chemicals such as lead, or who have served in the military. Most instances of ALS are sporadic, while only about 10% of cases are familial. Causes of ALS include sporadic or inherited genetic mutations, high levels of glutamate, protein mishandling. Genetic mutations associated with ALS include mutations in the genes SOD1, C9orf72, TARDBP, FUS, ANG, ATXN2, CHCHD10, CHMP2B, DCTN1, ErbB4, FIG4, HNRPA1, MATR3, NEFH, OPTN, PFN1, PRPH, SETX, SIGMAR1, SMN1, SPG11, SQSTM1, TBK1, TRPM7, TUBA4A, UBQLN2, VAPB, and VCP.

Frontotemporal Dementia

[00294] Frontotemporal dementia (FTD) is a form of dementia that affects the frontal and temporal lobes of the brain. It has an earlier average age of onset than Alzheimer's disease – 40 years of age. Symptoms of FTD include extreme changes in behavior and personality, speech and

language problems, and movement-related symptoms such as tremor, rigidity, muscle spasm, weakness, and difficulty swallowing. Subtypes of FTD include behavior variant frontotemporal dementia (bvFTD), characterized by changes in personality and behavior, and primary progressive aphasia (PPA), which affects language skills, speaking, writing and comprehension. FTD is associated with tau protein accumulation (Pick bodies) and altered TDP43 function. About 30% of cases of FTD are familial, and no other risk factors other than family history of the disease are known. Genetic mutations associated with FTD include mutations in the genes C9orf72, Progranulin (GRN), microtubule-associated protein tau (MAPT), UBQLN2, VCP, CHMP2B, TARDBP, FUS, ITM2B, CHCHD10, SQSTM1, PSEN1, PSEN2, CTSF, CYP27A1, TBK1 and TBP.

Amyotrophic lateral sclerosis with frontotemporal dementia

[00295] Amyotrophic lateral sclerosis with frontotemporal dementia (ALS with FTD) is a clinical syndrome in which FTD and ALS occur in the same individual. Interestingly, mutations in C9orf72 are the most common cause of familial forms of ALS and/or FTD. Additionally, mutations in TBK1, VCP, SQSTM1, UBQLN2 and CHMP2B are also associated with ALS with FTD. Symptoms of ALS with FTD include dramatic changes in personality, as well as muscle weakness, muscle atrophy, fasciculations, spasticity, dysarthria, dysphagia, and degeneration of the spinal cord, motor neurons, and frontal and temporal lobes of the brain. At the molecular level, ALS with FTD is characterized by the accumulation of TDP-43 and/or FUS proteins in the cytoplasm. TBK1 mutations are associated with ALS, FTD, and ALS with FTD.

Methods of Treatment

[00296] The disclosure contemplates, in part, treating neurological diseases (for example, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, corticobasal degeneration (CBD) and/or neuropathies such a chemotherapy induced neuropathy in a patient in need thereof comprising administering a disclosed inhibitor of STMN2 transcripts that include a cryptic exon, for example, a STMN2 AON. In some embodiments, provided herein are methods for treatment of a neurological disease in a patient in need thereof, comprising administering a disclosed STMN2 AON. In some embodiments of the disclosure, an effective amount of a disclosed inhibitor of STMN2 transcripts that include a cryptic exon may be administered to a patient in

need thereof to treat a neurological disease, and/or to increase, restore, or stabilize expression of STMN2 mRNA that is capable of translation to produce a functional STMN2 protein, thereby increase, restore, or stabilize STMN2 activity and/or function.

[00297] In some embodiments, treating a neurological disease comprises at least ameliorating or reducing one symptom associated with the neurological disease (for example, reducing muscle weakness in a patient with ALS). Methods of treating a neurological disease (for example, ALS, FTD, or ALS with FTD) in a patient suffering therefrom are provided, that include administering a disclosed inhibitor of STMN2 transcripts that include a cryptic exon, for example, a STMN2 AON. In some embodiments, methods of slowing the progression of a neurological disease, for example, a motor neuron disease, are provided.

[00298] Provided herein are methods of treating, reducing the risk of developing, or delaying the onset of a neurological disease in a subject in need thereof comprising administering a disclosed inhibitor of STMN2 transcripts that include a cryptic exon, for example, a STMN2 AON. The methods include for example, treating a subject at risk of developing a neurological disease; *e.g.*, administering to the subject an effective amount of a disclosed STMN2 AON. Neurological diseases that can be treated in this manner include motor neuron diseases, ALS, FTD, ALS with FTD, progressive bulbar palsy, pseudobulbar palsy, progressive muscular atrophy, primary lateral sclerosis, spinal muscular atrophy, and post-polio syndrome.

[00299] Methods of preventing or treating neurological diseases (for example, PD, ALS, FTD, and ALS with FTD) form part of this disclosure. Such methods may comprise administering to a patient in need thereof or a patient at risk, a pharmaceutical preparation comprising a STMN2 AON such as a STMN2 AON disclosed herein. For example, a method of preventing or treating a neurological disease is provided comprising administering to a patient in need thereof a STMN2 AON disclosed herein.

[00300] Patients treated using an above method may experience an increase, restoration of, or stabilization of STMN2 mRNA expression, which is capable of translation to produce a functional STMN2 protein, of at least about 5%, 10%, 20%, 30%, 40% or even 50%, thereby increase, restore, or stabilize STMN2 activity and/or function in a target cell (for example, a motor neuron) after administering an inhibitor of STMN2 transcripts that include a cryptic exon, after *e.g.* 1 day, 2 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more. Administering such inhibitor of

STMN2 transcripts that include a cryptic exon may be on, *e.g.*, at least a daily basis. The inhibitor of STMN2 transcripts that include a cryptic exon may be administered orally. In some embodiments, the inhibitor of STMN2 transcripts that include a cryptic exon is administered intrathecally or intracisternally. For example, in an embodiment described herein, an inhibitor of STMN2 transcripts that include a cryptic exon is administered intrathecally or intracisternally about every 3 months. The delay or amelioration of clinical manifestation of a neurological disease in a patient as a consequence of administering an inhibitor of STMN2 transcripts that include a cryptic exon disclosed here may be at least *e.g.*, 6 months, 1 year, 18 months or even 2 years or more as compared to a patient who is not administered an inhibitor of STMN2 transcripts that include a cryptic exon, such as one disclosed herein.

[00301] The inhibitors of STMN2 transcripts that include a cryptic exon, for example STMN2 AONs, of the invention can be used alone or in combination with each other whereby at least two inhibitors of STMN2 transcripts that include a cryptic exon of the invention are used together in a single composition or as part of a treatment regimen. STMN2 oligonucleotides can be used alone or in combination with each other whereby at least two STMN2 oligonucleotides are used together in a single composition or as part of a treatment regimen. The inhibitors of STMN2 transcripts that include a cryptic exon of the invention may also be used in combination with other drugs for treating neurological diseases or conditions.

Treatment and Evaluation

[00302] A patient, as described herein, refers to any animal at risk for, suffering from or diagnosed with a neurological disease, including, but not limited to, mammals, primates, and humans. In certain embodiments, the patient may be a non-human mammal such as, for example, a cat, a dog, or a horse. In certain embodiments, the patient is a human. A patient may be an individual diagnosed with a high risk of developing a neurological disease, someone who has been diagnosed with a neurological disease, someone who previously suffered from a neurological disease, or an individual evaluated for symptoms or indications of a neurological disease, for example, any of the signs or symptoms associated with neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, corticobasal degeneration (CBD) and/or neuropathies such a chemotherapy induced neuropathy.

[00303] “A patient in need,” as used herein, refers to a patient suffering from any of the symptoms or manifestations of a neurological disease, a patient who may suffer from any of the symptoms or manifestations of a neurological disease, or any patient who might benefit from a method of the disclosure for treating a neurological disease. A patient in need may include a patient who is diagnosed with a risk of developing a neurological disease, a patient who has suffered from a neurological disease in the past, or a patient who has previously been treated for a neurological disease.

[00304] “Effective amount,” as used herein, refers to the amount of an agent that is sufficient to at least partially treat a condition when administered to a patient. The therapeutically effective amount will vary depending on the severity of the condition, the route of administration of the component, and the age, weight, etc. of the patient being treated. Accordingly, an effective amount of a disclosed inhibitor of STMN2 transcripts that include a cryptic exon is the amount of the inhibitor of STMN2 transcripts that include a cryptic exon necessary to treat a neurological disease in a patient such that administration of the agent prevents a neurological disease from occurring in a subject, prevents neurological disease progression (*e.g.*, prevents the onset or increased severity of symptoms of the neurological such as muscle weakening, spasms, or fasciculation), or relieves or completely ameliorates all associated symptoms of a neurological disease, *i.e.* causes regression of the disease.

[00305] Efficacy of treatment may be evaluated by means of evaluation of gross symptoms associated with a neurological disease, analysis of tissue histology, biochemical assay, imaging methods such as, for example, magnetic resonance imaging, or other known methods. For instance, efficacy of treatment may be evaluated by analyzing gross symptoms of the disease such as changes in muscle strength and control or other aspects of gross pathology associated with a neurological disease following administration of a disclosed inhibitor of STMN2 transcripts that include a cryptic exon to a patient suffering from a neurological disease.

[00306] Efficacy of treatment may also be evaluated at the tissue or cellular level, for example, by means of obtaining a tissue biopsy (*e.g.*, a brain, spinal, muscle, or motor neuron tissue biopsy) and evaluating gross tissue or cell morphology or staining properties. Biochemical assays that examine protein or RNA expression may also be used to evaluate efficacy of treatment. For instance, one may evaluate levels of a protein or gene product indicative of a neurological disease, in dissociated cells or non-dissociated tissue via immunocytochemical, immunohistochemical, Western blotting, or Northern blotting methods, or methods useful for evaluating RNA levels such

as quantitative or semi-quantitative polymerase chain (*e.g.*, digital PCR (DigitalPCR, dPCR, or dePCR), qPCR etc.) reaction. One may also evaluate the presence or level of expression of useful biomarkers (*e.g.*, neurofilament light (NEFL), neurofilament heavy (NEFH), TDP-43 or p75 extracellular domain (p75^{ECD})) found in spinal cord fluid, cerebrospinal fluid, extracellular vesicles (for example, exosome-like cerebrospinal fluid extracellular vesicles (“CSF exosomes”), such as those described in Welton *et al.*, (2017) “Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis” *J Extracell Vesicles.*, 6(1):1-10; and Street *et al.*, (2012) “Identification and proteomic profiling of exosomes in human cerebrospinal fluid” *J Transl. Med.*, 10:5), urine, fecal matter, lymphatic fluid, blood, plasma, or serum to evaluate disease state and efficacy of treatment. One may also evaluate the presence or level of expression of useful biomarkers found in the plasma, neuronal extracellular vesicles/exosomes. Additional measurements of efficacy may include strength duration time constant (SDTC), short interval cortical inhibition (SICI), dynamometry, accurate test of limb isometric strength (ATLIS), compound muscle action potential (bio), and ALSFRS-R.

In certain embodiments, urinary neurotrophin receptor p75 extracellular domain (p75^{ECD}) is a disease progression and prognostic biomarker in amyotrophic lateral sclerosis (ALS). Phosphorylated neurofilament heavy chain (pNFH) in cerebrospinal fluid (CSF) predict disease status and survival in *C9ORF72*-associated amyotrophic lateral sclerosis (c9ALS) patients. CSF pNFH as a prognostic biomarker for clinical trials, which will increase the likelihood of successfully developing a treatment for c9ALS.

[00307] In evaluating efficacy of treatment, suitable controls may be chosen to ensure a valid assessment. For instance, one can compare symptoms evaluated in a patient with a neurological disease following administration of a disclosed inhibitor of STMN2 transcripts that include a cryptic exon to those symptoms in the same patient prior to treatment or at an earlier point in the course of treatment or in another patient not diagnosed with the neurological disease. Alternatively, one may compare the results of biochemical or histological analysis of tissue following administration of a disclosed inhibitor of STMN2 transcripts that include a cryptic exon with those of tissue from the same patient or from an individual not diagnosed with the neurological disease or from the same patient prior to administration of the inhibitor of STMN2 transcripts that include a cryptic exon. Additionally, one may compare blood, plasma, serum, cell, urine, lymphatic fluid, spinal cord fluid, cerebrospinal fluid, or fecal samples following administration of the inhibitor of STMN2 transcripts that include a cryptic exon with comparable samples from an individual not diagnosed with the neurological disease or from the same patient

prior to administration of the inhibitor of STMN2 transcripts that include a cryptic exon. In some embodiments one may compare extracellular vesicles (for example CSF exosomes), following administration of the inhibitor of STMN2 transcripts that include a cryptic exon with extracellular vesicles from an individual not diagnosed with the neurological disease or from the same patient

prior to administration of the inhibitor of STMN2 transcripts that include a cryptic exon.

[00308] Validation of inhibition of STMN2 transcripts that include a cryptic exon may be determined by direct or indirect assessment of STMN2 expression levels or activity. For instance, biochemical assays that measure STMN2 protein or RNA expression may be used to evaluate overall inhibition of STMN2 transcripts that include a cryptic exon. For instance, one may measure STMN2 protein levels in cells or tissue by Western blot to evaluate overall STMN2 levels. One may also measure STMN2 mRNA levels by means of Northern blot or quantitative polymerase chain reaction to determine overall inhibition of STMN2 transcripts that include a cryptic exon. One may also evaluate STMN2 protein levels or levels of another protein indicative of STMN2 signaling activity in dissociated cells, non-dissociated tissue, extracellular vesicles (for example, CSF exosomes), blood, serum, or fecal matter via immunocytochemical or immunohistochemical methods.

[00309] Modulation of splicing of STMN2 transcripts that include a cryptic exon may also be evaluated indirectly by measuring parameters such as autophagy, endocytosis, protein aggregation, and the presence or level of expression of useful biomarkers (*e.g.*, neurofilament light (NEFL), neurofilament heavy (NEFH), TDP-43, or p75^{ECD} found in plasma, spinal cord fluid, cerebrospinal fluid, extracellular vesicles (for example, CSF exosomes), blood, urine, lymphatic fluid, fecal matter, or tissue to evaluate efficacy of inhibition of STMN2 transcripts that include a cryptic exon. Inhibition of STMN2 transcripts that include a cryptic exon may also be evaluated indirectly by measuring parameters such as autophagy, endocytosis, protein aggregation, and the presence or level of expression of physiological biomarkers such as compound muscle action potential (bio). Additional measurements may include strength duration time constant (SDTC), short interval cortical inhibition (SICI), dynamometry, accurate test of limb isometric strength (ATLIS), compound muscle action potential, and ALSFRS-R. In certain embodiments, urinary neurotrophin receptor p75 extracellular domain (p75^{ECD}) is a disease progression and prognostic biomarker in amyotrophic lateral sclerosis (ALS). Phosphorylated neurofilament heavy chain (pNFH) in cerebrospinal fluid (CSF) predict disease status and

survival in c9ALS patients. CSF pNFH as a prognostic biomarker for clinical trials, which will increase the likelihood of successfully developing a treatment for c9ALS.

[00310] In some embodiments, the present disclosure provides methods of correcting splicing of a STMN2 transcript with a cryptic exon, and thereby restoring full length STMN2 protein expression in cells of a patient suffering from a neurological disease. Splicing of a STMN2 transcript may be corrected in any cell in which STMN2 expression or activity occurs, including cells of the nervous system (including the central nervous system, the peripheral nervous system, motor neurons, the brain, the brain stem, the frontal lobes, the temporal lobes, the spinal cord), the musculoskeletal system, spinal fluid, and cerebrospinal fluid. Cells of the musculoskeletal system include skeletal muscle cells (*e.g.*, myocytes). Motor neurons include upper motor neurons and lower motor neurons.

Pharmaceutical Compositions and Routes of Administration

[00311] The present disclosure also provides methods for treating a neurological disease via administration of a pharmaceutical composition comprising a disclosed inhibitor of STMN2 transcripts that include a cryptic exon. In another aspect, the disclosure provides a pharmaceutical composition for use in treating a neurological disease. The pharmaceutical composition may be comprised of a disclosed antisense oligonucleotide that targets STMN2 transcripts that include a cryptic exon, and a pharmaceutically acceptable carrier. As used herein the term “pharmaceutical composition” means, for example, a mixture containing a specified amount of a therapeutic compound, *e.g.*, a therapeutically effective amount, of a therapeutic compound in a pharmaceutically acceptable carrier to be administered to a mammal, *e.g.*, a human, in order to treat a neurological disease. In some embodiments, contemplated herein are pharmaceutical compositions comprising a disclosed inhibitor of STMN2 transcripts that include a cryptic exon, and a pharmaceutically acceptable carrier. In another aspect, the disclosure provides use of a disclosed inhibitor of STMN2 transcripts that include a cryptic exon in the manufacture of a medicament for treating a neurological disease. “Medicament,” as used herein, has essentially the same meaning as the term “pharmaceutical composition.”

[00312] As used herein, “pharmaceutically acceptable carrier” means buffers, carriers, and excipients suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. The carrier(s) should be “acceptable” in the sense of being

compatible with the other ingredients of the formulations and not deleterious to the recipient. Pharmaceutically acceptable carriers include buffers, solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is known in the art. In one embodiment the pharmaceutical composition is administered orally and includes an enteric coating suitable for regulating the site of absorption of the encapsulated substances within the digestive system or gut. For example, an enteric coating can include an ethylacrylate-methacrylic acid copolymer.

[00313] In one embodiment, a disclosed inhibitor of STMN2 transcripts that include a cryptic exon and any pharmaceutical composition thereof may be administered by one or several routes, including topically, intrathecally, intracisternally, parenterally (*e.g.*, subcutaneous, intramuscular, intradermal, intraduodenal, or intravenous), intralesionally, orally, rectally, buccally, sublingually, vaginally, pulmonarily, intratracheally, intranasally, transdermally, or intraduodenally. The term parenteral as used herein includes subcutaneous injections, intrapancreatic administration, intravenous, intracisternal, intrathecal, intramuscular, intraperitoneal, intrasternal injection or infusion techniques. For example, a disclosed inhibitor of STMN2 transcripts that include a cryptic exon may be administered subcutaneously to a subject. In another example, a disclosed inhibitor of STMN2 transcripts that include a cryptic exon may be administered orally to a subject. In another example, a disclosed inhibitor of STMN2 transcripts that include a cryptic exon may be administered directly to the nervous system, or specific regions or cells of the nervous system (*e.g.*, the brain, brain stem, lower motor neurons, spinal cord, upper motor neurons) via parenteral administration, for example, a disclosed inhibitor of STMN2 transcripts that include a cryptic exon may be administered intrathecally or intracisternally.

[00314] In some embodiments, an inhibitor of STMN2 transcripts that include a cryptic exon, for example a STMN2 AON, can be encapsulated in a nanoparticle coating. It is believed that nanoparticle encapsulation prevents AON degradation and enhances cellular uptake. For example, in some embodiments an inhibitor of STMN2 transcripts that include a cryptic exon is encapsulated in a coating of a cationic polymer, for example, a synthetic polymer (*e.g.*, poly-L-lysine, polyamidoamine, a poly(β -amino ester), and polyethyleneimine) or a naturally occurring polymer (*e.g.*, chitosan and a protamine). In some embodiments, an inhibitor of STMN2 transcripts that include a cryptic exon is encapsulated in a lipid or lipid-like material, for example, a cationic lipid, a cationic lipid-like material, or an ionizable lipid that is positively charged only

at an acidic pH. For example, in some embodiments, an inhibitor of STMN2 transcripts that include a cryptic exon is encapsulated in a lipid nanoparticle that includes hydrophobic moieties, *e.g.*, cholesterol and/or a polyethylene glycol (PEG) lipid.

[00315] In some embodiments, an inhibitor of STMN2 transcripts that include a cryptic exon, for example, a STMN2 AON, is conjugated to a bioactive ligand. For example, in some embodiments described herein, an inhibitor of STMN2 transcripts that include a cryptic exon such as a STMN2 AON is conjugated to a peptide, a lipid, N-acetylgalactosamine (GalNAc), cholesterol, vitamin E, an antibody, or a cell-penetrating peptide (for example, transactivator of transcription (TAT) and penetratine).

[00316] Pharmaceutical compositions containing a disclosed inhibitor of STMN2 transcripts that include a cryptic exon, such as those disclosed herein, can be presented in a dosage unit form and can be prepared by any suitable method. A pharmaceutical composition should be formulated to be compatible with its intended route of administration. Useful formulations can be prepared by methods well known in the pharmaceutical art. For example, see *Remington's Pharmaceutical Sciences*, 18th ed. (Mack Publishing Company, 1990).

[00317] Pharmaceutical formulations, in some embodiments, are sterile. Sterilization can be accomplished, for example, by filtration through sterile filtration membranes. Where the composition is lyophilized, filter sterilization can be conducted prior to or following lyophilization and reconstitution.

Parenteral Administration

[00318] The pharmaceutical compositions of the disclosure can be formulated for parenteral administration, *e.g.*, formulated for injection via the intravenous, intracisternal, intramuscular, subcutaneous, intrathecal, intralesional, or intraperitoneal routes. The preparation of an aqueous composition, such as an aqueous pharmaceutical composition containing a disclosed inhibitor of STMN2 transcripts that include a cryptic exon, will be known to those of skill in the art in light of the present disclosure. Typically, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for use in preparing solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified.

[00319] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including normal saline, phosphate buffer saline, artificial cerebrospinal fluid, sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.

[00320] Solutions of active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.

Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. In addition, sterile, fixed oils may be employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can be used in the preparation of injectables. The sterile injectable preparation may also be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P., and isotonic sodium chloride solution. In one embodiment, a disclosed STMN2 antisense oligonucleotide may be suspended in a carrier fluid comprising 1% (w/v) sodium carboxymethylcellulose and 0.1% (v/v) TWEEN™ 80. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[00321] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. Sterile injectable solutions of the disclosure may be prepared by incorporating a disclosed STMN2 antisense oligonucleotide (*e.g.*, inhibitor of STMN2 transcripts that include a cryptic exon) in the required amount of the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a

previously sterile-filtered solution thereof. The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter.

[00322] The preparation of more, or highly concentrated solutions for intramuscular injection is also contemplated. In this regard, the use of DMSO as solvent is preferred as this will result in extremely rapid penetration, delivering high concentrations of the disclosed inhibitor of STMN2 transcripts that include a cryptic exon to a small area.

[00323] Suitable preservatives for use in such a solution include benzalkonium chloride, benzethonium chloride, chlorobutanol, thimerosal and the like. Suitable buffers include boric acid, sodium and potassium bicarbonate, sodium and potassium borates, sodium and potassium carbonate, sodium acetate, sodium biphosphate and the like, in amounts sufficient to maintain the pH at between about pH 6 and pH 8, and for example, between about pH 7 and pH 7.5. Suitable tonicity agents are dextran 40, dextran 70, dextrose, glycerin, potassium chloride, propylene glycol, sodium chloride, and the like, such that the sodium chloride equivalent of the solution is in the range 0.9 plus or minus 0.2%. Suitable antioxidants and stabilizers include sodium bisulfite, sodium metabisulfite, sodium thiosulfite, thiourea and the like. Suitable wetting and clarifying agents include polysorbate 80, polysorbate 20, poloxamer 282 and tyloxapol. Suitable viscosity-increasing agents include dextran 40, dextran 70, gelatin, glycerin, hydroxyethylcellulose, hydroxymethylpropylcellulose, lanolin, methylcellulose, petrolatum, polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose and the like.

Oral Administration

[00324] In some embodiments, contemplated herein are compositions suitable for oral delivery of a disclosed inhibitor of STMN2 transcripts that include a cryptic exon, *e.g.*, tablets that include an enteric coating, *e.g.*, a gastro-resistant coating, such that the compositions may deliver an inhibitor of STMN2 transcripts that include a cryptic exon to, *e.g.*, the gastrointestinal tract of a patient.

[00325] For example, a tablet for oral administration is provided that comprises granules (*e.g.*, is at least partially formed from granules) that include a disclosed inhibitor of STMN2 transcripts that include a cryptic exon, *e.g.*, a STMN2 antisense oligonucleotide, *e.g.*, a STMN2 antisense oligonucleotide represented by any of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432, and pharmaceutically acceptable excipients. Such a tablet

may be coated with an enteric coating. Contemplated tablets may include pharmaceutically acceptable excipients such as fillers, binders, disintegrants, and/or lubricants, as well as coloring agents, release agents, coating agents, sweetening, flavoring such as wintergreen, orange, xylitol, sorbitol, fructose, and maltodextrin, and perfuming agents, preservatives and/or antioxidants.

5 [00326] In some embodiments, contemplated pharmaceutical formulations include an intra-granular phase that includes a disclosed inhibitor of STMN2 transcripts that include a cryptic exon, *e.g.* a STMN2 antisense oligonucleotide, *e.g.*, a STMN2 antisense oligonucleotide represented by any of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432, and a pharmaceutically acceptable salt, *e.g.*, a STMN2 antisense
10 oligonucleotide, *e.g.*, an antisense oligonucleotide represented by any of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432, and a pharmaceutically acceptable filler. For example, a disclosed inhibitor of STMN2 transcripts that include a cryptic exon and a filler may be blended together, optionally, with other excipients, and formed into granules. In some embodiments, the intragranular phase may be formed using wet
15 granulation, *e.g.*, a liquid (*e.g.*, water) is added to the blended inhibitor of STMN2 transcripts that include a cryptic exon compound and filler, and then the combination is dried, milled and/or sieved to produce granules. One of skill in the art would understand that other processes may be used to achieve an intragranular phase.

[00327] In some embodiments, contemplated formulations include an extra-granular phase,
20 which may include one or more pharmaceutically acceptable excipients, and which may be blended with the intragranular phase to form a disclosed formulation.

[00328] A disclosed formulation may include an intragranular phase that includes a filler. Exemplary fillers include, but are not limited to, cellulose, gelatin, calcium phosphate, lactose, sucrose, glucose, mannitol, sorbitol, microcrystalline cellulose, pectin, polyacrylates, dextrose,
25 cellulose acetate, hydroxypropylmethyl cellulose, partially pre-gelatinized starch, calcium carbonate, and others including combinations thereof.

[00329] In some embodiments, a disclosed formulation may include an intragranular phase and/or an extragranular phase that includes a binder, which may generally function to hold the ingredients of the pharmaceutical formulation together. Exemplary binders of the disclosure may
30 include, but are not limited to, the following: starches, sugars, cellulose or modified cellulose such as hydroxypropyl cellulose, lactose, pre-gelatinized maize starch, polyvinyl pyrrolidone,

hydroxypropyl cellulose, hydroxypropylmethyl cellulose, low substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, methyl cellulose, ethyl cellulose, sugar alcohols and others including combinations thereof.

[00330] Contemplated formulations, *e.g.*, that include an intragranular phase and/or an extragranular phase, may include a disintegrant such as, but not limited to, starch, cellulose, crosslinked polyvinyl pyrrolidone, sodium starch glycolate, sodium carboxymethyl cellulose, alginates, corn starch, crosmellose sodium, crosslinked carboxymethyl cellulose, low substituted hydroxypropyl cellulose, acacia, and others including combinations thereof. For example, an intragranular phase and/or an extragranular phase may include a disintegrant.

[00331] In some embodiments, a contemplated formulation includes an intra-granular phase comprising a disclosed inhibitor of STMN2 transcripts that include a cryptic exon and excipients chosen from: mannitol, microcrystalline cellulose, hydroxypropylmethyl cellulose, and sodium starch glycolate or combinations thereof, and an extra-granular phase comprising one or more of: microcrystalline cellulose, sodium starch glycolate, and magnesium stearate or mixtures thereof.

[00332] In some embodiments, a contemplated formulation may include a lubricant, *e.g.* an extra-granular phase may contain a lubricant. Lubricants include but are not limited to talc, silica, fats, stearin, magnesium stearate, calcium phosphate, silicone dioxide, calcium silicate, calcium phosphate, colloidal silicon dioxide, metallic stearates, hydrogenated vegetable oil, partially hydrogenated vegetable oil, corn starch, sodium benzoate, polyethylene glycols, sodium acetate, calcium stearate, sodium lauryl sulfate, sodium chloride, magnesium lauryl sulfate, talc, and stearic acid.

[00333] In some embodiments, the pharmaceutical formulation comprises an enteric coating. Generally, enteric coatings create a barrier for the oral medication that controls the location at which the drug is absorbed along the digestive track. Enteric coatings may include a polymer that disintegrates at different rates according to pH. Enteric coatings may include for example, cellulose acetate phthalate, methyl acrylate-methacrylic acid copolymers, cellulose acetate succinate, hydroxylpropylmethyl cellulose phthalate, methyl methacrylate-methacrylic acid copolymers, ethylacrylate-methacrylic acid copolymers, methacrylic acid copolymer type C, polyvinyl acetate-phthalate, and cellulose acetate phthalate.

[00334] Exemplary enteric coatings include Opadry[®] AMB, Acryl-EZE[®], Eudragit[®] grades. In some embodiments, an enteric coating may comprise about 5% to about 10%, about 5% to about 20%, 8% to about 15%, about 8% to about 20%, about 10% to about 20%, or about 12 to about 20%, or about 18% of a contemplated tablet by weight. For example, enteric coatings may include an ethylacrylate-methacrylic acid copolymer.

[00335] For example, in a contemplated embodiment, a tablet is provided that comprises or consists essentially of about 0.5% to about 70%, *e.g.*, about 0.5% to about 10%, or about 1% to about 20%, by weight of a disclosed STMN2 antisense oligonucleotide or a pharmaceutically acceptable salt thereof. Such a tablet may include for example, about 0.5% to about 60% by weight of mannitol, *e.g.*, about 30% to about 50% by weight mannitol, *e.g.*, about 40% by weight mannitol; and/or about 20% to about 40% by weight of microcrystalline cellulose, or about 10% to about 30% by weight of microcrystalline cellulose. For example, a disclosed tablet may comprise an intragranular phase that includes about 30% to about 60%, *e.g.* about 45% to about 65% by weight, or alternatively, about 5 to about 10% by weight of a disclosed STMN2 antisense oligonucleotide, about 30% to about 50%, or alternatively, about 5% to about 15% by weight mannitol, about 5% to about 15% microcrystalline cellulose, about 0% to about 4%, or about 1% to about 7% hydroxypropylmethylcellulose, and about 0% to about 4%, *e.g.*, about 2% to about 4% sodium starch glycolate by weight.

[00336] In another contemplated embodiment, a pharmaceutical tablet formulation for oral administration of a disclosed inhibitor of STMN2 transcripts that include a cryptic exon comprises an intra-granular phase, wherein the intra-granular phase includes a disclosed STMN2 AON or a pharmaceutically acceptable salt thereof (such as a sodium salt), and a pharmaceutically acceptable filler, and which may also include an extra-granular phase, that may include a pharmaceutically acceptable excipient such as a disintegrant. The extra-granular phase may include components chosen from microcrystalline cellulose, magnesium stearate, and mixtures thereof. The pharmaceutical composition may also include an enteric coating of about 12% to 20% by weight of the tablet. For example, a pharmaceutically acceptable tablet for oral use may comprise about .5% to 10% by weight of a disclosed STMN2 AON, *e.g.*, a disclosed STMN2 AON or a pharmaceutically acceptable salt thereof, about 30% to 50% by weight mannitol, about 10% to 30% by weight microcrystalline cellulose, and an enteric coating comprising an ethylacrylate-methacrylic acid copolymer.

[00337] In another example, a pharmaceutically acceptable tablet for oral use may comprise an intra-granular phase, comprising about 5 to about 10% by weight of a disclosed STMN2 AON, *e.g.*, a disclosed STMN2 AON or a pharmaceutically acceptable salt thereof, about 40% by weight mannitol, about 8% by weight microcrystalline cellulose, about 5% by weight hydroxypropylmethyl cellulose, and about 2% by weight sodium starch glycolate; an extra-granular phase comprising about 17% by weight microcrystalline cellulose, about 2% by weight sodium starch glycolate, about 0.4% by weight magnesium stearate; and an enteric coating over the tablet comprising an ethylacrylate-methacrylic acid copolymer.

[00338] In some embodiments the pharmaceutical composition may contain an enteric coating comprising about 13% or about 15%, 16%, 17% or 18% by weight, *e.g.*, AcyrLEZE® (*see, e.g.*, PCT Publication No. WO 2010/054826, which is hereby incorporated by reference in its entirety).

[00339] The rate at which the coating dissolves and the active ingredient is released is its dissolution rate. In an embodiment, a contemplated tablet may have a dissolution profile, *e.g.* when tested in a USP/EP Type 2 apparatus (paddle) at 100 rpm and 37 °C in a phosphate buffer with a pH of 7.2, of about 50% to about 100% of the inhibitor of STMN2 transcripts that include a cryptic exon releasing after about 120 minutes to about 240 minutes, for example after 180 minutes. In another embodiment, a contemplated tablet may have a dissolution profile, *e.g.* when tested in a USP/EP Type 2 apparatus (paddle) at 100 rpm and 37 °C in diluted HCl with a pH of 1.0, where substantially none of the inhibitor of STMN2 transcripts that include a cryptic exon is released after 120 minutes. A contemplated tablet, in another embodiment, may have a dissolution profile, *e.g.* when tested in USP/EP Type 2 apparatus (paddle) at 100 rpm and 37 °C in a phosphate buffer with a pH of 6.6, of about 10% to about 30%, or not more than about 50%, of the inhibitor of STMN2 transcripts that include a cryptic exon releasing after 30 minutes.

[00340] In some embodiments, methods provided herein may further include administering at least one other agent that is directed to treatment of diseases and disorders disclosed herein. In one embodiment, contemplated other agents may be co-administered (*e.g.*, sequentially or simultaneously).

Dosage and Frequency of Administration

[00341] The dosage or amounts described below refer either to the oligonucleotide or a pharmaceutically acceptable salt thereof.

[00342] In some embodiments, formulations include dosage forms that include at least 1 µg, at least 5 µg, at least 10 µg, at least 20 µg, at least 30 µg, at least 40 µg, at least 50 µg, at least 60 µg, at least 70 µg, at least 80 µg, at least 90 µg, or at least 100 µg of an inhibitor, for example, a STMN2 antisense oligonucleotide, of STMN2 transcripts that include a cryptic exon. In some
5 embodiments, formulations include dosage forms that include from 10 mg to 500 mg, from 1 mg to 10 mg, from 10 mg to 20 mg, from 20 mg to 30 mg, from 30 mg to 40 mg, from 40 mg to 50 mg, from 50 mg to 60 mg, from 60 mg to 70 mg, from 70 mg to 80 mg, from 80 mg to 90 mg, from 90 mg to 100 mg, from 100 mg to 150 mg, from 150 mg to 200 mg, from 200 mg to 250 mg, from 250 mg to 300 mg, from 300 mg to 350 mg, from 350 mg to 400 mg, from 400 mg to 450
10 mg, from 450 mg to 500 mg, from 500 mg to 600 mg, from 600 mg to 700 mg, from 700 mg to 800 mg, from 800 mg to 900 mg, from 900 mg to 1 g, from 1 mg to 50 mg, from 20 mg to 40 mg, or from 1 mg to 500 mg of a STMN2 antisense oligonucleotide.

[00343] In some embodiments, formulations include dosage forms that include or consist essentially of about 10 mg to about 500 mg of an inhibitor of STMN2 transcripts that include a
15 cryptic exon, for example, a STMN2 AON. For example, formulations that include about 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1 g, 1.5 g, 2.0 g, 2.5 g, 3.0 g, 3.5 g, 4.0 g, 4.5 g, or 5.0 g of a disclosed inhibitor of STMN2 transcripts that include a
20 cryptic exon are contemplated herein. In some embodiments, a formulation may include about 40 mg, 80 mg, or 160 mg of a disclosed inhibitor of STMN2 transcripts that include a cryptic exon. In some embodiments, a formulation may include at least 100 µg of a disclosed inhibitor of STMN2 transcripts that include a cryptic exon. For example, formulations may include about 0.1 mg, 0.2 mg, 0.3 mg, 0.4 mg, 0.5 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg of a
25 disclosed inhibitor of STMN2 transcripts that include a cryptic exon. The amount administered will depend on variables such as the type and extent of disease or indication to be treated, the overall health and size of the patient, the *in vivo* potency of the inhibitor of STMN2 transcripts that include a cryptic exon, the pharmaceutical formulation, and the route of administration. The initial dosage can be increased beyond the upper level in order to rapidly achieve the desired
30 blood-level or tissue level. Alternatively, the initial dosage can be smaller than the optimum, and the dosage may be progressively increased during the course of treatment. Human dosage can be optimized, *e.g.*, in a conventional Phase I dose escalation study. Dosing frequency can vary, depending on factors such as route of administration, dosage amount and the disease being

treated. Exemplary dosing frequencies are once per day, once per week and once every two weeks. In some embodiments, dosing is once per day for 7 days. In some embodiments, dosing is once every 4 weeks, once every 5 weeks, once every 6 weeks, once every 7 weeks, once every 8 weeks, once every 9 weeks, once every 10 weeks, once every 11 weeks, or once every 12 weeks. In some embodiments, dosing is once a month to every three months.

Combination Therapies

[00344] In various embodiments, a STMN2 AON as disclosed herein can be administered in combination with one or more additional therapies. The combination therapy of the disclosed oligonucleotide and the one or more additional therapies can, in some embodiments, be synergistic in treating any of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, corticobasal degeneration (CBD) and/or neuropathies such as a chemotherapy induced neuropathy.

[00345] Example additional therapies include any of Riluzole (Rilutek), Edaravone (Radicava), rivastigmine, donepezil, galantamine, selective serotonin reuptake inhibitor, antipsychotic agents, cholinesterase inhibitors, memantine, benzodiazepine anti-anxiety drugs, AMX0035 (ELYBRIO), ZILUCOPLAN (RA101495), dual AON intrathecal administration (*e.g.*, BIIB067, BIIB078), BIIB100, levodopa/carbidopa, dopaminergic agents (*e.g.*, ropinirole, pramipexole, rotigotine), medroxyprogesterone, KCNQ2/KCNQ3 openers, anticonvulsants and psychostimulant agents. Additional therapies can further include breathing care, physical therapy, occupational therapy, speech therapy, and nutritional support. In various embodiments, an additional therapy can be a second antisense oligonucleotide. As an example, the second antisense oligonucleotide may target a STMN2 transcript (*e.g.*, STMN2 pre-mRNA, mature STMN2 mRNA) to modulate the expression levels of full length STMN2 protein.

[00346] In various embodiments, the disclosed oligonucleotide and the one or more additional therapies can be conjugated to one another and provided in a conjugated form. Further description regarding conjugates involving the disclosed oligonucleotide is described below. In various embodiments, the disclosed oligonucleotide and one or more additional therapies are provided concurrently. In various embodiments, the disclosed oligonucleotide and one or more

additional therapies are provided simultaneously. In various embodiments, the disclosed oligonucleotide and one or more additional therapies are provided sequentially.

Conjugates

[00347] In certain embodiments, provided herein are oligomeric compounds, which comprise an oligonucleotide (*e.g.*, STMN2 oligonucleotide) and optionally one or more conjugate groups and/or terminal groups. Conjugate groups include one or more conjugate moiety and a conjugate linker which links the conjugate moiety to the oligonucleotide. Conjugate groups may be attached to either or both ends of an oligonucleotide and/or at any internal position. In certain embodiments, conjugate groups are attached to the 2'-position of a nucleoside of a modified oligonucleotide. In certain embodiments, conjugate groups that are attached to either or both ends of an oligonucleotide are terminal groups. In certain such embodiments, conjugate groups or terminal groups are attached at the 3' and/or 5'-end of oligonucleotides. In certain such embodiments, conjugate groups (or terminal groups) are attached at the 3'-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 3'-end of oligonucleotides. In certain embodiments, conjugate groups (or terminal groups) are attached at the 5'-end of oligonucleotides. In certain embodiments, conjugate groups are attached near the 5'-end of oligonucleotides.

[00348] Examples of terminal groups include but are not limited to conjugate groups, capping groups, phosphate moieties, protecting groups, modified or unmodified nucleosides, and two or more nucleosides that are independently modified or unmodified.

Conjugate Groups

[00349] In certain embodiments, a STMN2 AON is covalently attached to one or more conjugate groups. In certain embodiments, conjugate groups modify one or more properties of the attached oligonucleotide, including but not limited to pharmacodynamics, pharmacokinetics, stability, binding, absorption, tissue distribution, cellular distribution, cellular uptake, charge and clearance. In particular embodiments, conjugate groups modify the circulation time (*e.g.*, increase) of the oligonucleotides in the bloodstream such that increased concentrations of the oligonucleotides are delivered to the brain. In particular embodiments, conjugate groups modify the residence time (*e.g.*, increase residence time) of the oligonucleotides in a target organ (*e.g.*, brain) such that increased residence time of the oligonucleotides improves their performance (*e.g.*, efficacy). In particular embodiments, conjugate groups increase the delivery of the

oligonucleotide to the brain through the blood brain barrier and/or brain parenchyma (*e.g.*, through receptor mediated transcytosis). In particular embodiments, conjugate groups enable the oligonucleotide to target a specific organ (*e.g.*, the brain). In certain embodiments, conjugate groups impart a new property on the attached oligonucleotide, *e.g.*, fluorophores or reporter groups that enable detection of the oligonucleotide. Certain conjugate groups and conjugate moieties have been described previously, for example: cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4, 1053-1060), a thioether, *e.g.*, hexyl-S-tritylthiol (Manoharan et al., Ann. NY. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Lett., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, *e.g.*, do-decan-diol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, *e.g.*, di-hexadecyl-rac -glycerol or triethyl -ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937), a tocopherol group (Nishina *et al.*, Molecular Therapy Nucleic Acids, 2015, 4, e220; and Nishina *et al.*, Molecular Therapy, 2008, 16, 734-740), or a GalNAc cluster (*e.g.*, WO2014/179620).

Conjugate Moieties

[00350] Conjugate moieties include, without limitation, intercalators, reporter molecules, polyamines, polyamides, peptides, carbohydrates, vitamin moieties, polyethylene glycols, thioethers, polyethers, cholesterol, thiocholesterols, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, rhodamines, coumarins, fluorophores, and dyes. In particular embodiments, conjugate moieties are selected from a peptide, a lipid, N-acetylgalactosamine (GalNAc), cholesterol, vitamin E, lipoic acid, panthothenic acid, polyethylene glycol, an antibody (*e.g.*, an antibody for crossing the blood brain barrier such as anti-transferrin receptor antibody), or a cell-penetrating peptide (*e.g.*, transactivator of transcription (TAT) and penetratine).

[00351] In certain embodiments, a conjugate moiety comprises an active drug substance, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fen-bufen, ketoprofen, (*S*)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, fingolimod, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.

Conjugate Linkers

[00352] Conjugate moieties are attached to a STMN2 AON through conjugate linkers. In certain oligomeric compounds, the conjugate linker is a single chemical bond (i.e., the conjugate moiety is attached directly to an oligonucleotide through a single bond). In certain embodiments, the conjugate linker comprises a chain structure, an oligomer of repeating units such as ethylene glycol, nucleosides, or amino acid units.

[00353] In certain embodiments, a conjugate linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino. In certain such embodiments, the conjugate linker comprises groups selected from alkyl, amino, oxo, amide and ether groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and amide groups. In certain embodiments, the conjugate linker comprises groups selected from alkyl and ether groups. In certain embodiments, the conjugate linker comprises at least one phosphorus moiety. In certain embodiments, the conjugate linker comprises at least one phosphate group. In certain embodiments, the conjugate linker includes at least one neutral linking group.

[00354] In certain embodiments, conjugate linkers, including the conjugate linkers described above, are bifunctional linking moieties, *e.g.*, those known in the art to be useful for attaching conjugate groups to parent compounds, such as the oligonucleotides provided herein. In general, a bifunctional linking moiety comprises at least two functional groups. One of the functional groups is selected to bind to a particular site on a parent compound and the other is selected to bind to a conjugate group. Examples of functional groups used in a bifunctional linking moiety include but are not limited to electrophiles for reacting with nucleophilic groups and nucleophiles for reacting with electrophilic groups. In certain embodiments, bifunctional linking moieties comprise one or more groups selected from amino, hydroxyl, carboxylic acid, thiol, alkyl, alkenyl, and alkynyl.

[00355] Examples of conjugate linkers include but are not limited to pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(*N*-maleimidomethyl) cyclohexane-1-carboxylate

(SMCC) and 6-aminohexanoic acid (AHEX or AHA). Other conjugate linkers include but are not limited to substituted or unsubstituted C₁-C₁₀ alkyl, substituted or unsubstituted C₂-C₁₀ alkenyl or substituted or unsubstituted C₂-C₁₀ alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.

[00356] In certain embodiments, conjugate linkers comprise 1-10 linker-nucleosides. In certain embodiments, conjugate linkers comprise 2-5 linker-nucleosides. In certain embodiments, conjugate linkers comprise 3 linker-nucleosides.

[00357] In certain embodiments, such linker-nucleosides are modified nucleosides. In certain embodiments such linker-nucleosides comprise a modified sugar moiety. In certain embodiments, linker-nucleosides are unmodified. In certain embodiments, linker-nucleosides comprise an optionally protected heterocyclic base selected from a purine, substituted purine, pyrimidine or substituted pyrimidine. In certain embodiments, a cleavable moiety is a nucleoside selected from uracil, thymine, cytosine, 4-N-benzoylcytosine, 5-methyl cytosine, 4-N -benzoyl-5 -methyl cytosine, adenine, 6-N-benzoyladenine, guanine and 2-N-isobutyrylguanine. It is typically desirable for linker-nucleosides to be cleaved from the oligomeric compound after it reaches a target tissue. Accordingly, linker-nucleosides are typically linked to one another and to the remainder of the oligomeric compound through cleavable bonds. In certain embodiments, such cleavable bonds are phosphodiester bonds.

[00358] Herein, linker-nucleosides are not considered to be part of the oligonucleotide. Accordingly, in embodiments in which an oligomeric compound comprises an oligonucleotide consisting of a specified number or range of linked nucleosides and/or a specified percent complementarity to a reference nucleic acid and the oligomeric compound also comprises a conjugate group comprising a conjugate linker comprising linker-nucleosides, those linker-nucleosides are not counted toward the length of the oligonucleotide and are not used in determining the percent complementarity of the oligonucleotide for the reference nucleic acid.

[00359] In certain embodiments, it is desirable for a conjugate group to be cleaved from the STMN2 AON. For example, in certain circumstances oligomeric compounds comprising a particular conjugate moiety are better taken up by a particular cell type, but once the oligomeric compound has been taken up, it is desirable that the conjugate group be cleaved to release the unconjugated or parent oligonucleotide. Thus, certain conjugate linkers may comprise one or

more cleavable moieties. In certain embodiments, a cleavable moiety is a cleavable bond. In certain embodiments, a cleavable moiety is a group of atoms comprising at least one cleavable bond. In certain embodiments, a cleavable moiety comprises a group of atoms having one, two, three, four, or more than four cleavable bonds. In certain embodiments, a cleavable moiety is selectively cleaved inside a cell or subcellular compartment, such as a lysosome. In certain
5 embodiments, a cleavable moiety is selectively cleaved by endogenous enzymes, such as nucleases.

[00360] In certain embodiments, a cleavable bond is selected from among: an amide, an ester, an ether, one or both esters of a phosphodiester, a phosphate ester, a carbamate, or a disulfide. In
10 certain embodiments, a cleavable bond is one or both of the esters of a phosphodiester. In certain embodiments, a cleavable moiety comprises a phosphate or phosphodiester. In certain embodiments, the cleavable moiety is a phosphate linkage between an oligonucleotide and a conjugate moiety or conjugate group.

[00361] In certain embodiments, a cleavable moiety comprises or consists of one or more
15 linker-nucleosides. In certain such embodiments, the one or more linker-nucleosides are linked to one another and/or to the remainder of the oligomeric compound through cleavable bonds. In certain embodiments, such cleavable bonds are unmodified phosphodiester bonds. In certain embodiments, a cleavable moiety is 2'-deoxy nucleoside that is attached to either the 3' or 5'-terminal nucleoside of an oligonucleotide by a phosphate internucleoside linkage and covalently
20 attached to the remainder of the conjugate linker or conjugate moiety by a phosphate or phosphorothioate linkage. In certain such embodiments, the cleavable moiety is 2'-deoxy adenosine.

Terminal Groups

[00362] In certain embodiments, oligomeric compounds comprise one or more terminal
25 groups. In certain such embodiments, oligomeric compounds comprise a stabilized 5'-phosphate. Stabilized 5'-phosphates include, but are not limited to 5'-phosphonates, including, but not limited to 5'-vinylphosphonates. In certain embodiments, terminal groups comprise one or more abasic nucleosides and/or inverted nucleosides. In certain embodiments, terminal groups comprise one or more 2'-linked nucleosides. In certain such embodiments, the 2'-linked nucleoside is an
30 abasic nucleoside.

Diagnostic Methods

[00363] The disclosure also provides a method of diagnosing a patient with a neurological disease that relies upon detecting levels of STMN2 expression signal in one or more biological samples of a patient. As used herein, the term “STMN2 expression signal” can refer to any indication of STMN2 gene expression, or gene or gene product activity. STMN2 gene products include RNA (*e.g.*, mRNA), peptides, and proteins. Indices of STMN2 gene expression that can be assessed include, but are not limited to, STMN2 gene or chromatin state, STMN2 gene interaction with cellular components that regulate gene expression, STMN2 gene product expression levels (*e.g.*, expression levels of STMN2 transcripts that include a cryptic exon, STMN2 protein expression levels), or interaction of STMN2 RNA or protein with transcriptional, translational, or post-translational processing machinery.

[00364] Detection of STMN2 expression signal may be accomplished through *in vivo*, *in vitro*, or *ex vivo* methods. In a preferred embodiment, methods of the disclosure may be carried out *in vitro*. Methods of detecting may involve detection in blood, serum, fecal matter, tissue, cerebrospinal fluid, spinal fluid, extracellular vesicles (for example, CSF exosomes), or cells of a patient. Detection may be achieved by measuring expression signal of STMN2 transcripts that include a cryptic exon in whole tissue, tissue explants, cell cultures, dissociated cells, cell extract, extracellular vesicles (for example, CSF exosomes), or body fluids, including blood, spinal fluid, cerebrospinal fluid, urine, lymphatic fluid, or serum. Contemplated methods of detection include assays that measure levels of STMN2 gene product expression such as Western blotting, FACS, ELISA, other quantitative binding assays, cell or tissue growth assays, Northern blots, quantitative or semi-quantitative polymerase chain reaction, dPCR, Quanterix SR-X™ Ultra-Sensitive Biomarker Detection System powered by Simoa® bead technology, medical imaging methods (*e.g.*, MRI), or immunostaining methods (*e.g.*, immunohistochemistry or immunocytochemistry).

Additional Embodiments

[00365] Disclosed herein is a compound comprising an oligonucleotide comprising a nucleobase sequence at least 90% complementary to at least 10 contiguous nucleobases of a transcript comprising a sequence at least 90% identity to SEQ ID NO: 1391 or SEQ ID NO: 944, or a contiguous 15 to 50 nucleobase portion of SEQ ID NO: 1391 or SEQ ID NO: 944, wherein at least one nucleoside linkage of the nucleobase sequence is a non-natural linkage. Additionally

disclosed herein is an oligonucleotide comprising a nucleobase sequence at least 90% complementary to at least 10 contiguous nucleobases of a transcript comprising a sequence at least 90% identity to SEQ ID NO: 1391 or SEQ ID NO: 944, or a contiguous 15 to 50 nucleobase portion of SEQ ID NO: 1391 or SEQ ID NO: 944, wherein at least one nucleoside linkage of the nucleobase sequence is a non-natural linkage.

[00366] In one aspect, the oligonucleotide comprises at least a contiguous 10 nucleobase sequence that shares 90% identity with an equal length portion of any one of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432. In one aspect, the oligonucleotide comprises at least a contiguous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432. In one aspect, the oligonucleotide comprises at least a contiguous 10 nucleobase sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 31, 36, 41, 46, 55, 144, 146, 150, 169, 170, 171, 172, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 249, 252, 380, 385, 390, 395, 400, 975, 980, 985, 999, 1088, 1090, 1094, 1113, 1114, 1115, 1116, 1117, 1121, 1125, 1129, 1141, 1147, 1153, 1159, 1181, 1188, 1193, 1196, 1324, 1329, 1334, 1339, or 1344, 1339, or 1344, wherein at least one nucleoside linkage of the nucleobase sequence is a non-natural linkage. In one aspect, the oligonucleotide comprises at least a contiguous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 31, 36, 41, 46, 55, 144, 146, 150, 169, 170, 171, 172, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 249, 252, 380, 385, 390, 395, 400, 975, 980, 985, 999, 1088, 1090, 1094, 1113, 1114, 1115, 1116, 1117, 1121, 1125, 1129, 1141, 1147, 1153, 1159, 1181, 1188, 1193, 1196, 1324, 1329, 1334, 1339, or 1344.

[00367] Additionally disclosed herein is an oligonucleotide comprising a nucleobase sequence at least 90% complementary to at least a contiguous 10 nucleobase sequence of a transcript comprising at least 90% identity to SEQ ID NO: 944, or a contiguous 20 to 50 nucleobase portion thereof, wherein at least one nucleoside linkage of the nucleobase sequence is a non-natural linkage. In one aspect, the oligonucleotide comprises at least a contiguous 10 nucleobase sequence that shares 90% identity with an equal length portion of any one of SEQ ID NOs: 1-446 or SEQ ID NOs: 894-918. In one aspect, the oligonucleotide comprises at least a contiguous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 1-446 or SEQ ID NOs: 894-918. In one aspect, the

oligonucleotide comprises at least a contiguous 10 nucleobase sequence that shares at least 90% identity with an equal length portion of any one of one of SEQ ID NOs: 31, 36, 41, 46, 55, 144, 146, 150, 169, 170, 171, 172, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 249, 252, 380, 385, 390, 395, 400, 975, 980, 985, 999, 1088, 1090, 1094, 1113, 1114, 1115, 1116, 1117, 1121, 1125, 1129, 1141, 1147, 1153, 1159, 1181, 1188, 1193, 1196, 1324, 1329, 1334, 1339, or 1344, wherein at least one nucleoside linkage of the nucleobase sequence is a non-natural linkage. In one aspect, the oligonucleotide comprises at least a contiguous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 31, 36, 41, 46, 55, 144, 146, 150, 169, 170, 171, 172, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 249, 252, 380, 385, 390, 395, 400, 975, 980, 985, 999, 1088, 1090, 1094, 1113, 1114, 1115, 1116, 1117, 1121, 1125, 1129, 1141, 1147, 1153, 1159, 1181, 1188, 1193, 1196, 1324, 1329, 1334, 1339, or 1344.

[00368] Additionally disclosed herein is a stathmin-2 (STMN2) antisense oligonucleotide comprising a nucleic acid sequence that is at least 90% complementary with a continuous 10 nucleobase sequence of an STMN2 transcript comprising a cryptic exon comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 447 or a continuous 20 to 50 nucleobase portion thereof, wherein at least one nucleoside linkage of the nucleotide sequence is a non-natural linkage. Additionally disclosed herein is a stathmin-2 (STMN2) antisense oligonucleotide comprising a nucleic acid sequence that shares at least 90% identity with a continuous 10 nucleobase sequence of any one of SEQ ID NOs: 1-446, wherein at least one nucleoside linkage of the nucleotide sequence is a non-natural linkage. In one aspect, the nucleic acid sequence shares at least 90% identity with a continuous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of any one of SEQ ID NOs: 1-446.

[00369] Additionally disclosed herein is a stathmin-2 (STMN2) antisense oligonucleotide comprising a nucleic acid sequence that shares at least 90% identity with a continuous 10 nucleobase sequence of any one of SEQ ID NOs: 31, 36, 41, 46, 55, 144, 146, 150, 169, 170, 171, 172, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 249, 252, 380, 385, 390, 395, 400, 975, 980, 985, 999, 1088, 1090, 1094, 1113, 1114, 1115, 1116, 1117, 1121, 1125, 1129, 1141, 1147, 1153, 1159, 1181, 1188, 1193, 1196, 1324, 1329, 1334, 1339, or 1344, wherein at least one nucleoside linkage of the nucleotide sequence is a non-natural linkage. In one aspect, the nucleic acid sequence shares at least 90% identity with a continuous 11, 12, 13, 14, 15, 16, or 17 nucleobase sequence of any one of SEQ ID NOs: 31, 36, 41, 46, 55, 144, 146, 150, 169, 170, 171,

172, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 249, 252, 380, 385, 390, 395, 400, 975, 980, 985, 999, 1088, 1090, 1094, 1113, 1114, 1115, 1116, 1117, 1121, 1125, 1129, 1141, 1147, 1153, 1159, 1181, 1188, 1193, 1196, 1324, 1329, 1334, 1339, or 1344.

Modifications in General

- 5 [0001] While certain compounds, compositions and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds described herein and are not intended to limit the same. Each of the references, GenBank accession numbers, and the like recited in the present application is incorporated herein by reference in its entirety.
- 10 [0002] Although the sequence listing accompanying this filing identifies each sequence as either “RNA” or “DNA” as required, in reality, those sequences may be modified with any combination of chemical modifications. One of skill in the art will readily appreciate that such designation as “RNA” or “DNA” to describe modified oligonucleotides is, in certain instances, arbitrary. For example, an oligonucleotide comprising a nucleoside comprising a 2'-OH sugar moiety and a
- 15 thymine base could be described as a DNA having a modified sugar (2'-OH in place of one 2'-H of DNA) or as an RNA having a modified base (thymine (methylated uracil) in place of a uracil of RNA). Accordingly, nucleic acid sequences provided herein, including, but not limited to those in the sequence listing, are intended to encompass nucleic acids containing any combination of natural or modified RNA and/or DNA, including, but not limited to such nucleic acids having
- 20 modified nucleobases. By way of further example and without limitation, an oligomeric compound having the nucleobase sequence “ATCGATCG” encompasses any oligomeric compounds having such nucleobase sequence, whether modified or unmodified, including, but not limited to, such compounds comprising RNA bases, such as those having sequence “AUCGAUCG” and those having some DNA bases and some RNA bases such as
- 25 “AUCGATCG” and oligomeric compounds having other modified nucleobases, such as “AT^mCGAUCG,” wherein ^mC indicates a cytosine base comprising a methyl group at the 5-position.

- [0003] Certain compounds described herein (*e.g.*, modified oligonucleotides) have one or more asymmetric center and thus give rise to enantiomers, diastereomers, and other stereoisomeric
- 30 configurations that may be defined, in terms of absolute stereochemistry, as (R) or (S), as α or β such as for sugar anomers, or as (D) or (L), such as for amino acids, etc. Compounds provided herein that are drawn or described as having certain stereoisomeric configurations include only

the indicated compounds. Compounds provided herein that are drawn or described with undefined stereochemistry included all such possible isomers, including their stereorandom and optically pure forms, unless specified otherwise. Likewise, all tautomeric forms of the compounds herein are also included unless otherwise indicated. Unless otherwise indicated, compounds described
5 herein are intended to include corresponding salt forms.

[0004] The compounds described herein include variations in which one or more atoms are replaced with a non-radioactive isotope or radioactive isotope of the indicated element. For example, compounds herein that comprise hydrogen atoms encompass all possible deuterium substitutions for each of the ^1H hydrogen atoms. Isotopic substitutions encompassed by the
10 compounds herein include but are not limited to: ^2H or ^3H in place of ^1H , ^{13}C or ^{14}C in place of ^{12}C , ^{15}N in place of ^{14}N , ^{17}O or ^{18}O in place of ^{16}O , and ^{33}S , ^{34}S , ^{35}S , or ^{36}S in place of ^{32}S . In certain embodiments, non-radioactive isotopic substitutions may impart new properties on the oligomeric compound that are beneficial for use as a therapeutic or research tool.

15 EXAMPLES

[00370] The disclosure is further illustrated by the following examples. The examples are provided for illustrative purposes only, and are not to be construed as limiting the scope or content of the disclosure in any way.

Example 1: Initial Design and Selection of STMN2 Antisense Oligonucleotides

20 **[00371]** Antisense oligonucleotides complementary to STMN2 RNA were designed and tested to identify STMN2 antisense oligonucleotides (AONs) capable of acting as inhibitors of STMN2 transcripts that include a cryptic exon.

[00372] FIGs. 1A-1C depict portions of the STMN2 transcript and STMN2 antisense oligonucleotides that are designed to target certain portions of the STMN2 transcript.

25 Specifically, regions of the STMN2 transcript include branch points (*e.g.*, branch point 1, 2, and 3) a 3' splice acceptor region, an ESE binding region, TDP43 binding sites, and a Poly A region. STMN2 antisense oligonucleotides, are identified according to the position of the STMN2 transcript that the STMN2 antisense oligonucleotide corresponds to. For example, FIG. 1A depicts a STMN2 antisense oligonucleotide that targets positions 36 to 60 of the STMN2
30 transcript, which includes a branch point 1. Similarly, a different STMN2 antisense oligonucleotide targets positions 144 to 178 of the STMN2 transcript, which includes a branch

point 3. Other STMN2 antisense oligonucleotides can be designed using any of the sequences disclosed above (*e.g.*, SEQ ID NOs: 1-446, 894-918, 945-1390, or 1392-1432).

[00373] Generally, the length of the STMN2 antisense oligonucleotides are 25 nucleotides in length. However, variants of the STMN2 antisense oligonucleotides were also designed with
5 varying lengths (*e.g.*, 23mers, 21mers, or 19mers). Specific STMN2 AONs and AON variants that were designed and developed for testing are shown in below in Table 7.

Table 7: Identifying information of STMN2 AONs and AON variants including sequence and chemistry information.

<u>STMN2 AON</u>	<u>SEQ ID NO:</u>	<u>Sequence (5'-3')</u>	<u>Internucleoside Linkages</u>	<u>Sugar Moiety</u>
QSN-36	36	TTAAAAATGTTAAGACATAATAACCA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-31	31	AATGTTAAGACATAATAACCAGAGCT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-41	41	TAGATTTAAAAATGTAAAGACATAA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-46	46	TACCATAGATTTAAAAATGTAAAGA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-55	55	TGTAAAGATTACCATAGATTTAAAA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-144	144	AATCCAAATTAAGAGAGAGTGATGGG	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-146	146	AAAATCCAATTAAGAGAGAGTGATG	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-150	150	TTTAAAAATCCAATTAAGAGAGAGT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-169	169	CCTGCAATATGAATATAATTTTAAA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-170	170	TCCTGCAATATGAATATAATTTTAA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-171	171	GTCCTGCAATATGAATATAATTTTA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-172	172	AGTCTGCAATATGAATATAATTTT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC

QSN-173	173	GAGTCCTGCAATATGAATATAATTT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-177	177	TGCCGAGTCCTGCAATATGAATATA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-181	181	CTTCTGCCGAGTCCTGCAATATGAA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-185	185	AGGTCTTCTGCGGAGTCCTGCAATA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-197	197	CCTTTCTCTCGAAGGTCTTCTGCGG	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-203	203	TTTCTACCTTTCTCTCGAAGGTCTT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-209	209	TCTTATTTTCTACCTTTCTCTCGAA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-215	215	CCAAATTCCTTATTTTCTACCTTTCT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-237	237	GCACACATGCTCACACAGAGAGCCA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-244	244	CACACACGCACACATGCTCACACAG	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-249	249	TCTCGCACACACGCACACATGCTCA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-252	252	CTCTCTGCACACACGCACACATGTC	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-380	380	TGTTTTAATTCTTCAGTATTGCTA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-385	385	TCTTTTGTGTTTAAATTTCTTCAGTAT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC

QSN-390	390	AGCAATCTTTTGTGTTTAATTCTTC	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-395	395	GAGACAGCAATCTTTTGTGTTTAATT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-400	400	ATATTGAGACAGCAATCTTTTGTGTTT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-434	434	CTTAGAATAATTTGGTAAATAATAA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-436	436	CTCTTAGAATAATTTGGTAAATAAT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-438	438	TACTCTTAGAATAATTTGGTAAATA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-440	440	AATACTCTTAGAATAATTTGGTAA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-442	442	GAAATACTCTTAGAATAATTTGGTA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-445	445	GAAGAAATACTCTTAGAATAATTTG	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-446	446	GGAAGAAATACTCTTAGAATAATTT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-144-1/5-1/3	894	ATCCAATTAAAGAGAGAGTGATGG	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-144-2/3	895	AATCCAATTAAAGAGAGAGTGATG	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-144-2/5	896	TCCAATTAAAGAGAGAGTGATGGG	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-144-2/5-2/3	897	TCCAATTAAAGAGAGAGTGATG	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC

QSN-144-3/5-3/3	898	CCAATTAAAGAGAGAGTGAT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-144-4/3	899	AATCCAATTAAAGAGAGAGTGTA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-144-4/5	900	CAATTAAAGAGAGAGTGATGGG	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-144-p03	1419	A-A-T-CCAATTAAAGAGAGAGTGAT-G-G-G	Phosphorothioate linkages except for linkages indicated with "-", which are phosphodiester linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-144-p05	1420	AATCCAAT-T-A-G-A-GAGAGTGATGGG	Phosphorothioate linkages except for linkages indicated with "-", which are phosphodiester linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-173-2/3	901	GAGTCCTGCAATATGAATATAAT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-173-2/5	902	GTCCCTGCAATATGAATATAATTT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-173-2/5-2/3	903	GTCCCTGCAATATGAATATAAT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-173-4/3	904	GAGTCCTGCAATATGAATATA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-173-4/5	905	CCTGCAATATGAATATAATTT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-173-6/3	906	GAGTCCTGCAATATGAATA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-173-6/5	907	TGCAATATGAATATAATTT	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-173-po3	1417	G-A-G-TCCTGCAATATGAATATAA-T-T-T	Phosphorothioate linkages except for linkages indicated with "-", which are phosphodiester linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC

QSN-173-po5	1418	GAGTCCTG-C-A-A-T-A-TGAATATAATTT	Phosphorothioate linkages except for linkages indicated with "-", which are phosphodiester linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-185-2/5	908	GTCTTCTGCCGAGTCCTGCAATA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-185-4/3	909	AGGTCTTCTGCCGAGTCCTGCTGC	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-185-4/5	910	CTTCTGCCGAGTCCTGCAATA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-185-6/5	911	TCTGCCGAGTCCTGCAATA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-185-po3	1421	A-G-G-TCTTCTGCCGAGTCCTGCA-A-T-A	Phosphorothioate linkages except for linkages indicated with "-", which are phosphodiester linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-185-po5	1422	AGGTCTTC-T-G-C-C-G-AGTCCTGCAATA	Phosphorothioate linkages except for linkages indicated with "-", which are phosphodiester linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-237-2-3p	912	GCACACATGCTCACACAGAGAGC	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-237-2-5p	912	ACACATGCTCACACAGAGAGCCA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-237-2-5p-2-3p	914	ACACATGCTCACACAGAGAGC	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-237-4-3p	915	GCACACATGCTCACACAGAGAGA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-237-4-5p	916	ACATGCTCACACAGAGAGCCA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-237-6-3p	917	GCACACATGCTCACACAGAGA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-237-6-5p	918	ATGCTCACACAGAGAGCCA	All phosphorothioate linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC

QSN-237-po3	1423	G-C-A-CACATGTGCTCACACAGAGAG-C-C-A	Phosphorothioate linkages except for linkages indicated with "-", which are phosphodiester linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC
QSN-237-p05	1424	GCACACAT-G-C-T-C-A-CACAGAGAGCCA	Phosphorothioate linkages except for linkages indicated with "-", which are phosphodiester linkages	All nucleosides have 2'MOE sugar moiety; each "C" is 5-MeC

Example 2: Methods for Evaluating STMN2 Antisense Oligonucleotides

[00374] STMN2 antisense oligonucleotides were evaluated in SY5Y cells and human motor neurons. Specifically, Examples 3, 4, and 5 below describe results generated from evaluation of STMN2 antisense oligonucleotides in SY5Y cells. Example 6 and 7 below describe results generated from evaluation of STMN2 antisense oligonucleotides in human motor neurons.

[00375] STMN2 antisense oligonucleotides were evaluated in SY5Y cells. The cells were plated in 6-well or 96-well plates and cultured to 80% confluency. Antisense oligonucleotide (AON) to TDP43 was transfected with RNAiMax (Thermo Fisher Scientific, Waltham, MA, USA) to express the cryptic exon, thus preventing transcription of full-length STMN2 (STMN2-FL) product. Vehicle was treated with RNAiMax alone. Positive controls included cells that were treated with TDP43 siRNA alone (“siRNA TDP43”) and/or TDP43 AON alone (“AON TDP43” or “TDP43 AON”). siRNA TDP43 was purchased as ON-TARGETplus Human TARDBP (23435) siRNA – SMARTpool (#L-012394-00-0005) from Horizon/Dharmacon. TARDBP (23435) siRNA includes four individual siRNAs that targets four separate sequences:

- 1) Target sequence 1: GCUCAAGCAUGGAUUCUAA (SEQ ID NO: 1439)
- 2) Target sequence 2: CAAUCAAGGUAGUAAUAUG (SEQ ID NO: 1440)
- 3) Target sequence 3: GGGCUUCGCUACAGGAAUC (SEQ ID NO: 1441)
- 4) Target sequence 4: CAGGGUGGAUUUGGUAUA (SEQ ID NO: 1442)

[00376] TDP43 AON is a gapmer oligonucleotide and has the following sequence and chemistry:

5' A*A*G*G*C*T*T*C*A*T*A*T*T*G*T*A*C*T*T*T 3' (SEQ ID NO: 1443)

where * = phosphorothioate, underlined = DNA, other=2'MOE RNA; each “C” is 5-MeC.

[00377] To evaluate STMN2 AON ability to restore STMN2-FL, antisense oligonucleotides to STMN2 were co-incubated with TDP43 AON in RNAiMax. After 96 hours, transcript levels (e.g., STMN2 full length transcript, STMN2 transcript with cryptic exon, or TDP43 transcript) were detected by RT-qPCR using Taqman. Specifically, RT-qPCR was performed for detecting GAPDH using ThermoFisher TaqMan Gene Expression Assay Hs03929097_g1. RT-qPCR was performed for detecting STMN2 transcripts with cryptic exon using the following primer sequences: 1) Forward primer: 5' - CTCAGTGCCTTATTCAGTCTTCTC - 3' (SEQ ID NO: 1444), 2) Reverse primer: 5' – TCTTCTGCCGAGTCCCATTT-3' (SEQ ID NO: 1445) and 3) Probe: 5' - /56-FAM/ TCAGCGTCTGCACATCCCTACAAT /3BHQ_1/-3' (SEQ ID NO: 1446). RT-qPCR was performed for detecting full length STMN2 transcripts using the following primer sequences: 1) Forward primer: 5' – CCACGAACTTTAGCTTCTCCA – 3' (SEQ ID NO:

1447), 2) Reverse primer: 5' – GCCAATTGTTTCAGCACCTG – 3' (SEQ ID NO: 1448), and 3) Probe: 5' -/56-FAM/ ACTTTCTTCTTTCCTCTGCAGCCTCC /3BHQ_1/- 3' (SEQ ID NO: 1449).

[00378] RT-qPCR was performed on Applied Biosystems® 7500 Real-time PCR systems.

One cycle of reverse transcription was performed at a temperature of 50° C for 5 min. One cycle of RT inactivation/initial denaturation was performed at a temperature of 95° C for 20 seconds. Forty five cycles of amplification were performed at a temperature of 95° C for 1 second followed by 60° C for 20 seconds.

[00379] STMN2-FL or STMN2 cryptic signal (Ct) was normalized to GAPDH (deltaCt). To visualize the quantitative changes (e.g., % increase of STMN-FL), the normalized STMN2-FL signal was further normalized to the vehicle (treated with RNAiMax alone, deltadeltaCt). Relative quantity of transcript level was calculated using the equation $RQ=2^{-\text{deltadeltaCt}}$ and is used to describe the treatment condition comparison to normal, healthy levels (1.0).

[00380] Percent decrease of STMN2 with cryptic exon expression was calculated using the equation of:

$$100 - \left(\frac{\text{Mean relative quantity of STMN2 with cryptic exon in response to STMN2 AON}}{\text{Mean relative quantity of STMN2 with cryptic exon in response to TDP43 AON}} * 100 \right)$$

The percent increase of full length STMN2 mRNA transcript was calculated using the equation of:

$$\left(\frac{\text{Mean relative quantity of FL STMN2 transcript in response to STMN2 AON}}{\text{Mean relative quantity of FL STMN2 transcript in response to TDP43 AON}} \right) * 100$$

[00381] STMN2 antisense oligonucleotides were also evaluated in human motor neurons for potency in reducing cryptic exon and increasing STMN2 full length transcript. iCell human motor neurons (Cellular Dynamics International) were plated at 15×10^3 cells/well in a 96-well plate for RT-qPCR RNA quantification or 3×10^5 cells/well in a 6-well plate for western blot protein quantification according to manufacturer's instructions. Neurons were transfected with TDP43 AON and/or STMN2 AON using endoport (GeneTools, LLC.) or treated with endoport alone. Treatment conditions were tested in biological triplicate (qRT-PCR) or duplicate (western blot) wells. The same TDP43 AON described above is used here for evaluating human motor neurons. TDP43 AON is a gapmer oligonucleotide and has the following sequence and chemistry:

5' A*A*G*G*C*T*T*C*A*T*A*T*T*G*T*A*C*T*T*T*3' (SEQ ID NO: 1443)

where * = phosphorothioate, underlined = DNA, other=2'MOE RNA; each "C" is 5-MeC.

[00382] After 72 hours, antisense oligonucleotides and endoport were washed out and replaced with fresh media. After 72 additional hours, RNA was collected from the 96-well plates

for RT-qPCR or protein collected from the 6-well plates for western blot. RNA was isolated, cDNA generated and multiplexed RT-qPCR assay performed with taqman probes for STMN2 cryptic exon, STMN2 full length transcript and reference GAPDH quantification. The same primers for detecting GAPDH, STMN2 transcript with cryptic exon, and full length STMN2, as described above in reference to SY5Y cells, were applied here for conducting RT-qPCR for human motor neurons. For protein quantification, the soluble portion of the protein collection was denatured and separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes and probed with antibodies against GAPDH (Proteintech, 60004-1-1g), TDP-43 (Proteintech, 10782-2-AP), and Stathmin-2 (ThermoFisher, PA5-23049).

[00383] STMN2 antisense oligonucleotides were tested for their ability to increase or restore full-length STMN2 mRNA (*i.e.*, mRNA from which full-length STMN2 is translated) levels in TDP43 silenced cells (*e.g.*, SY5Y cells and human motor neurons). In some cases, STMN2 antisense oligonucleotides were tested for their ability to reduce STMN2 transcripts with cryptic exon. As described further below, the quantified percentage increase/restoration of STMN2-FL and/or percentage reduction of STMN2 transcripts with cryptic exon is described in reference to levels of STMN-FL and/or STMN2 transcripts with cryptic exon in a control group (*e.g.*, cells treated with 500 nM TDP43 AON).

Example 3: STMN2 Antisense Oligonucleotides Restore Full Length STMN2 and Reduce STMN2 Transcripts with Cryptic Exon in SY5Y cells

[00384] FIGs. 1B and 1C demonstrate the effectiveness of STMN2 AONs targeting different regions of the STMN2 transcript with cryptic exon. In particular, FIG. 1B depicts STMN2 AONs that were designed and evaluated in SY5Y cells. FIG. 1C depicts STMN2 AONs that were designed and evaluated in human motor neurons. STMN2 AONs represented by a solid line resulted in cells with increased STMN2-FL mRNA expression by greater than 50% over TDP43 AON treated alone. STMN2 AONs represented by a dotted line resulted in cells with increased STMN2-FL (full length) mRNA by less than 50% over TDP43 AON treated alone.

[00385] Referring to FIG. 2, TDP43 transcript was decreased by around 52% and STMN2-FL was decreased by around 57% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 36 increased TDP43 levels by 25% and increased STMN-FL levels by 55% (rescued to 67%). A 50 nM and a 500 nM treatment of a STMN2 AON with SEQ ID NO: 177 increased STMN-FL levels by 58% (rescued to 68%) and 53% (rescued to 66%) respectively. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 203 increased TDP43

levels by 15% and STMN-FL levels by 72% (rescued to 74%). A 50 nM and a 500 nM treatment of a STMN2 AON with SEQ ID NO: 395 increased STMN-FL levels by 49% (rescued to 64%) and 37% (rescued to 59%) respectively. Dotted line represents level of expression of FL-STMN2 in response to 500 nM TDP43 AON.

5 **[00386]** Referring to FIG. 3, the quantity of STMN2 transcript with cryptic exon was increased more than 20-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 173 reduced STMN2 transcript with cryptic exon levels by 68%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 181 reduced STMN2 transcript with cryptic exon levels by 65%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 197 reduced
10 STMN2 transcript with cryptic exon levels by 39%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 215 reduced STMN2 transcript with cryptic exon levels by 31%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 385 reduced STMN2 transcript with cryptic exon levels by 53%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 400 reduced STMN2 transcript with cryptic exon levels by 74%. Dotted line represents level of expression of STMN2
15 with cryptic exon in response to 500 nM TDP43 AON.

[00387] Referring to FIG. 4, STMN2-FL was decreased by around 59% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 173 increased STMN-FL levels to 166% (rescued to 68%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 197 increased STMN-FL levels to 146% (rescued to 60%). Dotted line represents level of
20 expression of FL-STMN2 in response to 500 nM TDP43 AON.

[00388] Referring to FIG. 5A, the quantity of STMN2 transcript with cryptic exon was increased more than 36-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 185 reduced STMN2 transcript with cryptic exon levels by 58%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 237 reduced STMN2 transcript with
25 cryptic exon levels by 87%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 380 reduced STMN2 transcript with cryptic exon levels by 70%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 390 reduced STMN2 transcript with cryptic exon levels by 58%. Dotted line represents level of expression of STMN2 with cryptic exon in response to 500 nM TDP43 AON.

30 **[00389]** Referring to FIG. 5B, STMN2-FL was decreased by 66% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 185 increased STMN-FL levels to 209% (rescued to 71%). A 500 nM treatment of a STMN2 AON with SEQ ID NO:

237 increased STMN-FL levels to 347% (rescued to 118%). Dotted line represents level of expression of FL-STMN2 in response to 500 nM TDP43 AON.

[00390] Referring to FIG. 6A, the quantity of STMN2 transcript with cryptic exon was increased more than 20-fold when treated with 500 nM TDP43 AON (two different syntheses). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 144 reduced STMN2 transcript with cryptic exon levels by 83 to 88%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 92 to 93%. Dotted line represents level of expression of STMN2 with cryptic exon in response to 500 nM TDP43 AON.

[00391] Referring to FIG. 6B, STMN2-FL was decreased by about 80% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 144 increased STMN-FL levels to between 376% and 429% (rescued to between 79% to 90%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 237 increased STMN-FL levels to between 490% and 538% (rescued to 103% to 113%). Dotted line represents level of expression of FL-STMN2 in response to 500 nM TDP43 AON.

[00392] Referring to FIG. 7A, the quantity of STMN2 transcript with cryptic exon was increased more than 23-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 173 reduced STMN2 transcript with cryptic exon levels by 83%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 177 reduced STMN2 transcript with cryptic exon levels by 83%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 181 reduced STMN2 transcript with cryptic exon levels by 72%. Dotted line represents level of expression of STMN2 with cryptic exon in response to 500 nM TDP43 AON.

[00393] Referring to FIG. 7B, STMN2-FL was decreased by about 58% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 173 increased STMN-FL levels to 219% (rescued to 92%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 181 increased STMN-FL levels to 188% (rescued to 79%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 185 increased STMN-FL levels to 174% (rescued to 73%). Dotted line represents level of expression of FL-STMN2 in response to 500 nM TDP43 AON.

[00394] Referring to FIG. 8A, the quantity of STMN2 transcript with cryptic exon was increased more than 20-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 197 reduced STMN2 transcript with cryptic exon levels by 65%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 237 reduced STMN2 transcript with

cryptic exon levels by 94%. Dotted line represents level of expression of STMN2 with cryptic exon in response to 500 nM TDP43 AON.

[00395] Referring to FIG. 8B, STMN2-FL was decreased by 59% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 197 increased STMN-FL levels to 185% (rescued to 76%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 237 increased STMN-FL levels to 227% (rescued to 93%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 380 increased STMN-FL levels to 171% (rescued to 70%). Dotted line represents level of expression of FL-STMN2 in response to 500 nM TDP43 AON.

[00396] Referring to FIG. 9A, the quantity of STMN2 transcript with cryptic exon was increased more than 50-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 144 reduced STMN2 transcript with cryptic exon levels by 92%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 173 reduced STMN2 transcript with cryptic exon levels by 82%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 96%. Dotted line represents level of expression of STMN2 with cryptic exon in response to 500 nM TDP43 AON.

[00397] Referring to FIG. 9B, STMN2-FL was decreased by 67% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 144 increased STMN-FL levels to 235% (rescued to 87%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 173 increased STMN-FL levels to 232% (rescued to 86%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 237 increased STMN-FL levels to 243% (rescued to 90%). Dotted line represents level of expression of FL-STMN2 in response to 500 nM TDP43 AON.

[00398] Referring to FIG. 10A, the quantity of STMN2 transcript with cryptic exon was increased more than 65-fold when treated with 500 nM TDP43 AON. A 200 nM treatment of a STMN2 AON with SEQ ID NO: 181 reduced STMN2 transcript with cryptic exon levels by 50%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 181 reduced STMN2 transcript with cryptic exon levels by 73%. Referring to FIG. 10B, STMN2-FL was decreased by 67% when treated with 500 nM TDP43 AON. A 50 nM treatment of a STMN2 AON with SEQ ID NO: 181 increased STMN-FL levels to 215% (rescued to 71%). A 200 nM treatment of a STMN2 AON with SEQ ID NO: 181 increased STMN-FL levels to 197% (rescued to 65%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 181 increased STMN-FL levels to 194% (rescued to 64%).

[00399] Referring to FIG. 11A, the quantity of STMN2 transcript with cryptic exon was increased more than 26-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 185 reduced STMN2 transcript with cryptic exon levels by 47%. Referring to FIG. 11B, STMN2-FL was decreased by 74% when treated with 500 nM TDP43 AON. A 50 nM treatment of a STMN2 AON with SEQ ID NO: 185 increased STMN-FL levels to 173% (rescued to 45%). A 200 nM treatment of a STMN2 AON with SEQ ID NO: 185 increased STMN-FL levels to 346% (rescued to 90%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 185 increased STMN-FL levels to 265% (rescued to 69%).

[00400] Referring to FIG. 12A, the quantity of STMN2 transcript with cryptic exon was increased more than 41-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 197 reduced STMN2 transcript with cryptic exon levels by 51%. Referring to FIG. 12B, STMN2-FL was decreased by 65% when treated with 500 nM TDP43 AON. A 20 nM treatment of a STMN2 AON with SEQ ID NO: 197 increased STMN-FL levels to 186% (rescued to 65%). A 50 nM treatment of a STMN2 AON with SEQ ID NO: 197 increased STMN-FL levels to 231% (rescued to 81%). A 200 nM treatment of a STMN2 AON with SEQ ID NO: 197 increased STMN-FL levels to 254% (rescued to 89%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 197 increased STMN-FL levels to 269% (rescued to 94%).

[00401] Referring to FIG. 13A, the quantity of STMN2 transcript with cryptic exon was increased more than 41-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 144 reduced STMN2 transcript with cryptic exon levels by 93%. Referring to FIG. 13B, STMN2-FL was decreased by 84% when treated with 500 nM TDP43 AON. A 50 nM treatment of a STMN2 AON with SEQ ID NO: 144 increased STMN-FL levels to 175% (rescued to 28%). A 200 nM treatment of a STMN2 AON with SEQ ID NO: 144 increased STMN-FL levels to 360% (rescued to 57%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 144 increased STMN-FL levels to 544% (rescued to 87%).

[00402] Referring to FIG. 14A, the quantity of STMN2 transcript with cryptic exon was increased more than 70-fold when treated with 500 nM TDP43 AON. A 200 nM treatment of a STMN2 AON with SEQ ID NO: 173 reduced STMN2 transcript with cryptic exon levels by 59%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 173 reduced STMN2 transcript with cryptic exon levels by 70%. Referring to FIG. 14B, STMN2-FL was decreased by 62% when treated with 500 nM TDP43 AON. A 200 nM treatment of a STMN2 AON with SEQ ID NO:

173 increased STMN-FL levels by 100% (rescued to 76%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 173 increased STMN-FL levels by 158% (rescued to 98%).

[00403] Referring to FIG. 15A, the quantity of STMN2 transcript with cryptic exon was increased more than 70-fold when treated with 500 nM TDP43 AON. A 200 nM treatment of a STMN2 AON with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 78%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 92%. Referring to FIG. 15B, STMN2-FL was decreased by 77% when treated with 500 nM TDP43 AON. A 50 nM treatment of a STMN2 AON with SEQ ID NO: 237 increased STMN-FL levels to 187% (rescued to 43%). A 200 nM treatment of a STMN2 AON with SEQ ID NO: 237 increased STMN-FL levels to 235% (rescued to 54%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 237 increased STMN-FL levels to 309% (rescued to 71%).

[00404] Referring to FIG. 16, STMN2-FL was decreased by 44% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 173 increased STMN-FL levels to 152%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 237 increased STMN-FL levels to 134%.

[00405] Referring to FIG. 17A, the quantity of STMN2 transcript with cryptic exon was increased more than 30-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 96%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 912 reduced STMN2 transcript with cryptic exon levels by 97%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 913 reduced STMN2 transcript with cryptic exon levels by 97%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 916 reduced STMN2 transcript with cryptic exon levels by 71%.

[00406] Referring to FIG. 17B, STMN2-FL was decreased by 76% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 237 increased STMN-FL levels to 338% (rescued to 81%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 912 increased STMN-FL levels to 163% (rescued to 39%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 915 increased STMN-FL levels to 196% (rescued to 47%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 916 increased STMN-FL levels to 225% (rescued to 54%).

[00407] Referring to FIG. 18A, the quantity of STMN2 transcript with cryptic exon was increased more than 19-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 185 reduced STMN2 transcript with cryptic exon levels by 83%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 908 reduced STMN2 transcript with cryptic exon levels by 85%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 910 reduced STMN2 transcript with cryptic exon levels by 78%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 911 reduced STMN2 transcript with cryptic exon levels by 78%.

[00408] Referring to FIG. 18B, STMN2-FL was decreased by 82% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 185 increased STMN-FL levels to 261% (rescued to 47%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 908 increased STMN-FL levels to 244% (rescued to 44%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 909 increased STMN-FL levels to 228% (rescued to 41%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 910 increased STMN-FL levels to 244% (rescued to 44%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 911 increased STMN-FL levels to 283% (rescued to 51%).

[00409] Referring to FIG. 19A, the quantity of STMN2 transcript with cryptic exon was increased more than 23-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 173 reduced STMN2 transcript with cryptic exon levels by 81%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 901 reduced STMN2 transcript with cryptic exon levels by 86%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 904 reduced STMN2 transcript with cryptic exon levels by 81%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 906 reduced STMN2 transcript with cryptic exon levels by 75%.

[00410] Referring to FIG. 19B, STMN2-FL was decreased by 83 % when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 173 increased STMN-FL levels to 365% (rescued to 62%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 901 increased STMN-FL levels to 306% (rescued to 52%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 904 increased STMN-FL levels to 312% (rescued to 53%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 905 increased STMN-FL levels to 188% (rescued to 32%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 906 increased STMN-FL levels to 288% (rescued to 49%).

[00411] Referring to FIG. 20A, the quantity of STMN2 transcript with cryptic exon was increased more than 35-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a

STMN2 AON with SEQ ID NO: 237 reduced STMN2 transcript with cryptic exon levels by 91%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 912 reduced STMN2 transcript with cryptic exon levels by 94%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 913 reduced STMN2 transcript with cryptic exon levels by 96%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 917 reduced STMN2 transcript with cryptic exon levels by 82%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 918 reduced STMN2 transcript with cryptic exon levels by 38%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 914 reduced STMN2 transcript with cryptic exon levels by 33%.

[00412] Referring to FIG. 20B, STMN2-FL was decreased by 80% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 237 increased STMN-FL levels to 425% (rescued to 85%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 912 increased STMN-FL levels to 450% (rescued to 90%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 918 increased STMN-FL levels to 205% (rescued to 41%).

[00413] Referring to FIG. 21A, the quantity of STMN2 transcript with cryptic exon was increased more than 11-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 173 reduced STMN2 transcript with cryptic exon levels by 72%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 902 reduced STMN2 transcript with cryptic exon levels by 85%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 903 reduced STMN2 transcript with cryptic exon levels by 55%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 1417 reduced STMN2 transcript with cryptic exon levels by 49%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 1418 reduced STMN2 transcript with cryptic exon levels by 57%.

[00414] Referring to FIG. 21B, STMN2-FL was decreased by 73% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 173 increased STMN-FL levels by 85% (rescued to 50%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 903 increased STMN-FL levels by 85% (rescued to 50%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 1417 increased STMN-FL levels by 74% (rescued to 47%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 1418 increased STMN-FL levels by 89% (rescued to 51%).

[00415] Referring to FIG. 22A, the quantity of STMN2 transcript with cryptic exon was increased more than 13-fold when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 144 reduced STMN2 transcript with cryptic exon levels by 91%.

A 500 nM treatment of a STMN2 AON with SEQ ID NO: 896 reduced STMN2 transcript with cryptic exon levels by 80%. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 894 reduced STMN2 transcript with cryptic exon levels by 85%.

[00416] Referring to FIG. 22B, STMN2-FL was decreased by 65% when treated with 500 nM TDP43 AON. A 500 nM treatment of a STMN2 AON with SEQ ID NO: 144 increased STMN-FL levels by 94% (rescued to 68%). A 500 nM treatment of a STMN2 AON with SEQ ID NO: 896 increased STMN-FL levels by 114% (rescued to 75%).

Example 4: Additional Experiments Demonstrating STMN2 Antisense Oligonucleotides Restore Full Length STMN2 and Reduce STMN2 Transcripts with Cryptic Exon in SY5Y cells

[00417] FIG. 25A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different QSN-144 STMN2 AONs and AON variants. FIG. 25B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different QSN-144 STMN2 AONs and AON variants. In particular, the STMN2 AONs and AON variants tested included: QSN-144 (SEQ ID NO: 144), QSN-144-2/3 (SEQ ID NO: 895), QSN-144-4/3 (SEQ ID NO: 899), QSN-144-2/5 (SEQ ID NO: 896), QSN-144-1/5 1/3 (SEQ ID NO: 894), QSN-144-2/5 2/3 (SEQ ID NO: 897), QSN-144-3/5 3/3 (SEQ ID NO: 898), QSN-144-po3 (SEQ ID NO: 1419), and QSN-144-po5 (SEQ ID NO: 1420).

[00418] Treatment with 500 nM TDP43 AON resulted in a 41.7 fold increase of STMN2 transcript with cryptic exon and a decrease of 70% STMN2-FL. The percentage decrease in STMN2 transcript with cryptic exon and the percentage increase in full length STMN2 in response to a 500 nM treatment of each respective STMN2 and AON variant is shown in Table 8.

Table 8: Effects of 500 nM treatment of QSN-144 STMN2 AON and QSN-144 AON variants.

STMN2 AON	SEQ ID NO:	Relative STMN2 Cryptic Exon Quantity	Percentage Decrease in STMN2 transcript with cryptic exon	Relative Full Length STMN2 Quantity ("rescued to")	Percentage Increase in FL STMN2
144-2/3	895	23.4	43.9	0.67	223.3
144-4/3	899	35.7	14.4	0.49	163.3
144-2/5	896	8.4	79.9	0.86	286.7

144-1/5-1/3	894	13.5	67.6	0.52	173.3
144-2/5-2/3	897	42.9	-2.9	0.42	140.0
144-3/5-3/3	898	43.7	-4.8	0.43	143.3
144-PO3	1419	41	1.7	0.32	106.7
144-PO5	1420	46.2	-10.8	0.29	96.7

[00419] FIG. 26A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different QSN-173 STMN2 AONs and AON variants. FIG. 26B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different QSN-173 STMN2 AONs and AON variants. In particular, the STMN2 AONs and AON variants tested included: QSN-173 (SEQ ID NO: 173), QSN-173-2/3 (SEQ ID NO: 901), QSN-173-4/3 (SEQ ID NO: 904), QSN-173-6/3 (SEQ ID NO: 906), QSN-173-4/5 (SEQ ID NO: 905), QSN-173-2/5 (SEQ ID NO: 902), QSN-173-6/5 (SEQ ID NO: 907), QSN-173-2/5 2/3 (SEQ ID NO: 903), QSN-173-po3 (SEQ ID NO: 1417), and QSN-173-po5 (SEQ ID NO: 1418). Treatment with 500 nM TDP43 AON resulted in a 15.4 fold increase of STMN2 transcript with cryptic exon and a decrease of 71% STMN2-FL. The percentage decrease in STMN2 transcript with cryptic exon and the percentage increase in full length STMN2 in response to a 500 nM treatment of each respective STMN2 and AON variant is shown in Table 9.

Table 9: Effects of 500 nM treatment of QSN-173 STMN2 AON and QSN-173 AON variants.

STMN2 AON	SEQ ID NO:	Relative STMN2 Cryptic Exon Quantity	Percentage Decrease in STMN2 transcript with cryptic exon	Relative Full Length STMN2 Quantity ("rescued to")	Percentage Increase in FL STMN2
173-2/3	901	5.8	62.3	0.83	286.2
173-4/3	904	6.5	57.8	0.6	206.9
173-6/3	906	7.6	50.6	0.46	158.6
173-4/5	905	16.4	-6.5	0.3	103.4
173-2/5	902	7.5	51.3	0.6	206.9
173-6/5	907	20.5	-33.1	0.37	127.6
173-2/5-2/3	903	9.3	39.6	0.43	148.3
173-PO3	1417	10.5	31.8	0.45	155.2
173-PO5	1418	9.9	35.7	0.49	169.0

[00420] FIG. 27A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different QSN-185 STMN2 AONs and AON variants. FIG. 27B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different QSN-185 STMN2 AONs and AON variants. In particular, the STMN2 AONs and AON variants tested included: QSN-185 (SEQ ID NO: 185), QSN-185-2/5 (SEQ ID NO: 908), QSN-185-4/5 (SEQ ID NO: 910), QSN-185-6/5 (SEQ ID NO: 911), QSN-185-4/3 (SEQ ID NO: 909), QSN-185-po3 (SEQ ID NO: 1421), and QSN-185-po5 (SEQ ID NO: 1422). Treatment with 500 nM TDP43 AON resulted in a 32.1 fold increase of STMN2 transcript with cryptic exon and a decrease of 71% STMN2-FL. The percentage decrease in STMN2 transcript with cryptic exon and the percentage increase in full length STMN2 in response to a 500 nM treatment of each respective STMN2 and AON variant is shown in Table 10.

Table 10: Effects of 500 nM treatment of QSN-185 STMN2 AON and QSN-185 AON variants.

STMN2 AON	SEQ ID NO:	Relative STMN2 Cryptic Exon Quantity	Percentage Decrease in STMN2 transcript with cryptic exon	Relative Full Length STMN2 Quantity ("rescued to")	Percentage Increase in FL STMN2
185-2/5	908	12.1	62.3	0.72	248.3
185-4/5	910	16.4	48.9	0.52	179.3
185-6/5	911	17.5	45.5	0.46	158.6
185-4/3	909	21.2	34.0	0.36	124.1
185-PO3	1421	27.2	15.3	0.4	137.9
185-PO5	1422	24.6	23.4	0.38	131.0

[00421] FIG. 28A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different QSN-237 STMN2 AONs and AON variants. FIG. 28B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different QSN-237 STMN2 AONs and AON variants. In particular, the STMN2 AONs and AON variants tested included: QSN-237 (SEQ ID NO: 237), QSN-237-2/3 (SEQ ID NO: 912), QSN-237-4/3 (SEQ ID NO: 915), QSN-237-2/5 (SEQ ID NO: 913), QSN-237-4/5 (SEQ ID NO: 916), QSN-237-6/3

(SEQ ID NO: 917), QSN-237-6/5 (SEQ ID NO: 918), QSN-237-2/5 2/3 (SEQ ID NO: 914), QSN-237-po3 (SEQ ID NO: 1423), and QSN-237-po5 (SEQ ID NO: 1424). Treatment with 500 nM TDP43 AON resulted in a 15.7 fold increase of STMN2 transcript with cryptic exon and a decrease of 65% STMN2-FL. The percentage decrease in STMN2 transcript with cryptic exon and the percentage increase in full length STMN2 in response to a 500 nM treatment of each respective STMN2 and AON variant is shown in Table 11.

Table 11: Effects of 500 nM treatment of QSN-237 STMN2 AON and QSN-237 AON variants.

STMN2 AON	SEQ ID NO:	Relative STMN2 Cryptic Exon Quantity	Percentage Decrease in STMN2 transcript with cryptic exon	Relative Full Length STMN2 Quantity ("rescued to")	Percentage Increase of FL STMN2
237-2/3	912	1.9	87.9	0.51	145.7
237-4/3	915	14.6	7.0	0.56	160.0
237-2/5	913	7.7	51.0	0.5	142.9
237-4/5	916	8	49.0	0.49	140.0
237-6/3	917	11.7	25.5	0.4	114.3
237-6/5	918	10.7	31.8	0.62	177.1
237-2/5-2/3	914	13.5	14.0	0.51	145.7
237-PO3	1423	6.7	57.3	0.53	151.4
237-PO5	1424	4.7	70.1	0.59	168.6

[00422] FIG. 29A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and reduction of the STMN2 transcript with cryptic exon mRNA levels using different STMN2 AONs (QSN-31, QSN-41, and QSN-46). FIG. 29B is a bar graph showing the results of RT-qPCR analysis of TDP43 and STMN2 full-length mRNA levels in the presence of TDP43 siRNA and TDP43 antisense, and restoration of the full-length STMN2 transcript using different STMN2 AONs (QSN-31, QSN-41, and QSN-46). In particular, the STMN2 AONs and AON variants tested included: QSN-31 (SEQ ID NO: 31), QSN-41 (SEQ ID NO: 41), and QSN-46 (SEQ ID NO: 46). Treatment with 500 nM TDP43 AON resulted in a 10.4 fold increase of STMN2 transcript with cryptic exon and a decrease of 59% STMN2-FL. The percentage decrease in STMN2 transcript with cryptic exon and the percentage increase in full length STMN2 in response to a 500 nM treatment of each respective STMN2 and AON variant is shown in Table 12.

Table 12: Effects of 500 nM treatment of QSN-31, QSN-41, and QSN-46 STMN2 AONs.

STMN2 AON	SEQ ID NO:	Relative STMN2 Cryptic Exon Quantity	Percentage Decrease in STMN2 transcript with cryptic exon	Relative Full Length STMN2 Quantity ("rescued to")	Percentage Increase of FL STMN2
31	31	2.6	75.0	0.38	108.6
41	41	4.1	60.6	0.46	131.4
46	46	8.7	16.3	0.48	137.1

Example 5: Dose response restoration of full length STMN2 mRNA and STMN2 protein using Stathmin-2 cryptic splicing modulator

[00423] The experiment was performed as previously described in human neuroblastoma SY5Y cells. The cells were plated in 6-well or 96-well plates and cultured to 80% confluency. TDP-43 expression in cells were knocked down using an AON to TDP43 to express the cryptic exon, thus preventing transcription of full-length STMN2 (STMN2-FL) product. Cells were additionally co-transfected with a STMN2 ASO (specifically, QSN-237-2/3 (SEQ ID NO: 912)) at varying doses (5 nM, 50 nM, 100 nM, 200 nM, and 500 nM). RNA and protein were isolated for QPCR and western blot assays.

[00424] FIG. 23 shows the dose response curve illustrating increasing restoration of full length STMN2 transcript with increasing concentrations of STMN2 AON. Generally, increasing concentrations of STMN2 AON increased full length STMN2 mRNA, decreased cryptic exon levels. Specifically, a 5 nM treatment of the STMN2 ASO resulted in ~40% restoration of full length STMN2 transcript. A 500 nM treatment of the STMN2 ASO resulted in nearly 100% restoration of full length STMN2 transcript. Additionally, the 500 nM treatment of the STMN2 ASO resulted in the significant reduction (close to 0%) of cryptic exon.

[00425] FIG. 24A shows a Western blot assay demonstrating the qualitative increase of full length STMN2 protein in response to higher concentrations of STMN2 AON. FIG. 24B shows the quantitated levels of full length STMN2 protein normalized to GAPDH in response to different concentrations of STMN2 AON. Generally, both FIG. 24A and 24B show that increasing concentrations of the STMN2 AON resulted in increasing concentrations of full length STMN2 protein. Specifically, as shown in FIG. 24B, lower concentrations (5nM and 50 nM) of the STMN2 AON resulted in full length STMN2 protein concentrations that were ~60% of the control group (cell only). Notably, the 500 nM treatment of the STMN2 ASO resulted in nearly 100% restoration of the full length STMN2 protein (in comparison to the cell only control group).

Example 6: Chemotherapy induced neuropathy as an indication that can be targeted by a Stathmin-2 cryptic splicing modulator

[00426] Referring to FIG. 30, it illustrates a bar graph showing reversal of cryptic exon induction using QSN-237 STMN2 antisense oligonucleotide (SEQ ID NO: 237) even in view of increasing proteasome inhibition. As a control, cells that were treated with endoportor alone (no AON) and then subsequently treated with MG132 (across all concentrations of MG132) demonstrated high levels of cryptic exon. This is indicative of TDP-43 pathology induced by proteasome inhibition in human motor neurons. MG132 causes TDP43 mislocalization leading to STMN2 mis-splicing and increased cryptic exon expression. The addition of QSN-237 (SEQ ID NO: 237) antisense oligonucleotide reverses cryptic exon induction with high potency (IC₅₀ <5nM). As shown in FIG. 30, increasing concentrations of QSN-237 (ranging from 5 nM up to 500 nM) significantly reduces the cryptic exon relative quantity.

[00427] In totality, this data establishes that the QSN-237 antisense oligonucleotide (SEQ ID NO: 237) protects against proteotoxic stress induction of cryptic exon expression. This is applicable in settings where neurons are to be protected from proteotoxic stress as a result of other therapies such as chemotherapeutics.

Example 7: STMN2 Antisense Oligonucleotides Restore Full Length STMN2 and Reduce STMN2 Transcripts with Cryptic Exon in Human Motor Neurons

[00428] FIG. 31A and FIG. 31B show bar graphs showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA levels and STMN2 full-length mRNA levels, which demonstrate reduction of the STMN2 transcript with cryptic exon mRNA levels and restoration of the full-length STMN2 transcript using different STMN2 AONs and AON variants. In particular, the STMN2 AONs and AON variants tested included: QSN-36 (SEQ ID NO: 36), QSN-55 (SEQ ID NO: 55), QSN-144 (SEQ ID NO: 144), QSN-144-2/5 (SEQ ID NO: 896), QSN-173 (SEQ ID NO: 173), QSN-173-2/5-2/3 (SEQ ID NO: 903), QSN-237 (SEQ ID NO: 237), QSN-237-2/3 (SEQ ID NO: 912), QSN 185 (SEQ ID NO: 185), QSN-185-2/5 (SEQ ID NO: 908), and QSN-252 (SEQ ID NO: 252).

[00429] Table 13 shows the dose-dependent effect (percentage decrease) of STMN2 AONs on levels of expression of STMN2 with cryptic exon. Additionally, Table 14 shows the dose-dependent effect of STMN2 AONs on restoration of levels of full length STMN2 transcript.

Table 13: Dose dependent effect of STMN2 AONs on expression levels of STMN2 with cryptic exon. Values are shown as percentage decrease of expression levels of STMN2 with cryptic exon relative to corresponding value derived from 500 nM TDP43 AON treated cells.

Dose	QSN-36	QSN-55	QSN-144	QSN-144-2-5p	QSN-173	QSN-173-2-5p-2-3p
5	-6	17	87		85	89
20		35	90	90	91	94
50	3	43	94	92	96	97
200		45	97	94	99	100
500	-37	21	98	97	100	100

Dose	QSN-237	QSN-237-2-3p	QSN-185	QSN-185-2-5p	QSN-252
5	99	98	11	-1	22
20	99	100	28	10	28
50	100	100	28	44	71
200	100	100	42	71	95
500	100	100	66	86	98

5

Table 14: Dose dependent effect of STMN2 AONs on expression levels of full length STMN2 transcript.

Dose	QSN-36		QSN-55		QSN-144		QSN-144-2-5p	
	Relative Quantity ("rescued to")	Percent Increase of FL STMN2	Relative Quantity ("rescued to")	Percent Increase of FL STMN2	Relative Quantity ("rescued to")	Percent Increase of FL STMN2	Relative Quantity ("rescued to")	Percent Increase of FL STMN2
5	0.19	69	0.54	136	0.63	524		
20			0.51	129	0.51	423	0.57	477
50	0.33	122	0.60	149	0.60	497	0.64	536
200			0.67	168	0.65	543	0.57	477
500	0.32	119	0.93	234	0.77	639	0.74	616

Dose	QSN-173		QSN-173-2-5p-2-3p		QSN-237		QSN-237-2-3p	
	Relative Quantity ("rescued to")	Percent Increase of FL STMN2	Relative Quantity ("rescued to")	Percent Increase of FL STMN2	Relative Quantity ("rescued to")	Percent Increase of FL STMN2	Relative Quantity ("rescued to")	Percent Increase of FL STMN2
5	0.52	437	0.65	499	0.68	525	0.52	397
20	0.58	483	0.72	556	0.79	606	0.55	426
50	0.74	619	0.88	677	0.83	640	0.76	581
200	1.01	840	1.03	791	0.83	636	0.68	527
500	1.15	954	0.96	736	0.97	743	0.73	560

Dose	QSN-185		QSN-185-2-5p		QSN-252	
	Relative Quantity ("rescued to")	Percent Increase of FL STMN2	Relative Quantity ("rescued to")	Percent Increase of FL STMN2	Relative Quantity ("rescued to")	Percent Increase of FL STMN2
5	0.55	184	0.59	196	0.64	121
20	0.75	252	0.74	248	0.55	104
50	0.83	275	0.86	288	0.77	144
200	1.19	396	1.15	384	1.04	197
500	1.02	340	1.49	498	1.04	197

[00430] FIG 32 is a bar graph showing the results of a western blot analysis of STMN2 protein levels, which demonstrates, which demonstrates restoration of the full-length STMN2 protein using different STMN2 AONs and AON variants. In particular, the STMN2 AONs and AON variants tested included: QSN-144 (SEQ ID NO: 144), QSN-144-2/5 (SEQ ID NO: 896), QSN-173 (SEQ ID NO: 173), QSN-173-2/5-2/3 (SEQ ID NO: 903), QSN-185 (SEQ ID NO: 185), QSN-185-2/5 (SEQ ID NO: 908), QSN-237 (SEQ ID NO: 237), and QSN-237-2/3 (SEQ ID NO: 912).

[00431] Table 15 below shows the expression levels of STMN2 protein in relation to control groups (endoporter and TDP43 ASO). Each of the STMN2 AONs and AON variants increased expression levels of STMN2 protein in relation to TDP43 ASO. In some cases, STMN2 AONs (*e.g.*, QSN-144 and QSN-173) and AON variants (*e.g.*, QSN-173-2/5-2/3) restored expression levels of STMN2 protein to levels above the endoporter control.

Table 15: Full length STMN2 expression of human motor neurons treated with STMN2 AONs or AON variants.

Group	percent of endoporter
Endoporter	100
TDP43 ASO	40
QSN-144	113
QSN-144-2/5	87
QSN-173	206
QSN-173-2/5-2/3	131
QSN-185	82
QSN-185-2/5	71
QSN-237	76
QSN-237-2/3	65

[00432] FIG. 33A is a bar graph showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA expression in human motor neurons in response to treatment using different STMN2 AONs. FIG. 33B is a bar graph showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels in response to treatment using different STMN2 AONs. In particular, the STMN2 AONs tested included: QSN-31 (SEQ ID NO: 31), QSN-41 (SEQ ID NO: 41), and QSN-46 (SEQ ID NO: 46).

[00433] Table 16 shows the dose-dependent effect (percentage decrease) of STMN2 AONs on levels of expression of STMN2 with cryptic exon. Additionally, Table 17 shows the dose-dependent effect of STMN2 AONs on restoration of levels of full length STMN2 transcript.

Table 16: Dose dependent effect of STMN2 AONs on expression levels of STMN2 with cryptic exon. Values are shown as percentage decrease of expression levels of STMN2 with cryptic exon relative to corresponding value derived from 500 nM TDP43 AON treated cells.

Dose	QSN-31	QSN-41	QSN-46
5	-62	-19	27
20	-26	18	57
50	-12	45	57
200	-60	17	44
500	-36	-7	18

Table 17: Dose dependent effect of STMN2 AONs on expression levels of full length STMN2 transcript.

Dose	QSN-31		QSN-41		QSN-46	
	Relative Quantity ("rescued to")	Percent Increase of FL STMN2	Relative Quantity ("rescued to")	Percent Increase of FL STMN2	Relative Quantity ("rescued to")	Percent Increase of FL STMN2
5	0.50	167	0.51	127	0.49	121
20	0.56	187	0.53	132	0.62	156
50	0.57	191	0.60	149	0.69	171
200	0.58	195	0.69	173	0.75	189
500	0.82	274	0.72	180	0.80	201

[00434] FIGs. 34A, 34C, and 34E are bar graphs showing the results of RT-qPCR analysis of STMN2 transcript with cryptic exon mRNA expression in human motor neurons, which demonstrates reduction of the STMN2 transcript with cryptic exon mRNA levels using different

STMN2 AONs. FIG. 34B, 34D, and 34F are bar graphs showing the results of RT-qPCR analysis of STMN2 full-length mRNA levels, which demonstrates the restoration of the full-length STMN2 transcript using different STMN2 AONs. In particular, the STMN2 AONs tested included: QSN-146 (SEQ ID NO: 146), QSN-150 (SEQ ID NO: 150), QSN-169 (SEQ ID NO: 169), QSN-170 (SEQ ID NO: 170), QSN-171 (SEQ ID NO: 171), QSN-172 (SEQ ID NO: 172), and QSN-249 (SEQ ID NO: 249). The dotted line represents 500 nM TDP43 ASO only level of expression.

[00435] Table 18 shows the dose-dependent effect (percentage decrease) of STMN2 AONs on levels of expression of STMN2 with cryptic exon. Additionally, Table 19 shows the dose-dependent effect of STMN2 AONs on restoration of levels of full length STMN2 transcript.

Table 18: Dose dependent effect of STMN2 AONs on expression levels of STMN2 with cryptic exon. Values are shown as percentage decrease of expression levels of STMN2 with cryptic exon relative to corresponding value derived from 500 nM TDP43 AON treated cells.

Dose	QSN-146	QSN-150	QSN-169	QSN-170	QSN-171	QSN-172	QSN-249
5	2	18	4	8	14	20	-1
20	33	40	50	-10	29	18	19
50	34	62	27	47	20	20	35
200	83	87	77	64	76	71	80
500	66	82	92	53	77	75	92

Table 19: Dose dependent effect of STMN2 AONs on expression levels of full length STMN2 transcript.

Dose	QSN-146		QSN-150		QSN-169		QSN-170	
	Relative Quantity ("rescued to")	Percent Increase of FL STMN2	Relative Quantity ("rescued to")	Percent Increase of FL STMN2	Relative Quantity ("rescued to")	Percent Increase of FL STMN2	Relative Quantity ("rescued to")	Percent Increase of FL STMN2
5	0.37	82	0.51	113	0.52	115	0.52	108
20	0.52	115	0.67	148	0.72	159	0.53	111
50	0.61	136	0.71	157	0.62	139	0.72	149
200	0.92	204	0.94	208	0.95	211	0.85	177
500	0.75	166	0.92	205	1.08	240	0.87	181

Dose	QSN-171		QSN-172		QSN-249	
	Relative Quantity	Percent Increase	Relative Quantity	Percent Increase	Relative Quantity	Percent Increase

	("rescued to")	of FL STMN2	("rescued to")	of FL STMN2	("rescued to")	of FL STMN2
5	0.63	131	0.62	130	0.55	104
20	0.56	116	0.60	126	0.55	104
50	0.61	127	0.55	116	0.58	110
200	1.03	214	1.00	209	0.81	152
500	1.03	214	0.95	198	0.97	183

INCORPORATION BY REFERENCE

[00436] The entire disclosure of each of the patent documents and scientific articles cited
5 herein is incorporated by reference for all purposes.

EQUIVALENTS

[00437] The disclosure can be embodied in other specific forms without departing from the
essential characteristics thereof. The foregoing embodiments therefore are to be considered
illustrative rather than limiting on the disclosure described herein. The scope of the disclosure is
10 indicated by the appended claims rather than by the foregoing description, and all changes that
come within the meaning and range of equivalency of the claims are intended to be embraced
therein.

CLAIMS

WHAT IS CLAIMED IS:

1. A compound comprising an oligonucleotide comprising linked nucleosides with at least a 19 contiguous nucleobase sequence that is at least 90% complementary to an equal length portion
5 of a transcript with at least 90% identity to SEQ ID NO: 944, or to a contiguous 19 to 50 nucleobase portion of SEQ ID NO: 944, wherein at least one nucleoside linkage of the linked nucleosides is a non-natural linkage.
2. An oligonucleotide comprising linked nucleosides with at least a 19 contiguous nucleobase sequence that is at least 90% complementary to an equal length portion of a transcript
10 with at least 90% identity to SEQ ID NO: 944, or to a contiguous 19 to 50 nucleobase portion of SEQ ID NO: 944, wherein at least one nucleoside linkage of the linked nucleosides is a non-natural linkage.
3. The oligonucleotide of claim 1 or 2, wherein the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that shares at least 90% identity with an equal length portion
15 of any one of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432.
4. The oligonucleotide of any one of claims 1-3, wherein the nucleobase sequence comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that shares at least 90% identity with an equal length portion of any one of SEQ ID
20 NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432.
5. The oligonucleotide of any one of claims 1-3, wherein the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that shares at least 90% identity with an equal length portion of any one of SEQ ID NOs: 31, 36, 41, 46, 55, 144, 146, 150, 169, 170, 171, 172, 173, 177, 181, 185, 197, 203, 209, 215, 237, 244, 249, 252, 380, 385, 390, 395, 400, 975, 980,
25 985, 999, 1088, 1090, 1094, 1113, 1114, 1115, 1116, 1117, 1121, 1125, 1129, 1141, 1147, 1153, 1159, 1181, 1188, 1193, 1196, 1324, 1329, 1334, 1339, or 1344,.
6. The oligonucleotide of any one of claims 1-5, wherein the nucleobase sequence comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that shares at least 90% identity with an equal length portion of any one of SEQ ID
30 NOs: 31, 36, 41, 46, 55, 144, 146, 150, 169, 170, 171, 172, 173, 177, 181, 185, 197, 203, 209,

215, 237, 244, 249, 252, 380, 385, 390, 395, 400, 975, 980, 985, 999, 1088, 1090, 1094, 1113, 1114, 1115, 1116, 1117, 1121, 1125, 1129, 1141, 1147, 1153, 1159, 1181, 1188, 1193, 1196, 1324, 1329, 1334, 1339, or 1344.

7. A compound comprising an oligonucleotide comprising linked nucleosides with at least a
5 19 contiguous nucleobase sequence, wherein the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that shares at least 90% identity to an equal length portion of any one of SEQ ID NOs: 894-918 or SEQ ID NOs: 1392-1432.

8. An oligonucleotide comprising linked nucleosides with at least a 19 contiguous
10 nucleobase sequence, wherein the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that shares at least 90% identity to an equal length portion of any one of SEQ ID NOs: 894-918 or SEQ ID NOs: 1392-1432.

9. The oligonucleotide of claim 7 or 8, wherein the nucleobase sequence comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that shares at least 90% identity to of any one of SEQ ID NOs: 894-918 or SEQ ID NOs: 1392-1432.

10. A compound comprising an oligonucleotide comprising linked nucleosides with at least a
15 19 contiguous nucleobase sequence, wherein the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that is at least 90% complementary to an equal length portion of nucleobases within any one of positions 121-144, 144-168, 146-170, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192, 171-191, 171-193, 172-192, 172-194, 170-194,
20 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944.

11. An oligonucleotide comprising linked nucleosides with a nucleobase sequence with at least a 19 contiguous nucleobase sequence, wherein the nucleobase sequence comprises a portion of at least 10 contiguous nucleobases that is at least 90% complementary to an equal length
25 portion of nucleobases within any one of positions 121-144, 144-168, 146-170, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192, 171-191, 171-193, 172-192, 172-194, 170-194, 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944.

12. The oligonucleotide of claim 10 or 11, wherein the portion of the nucleobase sequence is
30 100% complementary to an equal length portion of nucleobases within any one of positions 121-

144, 144-168, 146-170, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192, 171-191, 171-193, 172-192, 172-194, 170-194, 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944.

13. The oligonucleotide of claim 12, wherein the portion of the nucleobase sequence is 100% complementary to an equal length portion of nucleobases within any one of positions 144-164, 144-166, 145-167, 146-166, 146-168, 147-165, or 148-168 of SEQ ID NO: 944.

14. The oligonucleotide of claim 12, wherein the portion of the nucleobase sequence is 100% complementary to an equal length portion of nucleobases within any one of positions 173-191, 173-193, 173-195, 173-197, 175-195, 175-197, 177-197, or 179-197 of SEQ ID NO: 944.

15. The oligonucleotide of claim 12, wherein the portion of the nucleobase sequence is 100% complementary to an equal length portion of nucleobases within any one of positions 185-205, 187-209, 189-209, 185-207, 197-217, 197-219, or 191-209 of SEQ ID NO: 944.

16. The oligonucleotide of claim 12, wherein the portion of the nucleobase sequence is 100% complementary to an equal length portion of nucleobases within any one of positions 237-255, 237-257, 237-259, 239-259, 239-261, 241-261, 237-257, 249-269, 249-271, 252-272, 252-274, or 243-261 of SEQ ID NO: 944.

17. The oligonucleotide of claim 10 or 11, wherein the nucleobase sequence comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that is complementary to an equal length portion of nucleobases within any one of positions 121-144, 144-168, 146-170, 150-170, 150-172, 150-174, 169-193, 169-189, 169-191, 170-190, 170-192, 171-191, 171-193, 172-192, 172-194, 170-194, 171-195, 172-196, 173-197, 185-209, 197-221, 237-261, 249-273, 252-276, or 276-300 of SEQ ID NO: 944.

18. The oligonucleotide of claim 10 or 11, wherein the nucleobase sequence comprises a portion of at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous nucleobases that is complementary to an equal length portion of nucleobases within any one of positions 144-164, 144-166, 145-167, 146-166, 146-168, 147-165, 148-168, 173-191, 173-193, 173-195, 173-197, 175-195, 175-197, 177-197, 179-197, 185-205, 185-207, 197-217, 197-219, 187-209, 189-209, 191-209, 237-255, 237-257, 237-259, 239-259, 239-261, 241-261, 237-257, 249-269, 249-271, 252-272, 252-274, or 243-261 of SEQ ID NO: 944.

19. The oligonucleotide of any one of claims 1-18, wherein the oligonucleotide is 19 and 40 nucleosides in length.

20. The oligonucleotide of any one of the above claims, wherein the oligonucleotide comprises at least one nucleoside linkage selected from the group consisting of a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a phosphorodithioate linkage, a phosphotriester linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothiate linkage, a phosphorodiamidate (*e.g.*, comprising a phosphorodiamidate morpholino (PMO), 3' amino ribose, or 5' amino ribose) linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage, or any combination(s) thereof.

21. The oligonucleotide of any one of the above claims, wherein at least two, three, or four internucleoside linkages of the oligonucleotide are phosphodiester internucleoside linkages.

22. The oligonucleotide of any one of claims 1-20, wherein the oligonucleotide comprises at least two, three, or four modified internucleoside linkages.

23. The oligonucleotide of claim 22, wherein each of the modified internucleoside linkage of the oligonucleotide is independently selected from a phosphorothioate linkage, a phosphoramidate linkage, a phosphoramidothiate linkage, a phosphorodiamidate.

24. The oligonucleotide of claim 22 or 23, wherein all internucleoside linkages of the oligonucleotide are phosphorothioate linkages.

25. The oligonucleotide of claim 23, wherein the phosphorothioate internucleoside linkage is in one of a *Rp* configuration or a *Sp* configuration.

26. The oligonucleotide of any one of the preceding claims, wherein the oligonucleotide comprises at least one modified nucleobase.

27. The oligonucleotide of claim 26, wherein the at least one modified nucleobase is 5-methyl cytosine, pseudouridine, or 5-methoxyuridine.

28. The oligonucleotide of any one of the preceding claims, wherein the oligonucleotide comprises at least one modified sugar moiety.

29. The modified oligonucleotide of claim 28, wherein the modified sugar moiety is one of a 2'-OMe modified sugar moiety, bicyclic sugar moiety, 2'-O-(2-methoxyethyl) (2'MOE), 2'-deoxy-2'-fluoro nucleoside, 2'-fluoro-β-D-arabinonucleoside, locked nucleic acid (LNA), constrained ethyl 2'-4'-bridged nucleic acid (cEt), S-cEt, hexitol nucleic acids (HNA), and tricyclic analog (*e.g.*, tcDNA).

30. The oligonucleotide of any one of claims 1-23, wherein the oligonucleotide comprises three linked nucleosides that are linked through phosphodiester internucleoside linkages at the 5' end and three linked nucleosides that are linked through phosphodiester internucleoside linkages at the 3' end.

31. The oligonucleotide of any one of claims 1-20 and 22-29, wherein the oligonucleotide comprises one or more 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides that are linked through phosphorothioate internucleoside linkages, optionally wherein all nucleosides in the oligonucleotide comprise modified sugar moiety comprising 2'-MOE; further optionally wherein all cytosine nucleosides in the oligonucleotide comprise modified nucleobase 5-methyl cytosine; and further optionally wherein all internucleoside linkages are phosphorothioate linkages.

32. The oligonucleotide of any one of claims 1-23 and 25-29, wherein the oligonucleotide comprises three linked nucleosides that are linked through phosphorothioate internucleoside linkages at the 5' end and three linked nucleosides that are linked through phosphorothioate internucleoside linkages at the 3' end.

33. The oligonucleotide of claim 32, wherein the oligonucleotide comprises five linked nucleosides that are linked through phosphodiester internucleoside linkages.

34. The oligonucleotide of claim 33, wherein the each of the five linked nucleosides are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

35. The oligonucleotide of claim 33 or 34, wherein each of the linked nucleosides of the oligonucleotide are 2'-O-(2-methoxyethyl) (2'-MOE) nucleosides.

36. The oligonucleotide of any one of claims 1-35, wherein the oligonucleotide exhibits at least a 30%, 40%, 50%, 60%, 70%, 80%, or 90% increase of full length STMN2 transcript or

STMN2 protein, optionally wherein the increase is in comparison to a level prior to exposing a neuron to the oligonucleotide.

37. The oligonucleotide of any one of claims 1-36, wherein the oligonucleotide exhibits at least a 100% increase of full length STMN2 transcript or STMN2 protein, optionally wherein the increase is in comparison to a level prior to exposing a neuron to the oligonucleotide.

38. The oligonucleotide of any one of claims 1-37, wherein the oligonucleotide exhibits at least a 200% increase of full length STMN2 transcript or STMN2 protein, optionally wherein the increase is in comparison to a level prior to exposing a neuron to the oligonucleotide.

39. The oligonucleotide of any one of claims 1-38, wherein the oligonucleotide exhibits at least a 300% increase of full length STMN2 transcript or STMN2 protein, optionally wherein the increase is in comparison to a level prior to exposing a neuron to the oligonucleotide.

40. The oligonucleotide of any one of claims 1-39, wherein the oligonucleotide exhibits at least a 400% increase of full length STMN2 transcript or STMN2 protein, optionally wherein the increase is in comparison to a level prior to exposing a neuron to the oligonucleotide.

41. The oligonucleotide of any one of claims 36-40, wherein increase of the full length STMN2 protein is measured in comparison to a reduced level of full length STMN2 protein achieved using a TDP43 antisense oligonucleotide.

42. The oligonucleotide of any one of claims 1-35, wherein the oligonucleotide exhibits at least a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% rescue of full length STMN2 transcript or STMN2 protein, optionally wherein the increase is in comparison to a level prior to exposing a neuron to the oligonucleotide.

43. The oligonucleotide of any one of claims 1-35 and 42, wherein the oligonucleotide exhibits at least a 50%, 60%, 70%, 80%, or 90% reduction of the STMN2 transcript with the cryptic exon.

44. A pharmaceutical composition comprising one or more of the oligonucleotides of any one of claims 1-43, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

45. A method of treating a neurological disease and/or a neuropathy in a patient in need thereof, the method comprising administering to the patient an oligonucleotide of any one of

claims 1-43 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 44.

46. The method of claim 45, wherein the neurological disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, and corticobasal degeneration (CBD).

47. The method of claim 45, wherein the neuropathy is chemotherapy induced neuropathy.

48. A method of restoring axonal outgrowth and/or regeneration of a motor neuron, the method comprising exposing the motor neuron to an oligonucleotide of any one of claims 1-43 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 44.

49. A method of increasing, promoting, stabilizing, or maintaining STMN2 expression and/or function in a neuron, the method comprising exposing the neuron to an oligonucleotide of any one of claims 1-43 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 44.

50. The method of claim 48 or 49, wherein the neuron is a neuron of a patient in need of treatment of a neurological disease and/or a neuropathy.

51. The method of claim 50, wherein the neurological disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, and corticobasal degeneration (CBD).

52. The method of claim 50, wherein the neuropathy is chemotherapy induced neuropathy.

53. The method of any one of claims 48-52, wherein the exposing is performed *in vivo* or *ex vivo*.

54. The method of any one of claims 48-52, wherein the exposing comprises administering the oligonucleotide to a patient determined to have a transcript comprising a cryptic exon sequence of SEQ ID NO: 447.

55. The method of any one of claims 45-54, wherein the oligonucleotide is administered topically, parenterally, intrathecally, intracisternally, orally, rectally, buccally, sublingually, vaginally, pulmonarily, intratracheally, intranasally, intralesionally, transdermally, or intraduodenally.

5 56. The method of claim 54, wherein the oligonucleotide is administered orally.

57. The method of any one of claims 45-54, wherein a therapeutically effective amount of the oligonucleotide is administered intrathecally or intracisternally.

58. The method of any one of claims 45-46 or 50-57, wherein the patient is a human.

10 59. The pharmaceutical composition of claim 44, wherein the pharmaceutical composition is suitable for topical, intrathecal, intracisternal, parenteral (*e.g.*, subcutaneous, intramuscular, intradermal, intraduodenal, or intravenous), intralesional, oral, pulmonary, intratracheal, intranasal, transdermal, rectal, buccal, sublingual, vaginal, or intraduodenal administration.

15 60. A use of an oligonucleotide of any one of claims 1-43 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 44 in the manufacture of a medicament for the treatment of neurological disease or a neuropathy.

20 61. The use of claim 60, wherein the neurological disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, and corticobasal degeneration (CBD).

62. The use of claim 60, wherein the neuropathy is chemotherapy induced neuropathy.

25 63. A method of treating a neurological disease or a neuropathy in a patient in need thereof, the method comprising administering to a patient in need thereof a therapeutically effective amount of an oligonucleotide of any one of claims 1-43 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 44.

64. The method of claim 63, wherein the neurological disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral

nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, and corticobasal degeneration (CBD).

65. The method of claim 63, wherein the neuropathy is chemotherapy induced neuropathy.

66. The method of any one of claims 63-65, wherein the oligonucleotide or the pharmaceutical composition is administered topically, parenterally (*e.g.*, subcutaneous, intramuscular, intradermal, intraduodenal, or intravenous), intralesionally, orally, pulmonarily, rectally, buccally, sublingually, vaginally, intratracheally, intranasally, intracisternally, intrathecally, transdermally, or intraduodenally.

67. The method of any one of claims 63-65, wherein the oligonucleotide or the pharmaceutical composition is administered intrathecally or intracisternally.

68. The method of any one of claims 63-67, wherein a therapeutically effective amount of the oligonucleotide or the pharmaceutical composition is administered intrathecally or intracisternally.

69. The method of any one of claims 63-68, wherein the patient is human.

70. An oligonucleotide of any one of claims 1-43, or a pharmaceutically acceptable salt thereof, for use as a medicament in the treatment of a neurological disease or a neuropathy.

71. An oligonucleotide of any one of claims 1-43, or a pharmaceutically acceptable salt thereof, for use in the treatment of a neurological disease or a neuropathy.

72. The oligonucleotide for use of claim 70 or 71, wherein said neurological disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, and corticobasal degeneration (CBD).

73. The oligonucleotide for use of claim 70 or 71, wherein the neuropathy is chemotherapy induced neuropathy.

74. An oligonucleotide comprising linked nucleosides with a nucleobase sequence of any one of SEQ ID NOs: 1-446, SEQ ID NOs: 894-918, SEQ ID NOs: 945-1390, or SEQ ID NOs: 1392-1432, or a pharmaceutically acceptable salt thereof;

wherein oligonucleotide comprises at least one nucleoside linkage selected from the group consisting of: a phosphodiester linkage, a phosphorothioate linkage, an alkyl phosphate linkage, an alkylphosphonate linkage, a 3-methoxypropyl phosphonate linkage, a phosphorodithioate linkage, a phosphotriester linkage, a methylphosphonate linkage, an aminoalkylphosphotriester linkage, an alkylene phosphonate linkage, a phosphinate linkage, a phosphoramidate linkage, a phosphoramidothiate linkage, a phosphorodiamidate linkage, an aminoalkylphosphoramidate linkage, a thiophosphoramidate linkage, a thionoalkylphosphonate linkage, a thionoalkylphosphotriester linkage, a thiophosphate linkage, a selenophosphate linkage, and a boranophosphate linkage; and/or

wherein at least one nucleoside of the linked nucleosides is substituted with a component selected from the group consisting of a 2'-*O*-(2-methoxyethyl) nucleoside (2'-*O*-methoxyethylribonucleosides (2'-MOE)), a 2'-*O*-methyl nucleoside, a 2'-deoxy-2'-fluoro nucleoside, a 2'-fluoro- β -D-arabinonucleoside, a locked nucleic acid (LNA), constrained methoxyethyl (cMOE), constrained ethyl (cET), and a peptide nucleic acid (PNA).

75. The oligonucleotide of claim 74, wherein at least one internucleoside linkage of the oligonucleotide is a phosphorothioate linkage.

76. The oligonucleotide of claim 74 or 75, wherein the oligonucleotide comprises three linked nucleosides that are linked through phosphodiester internucleoside linkages at the 5' end and three linked nucleosides that are linked through phosphodiester internucleoside linkages at the 3' end.

77. The oligonucleotide of any one of claims 74-76, wherein the oligonucleotide comprises one or more 2'-*O*-(2-methoxyethyl) nucleosides that are linked through phosphorothioate internucleoside linkages.

78. The oligonucleotide of claim 74 or 75, wherein the oligonucleotide comprises five linked nucleosides that are linked through phosphodiester internucleoside linkages.

79. The oligonucleotide of claim 78, wherein each of the five linked nucleosides are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides.

80. The oligonucleotide of any one of claims 74-79, wherein each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides.

81. The oligonucleotide of claim 74 or 75, wherein all internucleoside linkages of the oligonucleotide are phosphorothioate linkages, optionally wherein each of the linked nucleosides of the oligonucleotide are 2'-*O*-(2-methoxyethyl) (2'-MOE) nucleosides, further optionally wherein the oligonucleotide comprises at least one 5-methyl cytosine modified nucleobase.

5 82. A pharmaceutical composition comprising the oligonucleotide of any one of claims 73-81, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

83. An oligonucleotide of any one of claims 1-43 or a pharmaceutically acceptable salt thereof capable of increasing, restoring, or stabilizing expression of the STMN2 mRNA capable of translation of a functional STMN2 and/or activity and/or function of STMN2 protein in a cell or a
10 human patient suffering from a neurological disease or disorder, wherein the level of increase, restoration, or stabilization of expression and/or activity and/or function is sufficient for use of the oligonucleotide as a medicament for the treatment of neurological disease or disorder.

84. The oligonucleotide of any one of claims 1-43 comprising one or more chiral centers and/or double bonds.

15 85. The oligonucleotide of claim 84, wherein the oligonucleotide exist as stereoisomers selected from geometric isomers, enantiomers, and diastereomers.

86. A method of treating a neurological disease and/or a neuropathy in a patient in need thereof, the method comprising administering to a patient in need thereof a therapeutically effective amount of an oligonucleotide of any one of claims 1-43 or a pharmaceutically acceptable
20 salt thereof, or a pharmaceutical composition of claim 44, in combination with a second therapeutic agent selected from Riluzole (Rilutek), Edaravone (Radicava), rivastigmine, donepezil, galantamine, selective serotonin reuptake inhibitor, antipsychotic agents, cholinesterase inhibitors, memantine, benzodiazepine antianxiety drugs, AMX0035 (ELYBRIO), ZILUCOPLAN (RA101495), dual AON intrathecal administration (*e.g.*, BIIB067, BIIB078),
25 BIIB100, levodopa/carbidopa, dopaminergic agents (*e.g.*, ropinirole, pramipexole, rotigotine), medroxyprogesterone, KCNQ2/KCNQ3 openers, anticonvulsants and psychostimulant agents, and/or a therapy (*e.g.*, selected from breathing care, physical therapy, occupational therapy, speech therapy, nutritional support), for treating said neurologic disease.

87. The method of claim 86, wherein the neurological disease is selected from the group
30 consisting of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's

disease (AD), Parkinson's disease (PD), Huntington's disease, brachial plexus injuries, peripheral nerve injuries, progressive supranuclear palsy (PSP), brain trauma, spinal cord injury, and corticobasal degeneration (CBD).

88. The method of claim 86, wherein the neuropathy is chemotherapy induced neuropathy.

5 89. The method of any one of claims 45-58, 63-69, and 86-88, wherein patient for treatment is identified by measuring the presence or level of expression of neurofilament light (NEFL), neurofilament heavy (NEFH), phosphorylated neurofilament heavy chain (pNFH), TDP-43, or p75^{ECD} in the plasma, the spinal cord fluid, the cerebrospinal fluid, the extracellular vesicles (for example, CSF exosomes), the blood, the urine, the lymphatic fluid, fecal matter, or a tissue of the
10 patient.

90. The method of claim 89, wherein the patient for treatment is identified by measuring phosphorylated neurofilament heavy chain (pNFH) in cerebrospinal fluid (CSF).

91. The method of claim 90, wherein the pNFH in the CSF of the patient is used to predict disease status and survival in *C9ORF72*-associated amyotrophic lateral sclerosis (c9ALS) patients
15 after initial administration and/or during on-going treatment.




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 2




FIG. 3




FIG. 4




FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B




FIG. 12A




FIG. 12B




FIG. 13A




FIG. 13B




FIG. 14A






FIG. 14B






FIG. 16




FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B




FIG. 19A




FIG. 19B





FIG. 20A



FILE 2023




FIG. 21A




FIG. 21B




FIG. 22A




FIG. 22B




FIG. 23




FIG. 24A






FIG. 24B






FIG. 27A




FIG. 27B





FIG. 28A






FIG. 29A




FIG. 29B




FIG. 30




FIG. 31A





FIG. 31B






FIG. 33A




FIG. 33B




FIG. 34A




FIG. 34B




FIG. 34C




FIG. 34D




FIG. 34E




FIG. 34F

SEQUENCE LISTING

<110> QURALIS CORPORATION

<120> OLIGONUCLEOTIDES AND METHODS OF USE FOR TREATING NEUROLOGICAL DISEASES

<130> QRL-002WO

<140>

<141>

<150> 62/949,817

<151> 2019-12-18

<150> 62/914,252

<151> 2019-10-11

<150> 62/856,264

<151> 2019-06-03

<160> 1449

<170> PatentIn version 3.5

<210> 1

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1

ggagggatac ctgtatatta caagt

25

<210> 2

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 2

aggagggata cctgtatatt acaag

25

<210> 3

<211> 25

<212> DNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 3
 caggagggat acctgtatat tacaa 25

<210> 4
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 4
 ccaggaggga tacctgtata ttaca 25

<210> 5
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 5
 accaggaggg atacctgtat attac 25

<210> 6
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 6
 taccaggagg gatacctgta tatta 25

<210> 7
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 7

ttaccaggag ggatacctgt atatt

25

<210> 8

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 8

cttaccagga gggatacctg tatat

25

<210> 9

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 9

gcttaccagg agggatacct gtata

25

<210> 10

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 10

agcttaccag gagggatacc tgtat

25

<210> 11

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 11
gagcttacca ggagggatac ctgta 25

<210> 12
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 12
agagcttacc aggaggata cctgt 25

<210> 13
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 13
cagagcttac caggaggat acctg 25

<210> 14
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 14
ccagagctta ccaggaggga tacct 25

<210> 15
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 15

accagagctt accaggaggg atacc 25

<210> 16

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 16

taccagagct taccaggagg gatac 25

<210> 17

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 17

ataccagagc ttaccaggag ggata 25

<210> 18

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 18

aataccagag cttaccagga gggat 25

<210> 19

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 19

taataccaga gcttaccagg aggga 25

<210> 20
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 20
 ataataccag agcttaccag gaggg 25

 <210> 21
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 21
 cataatacca gagcttacca ggagg 25

 <210> 22
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 22
 acataatacc agagcttacc aggag 25

 <210> 23
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 23
 gacataatac cagagcttac cagga 25

 <210> 24

<211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 24
 agacataata ccagagctta ccagg 25

 <210> 25
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 25
 aagacataat accagagctt accag 25

 <210> 26
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 26
 taagacataa taccagagct tacca 25

 <210> 27
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 27
 ttaagacata ataccagagc ttacc 25

 <210> 28
 <211> 25
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 28

gttaagacat aataccagag cttac

25

<210> 29

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 29

tgtaagaca taataccaga gctta

25

<210> 30

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 30

atgttaagac ataataccag agctt

25

<210> 31

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 31

aatgttaaga cataatacca gagct

25

<210> 32

<211> 25

<212> DNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 32
 aaatgttaag acataatacc agagc 25

<210> 33
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 33
 aaaatgttaa gacataatac cagag 25

<210> 34
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 34
 aaaaatgtta agacataata ccaga 25

<210> 35
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 35
 taaaaatgtt aagacataat accag 25

<210> 36
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 36
ttaaaaatgt taagacataa tacca 25

<210> 37
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 37
tttaaaaatg ttaagacata atacc 25

<210> 38
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 38
atttaaaaat gttaagacat aatac 25

<210> 39
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 39
gatttaaaaa tgtaagaca taata 25

<210> 40
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 40
agatttaaaa atgttaagac ataat 25

<210> 41
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 41
tagatttaaa aatgttaaga cataa 25

<210> 42
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 42
atagatttaa aaatgttaag acata 25

<210> 43
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 43
catagattta aaaatgttaa gacat 25

<210> 44
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 44
ccatagattt aaaaatgtta agaca 25

<210> 45
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 45
 accatagatt taaaaatggt aagac 25

 <210> 46
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 46
 taccatagat ttaaaaatgt taaga 25

 <210> 47
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 47
 ttaccataga tttaaaaatg ttaag 25

 <210> 48
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 48
 attaccatag atttaaaaat gttaa 25

<210> 49
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 49
 gattaccata gatttaaaaa tgтта 25

 <210> 50
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 50
 agattaccat agatttaaaa atgтт 25

 <210> 51
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 51
 aagattacca tagatttaaa aatgt 25

 <210> 52
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 52
 aaagattacc atagatttaa aaatg 25

 <210> 53
 <211> 25

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 53
 taaagattac catagattta aaaat 25

 <210> 54
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 54
 gtaaagatta ccatagattt aaaaa 25

 <210> 55
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 55
 tgtaaagatt accatagatt taaaa 25

 <210> 56
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 56
 ttgtaaagat taccatagat ttaaa 25

 <210> 57
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 57
 tttgtaaaga ttaccataga tttaa 25

<210> 58
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 58
 ttttgtaaag attaccatag attta 25

<210> 59
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 59
 attttgtaaa gattaccata gattt 25

<210> 60
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 60
 tattttgtaa agattaccat agatt 25

<210> 61
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 61

atattttgta aagattacca tagat

25

<210> 62

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 62

aatattttgt aaagattacc ataga

25

<210> 63

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 63

aaatattttg taaagattac catag

25

<210> 64

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 64

aaaatatttt gtaaagatta ccata

25

<210> 65

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 65
taaaatattt tgtaaagatt accat 25

<210> 66
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 66
gtaaaatatt ttgtaaagat tacca 25

<210> 67
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 67
agtaaaatat tttgtaaaga ttacc 25

<210> 68
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 68
aagtaaaata ttttgtaaag attac 25

<210> 69
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 69

gaagtaaaat attttgtaaa gatta 25

<210> 70

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 70

ggaagtaaaa tatTTtgtaa agatt 25

<210> 71

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 71

cggaagtaaa atatTTtgta aagat 25

<210> 72

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 72

tcggaagtaa aatatTTtgT aaaga 25

<210> 73

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 73

ttcggaagta aaatatTTtg taaag 25

<210> 74
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 74
 gttcggagt aaaatatttt gtaaa 25

 <210> 75
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 75
 agttcggag taaaatattt tgtaa 25

 <210> 76
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 76
 gagttcgga gtaaaatatt ttgta 25

 <210> 77
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 77
 tgagttcgga agtaaaatat tttgt 25

 <210> 78

<211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 78
 atgagttcgg aagtaaaata ttttg 25

 <210> 79
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 79
 tatgagttcg gaagtaaaat atttt 25

 <210> 80
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 80
 atatgagttc ggaagtaaaa tattt 25

 <210> 81
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 81
 tatatgagtt cggaagtaaa atatt 25

 <210> 82
 <211> 25
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 82

gtatatgagt tcggaagtaa aatat

25

<210> 83

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 83

ggtatatgag ttcggaagta aaata

25

<210> 84

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 84

aggtatatga gttcggaagt aaaat

25

<210> 85

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 85

caggtatatg agttcggaag taaaa

25

<210> 86

<211> 25

<212> DNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 86
 ccaggtatat gagttcggaa gtaaa 25

<210> 87
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 87
 cccaggtata tgagttcgga agtaa 25

<210> 88
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 88
 ccccaggtat atgagttcgg aagta 25

<210> 89
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 89
 tccccaggta tatgagttcg gaagt 25

<210> 90
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 90
atccccaggt atatgagttc ggaag 25

<210> 91
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 91
aatccccagg tatatgagtt cggaa 25

<210> 92
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 92
aaatccccag gtatatgagt tcgga 25

<210> 93
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 93
aaaatcccca ggtatatgag ttcgg 25

<210> 94
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 94
taaaatcccc aggtatatga gttcg 25

<210> 95
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 95
ataaaatccc caggtatatg agttc 25

<210> 96
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 96
aataaaatcc ccaggtatat gagtt 25

<210> 97
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 97
taataaaatc cccaggtata tgagt 25

<210> 98
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 98
gtaataaaat ccccaggtat atgag 25

<210> 99
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 99
 agtaataaaa tccccaggta tatga 25

 <210> 100
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 100
 gagtaataaa atccccagggt atatg 25

 <210> 101
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 101
 agagtaataa aatccccagg tatat 25

 <210> 102
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 102
 cagagtaata aaatccccag gtata 25

<210> 103	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 103	
ccagagtaat aaaatcccca ggtat	25
<210> 104	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 104	
cccagagtaa taaaatcccc aggta	25
<210> 105	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 105	
tcccagagta ataaaatccc caggt	25
<210> 106	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 106	
ttcccagagt aataaaatcc ccagg	25
<210> 107	
<211> 25	

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 107
 attcccagag taataaaatc cccag 25

 <210> 108
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 108
 aattcccaga gtaataaaat cccca 25

 <210> 109
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 109
 taattcccag agtaataaaa tcccc 25

 <210> 110
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 110
 ataattccca gagtaataaa atccc 25

 <210> 111
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 111
 cataattccc agagtaataa aatcc 25

<210> 112
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 112
 acataattcc cagagtaata aaatc 25

<210> 113
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 113
 cacataattc ccagagtaat aaaat 25

<210> 114
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 114
 acacataatt cccagagtaa taaaa 25

<210> 115
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 115

aacacataat tcccagagta ataaa

25

<210> 116

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 116

gaacacataa ttcccagagt aataa

25

<210> 117

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 117

agaacacata attcccagag taata

25

<210> 118

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 118

cagaacacat aattcccaga gtaat

25

<210> 119

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 119
gcagaacaca taattcccag agtaa 25

<210> 120
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 120
ggcagaacac ataattccca gagta 25

<210> 121
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 121
gggcagaaca cataattccc agagt 25

<210> 122
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 122
ggggcagaac acataattcc cagag 25

<210> 123
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 123

tggggcagaa cacataattc ccaga 25

<210> 124

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 124

atggggcaga acacataatt cccag 25

<210> 125

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 125

gatggggcag aacacataat tccca 25

<210> 126

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 126

tgatggggca gaacacataa ttccc 25

<210> 127

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 127

gtgatggggc agaacacata attcc 25

<210> 128
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 128
 agtgatgggg cagaacacat aattc 25

 <210> 129
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 129
 gaggatggg gcagaacaca taatt 25

 <210> 130
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 130
 agaggatgg ggcagaacac ataatt 25

 <210> 131
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 131
 gagaggatg gggcagaaca cataa 25

 <210> 132

<211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 132
 agagagtgat ggggcagaac acata 25

 <210> 133
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 133
 gagagagtga tggggcagaa cacat 25

 <210> 134
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 134
 agagagagtg atggggcaga acaca 25

 <210> 135
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 135
 aagagagagt gatggggcag aacac 25

 <210> 136
 <211> 25
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 136

taagagagag tgatggggca gaaca

25

<210> 137

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 137

ttaagagaga gtgatggggc agaac

25

<210> 138

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 138

attaagagag agtgatgggg cagaa

25

<210> 139

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 139

aattaagaga gaggatggg gcaga

25

<210> 140

<211> 25

<212> DNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 140
 caattaagag agagtgatgg ggcag 25

<210> 141
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 141
 ccaattaaga gagagtgatg gggca 25

<210> 142
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 142
 tccaattaag agagagtgat ggggc 25

<210> 143
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 143
 atccaattaa gagagagtga tgggg 25

<210> 144
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 144
aatccaatta agagagagtg atggg 25

<210> 145
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 145
aaatccaatt aagagagagt gatgg 25

<210> 146
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 146
aaaatccaat taagagagag tgatg 25

<210> 147
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 147
aaaaatccaa ttaagagaga gtgat 25

<210> 148
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 148
taaaaatcca attaagagag agtga 25

<210> 149
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 149
ttaaaaatcc aattaagaga gagtg 25

<210> 150
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 150
tttaaaaatc caattaagag agagt 25

<210> 151
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 151
ttttaaaaat ccaattaaga gagag 25

<210> 152
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 152
attttaaaaa tccaattaag agaga 25

<210> 153	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 153	
aattttaaaa atccaattaa gagag	25
<210> 154	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 154	
taattttaaa aatccaatta agaga	25
<210> 155	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 155	
ataattttaa aaatccaatt aagag	25
<210> 156	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 156	
tataatttta aaaatccaat taaga	25

<210> 157
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 157
 atataatttt aaaaatccaa ttaag 25

 <210> 158
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 158
 aatataattt taaaaatcca attaa 25

 <210> 159
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 159
 gaatataatt ttaaaaatcc aatta 25

 <210> 160
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 160
 tgaatataat tttaaaaatc caatt 25

 <210> 161
 <211> 25

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 161
 atgaatataa ttttaaaaat ccaat 25

 <210> 162
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 162
 tatgaatata attttaaaaa tccaa 25

 <210> 163
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 163
 atatgaatat aattttaaaa atcca 25

 <210> 164
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 164
 aatatgaata taattttaaa aatcc 25

 <210> 165
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 165
 caatatgaat ataattttaa aaatc 25

<210> 166
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 166
 gcaatatgaa tataatttta aaaat 25

<210> 167
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 167
 tgcaatatga atataatttt aaaaa 25

<210> 168
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 168
 ctgcaatatg aatataattt taaaa 25

<210> 169
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 169

cctgcaatat gaatataatt ttaaa

25

<210> 170

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 170

tcctgcaata tgaatataat tttaa

25

<210> 171

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 171

gtcctgcaat atgaatataa tttta

25

<210> 172

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 172

agtcctgcaa tatgaatata atttt

25

<210> 173

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 173
gagtcctgca atatgaatat aattt 25

<210> 174
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 174
cgagtcctgc aatatgaata taatt 25

<210> 175
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 175
ccgagtcctg caatatgaat ataatt 25

<210> 176
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 176
gccgagtcct gcaatatgaa tataa 25

<210> 177
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 177

tgccgagtc tgcaatatga atata 25

<210> 178

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 178

ctgccgagtc ctgcaatatg aatat 25

<210> 179

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 179

tctgccgagt cctgcaatat gaata 25

<210> 180

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 180

ttctgccgag tcctgcaata tgaat 25

<210> 181

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 181

cttctgccga gtcctgcaat atgaa 25

<210> 182
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 182
tcttctgccg agtcctgcaa tatga 25

<210> 183
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 183
gtcttctgcc gagtcctgca atatg 25

<210> 184
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 184
ggtcttctgc cgagtcctgc aatat 25

<210> 185
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 185
aggtcttctg ccgagtcctg caata 25

<210> 186

<211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 186
 aaggtcttct gccgagtcct gcaat 25

 <210> 187
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 187
 gaaggtcttc tgccgagtcc tgcaa 25

 <210> 188
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 188
 cgaaggtctt ctgccgagtc ctgca 25

 <210> 189
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 189
 tcgaaggtct tctgccgagt cctgc 25

 <210> 190
 <211> 25
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 190

ctcgaaggtc ttctgccgag tcctg

25

<210> 191

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 191

tctcgaaggt cttctgccga gtcct

25

<210> 192

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 192

ctctcgaagg tcttctgccg agtcc

25

<210> 193

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 193

tctctcgaag gtcttctgcc gagtc

25

<210> 194

<211> 25

<212> DNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 194
 ttctctcgaa ggtcttctgc cgagt 25

<210> 195
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 195
 tttctctcga aggtcttctg ccgag 25

<210> 196
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 196
 ctttctctcg aaggtcttct gccga 25

<210> 197
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 197
 cctttctctc gaaggtcttc tgccg 25

<210> 198
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 198
acctttctct cgaaggtctt ctgcc 25

<210> 199
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 199
tacctttctc tcgaaggtct tctgc 25

<210> 200
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 200
ctacctttct ctcgaaggtc ttctg 25

<210> 201
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 201
tctacctttc tctcgaaggt cttct 25

<210> 202
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 202
ttctaccttt ctctcgaagg tcttc 25

<210> 203
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 203
tttctacctt tctctcgaag gtctt 25

<210> 204
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 204
ttttctacct ttctctcgaa ggtct 25

<210> 205
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 205
atthttctacc tttctctcga aggtc 25

<210> 206
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 206
tattttctac ctttctctcg aaggt 25

<210> 207	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 207	
ttattttcta cttttctctc gaagg	25
<210> 208	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 208	
cttattttct acctttctct cgaag	25
<210> 209	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 209	
tcttattttc tacctttctc tcgaa	25
<210> 210	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 210	
ttcttatttt ctacctttct ctcga	25

<210> 211
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 211
 attcttattt tctacctttc tctcg 25

 <210> 212
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 212
 aattcttatt ttctaccttt ctctc 25

 <210> 213
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 213
 aaattcttat tttctacctt tctct 25

 <210> 214
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 214
 caaattctta ttttctacct ttctc 25

 <210> 215
 <211> 25

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 215
 ccaaattctt attttctacc tttct 25

 <210> 216
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 216
 gccaaattct tatTTTctac ctttc 25

 <210> 217
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 217
 agccaaattc ttatTTTcta ctttt 25

 <210> 218
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 218
 gagccaaatt cttatTTTct acctt 25

 <210> 219
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 219
 agagccaaat tcttattttc tacct
 25

<210> 220
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 220
 gagagccaaa ttcttatttt ctacc
 25

<210> 221
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 221
 agagagccaa attcttattt tctac
 25

<210> 222
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 222
 cagagagcca aattcttatt ttcta
 25

<210> 223
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 223

acagagagcc aaattcttat tttct

25

<210> 224

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 224

cacagagagc caaattctta ttttc

25

<210> 225

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 225

acacagagag ccaaattctt atttt

25

<210> 226

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 226

cacacagaga gccaaattct ttttt

25

<210> 227

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 227
tcacacagag agccaaattc ttatt 25

<210> 228
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 228
ctcacacaga gagccaaatt cttat 25

<210> 229
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 229
gctcacacag agagccaaat tctta 25

<210> 230
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 230
tgctcacaca gagagccaaa ttctt 25

<210> 231
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 231

atgctcacac agagagccaa attct 25

<210> 232

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 232

catgctcaca cagagagcca aattc 25

<210> 233

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 233

acatgctcac acagagagcc aaatt 25

<210> 234

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 234

cacatgctca cacagagagc caaat 25

<210> 235

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 235

acacatgctc acacagagag ccaaa 25

<210> 236
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 236
cacacatgct cacacagaga gccaa 25

<210> 237
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 237
gcacacatgc tcacacagag agcca 25

<210> 238
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 238
cgcacacatg ctcacacaga gagcc 25

<210> 239
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 239
acgcacacat gctcacacag agagc 25

<210> 240

<211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 240
 cacgcacaca tgctcacaca gagag 25

 <210> 241
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 241
 acacgcacac atgctcacac agaga 25

 <210> 242
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 242
 cacacgcaca catgctcaca cagag 25

 <210> 243
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 243
 acacacgcac acatgctcac acaga 25

 <210> 244
 <211> 25
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 244

cacacacgca cacatgctca cacag

25

<210> 245

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 245

gcacacacgc acacatgctc acaca

25

<210> 246

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 246

cgcacacacg cacacatgct cacac

25

<210> 247

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 247

tcgcacacac gcacacatgc tcaca

25

<210> 248

<211> 25

<212> DNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 248
 ctcgcacaca cgcacacatg ctcac 25

<210> 249
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 249
 tctcgcacac acgcacacat gctca 25

<210> 250
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 250
 ctctcgaca cacgcacaca tgctc 25

<210> 251
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 251
 tctctcgac acacgcacac atgct 25

<210> 252
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 252
ctctctcgca cacacgcaca catgc 25

<210> 253
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 253
tctctctcgc acacacgcac acatg 25

<210> 254
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 254
ctctctctcg cacacacgca cacat 25

<210> 255
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 255
tctctctctc gcacacacgc acaca 25

<210> 256
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 256
ctctctctct cgcacacacg cacac 25

<210> 257
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 257
tctctctctc tcgcacacac gcaca 25

<210> 258
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 258
gtctctctct ctcgcacaca cgcac 25

<210> 259
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 259
tgtctctctc tctcgcacac acgca 25

<210> 260
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 260
ctgtctctct ctctcgcaca cacgc 25

<210> 261
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 261
 tctgtctctc tctctcgac acacg 25

<210> 262
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 262
 gtctgtctct ctctctcgca cacac 25

<210> 263
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 263
 tgtctgtctc tctctctcgc acaca 25

<210> 264
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 264
 ctgtctgtct ctctctctcg cacac 25

<210> 265
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 265
 gctgtctgtc tctctctctc gcaca 25

<210> 266
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 266
 ggctgtctgt ctctctctct cgcac 25

<210> 267
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 267
 aggctgtctg tctctctctc tcgca 25

<210> 268
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 268
 caggctgtct gtctctctct ctcgc 25

<210> 269
 <211> 25

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 269
 gcaggctgtc tgtctctctc tctcg 25

 <210> 270
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 270
 ggaggctgt ctgtctctct ctctc 25

 <210> 271
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 271
 aggcaggctg tctgtctctc tctct 25

 <210> 272
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 272
 taggcaggct gtctgtctct ctctc 25

 <210> 273
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 273
 ttaggcaggc tgtctgtctc tctct 25

<210> 274
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 274
 cttaggcagg ctgtctgtct ctctc 25

<210> 275
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 275
 tcttaggcag gctgtctgtc tctct 25

<210> 276
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 276
 ttcttaggca ggctgtctgt ctctc 25

<210> 277
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 277

cttcttaggc aggctgtctg tctct

25

<210> 278

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 278

tcttcttagg caggctgtct gtctc

25

<210> 279

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 279

ttcttcttag gcaggctgtc tgtct

25

<210> 280

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 280

tttcttctta ggcaggctgt ctgtc

25

<210> 281

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 281
atttcttctt aggcaggctg tctgt 25

<210> 282
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 282
catttcttct taggcaggct gtctg 25

<210> 283
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 283
tcatttcttc ttaggcaggc tgtct 25

<210> 284
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 284
ttcatttctt ctaggcagg ctgtc 25

<210> 285
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 285

attcatttct tcttaggcag gctgt 25

<210> 286

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 286

cattcatttc ttcttaggca ggctg 25

<210> 287

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 287

acattcattt cttcttaggc aggct 25

<210> 288

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 288

cacattcatt tcttcttagg caggc 25

<210> 289

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 289

tcacattcat ttcttcttag gcagg 25

<210> 290
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 290
 ttcacattca tttcttctta ggcag 25

 <210> 291
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 291
 attcacattc atttcttctt aggca 25

 <210> 292
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 292
 cattcacatt catttcttct taggc 25

 <210> 293
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 293
 gcattcacat tcatttcttc ttagg 25

 <210> 294

<211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 294
 cgcatcacca ttcatttctt cttag 25

 <210> 295
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 295
 ccgcattcac attcatttct tctta 25

 <210> 296
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 296
 gccgcattca cattcatttc ttctt 25

 <210> 297
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 297
 agccgcattc acattcattt cttct 25

 <210> 298
 <211> 25
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 298

aagccgcatt cacattcatt tcttc

25

<210> 299

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 299

caagccgcat tcacattcat ttctt

25

<210> 300

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 300

acaagccgca ttcacattca tttct

25

<210> 301

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 301

cacaagccgc attcacattc atttc

25

<210> 302

<211> 25

<212> DNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 302
 ccacaagccg cattcacatt cattt 25

<210> 303
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 303
 gccacaagcc gcattcacat tcatt 25

<210> 304
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 304
 tgccacaagc cgcattcacat ttcatt 25

<210> 305
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 305
 gtgccacaag ccgcattcac attca 25

<210> 306
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 306
tgtgccacaa gccgcattca cattc 25

<210> 307
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 307
ctgtgccaca agccgcattc acatt 25

<210> 308
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 308
actgtgccac aagccgcatt cacat 25

<210> 309
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 309
aactgtgcca caagccgcat tcaca 25

<210> 310
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 310
caactgtgcc acaagccgca ttcac 25

<210> 311
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 311
tcaactgtgc cacaagccgc attca 25

<210> 312
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 312
gtcaactgtg ccacaagccg cattc 25

<210> 313
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 313
tgtcaactgt gccacaagcc gcatt 25

<210> 314
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 314
ttgtcaactg tgccacaagc cgcatt 25

<210> 315	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 315	
cttgtcaact gtgccacaag ccgca	25
<210> 316	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 316	
ccttgtcaac tgtgccacaa gccgc	25
<210> 317	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 317	
tccttgtcaa ctgtgccaca agccg	25
<210> 318	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 318	
atccttgtca actgtgccac aagcc	25

<210> 319
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 319
 catccttgtc aactgtgcca caagc 25

 <210> 320
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 320
 tcatccttgt caactgtgcc acaag 25

 <210> 321
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 321
 atcatccttg tcaactgtgc caca 25

 <210> 322
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 322
 tatcatcctt gtcaactgtg ccaca 25

 <210> 323
 <211> 25

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 323
 ttatcatcct tgtcaactgt gccac 25

 <210> 324
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 324
 tttatcatcc ttgtcaactg tgcca 25

 <210> 325
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 325
 atttatcatc cttgtcaact gtgcc 25

 <210> 326
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 326
 gatttatcat ccttgtcaac tgtgc 25

 <210> 327
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 327
 tgatttatca tccttgtaa ctgtg 25

<210> 328
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 328
 ttgatttatc atccttgta actgt 25

<210> 329
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 329
 attgatttat catccttgta aactg 25

<210> 330
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 330
 tattgattta tcaccttgta caact 25

<210> 331
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 331

ttattgattt atcatccttg tcaac

25

<210> 332

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 332

attattgatt tatcatcctt gtcaa

25

<210> 333

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 333

cattattgat ttatcatcct tgtca

25

<210> 334

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 334

gcattattga tttatcatcc ttgtc

25

<210> 335

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 335
tgcattattg atttatcatc cttgt 25

<210> 336
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 336
ttgcattatt gatttatcat ccttg 25

<210> 337
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 337
cttgcattat tgatttatca tcctt 25

<210> 338
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 338
gcttgcatta ttgatttatc atcct 25

<210> 339
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 339

agcttgcat attgatttat catcc 25

<210> 340

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 340

aagcttgcat tattgattta tcac 25

<210> 341

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 341

taagcttgca ttattgattt atcat 25

<210> 342

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 342

gtaagcttgc attattgatt tatca 25

<210> 343

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 343

agtaagcttg cattattgat ttac 25

<210> 344
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 344
tagtaagctt gcattattga tttat 25

<210> 345
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 345
atagtaagct tgcattattg attta 25

<210> 346
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 346
gatagtaagc ttgcattatt gattt 25

<210> 347
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 347
tgatagtaag cttgcattat tgatt 25

<210> 348

<211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 348
 atgatagtaa gcttgcatta ttgat 25

 <210> 349
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 349
 aatgatagta agcttgcatt attga 25

 <210> 350
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 350
 aaatgatagt aagcttgcatt tattg 25

 <210> 351
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 351
 taaatgatag taagcttgca ttatt 25

 <210> 352
 <211> 25
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 352

ataaatgata gtaagcttgc attat

25

<210> 353

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 353

cataaatgat agtaagcttg catta

25

<210> 354

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 354

tcataaatga tagtaagctt gcatt

25

<210> 355

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 355

ttcataaatg atagtaagct tgcatt

25

<210> 356

<211> 25

<212> DNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 356
 attcataaat gatagtaagc ttgca 25

<210> 357
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 357
 tattcataaa tgatagtaag cttgc 25

<210> 358
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 358
 ctattcataa atgatagtaa gcttg 25

<210> 359
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 359
 gctattcata aatgatagta agctt 25

<210> 360
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 360
tgctattcat aaatgatagt aagct 25

<210> 361
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 361
ttgctattca taaatgatag taagc 25

<210> 362
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 362
attgctattc ataaatgata gtaag 25

<210> 363
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 363
tattgctatt cataaatgat agtaa 25

<210> 364
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 364
gtattgctat tcataaatga tagta 25

<210> 365
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 365
agtattgcta ttcataaatg atagt 25

<210> 366
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 366
cagtattgct attcataaat gatag 25

<210> 367
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 367
tcagtattgc tattcataaa tgata 25

<210> 368
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 368
ttcagtattg ctattcataa atgat 25

<210> 369	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 369	
cttcagtatt gctattcata aatga	25
<210> 370	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 370	
tcttcagtat tgctattcat aaatg	25
<210> 371	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 371	
ttcttcagta ttgctattca taaat	25
<210> 372	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 372	
tttcttcagt attgctattc ataaa	25

<210> 373
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 373
 atttcttcag tattgctatt cataa 25

 <210> 374
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 374
 aatttcttca gtattgctat tcata 25

 <210> 375
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 375
 taatttcttc agtattgcta ttcata 25

 <210> 376
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 376
 ttaatttctt cagtattgct attca 25

 <210> 377
 <211> 25

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 377
 tttaatttct tcagtattgc tattc 25

 <210> 378
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 378
 ttttaatttc ttcagtattg ctatt 25

 <210> 379
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 379
 gttttaattt cttcagtatt gctat 25

 <210> 380
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 380
 tgttttaatt tcttcagtat tgcta 25

 <210> 381
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 381
 ttgttttaat ttcttcagta ttgct 25

<210> 382
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 382
 tttgttttaa tttcttcagt attgc 25

<210> 383
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 383
 ttttgtttta atttcttcag tattg 25

<210> 384
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 384
 cttttgtttt aatttcttca gtatt 25

<210> 385
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 385

tcttttggtt taatttcttc agtat

25

<210> 386

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 386

atcttttggt ttaatttctt cagta

25

<210> 387

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 387

aatcttttgt tttaatttct tcagt

25

<210> 388

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 388

caatcttttg tttaatttct ttcag

25

<210> 389

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 389
gcaatctttt gttttaattt cttca 25

<210> 390
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 390
agcaatcttt tgttttaatt tcttc 25

<210> 391
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 391
cagcaatctt ttgttttaatt ttctt 25

<210> 392
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 392
acagcaatct tttgttttaa tttct 25

<210> 393
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 393

gacagcaatc ttttgtttta atttc 25

<210> 394

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 394

agacagcaat cttttgtttt aattt 25

<210> 395

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 395

gagacagcaa tcttttgttt taatt 25

<210> 396

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 396

tgagacagca atcttttggtt ttaat 25

<210> 397

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 397

ttgagacagc aatcttttgt tttaa 25

<210> 398
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 398
 attgagacag caatcttttg tttta 25

<210> 399
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 399
 tattgagaca gcaatctttt gtttt 25

<210> 400
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 400
 atattgagac agcaatcttt tgttt 25

<210> 401
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 401
 tatattgaga cagcaatctt ttgtt 25

<210> 402

<211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 402
 atatattgag acagcaatct tttgt 25

 <210> 403
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 403
 gatatattga gacagcaatc ttttg 25

 <210> 404
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 404
 agatatattg agacagcaat ctttt 25

 <210> 405
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 405
 aagatatatt gagacagcaa tcttt 25

 <210> 406
 <211> 25
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 406

taagatatat tgagacagca atctt

25

<210> 407

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 407

ataagatata ttgagacagc aatct

25

<210> 408

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 408

tataagatat attgagacag caatc

25

<210> 409

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 409

atataagata tattgagaca gcaat

25

<210> 410

<211> 25

<212> DNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 410
 aatataagat atattgagac agcaa 25

<210> 411
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 411
 aaatataaga tatattgaga cagca 25

<210> 412
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 412
 taaatataag atatattgag acagc 25

<210> 413
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 413
 ataaatataa gatatttga gacag 25

<210> 414
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 414
aataaatata agatatattg agaca 25

<210> 415
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 415
taataaatat aagatatatt gagac 25

<210> 416
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 416
ataataaata taagatatat tgaga 25

<210> 417
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 417
aataataaat ataagatata ttgag 25

<210> 418
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 418
aaataataaa tataagatat attga 25

<210> 419
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 419
taaataataa atataagata tattg 25

<210> 420
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 420
gtaaataata aatataagat atatt 25

<210> 421
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 421
ggtaaataat aatataaga tatat 25

<210> 422
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 422
tggtaaataa taaatataag atata 25

<210> 423	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 423	
ttggtaaata ataaatataa gatat	25
<210> 424	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 424	
tttggtaaat aataaatata agata	25
<210> 425	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 425	
atttggtaaa taataaatat aagat	25
<210> 426	
<211> 25	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 426	
aatttggtaa ataataaata taaga	25

<210> 427
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 427
 taatttggt aataataaat ataag 25

 <210> 428
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 428
 ataatttggt aaataataaa tataa 25

 <210> 429
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 429
 aataatttg taaataataa atata 25

 <210> 430
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 430
 gaataatttg gtaaataata aatat 25

 <210> 431
 <211> 25

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 431
 agaataattt ggtaaataat aaata 25

 <210> 432
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 432
 tagaataatt tggtaaataa taaat 25

 <210> 433
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 433
 ttagaataat ttggtaaata ataaa 25

 <210> 434
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 434
 cttagaataa tttggtaaata aataa 25

 <210> 435
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 435
 tcttagaata atttggtaaa taata 25

<210> 436
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 436
 ctcttagaat aatttggtaa ataata 25

<210> 437
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 437
 actcttagaa taatttggt aataa 25

<210> 438
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 438
 tactcttaga ataatttggt aaata 25

<210> 439
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 439

atactcttag aataatttg taaat

25

<210> 440

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 440

aataacttta gaataatttg gtaaa

25

<210> 441

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 441

aaataactctt agaataattt ggtaa

25

<210> 442

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 442

gaaataactct tagaataatt tggta

25

<210> 443

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 443
agaaatactc ttagaataat ttggt 25

<210> 444
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 444
aagaaatact cttagaataa tttgg 25

<210> 445
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 445
gaagaaatac tcttagaata atttg 25

<210> 446
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 446
ggaagaaata ctcttagaat aattt 25

<210> 447
<211> 227
<212> DNA
<213> Homo sapiens

<400> 447
gactcggcag aagaccttcg agagaaaggt agaaaataag aatttggctc tctgtgtgag 60

catgtgtgcg tgtgtgagag agagagagac agacagcctg cctaagaaga aatgaatgtg 120

aatgcggctt gtggcacagt tgacaaggat gataaatcaa taatgcaagc ttactatcat 180
ttatgaatag caatactgaa gaaattaaaa caaaagattg ctgtctc 227

<210> 448
<211> 25
<212> DNA
<213> Homo sapiens

<400> 448
acttgtaata tacaggtatc cctcc 25

<210> 449
<211> 25
<212> DNA
<213> Homo sapiens

<400> 449
cttgtaatat acaggtatcc ctcct 25

<210> 450
<211> 25
<212> DNA
<213> Homo sapiens

<400> 450
ttgtaatata caggtatccc tcctg 25

<210> 451
<211> 25
<212> DNA
<213> Homo sapiens

<400> 451
tgtaatatata aggtatccct cctgg 25

<210> 452
<211> 25
<212> DNA
<213> Homo sapiens

<400> 452
gtaatatata ggtatccctc ctggt 25

<210> 453
<211> 25
<212> DNA
<213> Homo sapiens

<400> 453
taatatacag gtatccctcc tggta 25

<210> 454
<211> 25
<212> DNA
<213> Homo sapiens

<400> 454
aatatacagg tatccctcct ggtaa 25

<210> 455
<211> 25
<212> DNA
<213> Homo sapiens

<400> 455
atatacaggt atccctcctg gtaag 25

<210> 456
<211> 25
<212> DNA
<213> Homo sapiens

<400> 456
tatacaggt tccctcctgg taagc 25

<210> 457
<211> 25
<212> DNA
<213> Homo sapiens

<400> 457
atacaggtat ccctcctgggt aagct 25

<210> 458
<211> 25
<212> DNA
<213> Homo sapiens

<400> 458
tacaggtatc cctcctggta agctc 25

<210> 459
<211> 25
<212> DNA
<213> Homo sapiens

<400> 459
acaggtatcc ctctggtaa gctct 25

<210> 460
<211> 25
<212> DNA
<213> Homo sapiens

<400> 460
caggtatccc tcctggtaag ctctg 25

<210> 461
<211> 25
<212> DNA
<213> Homo sapiens

<400> 461
aggtatccct cctggtaagc tctgg 25

<210> 462
<211> 25
<212> DNA
<213> Homo sapiens

<400> 462
ggtatccctc ctggaagct ctggt 25

<210> 463
<211> 25
<212> DNA
<213> Homo sapiens

<400> 463
gtatccctcc tggaagctc tggta 25

<210> 464
<211> 25
<212> DNA
<213> Homo sapiens

<400> 464
tatccctcct ggtaagctct ggtat 25

<210> 465
<211> 25
<212> DNA
<213> Homo sapiens

<400> 465
atccctcctg gtaagctctg gtatt 25

<210> 466
<211> 25
<212> DNA
<213> Homo sapiens

<400> 466
tccctcctgg taagctctgg tatta 25

<210> 467
<211> 25
<212> DNA
<213> Homo sapiens

<400> 467
ccctcctggt aagctctggt attat 25

<210> 468
<211> 25
<212> DNA
<213> Homo sapiens

<400> 468
cctcctggta agctctggta ttatg 25

<210> 469
<211> 25
<212> DNA
<213> Homo sapiens

<400> 469
ctcctggtaa gctctggtat tatgt 25

<210> 470
<211> 25
<212> DNA
<213> Homo sapiens

<400> 470
tcctggtgtaag ctctggtatt atgtc 25

<210> 471
<211> 25
<212> DNA
<213> Homo sapiens

<400> 471
cctggtaagc tctggtatta tgtct 25

<210> 472
<211> 25
<212> DNA
<213> Homo sapiens

<400> 472
ctggtaagct ctggtattat gtctt 25

<210> 473
<211> 25
<212> DNA
<213> Homo sapiens

<400> 473
tggttaagctc tggtattatg tctta 25

<210> 474
<211> 25
<212> DNA
<213> Homo sapiens

<400> 474
ggtaagctct ggtattatgt cttaa 25

<210> 475
<211> 25
<212> DNA
<213> Homo sapiens

<400> 475
gtaagctctg gtattatgtc ttaac 25

<210> 476
<211> 25
<212> DNA
<213> Homo sapiens

<400> 476
taagctctgg tattatgtct taaca 25

<210> 477
<211> 25
<212> DNA
<213> Homo sapiens

<400> 477
aagctctgggt attatgtctt aacat 25

<210> 478
<211> 25
<212> DNA
<213> Homo sapiens

<400> 478
agctctggta ttatgtctta acatt 25

<210> 479
<211> 25
<212> DNA
<213> Homo sapiens

<400> 479
gctctgggtat tatgtcttaa cattt 25

<210> 480
<211> 25
<212> DNA
<213> Homo sapiens

<400> 480
ctcttggtatt atgtcttaac atttt 25

<210> 481
<211> 25
<212> DNA
<213> Homo sapiens

<400> 481
tctggtatta tgtcttaaca ttttt 25

<210> 482
<211> 25
<212> DNA
<213> Homo sapiens

<400> 482
ctggtattat gtcttaacat tttta 25

<210> 483
<211> 25
<212> DNA
<213> Homo sapiens

<400> 483
tggtattatg tcttaacatt tttaa 25

<210> 484
<211> 25
<212> DNA
<213> Homo sapiens

<400> 484
ggtattatgt cttacattt ttaaa 25

<210> 485
<211> 25
<212> DNA
<213> Homo sapiens

<400> 485
gtattatgtc ttaacattt taaat 25

<210> 486
<211> 25
<212> DNA
<213> Homo sapiens

<400> 486
tattatgtct taacattttt aaatc 25

<210> 487
<211> 25
<212> DNA
<213> Homo sapiens

<400> 487
attatgtctt aacattttta aatct 25

<210> 488
<211> 25
<212> DNA
<213> Homo sapiens

<400> 488
ttatgtctta acatttttaa atcta 25

<210> 489
<211> 25
<212> DNA
<213> Homo sapiens

<400> 489
tatgtcttaa catttttaaa tctat 25

<210> 490
<211> 25
<212> DNA
<213> Homo sapiens

<400> 490
atgtcttaac attttttaaat ctatg 25

<210> 491
<211> 25
<212> DNA
<213> Homo sapiens

<400> 491
tgtcttaaca tttttaaatc tatgg 25

<210> 492
<211> 25
<212> DNA
<213> Homo sapiens

<400> 492
gtcttaacat ttttaaatct atggt 25

<210> 493
<211> 25
<212> DNA
<213> Homo sapiens

<400> 493
tcttaacatt ttttaaatcta tggta 25

<210> 494
<211> 25
<212> DNA
<213> Homo sapiens

<400> 494
cttaacattt tttaaatctat ggtaa 25

<210> 495
<211> 25
<212> DNA
<213> Homo sapiens

<400> 495
ttaacatttt taaatctatg gtaat 25

<210> 496
<211> 25
<212> DNA
<213> Homo sapiens

<400> 496
taacattttt aaatctatgg taatc 25

<210> 497
<211> 25
<212> DNA
<213> Homo sapiens

<400> 497
aacattttta aatctatggt aatct 25

<210> 498
<211> 25
<212> DNA
<213> Homo sapiens

<400> 498
acatttttaa atctatggta atctt 25

<210> 499
<211> 25
<212> DNA
<213> Homo sapiens

<400> 499
catttttaaa tctatggtaa tcttt 25

<210> 500
<211> 25
<212> DNA
<213> Homo sapiens

<400> 500
atttttaaat ctatggtaat cttta 25

<210> 501
<211> 25
<212> DNA
<213> Homo sapiens

<400> 501
tttttaaadc tatggtaadc ttac 25

<210> 502
<211> 25
<212> DNA
<213> Homo sapiens

<400> 502
ttttaaatct atggtaatct ttaca 25

<210> 503
<211> 25
<212> DNA
<213> Homo sapiens

<400> 503
tttaaatcta tggtaatctt taca 25

<210> 504
<211> 25
<212> DNA
<213> Homo sapiens

<400> 504
ttaaatctat ggtaatcttt acaaa 25

<210> 505
<211> 25
<212> DNA
<213> Homo sapiens

<400> 505
taaacttatg gtaatcttta caaaa 25

<210> 506
<211> 25
<212> DNA
<213> Homo sapiens

<400> 506
aatctatgg taatctttac aaaat 25

<210> 507
<211> 25
<212> DNA
<213> Homo sapiens

<400> 507
aatctatgggt aatctttaca aaata 25

<210> 508
<211> 25
<212> DNA
<213> Homo sapiens

<400> 508
atctatggta atctttacaa aatat 25

<210> 509
<211> 25
<212> DNA
<213> Homo sapiens

<400> 509
tctatggtaa tctttacaaa atatt 25

<210> 510
<211> 25
<212> DNA
<213> Homo sapiens

<400> 510
ctatggtaat ctttacaaaa tattt 25

<210> 511
<211> 25
<212> DNA
<213> Homo sapiens

<400> 511
tatggtaatc ttacaaaat atttt 25

<210> 512
<211> 25
<212> DNA
<213> Homo sapiens

<400> 512
atggtaatct ttacaaaata tttta 25

<210> 513
<211> 25
<212> DNA
<213> Homo sapiens

<400> 513
tggtaatctt tacaaaatat ttac 25

<210> 514
<211> 25
<212> DNA
<213> Homo sapiens

<400> 514
ggtaatcttt acaaaatatt ttact 25

<210> 515
<211> 25
<212> DNA
<213> Homo sapiens

<400> 515
gtaatcttta caaaatattt tactt 25

<210> 516
<211> 25
<212> DNA
<213> Homo sapiens

<400> 516
taatctttac aaaatatttt acttc 25

<210> 517
<211> 25
<212> DNA
<213> Homo sapiens

<400> 517
aatctttaca aaatatttta ctcc 25

<210> 518
<211> 25
<212> DNA
<213> Homo sapiens

<400> 518
atctttacaa aatattttac ttccg 25

<210> 519
<211> 25
<212> DNA
<213> Homo sapiens

<400> 519
tctttacaaa atattttact tccga 25

<210> 520
<211> 25
<212> DNA
<213> Homo sapiens

<400> 520
ctttacaaaa tatatttactt ccgaa 25

<210> 521
<211> 25
<212> DNA
<213> Homo sapiens

<400> 521
tttacaaaat attttacttc cgaac 25

<210> 522
<211> 25
<212> DNA
<213> Homo sapiens

<400> 522
ttacaaaata ttttacttcc gaact 25

<210> 523
<211> 25
<212> DNA
<213> Homo sapiens

<400> 523
tacaaaatat tttacttccg aactc 25

<210> 524
<211> 25
<212> DNA
<213> Homo sapiens

<400> 524
acaaaatatt ttacttccga actca 25

<210> 525
<211> 25
<212> DNA
<213> Homo sapiens

<400> 525
caaaatattt tacttccgaa ctcac 25

<210> 526
<211> 25
<212> DNA
<213> Homo sapiens

<400> 526
aaaatatttt acttccgaac tcata 25

<210> 527
<211> 25
<212> DNA
<213> Homo sapiens

<400> 527
aaatatttta cttccgaact catat 25

<210> 528
<211> 25
<212> DNA
<213> Homo sapiens

<400> 528
aatattttac ttccgaactc atata 25

<210> 529
<211> 25
<212> DNA
<213> Homo sapiens

<400> 529
atattttact tccgaactca tatac 25

<210> 530
<211> 25
<212> DNA
<213> Homo sapiens

<400> 530
tattttactt ccgaactcat atacc 25

<210> 531
<211> 25
<212> DNA
<213> Homo sapiens

<400> 531
attttacttc cgaactcata tacct 25

<210> 532
<211> 25
<212> DNA
<213> Homo sapiens

<400> 532
ttttacttcc gaactcatat acctg 25

<210> 533
<211> 25
<212> DNA
<213> Homo sapiens

<400> 533
tttacttccg aactcatata cctgg 25

<210> 534
<211> 25
<212> DNA
<213> Homo sapiens

<400> 534
ttacttccga actcatatac ctggg 25

<210> 535
<211> 25
<212> DNA
<213> Homo sapiens

<400> 535
tacttccgaa ctcataacc tgggg 25

<210> 536
<211> 25
<212> DNA
<213> Homo sapiens

<400> 536
acttccgaac tcatatacct gggga 25

<210> 537
<211> 25
<212> DNA
<213> Homo sapiens

<400> 537
cttccgaact catatacctg gggat 25

<210> 538
<211> 25
<212> DNA
<213> Homo sapiens

<400> 538
ttccgaactc atatacctgg ggatt 25

<210> 539
<211> 25
<212> DNA
<213> Homo sapiens

<400> 539
tccgaactca tatacctggg gattt 25

<210> 540
<211> 25
<212> DNA
<213> Homo sapiens

<400> 540
ccgaactcat atacctgggg atttt 25

<210> 541
<211> 25
<212> DNA
<213> Homo sapiens

<400> 541
cgaactcata tacctgggga tttta 25

<210> 542
<211> 25
<212> DNA
<213> Homo sapiens

<400> 542
gaactcatat acctggggat tttat 25

<210> 543
<211> 25
<212> DNA
<213> Homo sapiens

<400> 543
aactcatata cctggggatt ttatt 25

<210> 544
<211> 25
<212> DNA
<213> Homo sapiens

<400> 544
actcatatac ctggggattt tatta 25

<210> 545
<211> 25
<212> DNA
<213> Homo sapiens

<400> 545
ctcatatacc tggggatttt attac 25

<210> 546
<211> 25
<212> DNA
<213> Homo sapiens

<400> 546
tcatatacct ggggatttta ttact 25

<210> 547
<211> 25
<212> DNA
<213> Homo sapiens

<400> 547
catatacctg gggattttat tactc 25

<210> 548
<211> 25
<212> DNA
<213> Homo sapiens

<400> 548
atatacctgg ggattttatt actct 25

<210> 549
<211> 25
<212> DNA
<213> Homo sapiens

<400> 549
tataacctggg gattttatta ctctg 25

<210> 550
<211> 25
<212> DNA
<213> Homo sapiens

<400> 550
ataacctgggg attttattac tctgg 25

<210> 551
<211> 25
<212> DNA
<213> Homo sapiens

<400> 551
tacctgggga ttttattact ctggg 25

<210> 552
<211> 25
<212> DNA
<213> Homo sapiens

<400> 552
acctggggat tttattactc tggga 25

<210> 553
<211> 25
<212> DNA
<213> Homo sapiens

<400> 553
cctggggatt ttattactct gggaa 25

<210> 554
<211> 25
<212> DNA
<213> Homo sapiens

<400> 554
ctggggattt tattactctg ggaat 25

<210> 555
<211> 25
<212> DNA
<213> Homo sapiens

<400> 555
tggggattttt attactctgg gaatt 25

<210> 556
<211> 25
<212> DNA
<213> Homo sapiens

<400> 556
ggggatttta ttactctggg aatta 25

<210> 557
<211> 25
<212> DNA
<213> Homo sapiens

<400> 557
gggattttat tactctggga attat 25

<210> 558
<211> 25
<212> DNA
<213> Homo sapiens

<400> 558
ggattttatt actctgggaa ttatg 25

<210> 559
<211> 25
<212> DNA
<213> Homo sapiens

<400> 559
gattttatta ctctgggaat tatgt 25

<210> 560
<211> 25
<212> DNA
<213> Homo sapiens

<400> 560
attttattac tctgggaatt atgtg 25

<210> 561
<211> 25
<212> DNA
<213> Homo sapiens

<400> 561
ttttattact ctgggaatta tgtgt 25

<210> 562
<211> 25
<212> DNA
<213> Homo sapiens

<400> 562
tttattactc tgggaattat gtgtt 25

<210> 563
<211> 25
<212> DNA
<213> Homo sapiens

<400> 563
ttattactct gggaattatg tgttc 25

<210> 564
<211> 25
<212> DNA
<213> Homo sapiens

<400> 564
tattactctg ggaattatgt gttct 25

<210> 565
<211> 25
<212> DNA
<213> Homo sapiens

<400> 565
attactctgg gaattatgtg ttctg 25

<210> 566
<211> 25
<212> DNA
<213> Homo sapiens

<400> 566
ttactctggg aattatgtgt tctgc 25

<210> 567
<211> 25
<212> DNA
<213> Homo sapiens

<400> 567
tactctggga attatgtgtt ctgcc 25

<210> 568
<211> 25
<212> DNA
<213> Homo sapiens

<400> 568
actctgggaa ttatgtgttc tgccc 25

<210> 569
<211> 25
<212> DNA
<213> Homo sapiens

<400> 569
ctctgggaat tatgtgttct gcccc 25

<210> 570
<211> 25
<212> DNA
<213> Homo sapiens

<400> 570
tctgggaatt atgtgttctg cccca 25

<210> 571
<211> 25
<212> DNA
<213> Homo sapiens

<400> 571
ctgggaatta tgtgttctgc cccat 25

<210> 572
<211> 25
<212> DNA
<213> Homo sapiens

<400> 572
tgggaattat gtgttctgcc ccatc 25

<210> 573
<211> 25
<212> DNA
<213> Homo sapiens

<400> 573
gggaattatg tgttctgccc catca 25

<210> 574
<211> 25
<212> DNA
<213> Homo sapiens

<400> 574
ggaattatgt gttctgcccc atcac 25

<210> 575
<211> 25
<212> DNA
<213> Homo sapiens

<400> 575
gaattatgtg ttctgcccc tcact 25

<210> 576
<211> 25
<212> DNA
<213> Homo sapiens

<400> 576
aattatgtgt tctgccccat cactc 25

<210> 577
<211> 25
<212> DNA
<213> Homo sapiens

<400> 577
attatgtgtt ctgccccatc actct 25

<210> 578
<211> 25
<212> DNA
<213> Homo sapiens

<400> 578
ttatgtgttc tgccccatca ctctc 25

<210> 579
<211> 25
<212> DNA
<213> Homo sapiens

<400> 579
tatgtgttct gccccatcac tctct 25

<210> 580
<211> 25
<212> DNA
<213> Homo sapiens

<400> 580
atgtgttctg ccccatcact ctctc 25

<210> 581
<211> 25
<212> DNA
<213> Homo sapiens

<400> 581
tgtgttctgc cccatcactc tctct 25

<210> 582
<211> 25
<212> DNA
<213> Homo sapiens

<400> 582
gtgttctgcc ccatcactct ctctt 25

<210> 583
<211> 25
<212> DNA
<213> Homo sapiens

<400> 583
tgttctgccc catcactctc tctta 25

<210> 584
<211> 25
<212> DNA
<213> Homo sapiens

<400> 584
gttctgcccc atcactctct cttaa 25

<210> 585
<211> 25
<212> DNA
<213> Homo sapiens

<400> 585
ttctgccccca tcactctctc ttaat 25

<210> 586
<211> 25
<212> DNA
<213> Homo sapiens

<400> 586
tctgccccat cactctctct taatt 25

<210> 587
<211> 25
<212> DNA
<213> Homo sapiens

<400> 587
ctgccccatc actctctctt aattg 25

<210> 588
<211> 25
<212> DNA
<213> Homo sapiens

<400> 588
tgccccatca ctctctctta attgg 25

<210> 589
<211> 25
<212> DNA
<213> Homo sapiens

<400> 589
gccccatcac tctctcttaa ttgga 25

<210> 590
<211> 25
<212> DNA
<213> Homo sapiens

<400> 590
cccatcact ctctcttaat tggat 25

<210> 591
<211> 25
<212> DNA
<213> Homo sapiens

<400> 591
cccatcactc tctcttaatt ggatt 25

<210> 592
<211> 25
<212> DNA
<213> Homo sapiens

<400> 592
ccatcactct ctcttaattg gattt 25

<210> 593
<211> 25
<212> DNA
<213> Homo sapiens

<400> 593
catcactctc tcttaattgg atttt 25

<210> 594
<211> 25
<212> DNA
<213> Homo sapiens

<400> 594
atcactctct cttaattgga ttttt 25

<210> 595
<211> 25
<212> DNA
<213> Homo sapiens

<400> 595
tcactctctc ttaattggat tttta 25

<210> 596
<211> 25
<212> DNA
<213> Homo sapiens

<400> 596
cactctctct taattggatt tttta 25

<210> 597
<211> 25
<212> DNA
<213> Homo sapiens

<400> 597
actctctctt aattggattt ttaaa 25

<210> 598
<211> 25
<212> DNA
<213> Homo sapiens

<400> 598
ctctctctta attggatttt taaaa 25

<210> 599
<211> 25
<212> DNA
<213> Homo sapiens

<400> 599
tctctcttaa ttggattttt aaaat 25

<210> 600
<211> 25
<212> DNA
<213> Homo sapiens

<400> 600
ctctcttaat tggattttta aaatt 25

<210> 601
<211> 25
<212> DNA
<213> Homo sapiens

<400> 601
tctcttaatt ggatttttaa aatta 25

<210> 602
<211> 25
<212> DNA
<213> Homo sapiens

<400> 602
ctcttaattg gattttttaa attat 25

<210> 603
<211> 25
<212> DNA
<213> Homo sapiens

<400> 603
tcttaattgg atttttaaaa ttata 25

<210> 604
<211> 25
<212> DNA
<213> Homo sapiens

<400> 604
cttaattgga tttttaaaat tatat 25

<210> 605
<211> 25
<212> DNA
<213> Homo sapiens

<400> 605
ttaattggat ttttaaaatt atatt 25

<210> 606
<211> 25
<212> DNA
<213> Homo sapiens

<400> 606
taattggatt tttaaaatta tattc 25

<210> 607
<211> 25
<212> DNA
<213> Homo sapiens

<400> 607
aattggattt ttaaaattat attca 25

<210> 608
<211> 25
<212> DNA
<213> Homo sapiens

<400> 608
attggatttt taaaattata ttcac 25

<210> 609
<211> 25
<212> DNA
<213> Homo sapiens

<400> 609
ttggattttt aaaattatat tcata 25

<210> 610
<211> 25
<212> DNA
<213> Homo sapiens

<400> 610
tggattttta aaattatatt catat 25

<210> 611
<211> 25
<212> DNA
<213> Homo sapiens

<400> 611
ggatttttaa aattatattc atatt 25

<210> 612
<211> 25
<212> DNA
<213> Homo sapiens

<400> 612
gatttttaaa attatattca tattg 25

<210> 613
<211> 25
<212> DNA
<213> Homo sapiens

<400> 613
atttttaaaa ttatattcat attgc 25

<210> 614
<211> 25
<212> DNA
<213> Homo sapiens

<400> 614
tttttaaaat tatattcata ttgca 25

<210> 615
<211> 25
<212> DNA
<213> Homo sapiens

<400> 615
ttttaaaatt atattcatat tgcag 25

<210> 616
<211> 25
<212> DNA
<213> Homo sapiens

<400> 616
tttaaaatta tattcatatt gcagg 25

<210> 617
<211> 25
<212> DNA
<213> Homo sapiens

<400> 617
ttaaaattat attcatattg cagga 25

<210> 618
<211> 25
<212> DNA
<213> Homo sapiens

<400> 618
taaaattata ttcattattgc aggac 25

<210> 619
<211> 25
<212> DNA
<213> Homo sapiens

<400> 619
aaaattatat tcatattgca ggact 25

<210> 620
<211> 25
<212> DNA
<213> Homo sapiens

<400> 620
aaattatatt catattgcag gactc 25

<210> 621
<211> 25
<212> DNA
<213> Homo sapiens

<400> 621
aattatattc atattgcagg actcg 25

<210> 622
<211> 25
<212> DNA
<213> Homo sapiens

<400> 622
attatattca tattgcagga ctcgg 25

<210> 623
<211> 25
<212> DNA
<213> Homo sapiens

<400> 623
ttatattcat attgcaggac tcggc 25

<210> 624
<211> 25
<212> DNA
<213> Homo sapiens

<400> 624
tatattcata ttgcaggact cggca 25

<210> 625
<211> 25
<212> DNA
<213> Homo sapiens

<400> 625
atattcatat tgcaggactc ggcag 25

<210> 626
<211> 25
<212> DNA
<213> Homo sapiens

<400> 626
tattcatatt gcaggactcg gcaga 25

<210> 627
<211> 25
<212> DNA
<213> Homo sapiens

<400> 627
attcatattg caggactcgg cagaa 25

<210> 628
<211> 25
<212> DNA
<213> Homo sapiens

<400> 628
ttcatattgc aggactcggc agaag 25

<210> 629
<211> 25
<212> DNA
<213> Homo sapiens

<400> 629
tcatattgca ggactcggca gaaga 25

<210> 630
<211> 25
<212> DNA
<213> Homo sapiens

<400> 630
catattgcag gactcggcag aagac 25

<210> 631
<211> 25
<212> DNA
<213> Homo sapiens

<400> 631
atattgcagg actcggcaga agacc 25

<210> 632
<211> 25
<212> DNA
<213> Homo sapiens

<400> 632
tattgcagga ctcggcagaa gacct 25

<210> 633
<211> 25
<212> DNA
<213> Homo sapiens

<400> 633
attgcaggac tcggcagaag acctt 25

<210> 634
<211> 25
<212> DNA
<213> Homo sapiens

<400> 634
ttgcaggact cggcagaaga ccttc 25

<210> 635
<211> 25
<212> DNA
<213> Homo sapiens

<400> 635
tgcaggactc ggcagaagac cttcg 25

<210> 636
<211> 25
<212> DNA
<213> Homo sapiens

<400> 636
gcaggactcg gcagaagacc ttcga 25

<210> 637
<211> 25
<212> DNA
<213> Homo sapiens

<400> 637
caggactcgg cagaagacct tcgag 25

<210> 638
<211> 25
<212> DNA
<213> Homo sapiens

<400> 638
aggactcggc agaagacctt cgaga 25

<210> 639
<211> 25
<212> DNA
<213> Homo sapiens

<400> 639
ggactcggca gaagaccttc gagag 25

<210> 640
<211> 25
<212> DNA
<213> Homo sapiens

<400> 640
gactcggcag aagaccttcg agaga 25

<210> 641
<211> 25
<212> DNA
<213> Homo sapiens

<400> 641
actcggcaga agaccttcga gagaa 25

<210> 642
<211> 25
<212> DNA
<213> Homo sapiens

<400> 642
ctcggcagaa gaccttcgag agaaa 25

<210> 643
<211> 25
<212> DNA
<213> Homo sapiens

<400> 643
tcggcagaag accttcgaga gaaag 25

<210> 644
<211> 25
<212> DNA
<213> Homo sapiens

<400> 644
cggcagaaga ccttcgagag aaagg 25

<210> 645
<211> 25
<212> DNA
<213> Homo sapiens

<400> 645
ggcagaagac cttcgagaga aaggt 25

<210> 646
<211> 25
<212> DNA
<213> Homo sapiens

<400> 646
gcagaagacc ttcgagagaa aggta 25

<210> 647
<211> 25
<212> DNA
<213> Homo sapiens

<400> 647
cagaagacct tcgagagaaa ggtag 25

<210> 648
<211> 25
<212> DNA
<213> Homo sapiens

<400> 648
agaagacctt cgagagaaag gtaga 25

<210> 649
<211> 25
<212> DNA
<213> Homo sapiens

<400> 649
gaagaccttc gagagaaagg tagaa 25

<210> 650
<211> 25
<212> DNA
<213> Homo sapiens

<400> 650
aagaccttcg agagaaaggt agaaa 25

<210> 651
<211> 25
<212> DNA
<213> Homo sapiens

<400> 651
agaccttcga gagaaaggta gaaaa 25

<210> 652
<211> 25
<212> DNA
<213> Homo sapiens

<400> 652
gaccttcgag agaaaggtag aaaat 25

<210> 653
<211> 25
<212> DNA
<213> Homo sapiens

<400> 653
accttcgaga gaaaggtaga aaata 25

<210> 654
<211> 25
<212> DNA
<213> Homo sapiens

<400> 654
ccttcgagag aaaggtagaa aataa 25

<210> 655
<211> 25
<212> DNA
<213> Homo sapiens

<400> 655
cttcgagaga aaggtagaaa ataag 25

<210> 656
<211> 25
<212> DNA
<213> Homo sapiens

<400> 656
ttcgagagaa aggtagaaaa taaga 25

<210> 657
<211> 25
<212> DNA
<213> Homo sapiens

<400> 657
tcgagagaaa ggtagaaaat aagaa 25

<210> 658
<211> 25
<212> DNA
<213> Homo sapiens

<400> 658
cgagagaaag gtagaaaata agaatt 25

<210> 659
<211> 25
<212> DNA
<213> Homo sapiens

<400> 659
gagagaaagg tagaaaataa gaatt 25

<210> 660
<211> 25
<212> DNA
<213> Homo sapiens

<400> 660
agagaaaggt agaaaataag aattt 25

<210> 661
<211> 25
<212> DNA
<213> Homo sapiens

<400> 661
gagaaaggta gaaaataaga atttg 25

<210> 662
<211> 25
<212> DNA
<213> Homo sapiens

<400> 662
agaaaggtag aaaataagaa tttgg 25

<210> 663
<211> 25
<212> DNA
<213> Homo sapiens

<400> 663
gaaaggtaga aaataagaat ttggc 25

<210> 664
<211> 25
<212> DNA
<213> Homo sapiens

<400> 664
aaaggtagaa aataagaatt tggct 25

<210> 665
<211> 25
<212> DNA
<213> Homo sapiens

<400> 665
aaggtagaaa ataagaattt ggctc 25

<210> 666
<211> 25
<212> DNA
<213> Homo sapiens

<400> 666
aggtagaaaa taagaatttg gctct 25

<210> 667
<211> 25
<212> DNA
<213> Homo sapiens

<400> 667
ggtagaaaat aagaatttgg ctctc 25

<210> 668
<211> 25
<212> DNA
<213> Homo sapiens

<400> 668
gtagaaaata agaatttggc tctct 25

<210> 669
<211> 25
<212> DNA
<213> Homo sapiens

<400> 669
tagaaaataa gaatttggct ctctg 25

<210> 670
<211> 25
<212> DNA
<213> Homo sapiens

<400> 670
agaaaataag aatttggctc tctgt 25

<210> 671
<211> 25
<212> DNA
<213> Homo sapiens

<400> 671
gaaaataaga atttggctct ctgtg 25

<210> 672
<211> 25
<212> DNA
<213> Homo sapiens

<400> 672
aaaataagaa tttggctctc tgtgt 25

<210> 673
<211> 25
<212> DNA
<213> Homo sapiens

<400> 673
aaataagaat ttggctctct gtgtg 25

<210> 674
<211> 25
<212> DNA
<213> Homo sapiens

<400> 674
aataagaatt tggctctctg tgtga 25

<210> 675
<211> 25
<212> DNA
<213> Homo sapiens

<400> 675
ataagaattt ggctctctgt gtgag 25

<210> 676
<211> 25
<212> DNA
<213> Homo sapiens

<400> 676
taagaatttg gctctctgtg tgagc 25

<210> 677
<211> 25
<212> DNA
<213> Homo sapiens

<400> 677
aagaatttgg ctctctgtgt gagca 25

<210> 678
<211> 25
<212> DNA
<213> Homo sapiens

<400> 678
agaatttggc tctctgtgtg agcat 25

<210> 679
<211> 25
<212> DNA
<213> Homo sapiens

<400> 679
gaatttggct ctctgtgtga gcatg 25

<210> 680
<211> 25
<212> DNA
<213> Homo sapiens

<400> 680
aatttggctc tctgtgtgag catgt 25

<210> 681
<211> 25
<212> DNA
<213> Homo sapiens

<400> 681
atttggctct ctgtgtgagc atgtg 25

<210> 682
<211> 25
<212> DNA
<213> Homo sapiens

<400> 682
tttggctctc tgtgtgagca tgtgt 25

<210> 683
<211> 25
<212> DNA
<213> Homo sapiens

<400> 683
ttggctctct gtgtgagcat gtgtg 25

<210> 684
<211> 25
<212> DNA
<213> Homo sapiens

<400> 684
tggctctctg tgtgagcatg tgtgc 25

<210> 685
<211> 25
<212> DNA
<213> Homo sapiens

<400> 685
ggctctctgt gtgagcatgt gtgcg 25

<210> 686
<211> 25
<212> DNA
<213> Homo sapiens

<400> 686
gctctctgtg tgagcatgtg tgcgt 25

<210> 687
<211> 25
<212> DNA
<213> Homo sapiens

<400> 687
ctctctgtgt gagcatgtgt gcgtg 25

<210> 688
<211> 25
<212> DNA
<213> Homo sapiens

<400> 688
tctctgtgtg agcatgtgtg cgtgt 25

<210> 689
<211> 25
<212> DNA
<213> Homo sapiens

<400> 689
ctctgtgtga gcatgtgtgc gtgtg 25

<210> 690
<211> 25
<212> DNA
<213> Homo sapiens

<400> 690
tctgtgtgag catgtgtgcg tgtgt 25

<210> 691
<211> 25
<212> DNA
<213> Homo sapiens

<400> 691
ctgtgtgagc atgtgtgcgt gtgtg 25

<210> 692
<211> 25
<212> DNA
<213> Homo sapiens

<400> 692
tgtgtgagca tgtgtgcgtg tgtgc 25

<210> 693
<211> 25
<212> DNA
<213> Homo sapiens

<400> 693
gtgtgagcat gtgtgcgtgt gtgcg 25

<210> 694
<211> 25
<212> DNA
<213> Homo sapiens

<400> 694
tgtgagcatg tgtgcgtgtg tgcga 25

<210> 695
<211> 25
<212> DNA
<213> Homo sapiens

<400> 695
gtgagcatgt gtgcgtgtgt gcgag 25

<210> 696
<211> 25
<212> DNA
<213> Homo sapiens

<400> 696
tgagcatgtg tgcgtgtgtg cgaga 25

<210> 697
<211> 25
<212> DNA
<213> Homo sapiens

<400> 697
gagcatgtgt gcgtgtgtgc gagag 25

<210> 698
<211> 25
<212> DNA
<213> Homo sapiens

<400> 698
agcatgtgtg cgtgtgtgcg agaga 25

<210> 699
<211> 25
<212> DNA
<213> Homo sapiens

<400> 699
gcatgtgtgc gtgtgtgcga gagag 25

<210> 700
<211> 25
<212> DNA
<213> Homo sapiens

<400> 700
catgtgtgcg tgtgtgcgag agaga 25

<210> 701
<211> 25
<212> DNA
<213> Homo sapiens

<400> 701
atgtgtgcgt gtgtgcgaga gagag 25

<210> 702
<211> 25
<212> DNA
<213> Homo sapiens

<400> 702
tgtgtgcgtg tgtgcgagag agaga 25

<210> 703
<211> 25
<212> DNA
<213> Homo sapiens

<400> 703
gtgtgcgtgt gtgcgagaga gagag 25

<210> 704
<211> 25
<212> DNA
<213> Homo sapiens

<400> 704
tgtgcgtgtg tgcgagagag agaga 25

<210> 705
<211> 25
<212> DNA
<213> Homo sapiens

<400> 705
gtgcgtgtgt gcgagagaga gagac 25

<210> 706
<211> 25
<212> DNA
<213> Homo sapiens

<400> 706
tgcgtgtgtg cgagagagag agaca 25

<210> 707
<211> 25
<212> DNA
<213> Homo sapiens

<400> 707
gcgtgtgtgc gagagagaga gacag 25

<210> 708
<211> 25
<212> DNA
<213> Homo sapiens

<400> 708
cgtgtgtgcg agagagagag acaga 25

<210> 709
<211> 25
<212> DNA
<213> Homo sapiens

<400> 709
gtgtgtgcga gagagagaga cagac 25

<210> 710
<211> 25
<212> DNA
<213> Homo sapiens

<400> 710
tgtgtgcgag agagagagac agaca 25

<210> 711
<211> 25
<212> DNA
<213> Homo sapiens

<400> 711
gtgtgcgaga gagagagaca gacag 25

<210> 712
<211> 25
<212> DNA
<213> Homo sapiens

<400> 712
tgtgagagag agagagacag acagc 25

<210> 713
<211> 25
<212> DNA
<213> Homo sapiens

<400> 713
gtgagagaga gagagacaga cagcc 25

<210> 714
<211> 25
<212> DNA
<213> Homo sapiens

<400> 714
tgagagagag agagacagac agcct 25

<210> 715
<211> 25
<212> DNA
<213> Homo sapiens

<400> 715
gcgagagaga gagacagaca gcctg 25

<210> 716
<211> 25
<212> DNA
<213> Homo sapiens

<400> 716
cgagagagag agacagacag cctgc 25

<210> 717
<211> 25
<212> DNA
<213> Homo sapiens

<400> 717
gagagagaga gacagacagc ctgcc 25

<210> 718
<211> 25
<212> DNA
<213> Homo sapiens

<400> 718
agagagagag acagacagcc tgcct 25

<210> 719
<211> 25
<212> DNA
<213> Homo sapiens

<400> 719
gagagagaga cagacagcct gccta 25

<210> 720
<211> 25
<212> DNA
<213> Homo sapiens

<400> 720
agagagagac agacagcctg cctaa 25

<210> 721
<211> 25
<212> DNA
<213> Homo sapiens

<400> 721
gagagagaca gacagcctgc ctaag 25

<210> 722
<211> 25
<212> DNA
<213> Homo sapiens

<400> 722
agagagacag acagcctgcc taaga 25

<210> 723
<211> 25
<212> DNA
<213> Homo sapiens

<400> 723
gagagacaga cagcctgcct aagaa 25

<210> 724
<211> 25
<212> DNA
<213> Homo sapiens

<400> 724
agagacagac agcctgccta agaag 25

<210> 725
<211> 25
<212> DNA
<213> Homo sapiens

<400> 725
gagacagaca gcctgcctaa gaaga 25

<210> 726
<211> 25
<212> DNA
<213> Homo sapiens

<400> 726
agacagacag cctgcctaag aagaa 25

<210> 727
<211> 25
<212> DNA
<213> Homo sapiens

<400> 727
gacagacagc ctgcctaaga agaaa 25

<210> 728
<211> 25
<212> DNA
<213> Homo sapiens

<400> 728
acagacagcc tgcctaagaa gaaat 25

<210> 729
<211> 25
<212> DNA
<213> Homo sapiens

<400> 729
cagacagcct gcctaagaag aaatg 25

<210> 730
<211> 25
<212> DNA
<213> Homo sapiens

<400> 730
agacagcctg cctaagaaga aatga 25

<210> 731
<211> 25
<212> DNA
<213> Homo sapiens

<400> 731
gacagcctgc ctaagaagaa atgaa 25

<210> 732
<211> 25
<212> DNA
<213> Homo sapiens

<400> 732
acagcctgcc taagaagaaa tgaat 25

<210> 733
<211> 25
<212> DNA
<213> Homo sapiens

<400> 733
cagcctgcct aagaagaaat gaatg 25

<210> 734
<211> 25
<212> DNA
<213> Homo sapiens

<400> 734
agcctgccta agaagaaatg aatgt 25

<210> 735
<211> 25
<212> DNA
<213> Homo sapiens

<400> 735
gcctgcctaa gaagaaatga atgtg 25

<210> 736
<211> 25
<212> DNA
<213> Homo sapiens

<400> 736
cctgcctaag aagaaatgaa tgtga 25

<210> 737
<211> 25
<212> DNA
<213> Homo sapiens

<400> 737
ctgcctaaga agaaatgaat gtgaa 25

<210> 738
<211> 25
<212> DNA
<213> Homo sapiens

<400> 738
tgcctaagaa gaaatgaatg tgaat 25

<210> 739
<211> 25
<212> DNA
<213> Homo sapiens

<400> 739
gcctaagaag aatgaatgt gaatg 25

<210> 740
<211> 25
<212> DNA
<213> Homo sapiens

<400> 740
cctaagaaga aatgaatgtg aatgc 25

<210> 741
<211> 25
<212> DNA
<213> Homo sapiens

<400> 741
ctaagaagaa atgaatgtga atgcg 25

<210> 742
<211> 25
<212> DNA
<213> Homo sapiens

<400> 742
taagaagaaa tgaatgtgaa tgcgg 25

<210> 743
<211> 25
<212> DNA
<213> Homo sapiens

<400> 743
aagaagaaat gaatgtgaat gcggc 25

<210> 744
<211> 25
<212> DNA
<213> Homo sapiens

<400> 744
agaagaaatg aatgtgaatg cggct 25

<210> 745
<211> 25
<212> DNA
<213> Homo sapiens

<400> 745
gaagaaatga atgtgaatgc ggctt 25

<210> 746
<211> 25
<212> DNA
<213> Homo sapiens

<400> 746
aagaaatgaa tgtgaatgcg gcttg 25

<210> 747
<211> 25
<212> DNA
<213> Homo sapiens

<400> 747
agaaatgaat gtgaatgcgg cttgt 25

<210> 748
<211> 25
<212> DNA
<213> Homo sapiens

<400> 748
gaaatgaatg tgaatgcggc ttgtg 25

<210> 749
<211> 25
<212> DNA
<213> Homo sapiens

<400> 749
aatgaatgt gaatgcggct tgttg 25

<210> 750
<211> 25
<212> DNA
<213> Homo sapiens

<400> 750
aatgaatgtg aatgcggctt gtggc 25

<210> 751
<211> 25
<212> DNA
<213> Homo sapiens

<400> 751
atgaatgtga atgcggcttg tggca 25

<210> 752
<211> 25
<212> DNA
<213> Homo sapiens

<400> 752
tgaatgtgaa tgcggcttgt ggcac 25

<210> 753
<211> 25
<212> DNA
<213> Homo sapiens

<400> 753
gaatgtgaat gcggcttgtg gcaca 25

<210> 754
<211> 25
<212> DNA
<213> Homo sapiens

<400> 754
aatgtgaatg cggcttgtgg cacag 25

<210> 755
<211> 25
<212> DNA
<213> Homo sapiens

<400> 755
atgtgaatgc ggcttgtggc acagt 25

<210> 756
<211> 25
<212> DNA
<213> Homo sapiens

<400> 756
tgtgaatgcg gcttgtggca cagtt 25

<210> 757
<211> 25
<212> DNA
<213> Homo sapiens

<400> 757
gtgaatgcgg cttgtggcac agttg 25

<210> 758
<211> 25
<212> DNA
<213> Homo sapiens

<400> 758
tgaatgcggc ttgtggcaca gttga 25

<210> 759
<211> 25
<212> DNA
<213> Homo sapiens

<400> 759
gaatgcggct tgtggcacag ttgac 25

<210> 760
<211> 25
<212> DNA
<213> Homo sapiens

<400> 760
aatgcggctt gtggcacagt tgaca 25

<210> 761
<211> 25
<212> DNA
<213> Homo sapiens

<400> 761
atgcggcttg tggcacagtt gacaa 25

<210> 762
<211> 25
<212> DNA
<213> Homo sapiens

<400> 762
tgcggcttgt ggcacagttg acaag 25

<210> 763
<211> 25
<212> DNA
<213> Homo sapiens

<400> 763
gcggcttgtg gcacagttga caagg 25

<210> 764
<211> 25
<212> DNA
<213> Homo sapiens

<400> 764
cggcttgtgg cacagttgac aagga 25

<210> 765
<211> 25
<212> DNA
<213> Homo sapiens

<400> 765
ggcttgtggc acagttgaca aggat 25

<210> 766
<211> 25
<212> DNA
<213> Homo sapiens

<400> 766
gcttgtggca cagttgacaa ggatg 25

<210> 767
<211> 25
<212> DNA
<213> Homo sapiens

<400> 767
cttgtggcac agttgacaag gatga 25

<210> 768
<211> 25
<212> DNA
<213> Homo sapiens

<400> 768
ttgtggcaca gttgacaagg atgat 25

<210> 769
<211> 25
<212> DNA
<213> Homo sapiens

<400> 769
tgtggcacag ttgacaagga tgata 25

<210> 770
<211> 25
<212> DNA
<213> Homo sapiens

<400> 770
gtggcacagt tgacaaggat gataa 25

<210> 771
<211> 25
<212> DNA
<213> Homo sapiens

<400> 771
tggcacagtt gacaaggatg ataaa 25

<210> 772
<211> 25
<212> DNA
<213> Homo sapiens

<400> 772
ggcacagttg acaaggatga taaat 25

<210> 773
<211> 25
<212> DNA
<213> Homo sapiens

<400> 773
gcacagttga caaggatgat aaatc 25

<210> 774
<211> 25
<212> DNA
<213> Homo sapiens

<400> 774
cacagttgac aaggatgata aatca 25

<210> 775
<211> 25
<212> DNA
<213> Homo sapiens

<400> 775
acagttgaca aggatgataa atcaa 25

<210> 776
<211> 25
<212> DNA
<213> Homo sapiens

<400> 776
cagttgacaa ggatgataaa tcaat 25

<210> 777
<211> 25
<212> DNA
<213> Homo sapiens

<400> 777
agttgacaag gatgataaat caata 25

<210> 778
<211> 25
<212> DNA
<213> Homo sapiens

<400> 778
gttgacaagg atgataaatc aataa 25

<210> 779
<211> 25
<212> DNA
<213> Homo sapiens

<400> 779
ttgacaagga tgataaatca ataata 25

<210> 780
<211> 25
<212> DNA
<213> Homo sapiens

<400> 780
tgacaaggat gataaatcaa taatg 25

<210> 781
<211> 25
<212> DNA
<213> Homo sapiens

<400> 781
gacaaggatg ataaatcaat aatgc 25

<210> 782
<211> 25
<212> DNA
<213> Homo sapiens

<400> 782
acaaggatga taaatcaata atgca 25

<210> 783
<211> 25
<212> DNA
<213> Homo sapiens

<400> 783
caaggatgat aatcaataa tgcaa 25

<210> 784
<211> 25
<212> DNA
<213> Homo sapiens

<400> 784
aaggatgata aatcaataat gcaag 25

<210> 785
<211> 25
<212> DNA
<213> Homo sapiens

<400> 785
aggatgataa atcaataatg caagc 25

<210> 786
<211> 25
<212> DNA
<213> Homo sapiens

<400> 786
ggatgataaa tcaataatgc aagct 25

<210> 787
<211> 25
<212> DNA
<213> Homo sapiens

<400> 787
gatgataaat caataatgca agctt 25

<210> 788
<211> 25
<212> DNA
<213> Homo sapiens

<400> 788
atgataaatc aataatgcaa gctta 25

<210> 789
<211> 25
<212> DNA
<213> Homo sapiens

<400> 789
tgataaatca ataatgcaag cttac 25

<210> 790
<211> 25
<212> DNA
<213> Homo sapiens

<400> 790
gataaatcaa taatgcaagc ttact 25

<210> 791
<211> 25
<212> DNA
<213> Homo sapiens

<400> 791
ataaatcaat aatgcaagct tacta 25

<210> 792
<211> 25
<212> DNA
<213> Homo sapiens

<400> 792
taaatacaata atgcaagctt actat 25

<210> 793
<211> 25
<212> DNA
<213> Homo sapiens

<400> 793
aatcaataa tgcaagctta ctatc 25

<210> 794
<211> 25
<212> DNA
<213> Homo sapiens

<400> 794
aatcaataat gcaagcttac tatca 25

<210> 795
<211> 25
<212> DNA
<213> Homo sapiens

<400> 795
atcaataatg caagcttact atcat 25

<210> 796
<211> 25
<212> DNA
<213> Homo sapiens

<400> 796
tcaataatgc aagcttacta tcatt 25

<210> 797
<211> 25
<212> DNA
<213> Homo sapiens

<400> 797
caataatgca agcttactat cattt 25

<210> 798
<211> 25
<212> DNA
<213> Homo sapiens

<400> 798
aataatgcaa gcttactatc attta 25

<210> 799
<211> 25
<212> DNA
<213> Homo sapiens

<400> 799
ataatgcaag cttactatca tttat 25

<210> 800
<211> 25
<212> DNA
<213> Homo sapiens

<400> 800
taatgcaagc ttactatcat ttatg 25

<210> 801
<211> 25
<212> DNA
<213> Homo sapiens

<400> 801
aatgcaagct tactatcatt tatga 25

<210> 802
<211> 25
<212> DNA
<213> Homo sapiens

<400> 802
atgcaagctt actatcattt atgaa 25

<210> 803
<211> 25
<212> DNA
<213> Homo sapiens

<400> 803
tgcaagctta ctatcattta tgaat 25

<210> 804
<211> 25
<212> DNA
<213> Homo sapiens

<400> 804
gcaagcttac tatcatttat gaata 25

<210> 805
<211> 25
<212> DNA
<213> Homo sapiens

<400> 805
caagcttact atcatttatg aatag 25

<210> 806
<211> 25
<212> DNA
<213> Homo sapiens

<400> 806
aagcttacta tcatttatga atagc 25

<210> 807
<211> 25
<212> DNA
<213> Homo sapiens

<400> 807
agcttactat catttatgaa tagca 25

<210> 808
<211> 25
<212> DNA
<213> Homo sapiens

<400> 808
gcttactatc atttatgaat agcaa 25

<210> 809
<211> 25
<212> DNA
<213> Homo sapiens

<400> 809
cttactatca tttatgaata gcaat 25

<210> 810
<211> 25
<212> DNA
<213> Homo sapiens

<400> 810
ttactatcat ttatgaatag caata 25

<210> 811
<211> 25
<212> DNA
<213> Homo sapiens

<400> 811
tactatcatt tatgaatagc aatac 25

<210> 812
<211> 25
<212> DNA
<213> Homo sapiens

<400> 812
actatcattt atgaatagca atact 25

<210> 813
<211> 25
<212> DNA
<213> Homo sapiens

<400> 813
ctatcattta tgaatagcaa tactg 25

<210> 814
<211> 25
<212> DNA
<213> Homo sapiens

<400> 814
tatcatttat gaatagcaat actga 25

<210> 815
<211> 25
<212> DNA
<213> Homo sapiens

<400> 815
atcatttatg aatagcaata ctgaa 25

<210> 816
<211> 25
<212> DNA
<213> Homo sapiens

<400> 816
tcatttatga atagcaatac tgaag 25

<210> 817
<211> 25
<212> DNA
<213> Homo sapiens

<400> 817
catttatgaa tagcaatact gaaga 25

<210> 818
<211> 25
<212> DNA
<213> Homo sapiens

<400> 818
atttatgaat agcaatactg aagaa 25

<210> 819
<211> 25
<212> DNA
<213> Homo sapiens

<400> 819
tttatgaata gcaatactga agaaa 25

<210> 820
<211> 25
<212> DNA
<213> Homo sapiens

<400> 820
ttatgaatag caatactgaa gaaat 25

<210> 821
<211> 25
<212> DNA
<213> Homo sapiens

<400> 821
tatgaatagc aatactgaag aaatt 25

<210> 822
<211> 25
<212> DNA
<213> Homo sapiens

<400> 822
atgaatagca atactgaaga aatta 25

<210> 823
<211> 25
<212> DNA
<213> Homo sapiens

<400> 823
tgaatagcaa tactgaagaa attaa 25

<210> 824
<211> 25
<212> DNA
<213> Homo sapiens

<400> 824
gaatagcaat actgaagaaa ttaaa 25

<210> 825
<211> 25
<212> DNA
<213> Homo sapiens

<400> 825
aatagcaata ctgaagaaat taaaa 25

<210> 826
<211> 25
<212> DNA
<213> Homo sapiens

<400> 826
atagcaatac tgaagaaatt aaaac 25

<210> 827
<211> 25
<212> DNA
<213> Homo sapiens

<400> 827
tagcaatact gaagaaatta aaaca 25

<210> 828
<211> 25
<212> DNA
<213> Homo sapiens

<400> 828
agcaatactg aagaaattaa aacaa 25

<210> 829
<211> 25
<212> DNA
<213> Homo sapiens

<400> 829
gcaatactga agaaattaaa acaaa 25

<210> 830
<211> 25
<212> DNA
<213> Homo sapiens

<400> 830
caatactgaa gaaattaaaa caaaa 25

<210> 831
<211> 25
<212> DNA
<213> Homo sapiens

<400> 831
aatactgaag aaattaaaac aaaag 25

<210> 832
<211> 25
<212> DNA
<213> Homo sapiens

<400> 832
atactgaaga aattaaaaca aaaga 25

<210> 833
<211> 25
<212> DNA
<213> Homo sapiens

<400> 833
tactgaagaa attaaaacaa aagat 25

<210> 834
<211> 25
<212> DNA
<213> Homo sapiens

<400> 834
actgaagaaa ttaaaacaaa agatt 25

<210> 835
<211> 25
<212> DNA
<213> Homo sapiens

<400> 835
ctgaagaaat taaaacaaaa gattg 25

<210> 836
<211> 25
<212> DNA
<213> Homo sapiens

<400> 836
tgaagaaatt aaaacaaaag attgc 25

<210> 837
<211> 25
<212> DNA
<213> Homo sapiens

<400> 837
gaagaaatta aaacaaaaga ttgct 25

<210> 838
<211> 25
<212> DNA
<213> Homo sapiens

<400> 838
aagaaattaa aacaaaagat tgctg 25

<210> 839
<211> 25
<212> DNA
<213> Homo sapiens

<400> 839
agaaattaaa acaaaagatt gctgt 25

<210> 840
<211> 25
<212> DNA
<213> Homo sapiens

<400> 840
gaaattaaaa caaaagattg ctgtc 25

<210> 841
<211> 25
<212> DNA
<213> Homo sapiens

<400> 841
aaattaaaac aaaagattgc tgtct 25

<210> 842
<211> 25
<212> DNA
<213> Homo sapiens

<400> 842
aattaaaaca aaagattgct gtctc 25

<210> 843
<211> 25
<212> DNA
<213> Homo sapiens

<400> 843
attaaaacaa aagattgctg tctca 25

<210> 844
<211> 25
<212> DNA
<213> Homo sapiens

<400> 844
ttaaacaaca agattgctgt ctcaa 25

<210> 845
<211> 25
<212> DNA
<213> Homo sapiens

<400> 845
taaaacaaaa gattgctgtc tcaat 25

<210> 846
<211> 25
<212> DNA
<213> Homo sapiens

<400> 846
aaaacaaaag attgctgtct caata 25

<210> 847
<211> 25
<212> DNA
<213> Homo sapiens

<400> 847
aaacaaaaga ttgctgtctc aatat 25

<210> 848
<211> 25
<212> DNA
<213> Homo sapiens

<400> 848
aacaaaagat tgctgtctca atata 25

<210> 849
<211> 25
<212> DNA
<213> Homo sapiens

<400> 849
acaaaagatt gctgtctcaa tatat 25

<210> 850
<211> 25
<212> DNA
<213> Homo sapiens

<400> 850
caaaagattg ctgtctcaat atatc 25

<210> 851
<211> 25
<212> DNA
<213> Homo sapiens

<400> 851
aaaagattgc tgtctcaata tatct 25

<210> 852
<211> 25
<212> DNA
<213> Homo sapiens

<400> 852
aaagattgct gtctcaatat atctt 25

<210> 853
<211> 25
<212> DNA
<213> Homo sapiens

<400> 853
aagattgctg tctcaatata tctta 25

<210> 854
<211> 25
<212> DNA
<213> Homo sapiens

<400> 854
agattgctgt ctcaatatat cttat 25

<210> 855
<211> 25
<212> DNA
<213> Homo sapiens

<400> 855
gattgctgtc tcaatatatc ttata 25

<210> 856
<211> 25
<212> DNA
<213> Homo sapiens

<400> 856
attgctgtct caatatatct tatat 25

<210> 857
<211> 25
<212> DNA
<213> Homo sapiens

<400> 857
ttgctgtctc aatatatctt atatt 25

<210> 858
<211> 25
<212> DNA
<213> Homo sapiens

<400> 858
tgctgtctca atatatctta tattt 25

<210> 859
<211> 25
<212> DNA
<213> Homo sapiens

<400> 859
gctgtctcaa tatatcttat attta 25

<210> 860
<211> 25
<212> DNA
<213> Homo sapiens

<400> 860
ctgtctcaat atatcttata tttat 25

<210> 861
<211> 25
<212> DNA
<213> Homo sapiens

<400> 861
tgtctcaata tatcttatat ttatt 25

<210> 862
<211> 25
<212> DNA
<213> Homo sapiens

<400> 862
gtctcaatat atcttatatt tatta 25

<210> 863
<211> 25
<212> DNA
<213> Homo sapiens

<400> 863
tctcaatata tcttatattt attat 25

<210> 864
<211> 25
<212> DNA
<213> Homo sapiens

<400> 864
ctcaatatat cttatattta ttatt 25

<210> 865
<211> 25
<212> DNA
<213> Homo sapiens

<400> 865
tcaatatatc ttatatttat tattt 25

<210> 866
<211> 25
<212> DNA
<213> Homo sapiens

<400> 866
caatatatct tatatttatt attta 25

<210> 867
<211> 25
<212> DNA
<213> Homo sapiens

<400> 867
aatatatctt atatttatta ttac 25

<210> 868
<211> 25
<212> DNA
<213> Homo sapiens

<400> 868
atatatctta tatttattat ttacc 25

<210> 869
<211> 25
<212> DNA
<213> Homo sapiens

<400> 869
tatatcttat atttattatt tacca 25

<210> 870
<211> 25
<212> DNA
<213> Homo sapiens

<400> 870
atatcttata tttattattt accaa 25

<210> 871
<211> 25
<212> DNA
<213> Homo sapiens

<400> 871
tatcttatat ttattattta ccaaa 25

<210> 872
<211> 25
<212> DNA
<213> Homo sapiens

<400> 872
atcttatatt tattatttac caaat 25

<210> 873
<211> 25
<212> DNA
<213> Homo sapiens

<400> 873
tcttatattt attatttacc aaatt 25

<210> 874
<211> 25
<212> DNA
<213> Homo sapiens

<400> 874
cttatattta ttatttacca aatta 25

<210> 875
<211> 25
<212> DNA
<213> Homo sapiens

<400> 875
ttatatttat tatttaccaa attat 25

<210> 876
<211> 25
<212> DNA
<213> Homo sapiens

<400> 876
tatatttatt atttaccaa ttatt 25

<210> 877
<211> 25
<212> DNA
<213> Homo sapiens

<400> 877
atatttatta ttaccaaatt tattc 25

<210> 878
<211> 25
<212> DNA
<213> Homo sapiens

<400> 878
tatttattat ttaccaaatt attct 25

<210> 879
<211> 25
<212> DNA
<213> Homo sapiens

<400> 879
atttattatt taccaaatta ttcta 25

<210> 880
<211> 25
<212> DNA
<213> Homo sapiens

<400> 880
tttattattt accaaattat tctaa 25

<210> 881
<211> 25
<212> DNA
<213> Homo sapiens

<400> 881
ttattattta ccaaattatt ctaag 25

<210> 882
<211> 25
<212> DNA
<213> Homo sapiens

<400> 882
tattatttac caaattattc taaga 25

<210> 883
<211> 25
<212> DNA
<213> Homo sapiens

<400> 883
attatttacc aaattattct aagag 25

<210> 884
<211> 25
<212> DNA
<213> Homo sapiens

<400> 884
ttatttacca aattattcta agagt 25

<210> 885
<211> 25
<212> DNA
<213> Homo sapiens

<400> 885
tatttaccaa attattctaa gagta 25

<210> 886
<211> 25
<212> DNA
<213> Homo sapiens

<400> 886
atttaccaaa ttattctaag agtat 25

<210> 887
<211> 25
<212> DNA
<213> Homo sapiens

<400> 887
tttaccaaatt tattctaaga gtatt 25

<210> 888
<211> 25
<212> DNA
<213> Homo sapiens

<400> 888
ttaccaaatt attctaagag tattt 25

<210> 889
<211> 25
<212> DNA
<213> Homo sapiens

<400> 889
taccaaatta ttctaagagt atttc 25

<210> 890
<211> 25
<212> DNA
<213> Homo sapiens

<400> 890
accaaattat tctaagagta tttct 25

<210> 891
<211> 25
<212> DNA
<213> Homo sapiens

<400> 891
ccaaattatt ctaagagtat ttctt 25

<210> 892
<211> 25
<212> DNA
<213> Homo sapiens

<400> 892
caaattattc taagagtatt tcttc 25

<210> 893
<211> 25
<212> DNA
<213> Homo sapiens

<400> 893
aaattattct aagagtattt cttcc 25

<210> 894
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 894
atccaattaa gagagagtga tgg 23

<210> 895
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 895
aatccaatta agagagagtg atg 23

<210> 896
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 896
 tccaattaag agagagtgat ggg 23

<210> 897
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 897
 tccaattaag agagagtgat g 21

<210> 898
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 898
 ccaattaaga gagagtgat 19

<210> 899
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 899
 aatccaatta agagagtg a 21

<210> 900
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 900
caattaagag agagtgatgg g 21

<210> 901
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 901
gagtcctgca atatgaatat aat 23

<210> 902
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 902
gtcctgcaat atgaatataa ttt 23

<210> 903
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 903
gtcctgcaat atgaatataa t 21

<210> 904
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 904
gagtcctgca atatgaatat a 21

<210> 905
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 905
cctgcaatat gaatataatt t 21

<210> 906
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 906
gagtcctgca atatgaata 19

<210> 907
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 907
tgcaatatga atataattt 19

<210> 908
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 908
gtcttctgcc gagtcctgca ata 23

<210> 909
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 909
 aggtcttctg ccgagtcctg c 21

<210> 910
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 910
 cttctgccga gtcctgcaat a 21

<210> 911
 <211> 19
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 911
 tctgccgagt cctgcaata 19

<210> 912
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 912
 gcacacatgc tcacacagag agc 23

<210> 913	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 913	
acacatgctc acacagagag cca	23
<210> 914	
<211> 21	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 914	
acacatgctc acacagagag c	21
<210> 915	
<211> 21	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 915	
gcacacatgc tcacacagag a	21
<210> 916	
<211> 21	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 916	
acatgctcac acagagagcc a	21
<210> 917	
<211> 19	

<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 917	
gcacacatgc tcacacaga	19
<210> 918	
<211> 19	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 918	
atgctcacac agagagcca	19
<210> 919	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 919	
ccatcactct ctcttaattg gat	23
<210> 920	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 920	
catcactctc tcttaattgg att	23
<210> 921	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 921	
cccatcactc tctcttaatt gga	23
<210> 922	
<211> 21	
<212> DNA	

<213> Homo sapiens	
<400> 922	
catcactctc tcttaattgg a	21
<210> 923	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 923	
atcactctct ctttaattgg	19
<210> 924	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 924	
tcactctctc ttaattggat t	21
<210> 925	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 925	
cccatcactc tctcttaatt g	21
<210> 926	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 926	
attatattca tattgcagga ctc	23
<210> 927	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 927	
aaattatatt catattgcag gac	23
<210> 928	
<211> 21	
<212> DNA	

<213> Homo sapiens

<400> 928

attatattca tattgcagga c

21

<210> 929

<211> 21

<212> DNA

<213> Homo sapiens

<400> 929

tatattcata ttgcaggact c

21

<210> 930

<211> 21

<212> DNA

<213> Homo sapiens

<400> 930

aaattatatt catattgcag g

21

<210> 931

<211> 19

<212> DNA

<213> Homo sapiens

<400> 931

tattcatatt gcaggactc

19

<210> 932

<211> 19

<212> DNA

<213> Homo sapiens

<400> 932

aaattatatt catattgca

19

<210> 933

<211> 23

<212> DNA

<213> Homo sapiens

<400> 933

tattgcagga ctcggcagaa gac

23

<210> 934

<211> 21

<212> DNA

<213> Homo sapiens	
<400> 934	
gcaggactcg gcagaagacc t	21
<210> 935	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 935	
tattgcagga ctcggcagaa g	21
<210> 936	
<211> 19	
<212> DNA	
<213> Homo sapiens	
<400> 936	
tattgcagga ctcggcaga	19
<210> 937	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 937	
gctctctgtg tgagcatgtg tgc	23
<210> 938	
<211> 23	
<212> DNA	
<213> Homo sapiens	
<400> 938	
tggctctctg tgtgagcatg tgt	23
<210> 939	
<211> 21	
<212> DNA	
<213> Homo sapiens	
<400> 939	
gctctctgtg tgagcatgtg t	21
<210> 940	
<211> 21	
<212> DNA	

<213> Homo sapiens
 <400> 940
 tctctgtgtg agcatgtgtg c 21

<210> 941
 <211> 21
 <212> DNA
 <213> Homo sapiens
 <400> 941
 tggctctctg tgtgagcatg t 21

<210> 942
 <211> 19
 <212> DNA
 <213> Homo sapiens
 <400> 942
 tctgtgtgag catgtgtgc 19

<210> 943
 <211> 19
 <212> DNA
 <213> Homo sapiens
 <400> 943
 tggctctctg tgtgagcat 19

<210> 944
 <211> 470
 <212> DNA
 <213> Homo sapiens
 <400> 944
 acttgtaata tacaggtatc cctcctggta agctctggta ttatgtctta acatttttaa 60
 atctatggta atctttacaa aatattttac ttccgaactc atatacctgg ggattttatt 120
 actctgggaa ttatgtgttc tgcccatca ctctctctta attggatttt taaaattata 180
 ttcatattgc aggactcggc agaagacctt cgagagaaag gtagaaaata agaatttggc 240
 tctctgtgtg agcatgtgtg cgtgtgtgcg agagagagag acagacagcc tgcctaagaa 300
 gaaatgaatg tgaatgcggc ttgtggcaca gttgacaagg atgataaatc aataatgcaa 360
 gcttactatc atttatgaat agcaatactg aagaaattaa aacaaaagat tgctgtctca 420
 atatatctta tatttattat ttaccaaatt attctaagag tatttcttcc 470

<210> 945	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 945	
ggagggauac cuguauauua caagu	25
<210> 946	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 946	
aggagggauc ccuguauauu acaag	25
<210> 947	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 947	
caggagggau accuguauau uacaa	25
<210> 948	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 948	
ccaggaggga uaccuguaua uuaca	25

<210> 949
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 949
 accaggaggg auaccuguau auuac 25

 <210> 950
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 950
 uaccaggagg gauaccugua uauua 25

 <210> 951
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 951
 uuaccaggag ggauaccugu auauu 25

 <210> 952
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 952
 cuuaccagga gggauaccug uauau 25

 <210> 953
 <211> 25

<212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 953
 gcuuaccagg agggauaccu guaua 25

 <210> 954
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 954
 agcuuaccag gagggauacc uguau 25

 <210> 955
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 955
 gagcuuacca ggagggauac cugua 25

 <210> 956
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 956
 agagcuuacc aggagggaua ccugu 25

 <210> 957
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 957
 cagagcuuac caggagggau accug 25

<210> 958
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 958
 ccagagcuua ccaggaggga uaccu 25

<210> 959
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 959
 accagagcuu accaggaggg auacc 25

<210> 960
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 960
 uaccagagcu uaccaggagg gauac 25

<210> 961
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 961

auaccagagc uuaccaggag ggaua

25

<210> 962

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 962

aaauaccagag cuuaccagga gggau

25

<210> 963

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 963

uaauaccaga gcuuaccagg aggga

25

<210> 964

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 964

auaaauaccag agcuuaccag gaggg

25

<210> 965

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 965
cauaauacca gagcuuacca ggagg 25

<210> 966
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 966
acaauauacc agagcuuacc aggag 25

<210> 967
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 967
gacauauac cagagcuuac cagga 25

<210> 968
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 968
agacauaaua ccagagcuua ccagg 25

<210> 969
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 969

aagacauaau accagagcuu accag 25

<210> 970

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 970

uaagacauaa uaccagagcu uacca 25

<210> 971

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 971

uuaagacaua auaccagagc uuacc 25

<210> 972

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 972

guuaagacau aauaccagag cuuac 25

<210> 973

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 973

uguuaagaca uaauaccaga gcuua 25

<210> 974
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 974
 auguuaagac auaauaccag agcuu 25

 <210> 975
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 975
 aauguuaaga cauaauacca gagcu 25

 <210> 976
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 976
 aaauguuaag acauaauacc agagc 25

 <210> 977
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 977
 aaaauguuaa gacauaauac cagag 25

 <210> 978

<211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 978
 aaaaauguua agacauaaua ccaga 25

 <210> 979
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 979
 uaaaaauguu aagacauaau accag 25

 <210> 980
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 980
 uuaaaaaugu uaagacauaa uacca 25

 <210> 981
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 981
 uuuaaaaaug uuaagacaua auacc 25

 <210> 982
 <211> 25
 <212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 982

auuuuuuuuu guuaagacau aauc

25

<210> 983

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 983

gauuuuuuuu uguuaagaca uaua

25

<210> 984

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 984

agauuuuuuu auguuaagac auau

25

<210> 985

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 985

uagauuuuuu aauguuaaga caua

25

<210> 986

<211> 25

<212> RNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 986
 auagauuuua aaauguuaag acaua 25

<210> 987
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 987
 cauagauuuu aaaauguuaa gacau 25

<210> 988
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 988
 ccgauagauuu aaaaauguua agaca 25

<210> 989
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 989
 accauagauu uaaaaauguu aagac 25

<210> 990
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 990
uaccauagau uuaaaaaaug uaaga 25

<210> 991
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 991
uuaccauaga uuuaaaaaaug uuaag 25

<210> 992
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 992
auuaccauag auuuaaaaaug uuaa 25

<210> 993
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 993
gauuaccaua gauuuaaaaa uguua 25

<210> 994
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 994
agauuaccuu agauuuuuuuuu auguu

25

```
<210> 995
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
        oligonucleotide
```

<400> 995
aagauuacca uagauuuaaa aaugu 25

```
<210> 996
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
        oligonucleotide
```

<400> 996
aaagauuacc auagauuuuaa aaaug 25

```
<210> 997
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide
```

<400> 997
 uaaagauuac cauagauuuu aaaaau 25

```
<210> 998
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
        oligonucleotide
```

<400> 998
guaaagauua ccuagauuu aaaaaa 25

<210> 999
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 999
 uguaaaagauu accauagauu uaaaa 25

<210> 1000
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1000
 uuguaaaagau uaccuagau uaaaa 25

<210> 1001
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1001
 uuuguaaaaga uuaccuagau uuuuaa 25

<210> 1002
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1002
 uuuuguaaaag auuaccuag auuuu 25

<210> 1003
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1003
 auuuuuguaaa gauuaccaua gauuu 25

<210> 1004
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1004
 uauuuuuguaa agauuaccau agauu 25

<210> 1005
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1005
 auauuuuugua aagauuacca uagau 25

<210> 1006
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1006
 aaauuuuugu aaagauuacc auaga 25

<210> 1007
 <211> 25

<212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1007
 aaaauuuuug uaaagauuac cauag 25

 <210> 1008
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1008
 aaaaauuuuu guaaagauua ccaua 25

 <210> 1009
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1009
 uaaaauuuuu uguaaagauu accau 25

 <210> 1010
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1010
 guaaaauuuu uuguaaagau uacca 25

 <210> 1011
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1011
 aguaaaauau uuuguaaaga uuacc 25

<210> 1012
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1012
 aaguaaaaua uuuuguaaag auuac 25

<210> 1013
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1013
 gaaguaaaau auuuuguaaa gauua 25

<210> 1014
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1014
 ggaaguaaaa uauuuuguaa agauu 25

<210> 1015
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1015

cggaaguaaa auauuuugua aagau

25

<210> 1016

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1016

ucggaaguaa aaauuuugu aaaga

25

<210> 1017

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1017

uucggaagua aaauuuuug uaaag

25

<210> 1018

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1018

guucggaagu aaaauuuuu guaaa

25

<210> 1019

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1019
aguucggaag uaaaauuuu uguaa 25

<210> 1020
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1020
gaguucggaa guaaaauuu uugua 25

<210> 1021
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1021
ugaguucgga aguaaaauau uuugu 25

<210> 1022
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1022
augaguucgg aaguaaaaua uuuug 25

<210> 1023
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1023

uauugaguucg gaaguaaaau auuuu 25

<210> 1024

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1024

auaugaguuc ggaaguaaaa uauuu 25

<210> 1025

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1025

uauaugaguu cggaaguaaa auauu 25

<210> 1026

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1026

guauaugagu ucggaaguaa aaauu 25

<210> 1027

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1027

gguauaugag uucggaagua aaaua 25

<210> 1028	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1028	
agguauauga guucggaagu aaaau	25
<210> 1029	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1029	
cagguauaug aguucggaag uaaaa	25
<210> 1030	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1030	
ccagguauau gaguucggaa guaaa	25
<210> 1031	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1031	
cccagguaua ugaguucgga aguaa	25
<210> 1032	

<211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1032
 ccccaggau augaguucgg aagua 25

 <210> 1033
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1033
 uccccaggua uaugaguucg gaagu 25

 <210> 1034
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1034
 auccccaggu auaugaguuc ggaag 25

 <210> 1035
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1035
 aaucuccagg uauaugaguu cggaa 25

 <210> 1036
 <211> 25
 <212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1036

aaauccccag guauaugagu ucgga

25

<210> 1037

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1037

aaaaucccca gguauaugag uucgg

25

<210> 1038

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1038

uaaaaucccc agguauauga guucg

25

<210> 1039

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1039

auaaaauccc cagguauaug aguuc

25

<210> 1040

<211> 25

<212> RNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1040
 aauaaaaucc ccagguauau gaguu 25

<210> 1041
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1041
 uaauaaauc cccagguaua ugagu 25

<210> 1042
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1042
 guaauaaaau ccccagguau augag 25

<210> 1043
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1043
 aguaauaaaa ucccaggua uauga 25

<210> 1044
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 1044
gaguaauaaa aucccccaggu auaug 25

<210> 1045
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1045
agaguaauaa aaucucccagg uauau 25

<210> 1046
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1046
cagaguaaua aaaucccccag guaua 25

<210> 1047
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1047
ccagaguaau aaaaucccca gguau 25

<210> 1048
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1048
cccagaguaa uaaaaucucc aggua 25

<210> 1049
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1049
ucccagagua auaaaauccc caggu 25

<210> 1050
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1050
uucccagagu aaaaaaaucc ccagg 25

<210> 1051
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1051
auucccagag uaauaaaauc cccag 25

<210> 1052
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1052
aaaucccaga guauaaaaau cccca 25

<210> 1053
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1053
 uaaauuccag aguaauaaaa ucccc 25

<210> 1054
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1054
 auaauuccca gaguaaaaa auccc 25

<210> 1055
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1055
 cauaauuccc agaguaauaa aaucc 25

<210> 1056
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1056
 acauaauucc cagaguaaua aaauc 25

<210> 1057
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1057
 cacauaauc ccagaguaa aaaau 25

<210> 1058
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1058
 acacauaauc cccagagua uaaaa 25

<210> 1059
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1059
 aacacauaa ucccagagua auaaa 25

<210> 1060
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1060
 gaacacauaa uucccagagu aaaua 25

<210> 1061
 <211> 25

<212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1061
 agaacacaua auucccagag uaaua 25

 <210> 1062
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1062
 cagaacacau aaaucccaga guaa 25

 <210> 1063
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1063
 gcagaacaca uaauucccag aguaa 25

 <210> 1064
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1064
 ggcagaacac auaauuccca gagua 25

 <210> 1065
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1065
 gggcagaaca cauaauuccc agagu 25

<210> 1066
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1066
 ggggcagaac acauaauucc cagag 25

<210> 1067
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1067
 uggggcagaa cacauaaauuc ccaga 25

<210> 1068
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1068
 auggggcaga acacauaaau cccag 25

<210> 1069
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1069

gauggggcag aacacauaau uccca

25

<210> 1070

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1070

ugauggggca gaacacauaa uuccc

25

<210> 1071

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1071

gugauggggc agaacacaua auucc

25

<210> 1072

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1072

agugaugggg cagaacacau aauc

25

<210> 1073

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1073
gagugauggg gcagaacaca uaaau 25

<210> 1074
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1074
agagugaugg ggcagaacac auaau 25

<210> 1075
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1075
gagagugaug gggcagaaca cauaa 25

<210> 1076
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1076
agagagugau ggggcagaac acaua 25

<210> 1077
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1077

gagagaguga uggggcagaa cacau 25

<210> 1078

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1078

agagagagug auggggcaga acaca 25

<210> 1079

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1079

aagagagagu gauggggcag aacac 25

<210> 1080

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1080

uaagagagag ugauggggca gaaca 25

<210> 1081

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1081

uuaagagaga gugauggggc agaac 25

<210> 1082
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1082
auuaagagag agugaugggg cagaa 25

<210> 1083
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1083
aauuaagaga gagugauggg gcaga 25

<210> 1084
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1084
caauuaagag agagugaugg ggcag 25

<210> 1085
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1085
ccaauuaaga gagagugaug gggca 25

<210> 1086

<211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1086
 uccaauuaag agagagugau ggggc 25

 <210> 1087
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1087
 auccaauuaa gagagaguga ugggg 25

 <210> 1088
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1088
 aauccaauua agagagagug auggg 25

 <210> 1089
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1089
 aaauccaauu aagagagagu gaugg 25

 <210> 1090
 <211> 25
 <212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1090

aaaauccaau uaagagagag ugaug

25

<210> 1091

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1091

aaaaauccaa uuaagagaga gugau

25

<210> 1092

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1092

uaaaaaucca auuaagagag aguga

25

<210> 1093

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1093

uuaaaaaucc aaauaagaga gagug

25

<210> 1094

<211> 25

<212> RNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1094
 uuuaaaaauc caauuaagag agagu 25

<210> 1095
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1095
 uuuuaaaaau ccaauuaaga gagag 25

<210> 1096
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1096
 auuuuaaaaa uccaauuaag agaga 25

<210> 1097
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1097
 aaauuuaaaa auccaauuaa gagag 25

<210> 1098
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 1098
uaauuuuuaaa aauccaauua agaga 25

<210> 1099
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1099
auaauuuuuaa aaauccaauu aagag 25

<210> 1100
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1100
uaauuuuuua aaaauccaau uaaga 25

<210> 1101
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1101
auauuuuuuu aaaaauccaa uuaag 25

<210> 1102
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1102
aaauaauuu uaaaaaucca auuaa 25

<210> 1103
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1103
gaauauauuu uuaaaaaucc aaaua 25

<210> 1104
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1104
ugaauauauu uuuaaaaauc caauu 25

<210> 1105
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1105
augaauauaa uuuuaaaaau ccaau 25

<210> 1106
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1106
uaugaauaua auuuuaaaaa uccaa 25

<210> 1107	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1107	
auaugauau aauuuuaaaa aucca	25
<210> 1108	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1108	
aaauaugaaua uaauuuuaaaa aaucc	25
<210> 1109	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1109	
caauaugaau auaauuuuaa aaauc	25
<210> 1110	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1110	
gcaauaugaa uauaauuuua aaaau	25

<210> 1111
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1111
 ugcauauga auauauuuu aaaaa 25

 <210> 1112
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1112
 cugcauauug aaauauuuu uaaaa 25

 <210> 1113
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1113
 ccugcauau gaauauuuu uaaaa 25

 <210> 1114
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1114
 uccugcaua ugaauuuuu uuuaa 25

 <210> 1115
 <211> 25

<212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1115
 guccugcaau augaauauaa uuuua 25

 <210> 1116
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1116
 aguccugcaa uaugaauaua auuuu 25

 <210> 1117
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1117
 gaguccugca auaugaauau aaauu 25

 <210> 1118
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1118
 cgaguccugc aaugaaua uaauu 25

 <210> 1119
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1119
 ccgaguccug caauaugaau auaau 25

<210> 1120
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1120
 gccgaguccu gcaauaugaa uauaa 25

<210> 1121
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1121
 ugccgagucc ugcaauauga auaua 25

<210> 1122
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1122
 cugccgaguc cugcaauaug aaaua 25

<210> 1123
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1123

ucugccgagu ccugcaauau gaaua

25

<210> 1124

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1124

uucugccgag uccugcaaua ugaau

25

<210> 1125

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1125

cuucugccga guccugcaau augaa

25

<210> 1126

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1126

ucuucugccg aguccugcaa uauga

25

<210> 1127

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1127
gucuucugcc gaguccugca auaug 25

<210> 1128
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1128
ggucuucugc cgaguccugc aaauau 25

<210> 1129
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1129
aggucuucug ccgaguccug caaua 25

<210> 1130
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1130
aaggucuucu gccgaguccu gcaau 25

<210> 1131
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1131

gaaggucuuc ugccgagucc ugcaa 25

<210> 1132
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1132
cgaaggucuu cugccgaguc cugca 25

<210> 1133
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1133
ucgaaggucu ucugccgagu ccugc 25

<210> 1134
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1134
cucgaagguc uucugccgag uccug 25

<210> 1135
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1135
ucucgaaggu cuucugccga guccu 25

<210> 1136
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1136
 cucucgaagg ucuucugccg agucc 25

 <210> 1137
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1137
 ucucucgaag gucuucugcc gaguc 25

 <210> 1138
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1138
 uucucucgaa ggucuucugc cgagu 25

 <210> 1139
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1139
 uuucucucga aggucuucug ccgag 25

 <210> 1140

<211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1140
 cuuucucucg aaggucuucu gccga 25

 <210> 1141
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1141
 ccuuucucuc gaaggucuuc ugccg 25

 <210> 1142
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1142
 accuuucucu cgaaggucuu cugcc 25

 <210> 1143
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1143
 uaccuuucuc ucgaaggucu ucugc 25

 <210> 1144
 <211> 25
 <212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1144

cuaccuuucu cucgaagguc uucug

25

<210> 1145

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1145

ucuaccuuuc ucucgaaggu cuucu

25

<210> 1146

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1146

uucuaccuuu cucucgaagg ucuuc

25

<210> 1147

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1147

uuucuaccuu ucucucgaag gucuu

25

<210> 1148

<211> 25

<212> RNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1148
 uuuucuaccu uucucucgaa ggucu 25

<210> 1149
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1149
 auuuucuacc uuucucucga agguc 25

<210> 1150
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1150
 uauuuucuac cuuucucucg aaggu 25

<210> 1151
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1151
 uuauuuuua ccuuucucuc gaagg 25

<210> 1152
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 1152
cuuauuuucu accuuucucu cgaag 25

<210> 1153
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1153
ucuuaauuuuc uaccuuucuc ucgaa 25

<210> 1154
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1154
uucuaauuuu cuaccuuucu cucga 25

<210> 1155
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1155
auucuaauuu ucuaccuuuc ucucg 25

<210> 1156
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1156
aaauucuuaau uuucacuuu cucuc 25

<210> 1157
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1157
aaaauucuua uuucacuu ucuc 25

<210> 1158
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1158
caaaucuua uuuucacuu uucuc 25

<210> 1159
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1159
ccaaauucu auuuucacuu uuuc 25

<210> 1160
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1160
gccaaauucu uauuuucac cuuuc 25

<210> 1161
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1161
 agccaaauuc uuauuuucua ccuuu 25

<210> 1162
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1162
 gagccaaau cuuauuuucu accuu 25

<210> 1163
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1163
 agagccaaau ucuuauuuuc uaccu 25

<210> 1164
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1164
 gagagccaaa uucuuauuuu cuacc 25

<210> 1165
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1165
 agagagccaa auucuuaauu ucuac 25

 <210> 1166
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1166
 cagagagcca aaucuuaau uucua 25

 <210> 1167
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1167
 acagagagcc aaauucuau uuucu 25

 <210> 1168
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1168
 cacagagagc caauucuua uuuc 25

 <210> 1169
 <211> 25

<212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1169
 acacagagag ccaaaucuu auuuu 25

 <210> 1170
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1170
 cacacagaga gccaaauucu uauuu 25

 <210> 1171
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1171
 ucacacagag agccaaauuc uuauu 25

 <210> 1172
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1172
 cucacacaga gagccaaauu cuuau 25

 <210> 1173
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1173
 gcucacacag agagccaaau ucuua 25

<210> 1174
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1174
 ugcucacaca gagagccaaa uucuu 25

<210> 1175
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1175
 augcucacac agagagccaa auucu 25

<210> 1176
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1176
 caugcucaca cagagagcca aaauuc 25

<210> 1177
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1177

acaugcucac acagagagcc aaauu

25

<210> 1178

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1178

cacaugcuca cacagagagc caaau

25

<210> 1179

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1179

acacaugcuc acacagagag ccaaa

25

<210> 1180

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1180

cacacaugcu cacacagaga gccaa

25

<210> 1181

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1181
gcacacaugc ucacacagag agcca 25

<210> 1182
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1182
cgcacacaug cucacacaga gagcc 25

<210> 1183
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1183
acgcacacau gcucacacag agagc 25

<210> 1184
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1184
cacgcacaca ugcucacaca gagag 25

<210> 1185
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1185

acacgcacac augcucacac agaga 25

<210> 1186
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1186
cacacgcaca caugcucaca cagag 25

<210> 1187
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1187
acacacgcac acaugcucac acaga 25

<210> 1188
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1188
cacacacgca cacaugcuca cacag 25

<210> 1189
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1189
gcacacacgc acacaugcuc acaca 25

<210> 1190
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1190
 cgcacacacg cacacaugcu cacac 25

<210> 1191
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1191
 ucgcacacac gcacacaugc ucaca 25

<210> 1192
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1192
 cucgcacaca cgcacacaug cucac 25

<210> 1193
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1193
 ucucgcacac acgcacacau gcuca 25

<210> 1194

<211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1194
 cucucgcaca cacgcacaca ugcuc 25

 <210> 1195
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1195
 ucucucgcac acacgcacac augcu 25

 <210> 1196
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1196
 cucucucgca cacacgcaca caugc 25

 <210> 1197
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1197
 ucucucucgc acacacgcac acaug 25

 <210> 1198
 <211> 25
 <212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1198

cucucucucg cacacacgca cacau

25

<210> 1199

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1199

ucucucucuc gcacacacgc acaca

25

<210> 1200

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1200

cucucucucu cgcacacacg cacac

25

<210> 1201

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1201

ucucucucuc ucgcacacac gcaca

25

<210> 1202

<211> 25

<212> RNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1202
 gucucucucu cucgcacaca cgcac 25

<210> 1203
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1203
 ugucucucuc ucucgcacac acgca 25

<210> 1204
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1204
 cugucucucu cucucgcaca cagc 25

<210> 1205
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1205
 ucugucucuc ucucucgcac acacg 25

<210> 1206
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 1206
gucugucucu cucucucgca cacac 25

<210> 1207
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1207
ugucugucuc ucucucucgc acaca 25

<210> 1208
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1208
cugucugucu cucucucucg cacac 25

<210> 1209
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1209
gcugucuguc ucucucucuc gcaca 25

<210> 1210
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1210
ggcugucugu cucucucucu cgcac 25

<210> 1211
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1211
aggcugucug ucucucucuc ucgca 25

<210> 1212
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1212
caggcugucu gucucucucu cucgc 25

<210> 1213
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1213
gcaggcuguc ugucucucuc ucucg 25

<210> 1214
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1214
ggcaggcugu cugucucucu cucuc 25

<210> 1215	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1215	
aggcaggcug ucugucucuc ucucu	25
<210> 1216	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1216	
uaggcaggcu gucugucucu cucuc	25
<210> 1217	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1217	
uuaggcaggc ugucugucuc ucucu	25
<210> 1218	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1218	
cuuaggcagg cugucugucu cucuc	25

<210> 1219
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1219
 ucuuaggcag gcugucuguc ucucu 25

 <210> 1220
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1220
 uucuuaggca ggcugucugu cucuc 25

 <210> 1221
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1221
 cuucuuaggc aggcugucug ucucu 25

 <210> 1222
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1222
 ucuucuuagg caggcugucu gucuc 25

 <210> 1223
 <211> 25

<212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1223
 uucuucuag gcaggcuguc ugucu 25

 <210> 1224
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1224
 uuucuucuua ggcaggcugu cuguc 25

 <210> 1225
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1225
 auuucuucu aggcaggcug ucugu 25

 <210> 1226
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1226
 cauuucuucu uaggcaggcu gucug 25

 <210> 1227
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1227
 ucauuucuuc uuaggcaggc ugucu 25

<210> 1228
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1228
 uucauuucuu cuuaggcagg cuguc 25

<210> 1229
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1229
 auucauuucu ucuuaggcag gcugu 25

<210> 1230
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1230
 caucauuuc uucuuaggca ggcug 25

<210> 1231
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1231

acauucauuu cuucuuaggc aggcu

25

<210> 1232

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1232

cacauucauu ucuucuuagg caggc

25

<210> 1233

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1233

ucacauucau uucuucuuag gcagg

25

<210> 1234

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1234

uucacauuca uuucuucuua ggcag

25

<210> 1235

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1235
auucacauuc auuucuucuu aggca 25

<210> 1236
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1236
cauucacauu cauucuucu uaggc 25

<210> 1237
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1237
gc auucacau ucauuucuuc uuagg 25

<210> 1238
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1238
cgauucaca uucauuucuu cuuag 25

<210> 1239
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1239

ccgcauucac auucauuucu ucuua 25

<210> 1240
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1240
gccgcauuca cauucauuuc uucuu 25

<210> 1241
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1241
agccgcauuc acauucauuu cuuc 25

<210> 1242
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1242
aagccgcauu cacauucauu ucuuc 25

<210> 1243
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1243
caagccgcau ucacauucau uucuu 25

<210> 1244
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1244
 acaagccgca uucacauuca uuucu 25

 <210> 1245
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1245
 cacaagccgc auucacauuc auuuc 25

 <210> 1246
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1246
 ccacaagccg cauucacauu cauuu 25

 <210> 1247
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1247
 gccacaagcc gc auucacau ucauu 25

 <210> 1248

<211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1248
 ugccacaagc cgcauucaca uucau 25

 <210> 1249
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1249
 gugccacaag ccgcauucac auuca 25

 <210> 1250
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1250
 ugugccacaa gccgcauuc cauuc 25

 <210> 1251
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1251
 cugugccaca agccgcauuc acauu 25

 <210> 1252
 <211> 25
 <212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1252

acugugccac aagccgcauu cacau

25

<210> 1253

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1253

aacugugcca caagccgcau ucaca

25

<210> 1254

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1254

caacugugcc acaagccgca uucac

25

<210> 1255

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1255

ucaacugugc cacaagccgc auuca

25

<210> 1256

<211> 25

<212> RNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1256
 gucaacugug ccacaagccg cauuc 25

<210> 1257
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1257
 ugucaacugu gccacaagcc gcauu 25

<210> 1258
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1258
 uugucaacug ugccacaagc cgcau 25

<210> 1259
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1259
 cuugucaacu gugccacaag ccgca 25

<210> 1260
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 1260
ccuugucaac ugugccacaa gccgc 25

<210> 1261
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1261
uccuugucac cugugccaca agccg 25

<210> 1262
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1262
auccuuguca acugugccac aagcc 25

<210> 1263
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1263
cauccuuguc aacugugcca caagc 25

<210> 1264
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1264
ucauccuugu caacugugcc acaag 25

<210> 1265
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1265
aucauccuug ucaacugugc cacia 25

<210> 1266
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1266
uaucauccuu gucaacugug ccaca 25

<210> 1267
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1267
uuaucauccu ugucaacugu gccac 25

<210> 1268
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1268
uuuaucaucc uugucaacug ugcca 25

<210> 1269	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1269	
auuuaucauc cuugucaacu gugcc	25
<210> 1270	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1270	
gauuuaucau ccuugucaac ugugc	25
<210> 1271	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1271	
ugauuuauca uccuugucac cugug	25
<210> 1272	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1272	
uugauuuauca auccuuguca acugu	25

<210> 1273
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1273
 auugauuuau cauccuuguc aacug 25

 <210> 1274
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1274
 uauugauuuu ucauccuugu caacu 25

 <210> 1275
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1275
 uuauugauuu aucauccuug ucaac 25

 <210> 1276
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1276
 auuauugauu uaucauccuu gucaa 25

 <210> 1277
 <211> 25

<212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1277
 cauuauugau uuaucauccu uguca 25

 <210> 1278
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1278
 gcuuuauuga uuuaucucc uuguc 25

 <210> 1279
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1279
 ugcauuauug auuuaucauc cuugu 25

 <210> 1280
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1280
 uugcauuauu gauuuaucau ccuug 25

 <210> 1281
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1281
 cuugcauuau ugauuuauca uccuu 25

<210> 1282
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1282
 gcuugcauua uugauuuauca auccu 25

<210> 1283
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1283
 agcuugcauu auugauuuau caucc 25

<210> 1284
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1284
 aagcuugcau uauugauuuu ucauc 25

<210> 1285
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1285

uaagcuugca uuauugauuu aucau

25

<210> 1286

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1286

guaagcuugc auuauugauu uauca

25

<210> 1287

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1287

aguaagcuug cauauugau uuauc

25

<210> 1288

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1288

uaguaagcuu gcuuauuga uuuau

25

<210> 1289

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1289
auaguaagcu ugcauuauug auuuu 25

<210> 1290
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1290
gauaguaagc uugcauuauu gauuu 25

<210> 1291
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1291
ugauaguaag cuugcauuau ugauu 25

<210> 1292
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1292
augauaguaa gcuugcauua uugau 25

<210> 1293
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1293

aaugauagua agcuugcauu auuga 25

<210> 1294

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1294

aaaugauagu aagcuugcau uauug 25

<210> 1295

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1295

uaaauagauag uaagcuugca uuauu 25

<210> 1296

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1296

auaaaugaua guaagcuugc auuau 25

<210> 1297

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1297

cauaaaugau aguaagcuug cauua 25

<210> 1298
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1298
 ucauaaauga uaguaagcuu gcauu 25

 <210> 1299
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1299
 uucauaaaug auaguaagcu ugcau 25

 <210> 1300
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1300
 auucauaaaau gauaguaagc uugca 25

 <210> 1301
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1301
 uauucauaaaa ugauaguaag cuugc 25

 <210> 1302

<211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1302
 cuauucauaa augauaguaa gcuug 25

 <210> 1303
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1303
 gcuaaucaua aaugauagua agcuu 25

 <210> 1304
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1304
 ugcuaaucau aaaugauagu aagcu 25

 <210> 1305
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1305
 uugcuauuca uaaaugauag uaagc 25

 <210> 1306
 <211> 25
 <212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1306

auugcuauuc auaaaugaua guaag

25

<210> 1307

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1307

uauugcuauu cauaaaugau aguaa

25

<210> 1308

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1308

guauugcuau ucauaaauga uagua

25

<210> 1309

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1309

aguauugcua uucauaaaug auagu

25

<210> 1310

<211> 25

<212> RNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1310
 caguauugcu auucaaaaau gauag 25

<210> 1311
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1311
 ucaguauugc uauucauaaa ugaua 25

<210> 1312
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1312
 uucaguauug cuauucauaa augau 25

<210> 1313
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1313
 cuucaguauu gcuaaucaua aauga 25

<210> 1314
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 1314
ucuucaguau ugcuaaucau aaaug 25

<210> 1315
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1315
uucuucagua uugcuauuca uaaaau 25

<210> 1316
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1316
uuucuucagu auugcuauuc auaaa 25

<210> 1317
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1317
auuucuucag uauugcuauu caaaa 25

<210> 1318
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1318
aauuuucuua guauugcuau ucaua 25

<210> 1319
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1319
uaauuuucuuc aguauugcua uucau 25

<210> 1320
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1320
uaauuuucu caguauugcu auuca 25

<210> 1321
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1321
uuuaauuucu ucaguauugc uauuc 25

<210> 1322
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1322
uuuaauuuc uucaguauug cuauu 25

<210> 1323	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1323	
guuuuaauuu cuucaguauu gcuau	25
<210> 1324	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1324	
uguuuaauuu ucuucaguau ugcua	25
<210> 1325	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1325	
uuguuuuaau uucuucagua uugcu	25
<210> 1326	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1326	
uuuguuuuaa uuucuucagu auugc	25

<210> 1327	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1327	
uuuuguuuua auuucuucag uauug	25
<210> 1328	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1328	
uuuuuguuuu aauuucuca guauu	25
<210> 1329	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1329	
ucuuuuuguuu uaauuucuuc aguau	25
<210> 1330	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1330	
aucuuuuguu uuaauuucuu cagua	25
<210> 1331	
<211> 25	

<212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1331
 aaucuuuuugu uuuaauuucu ucagu 25

 <210> 1332
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1332
 caaucuuuug uuuuaauuuc uucag 25

 <210> 1333
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1333
 gcaaucuuuu guuuuaauuu cuuca 25

 <210> 1334
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1334
 agcaaucuuu uguuuuaauu ucuuc 25

 <210> 1335
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1335
 cagcaaucuu uuguuuuaau uucuu 25

<210> 1336
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1336
 acagcaaucu uuuguuuuaa uuucu 25

<210> 1337
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1337
 gacagcaauc uuuguuuuaa auuuc 25

<210> 1338
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1338
 agacagcaau cuuuuguuuu aauuu 25

<210> 1339
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1339

gagacagcaa ucuuuuguuu uaauu

25

<210> 1340

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1340

ugagacagca aucuuuuguu uuaau

25

<210> 1341

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1341

uugagacagc aaucuuuugu uuuaa

25

<210> 1342

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1342

auugagacag caaucuuuug uuuaa

25

<210> 1343

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1343
uauugagaca gcaaucuuuu guuuu 25

<210> 1344
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1344
auauugagac agcaaucuuu uguuu 25

<210> 1345
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1345
uauauugaga cagcaaucuu uuguu 25

<210> 1346
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1346
auauauugag acagcaaucu uuugu 25

<210> 1347
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1347

gauauauuga gacagcaauc uuuug 25

<210> 1348

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1348

agauauauug agacagcaau cuuuu 25

<210> 1349

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1349

aagauauauu gagacagcaa ucuuu 25

<210> 1350

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1350

uaagauauau ugagacagca aucuu 25

<210> 1351

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1351

auaagauaua uugagacagc aaucu 25

<210> 1352	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1352	
uauaagauau auugagacag caauc	25
<210> 1353	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1353	
auauaagaua uauugagaca gcaau	25
<210> 1354	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1354	
aaauaagau auauugagac agcaa	25
<210> 1355	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1355	
aaauaaga uauauugaga cagca	25
<210> 1356	

<211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1356
 uaaauauaag auauauugag acagc 25

 <210> 1357
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1357
 auaaaauaaa gauauauuga gacag 25

 <210> 1358
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1358
 aaauaaauaa agauauauug agaca 25

 <210> 1359
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1359
 uaauaaaaua aagauauauu gagac 25

 <210> 1360
 <211> 25
 <212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1360

auaaauaaau uaagauauau ugaga

25

<210> 1361

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1361

aaauaauaa auaagauaua uugag

25

<210> 1362

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1362

aaauaauaaa uauaagauau auuga

25

<210> 1363

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1363

uaauaauaa auauaagaua uauug

25

<210> 1364

<211> 25

<212> RNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1364
 guaaaauaau aaauaaagau auauu 25

<210> 1365
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1365
 gguaaaauau aaauaaaga uauau 25

<210> 1366
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1366
 ugguaaaauaa uaaauaaag auaua 25

<210> 1367
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1367
 uugguaaaaua aaaaauauaa gauau 25

<210> 1368
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 1368
uuugguaaaau aaauaaauaua agaua 25

<210> 1369
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1369
auuugguaaaa uaauaaaauau aagau 25

<210> 1370
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1370
aaauuugguaa auaauaaaaua uaaga 25

<210> 1371
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1371
uaauuuggua aaauaauaaau auaag 25

<210> 1372
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1372
auaauuuuggu aaauaauaaa uauaa 25

<210> 1373
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1373
aaauauuuugg uaaauaauaa auaua 25

<210> 1374
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1374
gaauauuuug guaaauaaua aaaua 25

<210> 1375
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1375
agaauauuuu gguaauaaua aaaua 25

<210> 1376
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1376
uagaauauuu ugguaauaaua uaaau 25

<210> 1377	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1377	
uuagaauaau uugguaaaua auaaa	25
<210> 1378	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1378	
cuuagaauaa uuugguaaua aaaua	25
<210> 1379	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1379	
ucuuagaaua auuugguaaa uaaua	25
<210> 1380	
<211> 25	
<212> RNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Synthetic oligonucleotide	
<400> 1380	
cucuuagaau aaauugguaa auaua	25

<210> 1381
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1381
 acucuuagaa uaauuuggua aaaua 25

 <210> 1382
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1382
 uacucuuaga auaauuuggu aaaua 25

 <210> 1383
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1383
 auacucuuag aaauauuugg uaaau 25

 <210> 1384
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1384
 aaauacucua gaauauuug guaaa 25

 <210> 1385
 <211> 25

<212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1385
 aaauacucuu agaauaauuu gguaa 25

 <210> 1386
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1386
 gaaauacucu uagaauaauu uggua 25

 <210> 1387
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1387
 agaaauacuc uuagaauaau uuggu 25

 <210> 1388
 <211> 25
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1388
 aagaaauacu cuuagaauaa uuugg 25

 <210> 1389
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1389
 gaagaaauac ucuuagaaua auuug 25

<210> 1390
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1390
 ggaagaaaua cucuuagaau aauuu 25

<210> 1391
 <211> 55361
 <212> DNA
 <213> Homo sapiens

<400> 1391
 agctcctagg aagcttcagg gcttaaagct ccactctact tggactgtac tatcaggccc 60
 ccaaaatggg gggagccgac agggaaggac tgatttccat ttcaaactgc attctggtac 120
 tttgtactcc agcaccattg gccgatcaat atttaatgct tggagattct gactctgcgg 180
 gagtcatgtc aggggacctt gggagccaat ctgcttgagc ttctgagtga taattattca 240
 tgggctcctg cctcttgctc tttctctagc acgggtccac tctgcagact cagtcctta 300
 ttcagtcttc tctctcgctc tctccgctgc tgtagccgga ccctttgcct tcgccactgc 360
 tcagcgtctg cacatcccta caatggctaa aacagcaatg gtaaggcact gcgcctcggt 420
 ctccgtcggc tctacctgga gccacactct cacctcctct cttgagctct agaagcattc 480
 agagatattt tataaagaaa aagatgttaa tggtaacaca ggaccaggaa ggacagggca 540
 gttctggggg aggtgggagg gcagagaaga ggtctatgga aatctaaagc gaagaatttc 600
 ttttaaaagg tagaagcggg taagttgccc tcctatgggt agagaattta ttctgtttcc 660
 atatttaaaa ttaggactca atcgtgaggg gaggaagcta ccttaactgt ttgccttaaa 720
 tgggcttaag ggacattttg gaaagtgcct tataacgacc tttttttttt ttatttcttc 780

tctagtttaa	gaagaaaata	ggaaaggggt	aaaggggaagg	tgggagaaag	gaaaaagaaa	840
attgcaaagt	caaagcggtc	ccatcccgt	gtttgaaaga	tgggtggaga	cggggggagg	900
ggatggagag	aactgggcac	attttacggt	attgtctcgt	cgaagaaacc	gctagtcctg	960
gggtgcggtg	cagggaggta	agacggcggg	ggacaggggtg	ggggtaggac	ctccgctcct	1020
ttgttttagg	gcaagggagg	ggaaggagag	aggaagtcgc	ggagggcgtg	gagggcgcg	1080
gtgggcagct	gcaggggcgg	ggaagcgcgc	ggcagggagg	ggtggaggga	cagcggcttc	1140
gaaggcgctg	gggtggggtt	tctttgtgtg	cggaccagcg	gtcccggggg	gaggcacctg	1200
cagcgtggg	cgcacaatgc	ggacagcccc	acccagtgcg	gaaccgcgca	gccccgcccc	1260
cccgcccggt	gctgcatctt	cattcgaaag	ggggtcgggt	ggggagcgca	gcgtgacacc	1320
caggagccca	accctgcggg	gacagcggcg	ccacgccccg	cgctccccgc	tcccgactcc	1380
ccgccgcggc	ttccaagaga	gacctgacca	ctgacccccg	cctccccacg	ctggcctcat	1440
tgttctgctt	ttaagagaga	tgggaaaagt	gggttaacat	ttttcttttc	ggaagcaa	1500
tacatagagt	gtttagacat	agacacagat	aaagggttct	ttgaagacct	ttgatcgttt	1560
gcgggaaaag	cttctagaac	ctagacatgt	gtatgtataa	taatagagat	gacatgaa	1620
cgtatataaa	gcaaaagagg	tcaaagtctt	aagttaagcc	acgcgaaatt	tccgttttgt	1680
gggtcagaca	gtgccaaata	tcggcaat	cataagctca	gagagacaag	acagtggaga	1740
cacaggatga	ccggaaga	ttctggattc	agggccttca	tccgcaattg	gtcttgtgcc	1800
ttgagtggcc	acggttctgg	cgctcagtgg	ccccgggggtg	aaaaggcagg	gtggggcctg	1860
gggtcctgtg	gcagctggaa	gcacgtgtcc	cccgggactt	ggttgcagga	tgcgagaca	1920
gggaaagctg	ccgaaaggac	tccatctgcg	cggctccgcc	ctgccctacc	ctccccgcgg	1980
agccggggag	acctcaggct	ccgagactgg	cggggaagag	gaatatggga	ggggcagttg	2040
agctgtatgc	agtcctggaa	cctctttttt	cagccccgca	gtccacaacg	gcccagcac	2100
cccttgatgt	gcgcagaccc	ccggcgtggc	tctcagcccc	agcaccgagc	ccctcccagc	2160
caagcgggtg	gctctgcaga	aaagctggct	cgagccccgc	ccggccacac	aaaggcgcgg	2220
ccccaccag	cccgggcgcg	agaccgcaga	ggtgaccccc	ttcccaggga	ttcaggagg	2280
gctgtctctt	ctcgcccacc	cacggtccgc	ggagctcggg	gctttttttt	ccccagcca	2340
agccccccgc	ccaccctctg	ttctctatga	ttttccagaa	tggagacccc	gcgaggggct	2400

tctctaaggg agaccctcgc tcctccagcg gggcgcggct cggccccacc cctcccagct	2460
gaggcccaga gccgcctacc gctggccggg tgggggcgca cgtggcgact ggggtgtgtgg	2520
agcgcagcca gccctgcaga gccccgcgcc gcgccctgcg ctccccctccc cggagttggg	2580
cgctcgcccc cgcggtgcag ccggggagac cggtttctgc gcagtgtcct gagctacccc	2640
cgctttccac aattcgcagt tcactcgcac gtccagaaag gttctgagaa tgggtgggtg	2700
gggcgatctc gcctcgcttt ctgcaccct cagaaagggt tccgctgcag gctagtggct	2760
gcaaactcat cgtcatcatc agtattatta tcatttcaaa tcgttggttat tatttaatga	2820
ttcagtagcc ttgtttgttc tcatttgttc aaaagggacg tggattgctc ttggttaagg	2880
attaaccctt gttgcgttcg ctttgcttcc tcctaattgc cctcatccct ttccccaca	2940
aaaaggtaaa tttgtctcca gttgttcatt ttaagttata aagcaaatat atttttgctt	3000
cctgccagga ttatgtatgt tcatgtggct aagatacatg tgcaagtgct tgctaagagc	3060
agggtttgtg tgccaacgat tgctggaaaa ttctctgcaa agaattgttt gtggctgcaa	3120
tgggtgagaa tacacatata taattgagat gatcttcaac ataaggttat atctataaat	3180
atataaatat agtttatgca caaaatttta agttttttcc cctgaaactg ttcttccaac	3240
tgctgattct tgatacagcc tcaatcctac acagatacat ggatcgtgaa atggtagccg	3300
ccatccaaat aaaaatccca ccccaaatat gacaaacgca agcatccttt ctggccataa	3360
tttaactgca ttgcaaadc atgaaaaaaaa cactacttct gcagtattaa aataatagat	3420
tttgaaatta attccaattt caaagataat taattatcag ggcgagtgtc tttttcctga	3480
ttcattaaac aattatgtat tcagcatgat tgtaagagggt gcatataata ttccccatta	3540
tcttttctaa tgaagtgggc accttctgaa tggatatata agtaactaga aatgaaaagc	3600
tgaggatttg gtcagaattt caggataaaa ctgaaagaaa tggcagtagt ttatcaatta	3660
atctcatgta tttagtttat accagggtgag taagctgagc ctgcaataaa cactctctgt	3720
cccagtgtaa cacgtcgcag gtagctagaa tgataggata aattaataga ccttgtgggtg	3780
tttgtctatg cacgttaaaa ttctctgaga gaaagtatat tttaaaatga taattaagat	3840
tggacatttg tgctattaaa atctacaact ttagtcaaaa ttcacaatgg ttttttttta	3900
caataatgtg acttacagat ttgtagtaaa ttattctatt ctaaaagaga aatgagtgtt	3960
tttattgtta cagctattac ctcatthaata tttttagcaa acttttattt gttgcattga	4020

aagcagtttt aattactttg ggttttttatt tttcaaatta ctaatggata gatggtggaa	4080
taagcattta atcatttggc acaatatgac ttccatcaaa tagctcattc tcagtgatta	4140
aaaaatgcta caagaggcta caatttactc agattcagga aatgtccttt cagagtgcc	4200
taaggctgat tcatataata aaatagtttt cttccctata atttaagatc aaatagttac	4260
ttagttctgt gaatacctag cagtagctat caaacagaat tttaaagtta aatctgtaca	4320
actaacaatg aagtggagga tgaatcgata catattgaat ggaagacttt gtcattgata	4380
aattcaggcc atcttttagga aaattccgga tttatcaatc accattatctt tttacttcaa	4440
ctgagtgtga ctgatcacat gctcaggcta ccttggtagc tcattgctca caggaggctg	4500
aaaaaagctg gcctccgagc aggaggaagc tcagagcaca aacctaggcc tgggcgtggc	4560
cactggggagc tgctgatagc gaaccccagc tcacaccagt ttcttttttg gtcgtgggaa	4620
gaaaaacaca tattatcctg ttgtcacaag atctgtgacc ttatatgaaa aaatgctaga	4680
atctttttcat taaaaaagaa aatactgaac tagccagtga cccagatggtt ttcagaacct	4740
agactgggtc tgtccattgg aaaacctcgg tgtctgcatt aacttttcac cacactagag	4800
ggcaatcatg ttctctaaaa aagcagatga ttgatgtaaa cctagttcca aatattaact	4860
gtttaataaa atcttttctt ttaccaggaa cattcaagtg tttattcaat aagctgatgc	4920
catgctttac cctagtggat gaacagagct tgtacaattt tcaaggagac aggatgaaat	4980
gagtgggtcat aatctgaaag tagatacacg ccctgggttaa ttattccctg atggttttac	5040
ttctcagttt tattacattg ttattataat accatttatg ttacttctga gattttgtag	5100
tggataaata gtagaaaaat gtcagtagta atagcaaagt tatttagcag ccgaatattt	5160
taatgcttaa aaataaagga ataaattaaa gaaaatcatt gtttacttct tcatcgattg	5220
aaatgtgccc cctgttcaga gcacatctga atatcagagt ctccacctgc agagaacatg	5280
cagcttagcg agtaaaacag gcaggtatgt gatactgagg aggtgtacca aaaactgact	5340
gctgttattt ttcccatctt ctaagtctgt ctttcttttc catttaaaga taccttttta	5400
aatctaattc aatgtgattt caatctagtt ttatcagatt tcaacaatta ttgagcatct	5460
ccttgtagtg gttttctgtt tattagaaaa tcgatgttaa ttttaacgaa gtaagaagaa	5520
atatataagt ataaactaat tttgggtatc atcaaaagtg gatTTTTTaa atatgcattg	5580
atagaattat tttttgatta catTTTTatgt aattctaadc cagctataaa atatttaata	5640

gtgtcatatt actgtgttcc tcaaactttg atgtgcatat gaattacctt tgattttcat	5700
taaaatgcaa attctgattc aatacatctg gcttgaggca gacattctgt cttccgaaca	5760
agctcccaga tgatgctgat tctgaccact aaacacatca gttttaggga tattaacttg	5820
taatatacag gtatccctcc tggttaagctc tggtattatg tcttaacatt tttaaactta	5880
tggtaatctt tacaaaatat ttactttccg aactcatata cctggggatt ttattactct	5940
gggaattatg tgttctgccc catcactctc tcttaattgg atttttaaaa ttatattcat	6000
attgcaggac tcggcagaag accttcgaga gaaaggtaga aaataagaat ttggctctct	6060
gtgtgagcat gtgtgcgtgt gtgcgagaga gagagacaga cagcctgcct aagaagaaat	6120
gaatgtgaat gcggcttggtg gcacagttga caaggatgat aaatcaataa tgcaagctta	6180
ctatcattta tgaatagcaa tactgaagaa attaaaacaa aagattgctg tctcaatata	6240
tcttatattt attatttacc aaattattct aagagtattt cttcctgaat accatgtgag	6300
aaaattctta agaatttatt gagtatgact gtatatttga aaagagtgtt ttcttctgct	6360
tatctaagcc aataaaggat cttcattatt caattctaac tttctaagga agtcaaccta	6420
cagatcagaa agaggatctt caaggaatag catcaaagac atagtcaggt ctcccatgca	6480
gtgactggct gaccatgcag ccattaccac ctttctggaa atattatgct gcaaaaatga	6540
tacaatacac gaaatatctc aaattaaaaa atataacatt tcccaaatag ggcaactaaa	6600
acatgatccc aaataaaaact agcttcaggg tttgcagaat atactgttac tcaacacaaa	6660
gttggactaa gtctcaaagt tagccattca gttgttggtta acagttcatt tcagggtctc	6720
tcagaagctg ggaaactttc cttttttgca atttcttgta cattgaagga aaggaagaca	6780
cacttaagac agcattacaa aagtaattca tgtttttaaat gtttaattct ggcaagtcggg	6840
cagggtctctc tgtataacct cttttggaga tgacaaaaat ctaaacttga gggcctcgag	6900
ccaataagtc ttcctatttc ttactcaaa ctttttcccg caatgggtgct ttctttcaac	6960
tgtttttctg gtgtattcat aaattccaga ttctctatgg gaagtaactt ttattgattg	7020
atttaaccct tgtatagcac atataacatg caaggcattg ttctaagaac tttccacata	7080
ttaactgtgt taatcactta ataatcctaa gtaggttcta ttacagatat ggaaactgag	7140
gcacagaaaag ttgaagtatc ttactcaagg tcacacagtt agtcagatcc agaatttggg	7200
cccaggccat ctggcttcgg aatccatctt tcaccgattg ctgctagtct catatctgtt	7260

ccatgttaga ggtgagctcc cattgcagag gtcacacctg tgatatcacc attttattta	7320
aacagaccag agatggtctt ctcctttctg atcacagact caccttgaag agaaaatact	7380
tccaaattga tgcctagttt taatagctta cctggggctt attcaaataa ttgccatgat	7440
ttaggctttg ggagaaagag agctatgagg ccgtgtgggt tgtaacgtat gagacacatg	7500
gcgttctgca ggctcagcac agcatcgatt tctgggtggga acacactctg atgaccagtt	7560
ccagaaataa cattgactta atctcctcag tcccatcatg gttagcacat ttcaaaatgc	7620
ctccttaact acttccatag gccagagata tttagtttta acattttgtt gaataaaata	7680
aatttacaca ttcacattta atataactat tagatgttat ttcaagattc tcttcatatt	7740
accatcaaag caggcaggca ggcaggagag aactgtagga aggttttgaa tcccttgtga	7800
aacattttta attatctttt aataaaggaa tcaggccctg tcatttgtca aggagacatt	7860
tgtagtagta aagcttgtgt ttataatatc cttttttatt agtcatgatt aaagataaca	7920
tttgtgtaca tttgttctca caaaacactt ttatatgagt gtaaaggtta attaatgcat	7980
ttcagccatc attttgctgg tcatgtggaa atatagcttc tttaggaatt gtacttagag	8040
taggagccac atattatact ataaaacat aacaaaaata ttttaagttt gttctcactt	8100
gttggtgacc tccagagtaa aatatttaat actctggaaa gttatgggtt tcaaaattta	8160
ttttatggca agaaatagat aattacagtt ctcatagagc acatttaaaa taatttattt	8220
ttatagggca aaaatattgc ctaggactga atgatttttt tttttttaca aagattgtaa	8280
agcaacgcct gcaagagtgc ccatttagca gttattcttc tggaataatt gtattttgga	8340
tggtggagtt cgcacattaa ccattagtac aagtaccaa tataacaata gatcatcagg	8400
ataataaatc tgtccatctt ttagttgtat gtctttatat caggataaag agaattgagt	8460
gaaatttatc taaacctagt cccacaaata cttttacaag agagcatgtt aaagtgtaaa	8520
ttaaattttt attagcattc tactctgtct ttggaagttt tttttcctta tgaaatgcag	8580
ccataaagtt taacttccat taacaaagct gctcacagta aacctattat aataatagtt	8640
tcccagtttg ggcttcctag tgaggagcaa cctaactcac acgaaacaac cccaacttat	8700
aatatattga ctgttacaaa actgagacca gaaaatccca tcaagatgggt actgttatca	8760
tttccagact ctcgggaaga acattaatca tctcaggcac ttttaggata gacttattgc	8820
agcctccctg ggaactctgc ttcagaacat aattattttt attaatgcag agttactttt	8880

tatttccaac	aaaaatatct	attgttatta	tttaagtctt	acagctttat	ctgagaaatt	8940
ccaattagca	cccttctcat	aataaatatt	caaacacatg	aaaaattacc	aaagttgttc	9000
tagtctttta	atgacatatt	acatgatcct	gcactcttgt	cactttaaaa	attatctttt	9060
tattatattt	ctgatgattt	ttttcttata	tagtttttta	aaaggagcag	gcaagcatag	9120
aagactaaaa	aatgttcaaa	agaaaaatta	aatcgcatga	tctatctata	tgggaccttg	9180
tcatttttag	aaaacattca	cctgcttcat	ccttttgaat	cttcatataa	tccctctgag	9240
atgggcatac	tatacaagtt	gtcttattta	aagattggta	aatttaagct	caaataattt	9300
attcagtggc	aagcctcaga	ggcagactcg	gaacacaggt	ctaatatata	ttatatatat	9360
attataacat	ataatatata	tattacatat	aataaagttg	tgtatattat	ttacctatca	9420
aaatatttat	atgtaatata	taaatatgtt	atatatcatg	tatgtgccta	tttcatacat	9480
atatacacat	tcatgcaaaa	taaggtttag	cactccctcc	actgtcctgt	aataaaacat	9540
gcacagtgag	aatagtcata	cacgaggcat	atttgtcttc	agtttaaagt	cattgatagt	9600
cagtgtcact	aactaaagta	aaatagattg	gagcaccaac	tttgttctga	agcctgtgcc	9660
aggtattatg	agaacaaaaa	taaaaatgtt	cctcaccctt	ggtggattta	gtcttttgca	9720
gaaaaaaaga	tcctgtacat	gtcagaaagt	tcaatagtaa	taatggtaat	ttataactat	9780
aaatggaagt	caccatctca	caatttcacc	atcttaacaa	ttttgttaaa	ctgccctaca	9840
atattacaag	atagtacata	atgatacact	agtaacatca	actaggaagt	accaagatcc	9900
accaaaaaggc	tgaaaaattt	aaatatttaa	tgagtccatc	aaccaatctg	gccagagaat	9960
tctttaatta	aaatgcttcc	caaattttac	tgagaatcag	cagcgtttga	ggagctagcc	10020
tccacccccca	gaggttctca	ctctattagg	tctgaagcag	gtcccatgga	tttgcatttc	10080
taacaagctc	ccaggtgggtg	ctgatgaggc	tgattcagaa	ccacacttgg	agtagaccta	10140
aaacagcagt	gacctgtagg	gtccccaagc	agcaggccag	gacagcatgt	gagttacgtc	10200
ctctgtggag	ctctgcaaca	aggcgtcaag	aggtcagagt	ctaagtcccc	atcagctctg	10260
cccttctcca	ccagtgtctgc	tggtgctgca	tggaaggaag	agcccagaag	ggattctgag	10320
tttcagtctt	tactcttgct	gacgcacctt	ggtcagggtca	attttcctgt	ttgttcctct	10380
aattcagcat	ctgtaaaata	gccatgtgaa	ctgccttgct	catatcagag	ggtctttttc	10440
agactcaagg	aaaaaacgt	gaaagtgatt	agtgtctgtc	aagtagtata	taaatgcaag	10500

aagttgagtt tttaaattgt cattagatat aaatacccat gtgcatgcat ttagaatgag	10560
taaagaggga acaaggagcg caatcaaaaa ctgcgtcatt tgctttttga aaaatacttt	10620
ctatgtaatg aaaagtgaag taaaatgtta attgagtccc tctgacaaca gcatcagacg	10680
ttttgcagtt cttgtgatta gaaccacact ggccagccct tcttcctcct aaagaagagc	10740
cttcttcttc ttaaatgaag gttggctcag aagaagcaat taactcattc aacgttttgt	10800
tacagtcaat ccacatccaa cttttcccca actcaatctg ctttaaggga aggatggtaa	10860
gtggtggccc aagatggcaa ccatcaagct tagagaatct ctagaagcag ggggtgtccc	10920
agcaagtaga cactgaaaat atgagagggc tgataagcca gagataaaac tcagtactta	10980
ctttgcttct agtccatgtc tacccttttc ttggcaccac cttgacacta ccctctgagt	11040
ccaccttcct gagatggtag aaactctgct tagacaaagc agcccatgtc caaagggtgt	11100
agggtcagtt ttaaagctgc cttcaaaagt taaaacagaa gtgtaaagtt ctgtgcaatt	11160
aaaaataatc agcttgtctt ggaactcaaa cgaatgtaaa atcctatgaa aattaaaaag	11220
cagtaccaca agttacccca aaagtcctta ggtcagtaac tgttcctgtt acaggtaaga	11280
gagagcatgg attagaggtg ggcgtgggta tccagtggac atgggttttga accatgctcc	11340
actactactc actatctgag aattctttaa tttattaatc atttctatat tataattttc	11400
tcagttatga aatgggaaaa caatacctaa atcacatggg tggttaagtaa gcaattgatt	11460
gttaagcatt tggatcatcaa aaatattaat ccccttcctt gattccctag ataaatgatg	11520
aaaatactaa ataaaaataa taaaaattta aagtgaacat ctcaattctt atactttgtt	11580
aatttctaca tgtattacaa atctactaga aattacttgg aattgaggaa atgattactg	11640
cttaataatt ctttgtggta gagggagagt tggatatcata tttatgagac agcagccaat	11700
atagtatatc tcaaaggaaa aaatccattc tacataatgc cagaatttaa tagttaagca	11760
ttttatctag gtcacagcac aataagcaag atggataatt aaaataaaaag tatatttctc	11820
ttgcatatat ttctcatttc atgttttcct atcatatttt atatcttacc ttacttcaaa	11880
tacatatata ctttcaataa aactgagcct tcttgcttac ccaggaagtt tcatcattca	11940
gtagaaataa aagatgactt tagaaatatt aaaatacaaa aatctacact gaggtctttt	12000
gaatgcagga aaaagaatta tatcacacac acacgtacac gcacgcatgc atacacacac	12060
acagaacctc tcgttctttc ttaacatctt atcaatccat cagtttctact cccactccgt	12120

atcacctgac tgtgcacaat atctcattgc cacctcccag tcttctccct gcctggcacc	12180
ctcctgctct cctgcttcca ctttaaacac ctttccttca gctaggctctt ttctttcagg	12240
gatcctcccg ttgctttctt atctggatca atttagcctt cctcttctcc acccattagt	12300
ggataagcac gacaaagaca ctagagtcaa ataatacaaa cagaatatac cttagatgag	12360
tatggatgatg aaaaggatat ggatacttag agtttagcac tattctctca gccactcagg	12420
aaagcaacgc ctttacaatc aatagtgttt caggtaccaa tcaataatct gttattgcta	12480
tttttaaaat ctataaggta tcagtaaaat gtaattacta gagcaacaaa gatatcttgt	12540
gaaatcaaat tagtattcat ccagcaactg agtacaaagg tttaaggagg gataactacc	12600
aataccaaaa cattttaagc attttgTTTT gcctcctaaa tatcaaatca tgtaaattgtg	12660
tggtacataa attaggaatt atatttatga catagctgca gacatattaa gagaaatatg	12720
tgcttatatt tacaagtata gtacagttct ttttcatatt agatactgtt gatgataatc	12780
tgcatataaa aatgctcaat attttttcac atttataagc cataaaatac agctaataaa	12840
atgtgtttct actttctcat aaacatggaa tagtgacaaa caaggagctt tatatgaaag	12900
caccattaca atttaaactc tcacaaggtc ataatatatt gcactaagca ggagagttca	12960
gcttatTTaa aaaaaaaaaat aaactctaata gaggttctgg aatgcagagc caaagcataa	13020
agatggaaat aaaagaattg catgtcttct gaactgactt gggtgatgat ttttttaaaa	13080
aaggTTTTgt gtcttctgac ttgggtgatg attttttaaa aaaacgtttt gtggtagaac	13140
aaataaggta aatgaaattc agtatTTagg atgaaaagtt tttctaattt caggaacaac	13200
attgaagaaa tattgaacta agcagctttg aaagaatcag attccatttg ttgaaatttt	13260
tctgagaatg aattttttta agacagtgtg cacagttgca gtgtgtattg gttatggatt	13320
gtggcaagct atattacaac ttaccaaga aataaggagg ctgggcgtgg tggctcacac	13380
ctgtaatccc agcactttgg gtggccgagg cgggcggatc acgaggtcag gagatcgaga	13440
ccatcctggc taacacggtg aaaccccgtc tctactaaaa gtacaaaaaa ttagccgggt	13500
gtggtggcgg gtgcctgtag tcccagctac tcgggaggct gaggcaggag aatggcgtga	13560
atccgggagg gggagtttgc agtgagccga gattgtacca ctgcactcca gcctgggcga	13620
cagagcgaga ctccgtctca aaaaaaaaaa aaaaaaaaaa aaaagaaaga aagaaagaag	13680
gaaaaaagtc acttgaaaag aatactggac tttgtgtcca gcttgcatag ctgaaaagaa	13740

taaaaacctg tccacttaaa ctcatgtcaa aaagaagatg tcactcctac aaatagcaaa	13800
gagtcagtga attattctat ccagaaaagt atacatttca tcccttttga taaatttttag	13860
aagtgaacta tgaatacata cgggtgaggat agccagctaa gaagtcaaga aggattttctc	13920
aaatttgctg ctacagaaaga tcatactctc caaaaaaca ataatagcag gctttccaag	13980
tcaaccttga atccagcttt cttttatctt tccttcttgt gaactttcac tagtttacta	14040
tctaacaatg aatttgacga tagccacata ccatcttata gcaatatttg ttatcatatc	14100
ccttggtatt tatcattcac ctgctctgct tgagccagct acaagtcaca tgtcccacgc	14160
actttttcct gtttgatttt ttacagcact ttgagacatg tctcattatt cctacttgac	14220
aggaaagaag ccatggaaag ttgagtgact tgctcctgat cacaaatgct ggccaaggaa	14280
gagtcgagtt tcaaactcaa tgatctttcc actgcactct agattcctca ttttgaacta	14340
tttttttatt ttttgacta tagacttttt tccacatttt gaactgtttt ttattttttg	14400
cactatagac ttttctctta taccacaacta tattgatgac ttcttttagg ctagaaactt	14460
gtttcactta ctttcccttt cttcagattg ctgcaatatt ggccaacatg tattgggtac	14520
ttactgagtc aagtactgtg attgtgcaa gtatcttata ggaggattat catcctcatt	14580
tttacaggtg agaaaggaaa ggaggtaaag tcacacacag ccaacaaaaa tggtagcacc	14640
aggatttgaa acaaatcagt ctgacccaag ttgactttgt taaccactgt atgcacagtc	14700
ttcttagaca tagtaagagc tctaattgtg tttgggtgatt tgattattat gacaaagtaa	14760
gtaaggggaag caggagagaat tataagaaat aaggctccac aacacttggc tatagcaaag	14820
ccccttaaaa cttcaaaagg tcacccaaag aataaagatc aggtctgggag cagtggctca	14880
cgcctgtaat ccagcactt tgggaggccg aggtgggtgg atcacctgag ttcaggagtt	14940
cgagaccagc ctggacaaca tgggtgaaacc ctgtctctac taaaaataca aaaattagct	15000
ggatgtggtg gttgccgcct gtaatcccag ctacttggga ggctgaggca gggagaatcg	15060
cttgaacca ggaggtggag gttgcagtga gccgagatca tgccactgca ctccagcctg	15120
ggcaacaaga gcaaaaaact ctgactcaaa aaaataaata aatcaatcaa taaaataaag	15180
atcaatttgg agaaattaat gcttattaat aagcaatgtc ttgcacagca cttcagtttc	15240
tcaatacatt acctaactca atccttaca caacacccta tccccatttt gtggataaat	15300
aaactcatgt tcagaagggt gaataaatta tctaagggtta atagttcctg acctagagct	15360

caaatcttca gtttctatca tattcttgcc cttaccctgg ggtagctaac attcactcac	15420
tagtattgga gctaaaataa gggagagaac atataaatga atacaaagga gacattcacc	15480
tgccttctct ttctccttac atagagaagg ttgattatct gctattgtga agtttgcctt	15540
ttgaaggata gaaatgagaa gactttctta aattttgcct ctacgccaag aaattagagt	15600
ggtagcacca gtagttccat tttaaacta tctactgtagc taaagctatg tggtaagggc	15660
caaggaaaag aagtattctt gcacttcaaa atgcactgaa ataccagtca gtagcataat	15720
ataaaggaat ttagtggaga gaagagttga cctcaatctg gctccaacat ctcggctctt	15780
aaccctacc ctacacttgt tcttcatggg gaagctaatt gggccactgg aagattcagc	15840
agctaccatt tgcagctgag ggacagcccc tccctgctta gcaaccaatg gatatgcatt	15900
tatggaacac ctgctaactg cgacacacac tcctatgtat gagggaaaat acaaaaaatg	15960
ttaaaggaga tgccttcctt tgccctcagg aaacttaagt atagttgcaa agaaatgatt	16020
agcagcaaac gaaaccatgg agaagtaagg gctaaggtct gtgaaacaag cctagaaaat	16080
aaccttgtcc ttgaaaaaca caaaaagaaa gaaagaaaga aaagaaactc caaggccctt	16140
gtgaaggaaa ccattaagtt tgcttcactt ctgtgttttag gaagacacaa acccagtctt	16200
aatgaacctc aaggccacaa ctactggaga catttaggaa ttgtcaccac attctaattg	16260
atatatcctc tgtttgcccc ttctatttaa tattttgtaa aatttttgaa gatatgagca	16320
atgtttaaaa ccatgaatcc cccttttttt ataagtaata tttaggctga ataaacaaga	16380
gaaaatagga cataaagggg agccaacgtg tgccttcatt tataatgtat tcccaagttg	16440
tgagtttggt ttatcagcaa ttatcatgc caaattccaa gtcataattt tctatgcaga	16500
tcaaacactt gattctatct ttgccttaat ttttttattg ggtagtttta tgaccaagtc	16560
atatggtatt ttctgtgaca gataaaatgc acaggttatt ccaatctggc tcagccagtc	16620
atagcaacat gtagtccttc tcatgtctta agaatgagta tcaagaattc aaaggaggtt	16680
ccagatggca tccaaaaagc ttacagttta tgcatcactt attctaacag tagaaaaaga	16740
atatttgaag ccaaaaatag accttgcatt tagcatgtgg aagagtagaa attgccctga	16800
tagttaaaca atttgaaatt caagacatta atttctttat gaagcatttg tcacatcata	16860
ggtaatatct tatgcctatc atatatatac ttattatgaa atacaaagaa attattcatt	16920
ctatctaaga ctttgtatcc tttaaccaata tctctccatt ctccacctc caccctagcc	16980

cctggaaacc acccttctac tctctgcttc tatgagttct tttttagtga gatcatgcag	17040
tatttgtctt tctgttcctg tcttatttca cttgacataa tgtccttcag gcttatccat	17100
gttgtcacia atgacagaat ttccttctta aggctgaata gtattccatt gtgtgtatgt	17160
agcacatttt ctttattaat tcatttgttg atggatactc atattgattc catatcttgg	17220
gtcttgtgaa taatgatgca gtgaacatag gaggcagat atctttttga catactgatt	17280
ccactttgat gggatatata cccagtagtg ggactgctgg atcatctagt agttttattt	17340
ttttttattt tttatttttt ttattttgag acagagcctt gctatgtcgc ccaggctgga	17400
gtacagtggg gccatctagg ctactgcaa tctctgcctc ctgggttcaa gcaattttcc	17460
tgcctcagcc tcctgagtag ctgggattac aggcacgcac caccatgccc ggctaatttt	17520
tgtatgttta gtagagacgg ggtttcacca tgtctcgaac tcctgtcttc aagtgatccg	17580
tccacctcag actcccaaag tgctgcgatt acagggtgtga gccaccacgc ctggcctagt	17640
agttctgttt ttaatttttt gaggagcctc catactgctt tccataatgg ctctaggaat	17700
ttacattcca ccagcagtgc acaaggattg cttttctcca cattctggct aaccagtctc	17760
ctgtcttttt gagaacagac atttcaacac gtgtgagata atatctcatt gtggttttga	17820
tttgcatthc cctgatgatt agtgatcttg tgcctttttt catataactg ctggacatta	17880
atatgccttc ctttgagaac tgtgtataca ggagaaaata atcacttctc agaggagctt	17940
tcatttcaaa atatccggga aaaaaataga aaaaatggaa aatttatcct agagtaagtt	18000
gtcttttata ttttgaccct gtttgtgaca taaactggat gatacaaaac tggaatgcaa	18060
aggctttagg aggattactt acttacttgt atattgcttt aggttgtttg cagaaaatta	18120
tactaattga agttcaggct atgatgtgat aaaatctatg tcaggagatg agtctacatg	18180
caaagtttga ggaagtgaca tttgagtttc aaaacaaaaa agcaattttc aatgtcatat	18240
ctaggttaac ccaaaagatt tctttcacc ctttttagctg cctctaagat ggatgctgag	18300
gataattaca ctgtagaaca ataggacgat gcttcacact cacctcacag gctctgttat	18360
tcccacatac tgccagagat actccaaaat aaaatcactg caacatcagg cagttataaa	18420
cctcaacggg attattttct atttatatac agtatatttt atattttaca agtataaaaat	18480
agaatatatt tattctattc tctttgacac aaagtgacca taagacatat tacttaagta	18540
tgactagcaa agtcatgggg cttgtcattc aggaggaaac tcttaactaa ctgttcagtt	18600

tttgttcact	gcaccattta	cataagccaa	actaatgctt	cacactgtgc	aaaacaatgc	18660
acagtgttgt	gaatgaatgg	ctaaaataaa	actctaata	gtggggtttg	aaaaatgcaa	18720
ctttagaaaa	ctgttgagaa	aatgttgcac	actgcgcat	ttacaaaatt	tcgttgaagg	18780
acactggata	ttcttttttag	gattatggag	ggaagcaaaa	ttttggctcc	tacatgcagt	18840
ttttgtggcc	tttgcctgaa	atagtcatct	cccattaatt	atttagatat	cattcatttc	18900
ctaagacaac	attaggggag	actgccttaa	gtacaatttg	tacactaccc	agataagaat	18960
tcttttttgg	gaaacatcga	taaatattac	ttggcagtaa	caccaagtta	aaatatttgt	19020
ttcacagtgc	acgttaataa	ctattataga	taaagtgaat	tttataagac	atactcagat	19080
ctaaaacagc	aatatggagc	tcttcaaata	cattgaaact	tcataaccagc	ctacggaagt	19140
agaggttttt	atgcaaactc	ttcaagaaat	atgctctgaa	cttttaattc	cttagattga	19200
tagaggaatt	aaatcatgat	ataactaata	ggtttgttgt	acaaattgct	gctgcttaat	19260
ctgactctgt	gtcttcccag	tgttctatat	gaattagata	ttccattatc	taaagacaat	19320
caaccccatc	ccacggtgat	agctctagga	ctccctttga	gttcattaaa	tctgtattct	19380
cagtctccaa	acttctgggt	aattcaaaca	gaaaagtcaa	ctggcccatg	aactaaaata	19440
aagtcactct	aatttttttt	ttattttgca	gtgtgataaa	agtctcgcac	tttttatttc	19500
tgaaagtttc	tgctttcact	gagagcataa	taggctatcc	acccttatgc	aatcttacat	19560
acaaagtcat	agtcaggcta	aattcaaaaa	cacatgtgag	atagaagtca	acgtttattt	19620
tctggagaaa	agccacacat	tacaacaaag	tgaacaatga	agctggcatc	cttatcactg	19680
gtgacaaaaa	catttgtgac	tctggacatt	ggccccacaa	atgcgataaa	cattctgcat	19740
aggaagtgag	ttttgctaata	taaaaatgga	tccaaaatac	tttctactct	tcagccaaga	19800
attaaaaagt	aatagggagg	aattgaaatc	acttgggtgc	tacattgagc	cattctggag	19860
aagcaattca	gagaatgtca	tggcagcctc	aaattgctgc	tcaggagcat	cccagcttag	19920
aagattgcag	gaaaggaaga	gcaaagtcac	tcttacatga	gaactgtcct	taaccagatg	19980
aatagactct	ccatttttta	ccctggcttt	gtctcattta	agtcccaacc	aatctagcta	20040
tcatttttag	ttttactacc	tgctagtatt	taggagctta	gggggataaa	aaaatccctc	20100
aatactcaga	attagacttg	gtgataaaaa	tcttgacaca	taaacagaat	aaagcgcttt	20160
cattactcct	ctaaaccaca	gtgtcatttg	gtctctatca	aggactgtaa	gaatttcttt	20220

catcagggga	aagaaaaaaa	ggacaagagc	ctgcaagatg	tagcggaact	ctcattaaac	20280
acagcaggag	ctttaactgg	aatccagagt	aagggtgagg	accagggttac	aacaattttac	20340
tgctttttatt	acaatttttga	tcacaaggac	tgattcatgt	catctagttt	cttttccttg	20400
tcactatcac	tggtgctaag	aatacatcaa	attgaaat	aagagcctca	tatgtttctg	20460
tataaccag	tgatgggttg	tactgctttg	accttcttaa	atgtcccttt	atttcatttg	20520
atatccattc	ccatagaaaa	actataatgc	tttggttgg	caaaatatta	atctttcaaa	20580
acctccctgg	cttagaaaac	caaatttttg	tagagagaga	tgggtagaat	ctaattttat	20640
tctaaagcaa	ttagcattac	atcatcacag	cagaaatatt	tagaatatta	cctcatgtca	20700
gtgatcttct	gatattgtta	aaagggtatt	ttaaaatctg	agttatttct	ttttcttttt	20760
aaagttacat	cattaattac	atactcatca	accaaataat	tttatgctcc	aaatttgaac	20820
cgatatagta	tgtaagaagt	gttcaaaatg	aaattatttt	ggtctatttt	gtctttgaag	20880
aagatcacag	ggatggacct	cccaaaggga	tttttaaattg	ggattacata	tctgactttt	20940
aaaaaaaaatt	atctgacctt	gagttatagt	gccccaaagt	aagcaaagtt	ccaacacac	21000
agtatcatca	gaattgagtt	aaaattatca	ccaggggctt	aatttctgaa	attaaaaagg	21060
aatgtttatt	tccttatgaa	aagaaaagga	acaaaaaatg	aacttcaagg	tagctgattt	21120
ctgtctatgt	taagacttag	gtaatgggag	aaagggaaaa	ggaaggacag	aattaggaga	21180
ggagcagtgt	ttaacaattg	cgggtgcaag	actcaagttt	tttagaatcc	attagcagag	21240
aaccctattt	ctcccattaa	ctgctgtcct	tttaaattcct	ggcaccagct	ctgaggactg	21300
caggggtccat	agctagtgcc	ccactctacc	cagtttaaag	acaccactgc	ctggaaatga	21360
caggggtttt	tttcttaagg	aaagaggtgc	tttctgccac	gtatatataa	attggtgaagc	21420
ttcaaataaa	gtgcttttgt	cctttctgtc	tatcagaaac	tgtgcaaatac	gaattgctgt	21480
aaaaccaagg	gcaagagaca	tcaatcctgc	attctatagc	atctgatttt	atcctttatc	21540
cccaggcaca	tttcaaaagg	aaaaaaatga	ggttgcat	aaattgagta	tttgggactt	21600
gccaggaaaa	cctcccgcta	gactaatatg	attgcaggga	aaacaagaga	aaggaaaagt	21660
ggagagggag	tgtgctaaca	gatcctgggc	ctcgtcagca	gagccgtcct	gagcacaagg	21720
ccatggtcag	acatctggtc	ccgcgaatga	cgttttcttt	atggtcatta	agaacaccag	21780
tgtgtcggga	cacaaacaag	tatttcctttc	agggattatg	acacattttc	tcccaaagta	21840

gtatattaat gacatttcca gagcattctt tactatcttt tatatgtgat caggaagact	21900
aatacatatc actacttctt ttacacacag cattagccaa aactaaagtg tcaaatacaa	21960
ttttgcctag gatgaataaa cagaagaaat ttttatgata ctgcactatc aattccaaat	22020
taaataacaa caaaatgata agtgttaaaa ttcatattaa tgattgttcc cacacaagcc	22080
ggaaaaaatc tttctaagaa gtctttcatg agttaatccc atctttcaaa gtgttcagtg	22140
gctccgaatt cagttactgt ttcctatcag ttcttctttc attaagtctc ttcccttttt	22200
tttctctttg cactatttcc cttagccggg tacataatct gctgtgcttt attcatttgt	22260
gtcttaagtt tgtttccga tgacatacct ttccagcaac gccatctggg gagtttgggc	22320
aactgtacca cgttaggagg aaacccttct tcacaggaga gtgtgccttt gctgcaggga	22380
aggaattagg atttgcttgg actgtggttg cagctggctt ttaaggatct ccttagaatg	22440
caagcaactc atcaatgaga atctctgcaa tggttgtcac tgggtagagt catgctatgt	22500
ggggtcatag cctttgaaac aaataacagt aaagataaaa atgctattaa aggaatcacc	22560
accacagag gttaactggg ttttgtcccc agaccacctc gaacaagaaa gaacattttt	22620
atcagtcatt ttcttagttt tagctgataa aacaaagtac catagactag gtggcttata	22680
aacaacagaa atttattttt cacagctttg gaaactggaa gtctgagatc aggccgccag	22740
aatgatcaga ttctagttag ggcctacttt gcttttgcag actgccaact tctagctgca	22800
ttttcatgtg gcaaaaggag attgagctag ctctctggtc tcttcttata aggacactaa	22860
tcccattcat gaaggcttca cttcatcat ctaattactc tccaaagacc ccacctcaa	22920
atactatcac attgggaatt agatttcaaa taaaaatttt gcggggacac aaatattcag	22980
tccataatag taatgattac tcattataca tagggctcta aatgtgctag cttctgatag	23040
tttttacact cacttctctt tattagcttg tcaagcataa ttagggcagt ggccttactg	23100
aaaattattg aatttagttt cctaaggaca gatattgagg agttttttct tcactaaaaa	23160
ttcacgttcc gatacagctt tcactgttta ctactttgtg agatggaaaa tcttttattt	23220
tatttttatg tttggattga cccttcttaa taaagtcggc atgtaatatg cttcatgtgt	23280
ttctaatatg tgcttaattt tgcaaaatgt ttgcatacc agaatgcatt tctcttccaa	23340
aaaaggtacc agcctacaaa accttgctgt tactgttttc aattagttca tggaattaa	23400
tgtattaaat gttttatgct ctggcagaaa ttatgattct cacttaactc catataaatc	23460

tggatctgcc tgggccttta taagtgcac aatttcatta actgaataaa caaatgatac	23520
aaagaaattht ggttttagcct tctaaaattc caaaggcggt caacaaaata tctcagaatg	23580
gatgttccag gacttttatg gcacaggaca acatgtattg cttattttta gaaaataagc	23640
taaatagtga ggggattctt ttagcagatc ctcaggatgt gttagggtga atcataggca	23700
aatgatattht gatcattgca cctgttaaca cattgaacct catcctaata ttgtagagct	23760
agaagaaagc cttctggcag tttttaaata gattgattta ctgcaattta tccagaagct	23820
tcaccgttgt cactggctac atgtgacttht ggcctctgtg gggctatatc ctcatttgta	23880
aaattgggtg tgaggtaggt ggacagttga ctaaataatc tcttagaata attctagtat	23940
ctgtggatct aaagcatcca ggggttgaat atgtttcttht ctggccaaga aaagatgcac	24000
ctgtcaataa tgcccaaact catcttctga gaatcctctt tccaagata cccactctcc	24060
cttgggttat attatagtaa tgatcagaag cccctgcca gaagaaactg ttaacctggg	24120
aggtctatat tttatttcac agccatctgt ttatacttht tcacaagtta gtgcacagta	24180
tacccatcat tttctacat tttccttaat ttattaattht tactaattgc ataattaaca	24240
aaagtaagaa gattttacct ccttatcccc atctggtagt ttgcagatac ttggcctgat	24300
gacaactgac agtgatgaga tactcaccaa gtttaccagg gcaggaggct tcctagagaa	24360
aaaatgagaa aatgaaatgg ggaaggggag tgaaggattg aggaggtgac aatctggact	24420
cttgcaactg catggcaagg ttggcacaca agctgggttg caacggaggg aaggagatcc	24480
ttatcagatg taatcagagc tcagatcgag ggctttgggtg tgtgtagaaa gagggagaga	24540
caaagaactt aaaacagagc tgccatttga ccttgcaatc ccattacttg gtgtataccc	24600
aaaggagaat aaatcattct attaaaaaga cacatgtgct tgtatgttca tggcagcact	24660
attcacaata gctaagacat ggaatcaaac taggtgtcca tctatggcag attggataaa	24720
gaaaatgggg taaatataaa gcatgcaata caacatggcc ataagaaaa atgaaatcat	24780
gtcctttgct gcaacatgga tgcagttggg acccataatc ctaagtgaat taacacagga	24840
acagaaaacc aaatacagca tgttctcact tataagtggg agctaaacac tgagcacaca	24900
tggacataaa tatgagaaca ataaacactg tggactacta gaggggggaa ggagagaggt	24960
ttgtaaaact acctatcagg tgctatgctc aatacctggg tgatgggatt tacacccaa	25020
acatcagcat catttaatat tcccatgtaa aaagactgca catatacccc ttgtatctaa	25080

aataaaaactt gaaattaaaa aaaaaagaaa gaaagaaaga ggctggaaat agaggctcac	25140
acctgtaatc ccagcacttt ggggtggccaa ggtgggtgga ttgcttgagc ccgggaattc	25200
aagaccagcc tgagaaacct ggtgaaactc tgtctgtaca aaaaatacaa aaattatcca	25260
ggcatggtgg agcgcacctg tagtcccagc taatggggag gctgaggggg gaacatcact	25320
tgagcccagg aggtggaggt tgcagtgagc tgggatcaca ccactgcact acagcctggg	25380
taacagagca actctgtctc aaagagagag aggaaagaaa aaagaaaaga tggacagata	25440
agaaaatgca cttggagatt aagagaaagc agcaacatag gaccctggat aatgtgtttg	25500
cttaataact atcctgatga gttatctgac tattcccaaa tgagtacgtg gcaattcagg	25560
ctgaaccatc agagtagccc tccggaatct tacttatgta caatagacct gcatgcacat	25620
ttactagaat gagcctctct ctctggtaat catgtctgct tccactaatt ccatctgttt	25680
cctctctctc cctcctatcc tgctagatct taattccttc gaccttcctt tgtttttcta	25740
actccccttc tttctcttgt tatttaacct gctatactat gcaattgatc tcctctgcac	25800
taaggaacat gcacttcaga attctgttga catcttgcat tcctttatat ttagtgaaag	25860
aatgcaaagg agtctacctg gcaatattca ctctgcagga ggcaataatt attattcaaa	25920
ttaaaggaag cagtaaagag aaattcagaa aaaatgaaat atactaatct tcagcttttc	25980
atttcagcct acaaggaaaa aatgaaggag ctgtccatgc tgtcactgat ctgctcttgc	26040
ttttacccgg aacctcgcaa catcaacatc tatacttacg atggtgagta acctaggata	26100
gacatacccc tgctagctag atcatttgga aagggtgaca tatatttggt tcttacagct	26160
cctgatataa ttacatcaat attttgtagc tctcactatt gacttgccgt gtctagctat	26220
tatgtccaat tgattaccta ttgctgaaaa cagtttgaat ttgggtgctaa taacaacaca	26280
tcaatgtctg ttaagaaatg tggatggatt cttattaaca gccacatcca gcatatcaac	26340
atccacaata tgtctaaggt ctttctttgc aaataattta ataggctaag ccataattgg	26400
agtagatcat aatttgtaag aaaatgcttt atacttagaa aactcaagag aaagaatcaa	26460
caaccataat tgtttttgct ttattgtagt ctttataaag tttctatact ttgtatatac	26520
atgtcaacca gctaataata ataataattg gctcaataaa taaaactgac ttacgactga	26580
ggccctagat aaagagggtc tgaaaagaaa agcctaaaga attagcatgg caattaacat	26640
gattgaggtg caactcttta ggtttgattt atcctgattc attttgctta ctttggctct	26700

gccacaatcc	acatgatctt	ggtcaaatag	atacttggat	tctctaagtc	tcatttaact	26760
ctagcatctt	cctcttggag	ttgttgtgag	gtttaaacgg	tttaatgtaa	gtcaaataatg	26820
caaaaccaag	cctagctcat	tatatcactc	tacaatgata	gctatcatta	tcaacatcat	26880
ccttacctaa	ttcagtcaat	ttaactaaaa	tatttttatac	agttctatgt	atcctagata	26940
tccctaaggc	atatttttact	aactctcagg	ctcacaaata	tttttctttt	ccatatatgt	27000
aaagaaagac	attaatgaca	aaacaaactg	accttgtggc	agttaacccc	ttctgcacct	27060
ttaaagccta	ttcaaggact	caaaggcatt	taccttccaa	agttattcta	tcgtagcaca	27120
aaaatcataa	atgctaatta	actgttccat	aaggaaatgt	cctccatgtg	aaaggaattc	27180
tgtctccaaa	caaaacattc	attagaatgc	agggccaatg	cctactttgt	acaaattcat	27240
tcggtcagca	aataaattag	acagaccttt	attatttgct	agatgtagct	gtgaagaagg	27300
atccagctat	gtttcttatg	agactaatgt	cgaactatgg	gttgtcactg	aggatccaga	27360
gttccatagg	gcgtagtcct	caccttcaaa	gaattcaggg	cttagtagaa	gagtcttaca	27420
caaatgacta	gaatgtagaa	cacagagtgg	ttaggacaaa	ggagccaggg	atgggtttttg	27480
ctgggttagg	gaatgaaaaa	aggggaagaa	aatatgtgaa	gttatgtgtg	agctgattct	27540
tgaaataagc	tgttttttatt	tgcttgcgtt	ctcttataat	cctttttccat	aggcttccat	27600
aattttttatt	gagctgtatt	taaagttgaa	tagataattc	aacatttctc	gtaaactgtg	27660
cttcctaaaa	gagtccgtag	agaatttcaa	atttctgcag	tctttaactt	gacctggtat	27720
ttctatgtta	gataataacg	tgacttgttt	attgcaggca	aacattataa	caataaatta	27780
ttattattgt	ttacatttgt	aagcactaag	tatatggctt	gtgctttgca	ttcagcatcc	27840
tttatcattt	aatcttcaca	accaccttag	aaggaaggta	ctcttttttat	ttccatcttt	27900
taaatgagga	aataaaaagca	taaagaagtt	aattaactta	cctagtgtca	cacagctatt	27960
aagagggggct	tactatttgg	atgcaaatat	aggcagttct	aattccagag	cctctaattct	28020
aaggcattta	aaaccccatc	accttatcaa	ataagctgtt	tttatattgcc	cgtgttctct	28080
tataatcctt	atccataggt	ttccataaatt	tttataaaaat	tgtattttaa	atttaagtat	28140
aatcttggat	gccatcagga	aaatgaaaaa	cattttttaca	tttgtgaagg	aaaaagccca	28200
catcatttcc	aatatagtta	ttgagttagt	attatctaga	ctatctatta	gcagctaagg	28260
atctgaggtc	aaggcctgcc	agcctggcat	tttacttgac	cacaacctcc	atgtgcacta	28320

accaggctgc	taaaagaaca	ttaacgggaa	cataacctgc	tggcttggtt	gccacaattt	28380
taaaaagacg	ttaataaatt	agagagcact	tagaggttag	gaaataatat	ggtggtaaag	28440
atctagaaac	agtgtcattc	tggggcactt	gaagatgttt	agcctggggg	aacaacttga	28500
aatggaacat	aactgttttc	aaatacttga	aaaatggtgg	tgcaccacag	agaatggcct	28560
aatcatgggt	agcttcagac	ttcaaacaag	gatcagtggg	ctaaaaccag	agagatggag	28620
tttgggactc	aaagaatgct	catctgaaat	tgagggtga	ccagcgaggt	tcttttaaaa	28680
atcattgcat	tttactaaat	tgtgagttct	gtaattataa	atgtcctagc	aggtgctagc	28740
tgtcatcttt	tctattataa	attatactat	tttatgttat	aatttgtatt	atacaggctt	28800
aaaacataag	ggtctgataa	tctgcttatt	tttaatacat	aagccactga	tagaaaataa	28860
gtggctaacc	attcttcagt	tcttttttta	attgacaaaa	attgtatatg	tttgcggtgt	28920
atggcatatt	ttgaaatatg	tatacattag	agaatggcta	agtgaagcaa	attcacatat	28980
gcattacctc	acacacctgt	cattttattt	tgatgagaac	aaaaaatcta	ctctttcagt	29040
gattttcaag	aatacagtac	attgttatta	acaatagtca	gcatgggtga	caataagtct	29100
tctgcggccg	ggcgtgggtg	ctcacgccta	taatcccagc	actttgggag	gccaaggctg	29160
gcagatcacg	aggtcaggag	ttcgagacca	gcctgaccaa	catgctgaaa	ccttgcctct	29220
actaaaaata	gaaaaattag	ctgagtgtgg	tggtgaagcg	ctgtagtccc	agctactcag	29280
gaggctgagg	caggagaatt	gcttgaacct	gggaggcgga	ggttgcagtg	agtcgagata	29340
gtgccactgc	actccagcct	ggcaaaagag	ggaaactccg	tctcaataat	aagtctcttg	29400
catttgttct	tcctgtttta	ctgaaattat	gtattctttg	atcaacatct	ccccagtctc	29460
cacccctaac	ccctggtaac	cacaattcta	ctctgcttcc	gtgagttcaa	ctttatgaat	29520
agtccacatg	taagtgagat	catgtggtat	ttgtctttct	gtgcctagct	tatttctactt	29580
agcatagtgt	cctccagggt	cacccatgtt	gtcaaaaatg	acaggatttc	ccccaaacttt	29640
tttaaggctg	aacagtattc	catgtgtatg	tgtataaatt	agattagtag	atgttgccac	29700
tccctcctcc	accacagtgg	ctctatccct	ggctcctggc	tccagccgag	tacactagag	29760
gaggatattc	taaacagcaa	caacacagga	gcaaagacat	tacaatgggg	tgttgtctta	29820
ttgcccccat	tagactgtaa	gcatcttgaa	gacaaggacc	cccatcacag	agtgatgttg	29880
tcatccctgg	agtgggcact	gtgcatgatt	gatgactgga	agcaatgaac	atacagaagg	29940

gcaaaacaga aatcagcagg atgctttgca tttcagcatt gactttgcca aatatgcccc	30000
actgttcagg gagttacatt ggttctaacg aagctcctgt gattcctaag cacaggaatg	30060
gtgataatat atataatggt gcatgcatat atacgcatat ctagataatg atatctcatt	30120
atatgtgaga actgaagaac tccgttatgt ttctcgtcta accaaaaagg gcctacagct	30180
acgataatth ccaaacaat aaatctgtgc tacttgatth tcatgcaaag ctcatatthg	30240
ttcaaaagga aaataaagct taatttaaaa tcaatthagg ctatthttat ctaagtatgc	30300
ttaccgttat tcaactccct gcagatatth tcaaatttct caatatggta aatattthatt	30360
ctgttaaaat atatccatag ttacactaaa gacagagagg tcttatatgt tctaaacaac	30420
atagagcaaa tgctcataaa cagcattthta ttcctatctc ccggaataac aacgctactt	30480
ccaattgctg gaatctaaat tattaataa aacccatgct gcaagctthg tatgcttaac	30540
attctcaaat gttcacttht cagatatgga agtgaagcaa atcaacaac gtgcctctgg	30600
ccaggcttht gagctgatct tgaagccacc atctcctatc tcagaagccc cacgaactth	30660
agcttctcca aagaagaaag acctgtccct ggaggagatc cagaagaaac tggaggctgc	30720
agaggaaaga agaaaggtaa cthtttccat aggtthtctt tctctctctc cctcccctgc	30780
tcctccctct cacacactcg ggcacacatg cacgcacaca cacacacaca cacacacaca	30840
cacacacaca cacacacata cagagagcaa tgacagctga acctgtgcca tgccaacatg	30900
tataggthtt cagtagacac agagccaggc tagttggggg aaaaactgta agatagatgc	30960
taattthtagg ctagccaaac cagagctctc agaaatccaa agagcttcag tgctctagt	31020
ccccttcccg tatattgaat ccccttatta taaaagcctc ccttccctag accatcaggc	31080
agaagcactg tagagaaaac acagccctgg cgaactccag tgggtggggag gggaagaagt	31140
gtgcttcct ccctctcagg atctgtgtca cccctthgt caggcgtggg tttccttgga	31200
attacaaatt accagatctt ccctccaaga tctttcctgc ccagggttag ggccaagagc	31260
ttgcccctht cctcttcaga gtcccactgc ctgcccctgga agttggctct tccaagatca	31320
ggaccttctc tgagttctth gaatatgttc tttatcttht tctaagactt gatggggatt	31380
tttctcttht tgccattggg ccctgcttat attaaagagc tttcctthtg ccaaacttht	31440
actthtccat aatcacatgg ctaagaagag ccaagggtat tatttgagaa cacttagaaa	31500
tcctagggac tgtgtacaca aacagaagtt gtttgaatgt gtctgttcca accatgtggg	31560

tatggtagtt aatcccatca aggtactcac gatcatccaa aaatggaatt cttttatgta	31620
attcatcccc acattgtatt tcccaatatt ttttatgata taattttaga atcaggtaat	31680
cactaagaac atgttccttg cacagtttta tgatgttttc tctaaaaagt cagccaaaac	31740
tttggacact tctatgttgg ataattaaaa acagaatgaa gataatcctc ctcctaaaga	31800
ttgaattctc caagagagaa tgcaggacaa acacagatgt gctgtgtata gtatatgtgc	31860
atatatacat gcatatatgt acacaaatat gtgtattatc aaataatgag gctcaaocat	31920
tagaaatcct tagattaaat tttctaaaca agaaaacact aatctttgta gttgaaaaaa	31980
aatcctccta tgatatgtaa tatgctgata tcaattttca cctaagagtg atgttctcca	32040
aatgtccgat gagcatgtca tatatatata tatgaatttt tatatatata attacaatgg	32100
taattggtat atagagatat ctatatata gatatatata gctatctcta tatattacat	32160
ataccaatta tagatataaa tataacaatg gtaactgggtg tatatgtgat gtgtatatat	32220
gtatatgtat accataatta tatattaata ttgtatatat gccataatta tatattaata	32280
ttggtatata tacacatga ttatatatta atattgggtg gtgtatgtgt gtgtgtatat	32340
atatatatat atataaaata ctagttatca ttgttctaga tttaaaaaac aggaacctga	32400
gctactaact cgactatata tatatatata tatacaggaa gttgctttta aacattttta	32460
tcagcttttt tattgttatt tttagcttta ttctcatagt aaagctaaaa taaattattc	32520
aacattatca aaactttgct gccagcagat gtaagcaata cctaaaacag tggagagcat	32580
gttgcacca aagcagttta agctctgacc caagcactgg catcttatag gcactgggta	32640
gagataagag tcataggtcg acatatattg agatgctatg acttgattag aatatggagt	32700
cagtgactga ggtgaaatta aaactcaaac cacaattcaa catcctgatt taggatgttg	32760
ctggtgtttc taggtactac acttaatttg aaagaaatta ttgaggataa aaaaagaact	32820
gggatcaaca aaattaacta ggtgttctta taagagtccc tgaggttact aattaatgaa	32880
actgataaag ctcctgcacc ctgacagcaa gaaattatca atgattatac atttaaaca	32940
ttgaattgaa ctagaaactg gccacatggt taaaagacat ttacaaatgt aatcatccag	33000
tggtatgatg cccagaaaaa aaaaattcct tagaatgctt taaaagccgt attccatcac	33060
ctttccagtt atttgttaaa cattttgtaa tgcaaaaata accatataga ttatgcccta	33120
gtggtcgggt tttattttta gttttttatg gttttttttt gttaatggta gagttttaat	33180

taaaagaaaa	tacaactaat	tagcagaaag	tgccaacttt	aaaaaatcac	taattgattt	33240
tattctattg	ggttatactg	acttaattag	cactaattta	aagaactatt	aattatcttt	33300
aaagagtctt	tagcaagtgc	atatatctca	gtaattatgt	tagtaaggac	atgcctataa	33360
ccaaaacca	actcaactag	ttaaaacaaa	aagcaaatat	gtgactaaaa	agtctaggag	33420
tggctacagc	atcaggaaca	gctggatcca	gggatcacag	tattatcaga	aaactttctt	33480
tcagtgcctg	tcattctctt	ctgcatttaa	ctggtttcat	tatcaagaaa	gtttaatttc	33540
aatagtcagt	tccaaattat	ttttctcaca	acttagcaac	tccagcagaa	acagagcttc	33600
tttttcccaa	tagtttaaca	aaagtcccga	aattgagtct	caatggcctg	gcctggatca	33660
caggcccaac	ccagaaccaa	tcattatggc	caagaggatg	tagtagtttg	atatgctagc	33720
ctgaatcaca	tgcccaccac	tgacctgcaa	aggatttttag	gtaagatccc	tggggtaaga	33780
attgtggagg	ggtagttccc	cagaagaaaa	tcgagggtgt	ctcacaagag	gaaggggtaa	33840
tggatcttaa	ataaacaaaa	ctatagatgt	ccacattttc	tatctataaa	tgtttagtgt	33900
tactataaca	attagaataa	ttatttagtt	catacactat	tcaatttgta	tctcccttct	33960
gttgccctgt	tgccgttatt	ttcttacaga	tagaatgaaa	aatattaatc	taggcagctc	34020
tgtgaaacag	tactgtccaa	ggaatataac	gtgagccagg	ccgggtgtgg	tggctcatgg	34080
ctataatccc	agcacttttg	gacgccgagg	cagggtggatc	acctgagatc	aggagttaa	34140
gaccagcctg	gccaacatgg	caaaacccca	tctctactaa	aaatacaaaa	attcgcaggg	34200
catagtggcg	agtgccctgta	atcccagcta	ctggggaggc	tgaggcagaa	gaattgcttg	34260
aaccaggag	gtggagggtg	cagtgaacca	agatgggtacc	attgcactcc	agcctggatg	34320
acagagcaag	actccatctc	aaaaaaaaaa	aagaaagaaa	tgtaatggga	gccatatgtg	34380
tattttttaa	tgttctagaa	gccacatttt	ttaaaataaa	agaaatatga	aatgaatttt	34440
agtaaaatat	tcttcaccca	atatattcaa	aacattattt	caatatgcat	gtaatcaata	34500
tagaagtatt	aatgagctgt	ttcacattat	tttattcata	ctaagtgttt	gaaatccagt	34560
gtgtatttta	cgttttacaac	tcattttcaat	tcattgttaga	catattccta	gtgcctagta	34620
gccaaaggca	gccagtagca	cagatacgga	tattaaaaca	gaaaacacct	agtgaataat	34680
ggggaaattt	taggcctaag	tttttaaaat	ccataccaga	taattattca	gattcaaatt	34740
tactttgttt	tttcatatat	attcttttaa	aattacatta	atatgggaac	tcagaaagtt	34800

caaaagaaat ttccattcta tggtttttagt ctttacattg tcagaactaa tgcaagtgtg	34860
aagtttagga tgtactgtaa gtaataggat cttctaaatc tcatgccttc ttcagctacc	34920
tactctgttt ctatttcagt tcctcactgt ggggagggga cttctctgaa cctaggtttc	34980
atctctcact ctcgttcatg gtaaacaggt tttcctttgt ggcacctagc acaattagta	35040
agtaattagt atttactggc atattagtat atatatgcat atgtatttat ttaaccctat	35100
gtcttctact agattataaa ctccatgaag atagaacttg tcttttgttt aatagtgcct	35160
ggcaatagtt attactgtaa acatTTTTTT tctttcttat tcaactcctg ttagtcattg	35220
cctgagtact acaaatgttt ttaagtaa ataaataa taactttcag ggccaaatgt	35280
gaaagcggca atatatagct tgttttgatt ttttattcca ccctcccatc ctaaaacaat	35340
tatagtcact aagtttcaa atgacatctg aaattgcact aaggaaatcc tagtctgggc	35400
aaaatcactc agtcaacaga tatttatcaa gcacttacta tttggcaggc cctgttctag	35460
acacagggga tactcatcaa acttacattc cagtggggga gaaagagcta ataaatacat	35520
acacagcata ttagatgatg caaaattagc aggacaaaga gaactggggg tgtgggggtg	35580
aaagaagcta atattatatg ttattattac tatatataat aatataatta ttggatagtc	35640
aaaaaaaaac ctcttgaata agacatttga aaagaagcac aaaggtagca agggagtagg	35700
gcgggcagct cttctctggg acctgaacat tcaaatgat gagagcagca ggtgcggagg	35760
ccctgaaata ggaatgtatg aggtgtgttt gagaaataac atggaggcca gcgtggctga	35820
agctgagagc agggggagag tggtagcaac tgaagtcaga ggtcacaatt aaggactttg	35880
acttcacatg aaatgggaga tcatgaagga taataaagcc atttcactac tttatgtgaa	35940
tcacagcatc tttttaaaga agtatccttt tttaaagggg gagatgacta gaaaaataaa	36000
tagtgttaga taaatagaga aaacaggaaa acattctaga ctaagacagt gattccagaa	36060
ctaaggatcc acagaggcga gaatgcagaa agtgtaggtt tcagagcagt gggtagacta	36120
agggtttgga ctagtggatt tggataggga gttggagagt agcgaggtag gattaggag	36180
ggctgtgaat gccagggttag tgtgcaaact ccattatata agcagtaagg agtcactaca	36240
gacttttcaa aaatacatat atgttccacc tggccacagg gttagcaaca ttttcgttgc	36300
cctggacca tttccttccc aataagttac aggtttgtga agattctacc tagcaaakat	36360
attactttta aataactatt aataaattat cttacatga ttataatcaa aggaatctgt	36420

aattgcta	at	tatttctgat	tattataaaaga	taagcagt	at	tgcactaaat	tgacataatt	36480		
ctaactcaaa	g	taaatatac	agatagac	at	ggctatagat	gtgaaat	atg	at	tatttctgtta	36540
gggcttttta	a	aatttaaaaa	aacttacgag	ttctcctccc	tccccctacc	cttaatacct	36600			
tgaaggcctc	ttt	gtgggac	ttcagggacc	ccttcaggga	actatgacct	aggctgtatt	36660			
tgggggggctt	tct	gggttta	tagctggaag	gctgccacag	aggcatcgcc	acttgggctc	36720			
agattcactt	tgt	gttcaat	gttttggcaa	tgtccccacc	tccccattcc	atctgttgac	36780			
actattgcag	cact	gaccat	ctggttacta	ggttggagga	tactccctcg	ggctcctttg	36840			
aaccagaatt	agt	gctccag	tgattagata	atagaagaag	cttgtcataa	aaagaataag	36900			
ccctttccct	gct	ttttctc	cattccttga	ttatcgctgg	tagtcagtga	tgatcatctc	36960			
tatgagtcta	tat	caatctc	atcaggtcag	tttgaacctc	atctcttgaa	atcaaagttt	37020			
ccataatgca	act	gaccac	aagggtgaaa	tgacatgaat	gctttaacca	tccatttatc	37080			
atattattcat	tcatt	caacc	aacatgtatt	tagcaagagg	cagcagagtt	agcataacta	37140			
tacatcccag	ttg	ggccagg	acaactccag	ctaactctcg	ttgttttgat	accattatta	37200			
attattttctc	ttt	actctca	taagtgttcc	actttggaca	atcaattaca	tgagcatcct	37260			
tagcagggca	cagt	gttttaa	gggcatcttt	aaaatattgt	ctttaagaac	atgtgggttaa	37320			
gagaatgtct	gtgtt	caaat	cctggttcca	ccacttaaaa	gctgtgtgac	ctcaagcaag	37380			
tgacttaatc	tcc	gtatgtc	ctcctttgtc	aatctgtaaa	atgagactag	taatagaact	37440			
tatggagtta	gtgt	gagaat	tggaagggtta	ctctacaata	aagacatata	accagcatgg	37500			
taaaagggtt	agca	attact	atgtgaagaa	gcatccagtt	tctgacctca	cagagattat	37560			
ctagcaaact	cat	gatttta	taaagaaaag	aagttttctca	tcaacagaga	ctgaaatgct	37620			
accatacaat	ata	gttgct	tttttttttt	tttttttttt	gagacggagt	ctcgctctgc	37680			
cactcaggct	cagg	ctggag	tg	cagtgttg	ccaccttggc	taattgcaac	ctccacctcc	37740		
caggttcaag	caatt	ctcct	gcctcagtct	cccaagtagc	tgggattata	ggcaccacc	37800			
accacacca	gcta	at	tttttttag	tagagacaag	gttttgtcat	gttggccaga	37860			
ctgggtctcaa	act	cctgacc	tcaggtgatc	caccacctc	agccttccga	agtgtgtggca	37920			
ttacaggcat	gag	ccaccat	gcccggccaa	tattttttaa	tattataaaa	tattccttat	37980			
caaattgcat	aga	agaaaag	acagtttgat	aggtaataga	tatataaata	ggtcaggcca	38040			

actaaaagtg	tcctgaaaaa	attaatat	tgaaaacaaa	aggattttta	tgacattgat	38100
aaaatctcac	cctaaaagag	attaaattaa	aatcaccct	acttgaacca	gttcagtgag	38160
atttcattag	catgctctca	ttactggcat	aatcagcttc	aaagtcacta	agcctctgaa	38220
aggaagatgt	gttgcttatt	cttaataaaa	tggcataaaa	gtagatcatt	agtcacaaaa	38280
catgatagac	ttaccttttc	catttgttgg	catctcacat	tgtagatggc	aattaaaatg	38340
gaatccaggg	aaagaggggg	tggtttgtat	agcaatggat	tatgaaacaa	agtactggat	38400
tattcaccgc	ttgacattca	ggaaacattc	tgctccttac	agaatatggc	acgtggggcca	38460
cagaatcttc	cgtgtgctac	cttctcggtg	aagaagagca	cccccaagtt	tcttttccta	38520
ggagctaacc	acagtaaacc	cattacacac	tttagcagaa	gggctcattc	taaaggtctt	38580
aggattttta	tcatttttaa	tttcctgtta	tgcttcaggc	tcttcaacac	aaagtgaata	38640
ttgtactctt	tggtttttaca	taattatatt	caattgtcat	atttcaacag	gacattat	38700
gtgactttag	atgggtcaat	aatgattttc	attgtcagca	gtaaagtcaa	taattacaga	38760
cacatcacct	accctacttg	tgtaaaagca	ttttttggta	ctaggagatt	tagtgtctga	38820
tcaacgggcc	tggtatagcaa	gtaatatatc	ccccaaataa	tgaaaagtga	caagaaaata	38880
aatatgttta	cttcagaaat	aaatggaaaa	ttagtgtctat	ctaaaatgta	gtcttaagtc	38940
tcatctgtgt	acataaagta	aaatgagttt	tatgtactag	ttactcaa	ttatcttcca	39000
ctccatttgt	atagtaatta	aactcttaca	ctcagtaata	tacaaattgg	taattaacct	39060
ctttgcaaaa	tgttaaagtg	ttcctaaatg	tacaataagt	ctcctttcct	gtctcattgt	39120
ttttcgcttc	acgtacctct	catgtaatta	tttcaatgat	tgagttcagt	gtgaggaggt	39180
ttatgcctag	aaaagggtgct	caccaataac	gtgcctcagt	tcccataata	gcaagatcga	39240
gaaggttctt	tagtctcccg	gaacgtcacg	ttgaacatct	cagttctata	ttttgccttg	39300
acatttgcat	tatatcagct	gatcattgtc	ttgcccta	tttccctttt	aatatttttag	39360
tgaccttcta	tgttaggtac	aggttattta	gaagtgttcc	tccaaggcca	gatacttttt	39420
ccttgaacaa	tttattttta	acaactttta	gcgattttct	cacttcacca	ccctccgttt	39480
cataagtcca	cgcaatcaca	attcctttct	gctaactctgc	acagtcaaga	tataaagtaa	39540
gaataacctat	ttgaacatgt	agtgagaact	ttacttctct	gccaaaaatg	aaggaaaatg	39600
ctgccacttt	tgtatgtcac	atgtttttta	ttctacagcc	tcactcactt	catgtcatgt	39660

tttagtgcag	ttttctggac	taactgctta	ttttctcatt	gattaaactg	cctatttgct	39720
cattggaatt	agagccaatt	tttttccttg	agggtctgac	tagaagatta	aactatgttc	39780
atgtgagaat	caatttctac	ctaagaaatg	agttagagga	gttatgggca	gcaatatcta	39840
tctggatgct	acactgtgaa	aaaggaagcg	aggttatgcc	tttctacccc	aatggggtag	39900
cagagacctc	aggaactgag	gtagatgccc	ccctggttat	tagcgcccct	gaataatttg	39960
ttcaaaaatt	gactgctgga	caggtgtcgt	gttgcacgcc	tgtagtccca	gctgtgcagg	40020
aggctgaggc	aagaggatct	cttgagccca	ggaatttgag	gctatagtaa	actaaggcca	40080
caccactata	ctccagcctg	agcaacaaag	caagaccctg	tctctaaatt	taaaaaaaaa	40140
tattgaatgc	ttatgaatag	agactaatat	aggaagtcac	aagtatttcc	ttgggataga	40200
atgctttcca	ccataattga	cttgacatcc	tgtatttttg	tatgtgtgga	cttaagtttt	40260
aaatatttga	aacacagaca	attattaagt	cctgcaaattg	tgtgagttaa	tagtggatat	40320
aacattccct	tccagggtgt	aagaaaaggt	accacagaag	tgagcagccc	tgaagcacag	40380
cctggcctag	tttggcaggt	ctctgtgagt	tagcagcaga	ctcacgtgac	cacactctgt	40440
actgccttct	gtttctgttt	caccccatta	attgtgctaa	agaaatgcac	ttgacaccta	40500
tgctgtgtaa	tctcatttag	ccccaatagc	aacaaaagta	ctaaccctat	taaattgagt	40560
catttcaaac	tgagccaaat	gttgcaactc	agtaaattga	gtaggcattg	gttataatgg	40620
gaattctcca	ttattcataa	tggaaccac	aggagtttgt	tcatgcagat	caaattgtgtc	40680
ccaccaaggc	aagaagtatg	gaaaagtggg	gttgctgtat	taccttgtaa	tttcaaagcc	40740
ttcccgtctg	aatcttattt	ccctgctgtt	tcctcttgac	tttggttctt	tcacaaagga	40800
aaattaagaa	cacaaatata	aacattaagt	taaaacacaa	ctgaacaaag	tgccaaactt	40860
aattggagca	tctgaaaatg	aaacattagg	cagttgcagt	ggcctcttga	taataattca	40920
cagtaactct	ctgtaagctg	atcctgtctg	aagagcagca	ggcacaaggc	ccctggccat	40980
gaagtccatc	tcaaagggcc	aggctcagca	aagcaggatg	caaaccagg	ctttccaaat	41040
accaggttgg	ggctcatgtc	actgtgccac	aggagcttct	gtagaaaggc	tacttgaaaa	41100
aagtggccat	taaaaatcca	ggtggatcct	atctagggca	gtgttggaag	cactgatcta	41160
tgggaggagg	agcaggaagg	aattgtttta	ccactgagca	gaaatgttac	attgctacct	41220
gccttttagca	gctgtggctg	atgggtacca	gttgctaaga	agagcattac	ctaacagtgt	41280

attaagatag	aaaaatgatt	ttaaagcacg	gcacttagag	aatgttgaag	ttttactttg	41340
ctttattttg	atttgtttgg	tttgactttg	tctcctggag	catcctccat	ggattttctgt	41400
tcattacaag	agaaacctag	ggctctaacc	caattcctaa	ttcttggaca	cattgcaccc	41460
ttgttttgtg	ataatccagc	cttcttcctt	gagaagggtt	gctggactgg	aggttacatg	41520
tattgaattt	tctaaaatga	aggtgcaaag	ctgtctcctc	ttatttcttt	gtggtgctca	41580
cttcactgtg	agatttccta	tcaatacagc	ccaagtcagt	gggcatgcat	gaggtggaga	41640
tgagggagtt	aggaaggact	tggactctca	tcaaccatca	ggatccctga	atccactaac	41700
tgttcataat	caaagaagtt	tgaacaaata	cttcacacac	atgaaattgc	caaaattttg	41760
catttgagtt	gttataaccag	taagtccagt	tgccatcatc	tccttgtcac	aagtgtctta	41820
aattttgctt	ttgataataa	tgattaccac	tcattcagta	ctaacttact	tgatattaga	41880
cactgcatta	aataccttgc	aaacattatt	ttgtttgatc	ctgacaacca	tatgagatag	41940
gtactattct	tatccattac	caaaaaaatt	aatttcatga	agacttttcc	cagagagaga	42000
aactttaaat	atttacacac	acacctctct	ccctgtaaca	attccgtagt	cctgataaca	42060
gcaaataagc	aaagtctgtg	taggatgctt	taccaacagt	cccacctaga	ggcaggagag	42120
tgaaccagct	agaaaatatt	ttattcatat	ttcttccaga	aaggctccat	tggagtttga	42180
actcaattta	tgttataatt	ttcttattat	ttttgtattg	gttttcctga	aaccaataca	42240
aagtaagaaa	gcattggttc	cactaaaaat	gtcctaaaac	cagccaagca	cagtgggtca	42300
cacctataat	cccagtactt	tgggaggccg	aggcggttgg	atcacttaag	ccaggagttc	42360
aagactagcc	tggccaacat	gacgaaacc	catctctact	aaaaatacaa	aaattagcag	42420
ggtgtggtag	cacacacctg	taatctcagc	tactcaggaa	gctgagacat	gagaatcgct	42480
tgaacctcag	aggcagagat	tacagtgagc	agagatcacg	ccactgtact	tctgcctggg	42540
tgacagagcg	agactctatc	taaaaaaaaa	taaacacata	aatagtaaaa	tgtcctgaaa	42600
ccattatggg	gttaaagcaa	gaggcagggc	tggttcccag	gattttctgt	ctaattctca	42660
gtgagccaca	gacctattcc	tgatcaactt	gagaataaac	acatcagtaa	agatgtgtaa	42720
ggctgtctga	ctttcccatt	tctgtagaat	tttatttgaa	gagaagtttc	tcctttctcc	42780
aggccccata	ttgttttatac	aaaaagacct	ttccagtaaa	tgtccacaac	cactaccatc	42840
aactaaaatg	ttttcccact	aatgctttca	atggtaatca	gtatttaaca	gggcacttag	42900

gattatTTTT	tgatcaacca	ttgttttagat	attcccactt	ataattactc	ctgtgaagga	42960
ttgcctcggg	gcatcagctg	atcctgagaa	attatccaga	agccatgagt	gtgtaataat	43020
ttagtcttaa	acctaaatag	gtcagtattg	ggtgggactt	ttctcagctg	cataatgggg	43080
agaataaaaa	gaatatggaa	agaagttacg	taacacatcc	tgggtcacao	acagaggtaa	43140
gacttgaaca	caggcctgac	atcaaagccc	atgccagtat	gacttacaaa	aggtagactg	43200
gactacctgc	atttgagtca	ctagtgatgc	ttatcactgg	gcctcaccaa	agaaccttgg	43260
aatcagaatc	tttggaggta	gatgccaggc	acctgcattg	ttatcaagtg	ctccagtgat	43320
taccattcac	tgtacagagc	caaacagact	cctgatgctg	gaagaaaatt	acagtgctca	43380
aagtgcaggg	cagggtgtac	atctggatct	aaatcactga	gcaaccacag	ggtttcaaga	43440
gaggggtcaaa	acaaggactt	tctgctctct	gtggccaagg	ggacactaag	tttgcactgt	43500
tctcagatct	caaagagac	tttggtgtat	gggggatagg	gaggggggaa	gggggtgtga	43560
aataaaaagga	gaaagtgaat	ttgattatTT	gattgatgaa	aattgaaaag	cttattgtag	43620
ggcctagcct	acagttgatg	aaaaaacaat	ggatcaggaa	gaagatcaga	acttgtctca	43680
gtcctcaact	gttttctca	ggctttgggt	gaatattgcc	atcctgtaat	tcattatagc	43740
attttctgtt	gcataaacgc	ttagcaacaa	agcctTTTTT	taaaaaaatt	tgtaactcct	43800
caatgaggat	taaatgcttc	ttcttctaag	acagtccgaa	atatactcac	agctgaaaat	43860
tcagctaacc	gcatttccca	actagccaca	ttctatagaa	aactctaagc	catgcagatg	43920
agtacagact	tgacaatagt	gctcaaggct	gggagtacta	ttcatctgaa	aagaatgctc	43980
cctccaattg	gtgggccgtt	attctgctag	gtttgtgttt	ggataattat	aagatggcta	44040
tgTTTTTctt	ccccagtctc	aggaggccca	ggtgctgaaa	caattggcag	agaagaggga	44100
acacgagcga	gaagtccttc	agaaggcttt	ggaggagAAC	aacaacttca	gcaagatggc	44160
ggaggaaaag	ctgatcctga	aaatggaaca	aattaaggaa	aaccgtgagg	ctaacttagc	44220
tgctattatt	gaacgtctgc	aggaaaaggt	aatctcagca	gagtcctgag	cagatggata	44280
tattcatatg	cagcacagct	gggtgaactt	ccatatgcct	gagcacagag	acgaagtcaa	44340
aatttgctgc	aggtgtgagg	acaactaact	cccatgggca	gggtctcaca	gtgtagcatt	44400
gagttagcag	gaggtgcaac	atggtagaga	aatgggaatc	catcatgaaa	gctggaattt	44460
tgtcaaattt	tcccatgggtg	agtggattca	gggaggctga	ttcatgcttt	tgaaatgtgt	44520

aagacttcta	tacaagcctc	acgaggcaat	ctgtaggaaa	aatgttacac	tggaaatatt	44580
aatgtctata	tattatattg	atataagtat	aaataacatt	tgatttaata	tttgtttaat	44640
atatgacatt	aaatatatat	ttaattaaaa	tattaaatta	gaaaaatata	tttgccagaa	44700
aaggccaggg	tatttatgaa	cactggtaag	cccattctag	ggtataatag	catcacatgg	44760
gaccatagca	aagattagct	cataggggat	gtttcatcca	gttctggtat	cctggtgccc	44820
ttctcttcaa	caacctaaac	atatattcat	tcccatgagt	caggaggagc	tgtgctggag	44880
ttcttctgaa	aaatgctgtc	tttcactttt	gtactctcta	tgctgtctcc	cacctatccc	44940
ctcaaaaaac	ctttcctttg	aaaatataca	gtatagctgt	gagtagttta	gctgtgtccg	45000
tttccagaaa	ttggaataag	cattgagaaa	tgggatgttt	gagaaagacg	cctcaatcct	45060
tttctgagca	gtcagtcacc	cttcccgcga	gtagcaagtg	cctttgtgtg	ataggcattg	45120
gagatgcaga	gcaaaacagg	agtgtgcctg	tcatcagagc	cctgagagtt	taattagatg	45180
agcctcctgt	tttctatttc	tcagagtttc	atgtcttctg	ttagagatgg	cccttctcat	45240
ctaaggttca	aaaaacctta	tcctgaagtt	ctgatgattc	tgttttcatt	ctcagtctct	45300
gactgcaa	atccaactag	aaacaaagga	aatcaggcat	gaaaactttt	aaagatataa	45360
ttgcatggag	atcttcattt	gtgctcgtga	ggaatTTTTg	aaagcattgc	tggggaaggg	45420
tgtgtgggct	ctgatgcagc	agtaagacac	tgaggctctc	agagggtccg	ggacgagtac	45480
tgctgacttg	ggcaagaacc	ggaatagtta	cctgatgcct	tatccgaaac	atgaaagttc	45540
ggattaaatt	tgtatttata	agctagtgtt	tttatactct	cagaacaatg	tcattgcgtt	45600
tcaccaag	gagtcaagtc	acgatttgga	agaggcaaca	gaatttggct	ctctccaggt	45660
gatttatggc	ggtataggaa	cacatgtttt	actcagatac	aggggagcaa	agttccattt	45720
gctaaagttt	actcccctga	ccttcaacca	gtcagtcttc	ctccatctgc	caccactttg	45780
cacttctcca	gagaactaag	gatgttcccg	cttgaccagt	gctcataaca	tggacagcag	45840
agggccactg	tgtgatctct	ttgagatcac	tgtgactcaa	ccttcttctc	acatcctagg	45900
ccctaaaaca	attaagtga	gttgctagga	acggtacctg	ctgatcttat	tgcagcattc	45960
tcaattaggc	ctcaatgcaa	gatttatatc	actggcagtc	ctggagcatt	tttgtttttc	46020
aaattacaca	tacccaaaca	cacggcatag	cctccttttt	tgtttgtttg	tttttttgag	46080
atagagtctc	gctgtgtcgc	ccaggctgga	gtgcagtggc	acgatctcag	ctcactgcaa	46140

cctctgcctc	ctgggttcaa	gtgatttctca	tgtctcagcc	tcccaagtag	ctgagattac	46200
aggcgtatac	caccacgccc	agctaatttt	tgtattttta	gtagagacag	ggttttgccg	46260
tgttggccaa	gctggtctca	aactcctgac	ctcaagtgat	ccacccacct	cggcctcccg	46320
aagtgcctggg	attacaggtg	tgagccaccg	tgcccagcca	gggcataatcc	ttcttgattt	46380
caattgtaaa	atagttcaaa	aattttccat	attttatcta	atatttccag	aagtgcctagc	46440
ttttaacgga	ccattttttt	cctctgtgtg	tttttttctc	ttcacctagc	ccagccatgc	46500
tcagctcatt	tttgtactct	ttccactccc	aaccaaattt	agtgccctcc	cccatacatg	46560
catacatgta	catctgcaca	ccacttttcc	tgcaaataat	caacccaaag	agtgcttaaa	46620
attcctgaca	tcaaccaca	gaatctccaa	ggatgggacc	cagcatccat	acattttaaa	46680
aactctccat	atagttccaa	tatgcagcca	gatttgagaa	ctagtgggtc	gtagcctgtt	46740
ctgatttaaa	tctcagctct	cagcagtcta	tcccacgtca	cataatgcag	cccagagaaa	46800
ttctaggacc	acattttttt	ctggtatttc	atagctaata	aggtgctttt	caaatactaat	46860
aggatctttg	gccagtgtca	gtcaagatct	tttatctcct	caataaaaaag	gaaataccat	46920
atttactttg	atttgatgta	tatcacatag	gtggatttaa	tacaaaattg	tggtttacat	46980
attgtgaatg	tgtatactaa	aactactttg	ctttttccta	aaataagaca	aagttttata	47040
ttggaagtaa	tatttagcat	tttgtttgaa	tgaagttact	cctattaaat	tagaaattta	47100
aaagaggggc	agtaataaca	gtaaagccaa	aaggcatgac	actgccaacg	taacataagc	47160
tgctctgaaa	tctaccatat	caaaagataa	ttatgctggg	catggtggct	cacacctgta	47220
atcccagcac	tttgggaggc	caaggcaaga	gaattgcttg	aagccaggag	ttcgagacca	47280
gcctgggaaa	tataatgata	ccttgcctca	aacaaaaatt	caaaaattag	ccagcagtgg	47340
tggcacactt	gtaaaaatgc	ctgtagtcat	agctacttca	gaggctgaga	tgaaaggatt	47400
gcttgggcca	aggagttcga	gactgcactc	caacctggga	aatattgtgc	cactgcactc	47460
caacctggga	aacagaacaa	gaccctgtct	ctaaaataaa	aagaaaaaaa	aagatgacca	47520
cttctgaaat	gacacctatc	aatgagttaa	tcattcaatg	aatatgtatt	gagtccttac	47580
tatatgctta	ggaacctttg	taatatcatt	accaaccatg	tctttcccaa	tacagacaat	47640
acaaaattca	gcaataaata	atatagcacc	aacaattaga	gaataagaca	acatgtagta	47700
tggtccaata	tagacagtaa	atacaaagac	actgaataat	atcagtaaaa	gtaaattcac	47760

atcaaggtca ctacaccatg cgcccaccct tatgatagcc ctactggcc ctatcaatta	47820
agcaagagac atgataacaac tctgtgcaag cttttccaca atctgcctac cattcagcac	47880
tcagtcgctc ttcccttcaa ttaagagaat tgagcattca agcatatttt caccatgatg	47940
cccataatgg tatcttcaat gtcactgact gataaattcc cagaaacccc tcagagcccc	48000
agccatgtta gctcaaagcc tttagctaaa actgaaagcc taaagcaaaa gcagcccctgg	48060
ctgcacttcg gaatctactg gacagctctt taagggattc tgatttaatg tctggaatag	48120
ggccaagaac cttgtattat tttaaaggct cactagtagg ctctaataatt tagccgtgggt	48180
tgagaaccac tgtgctaaat gtttcttaaa tatgctttgt gatgtcatca taaattatat	48240
tttagtattt tttgtctttg ttgcataagt gttcttttctt cctccaaaga agaatgttac	48300
actcatttct tatttcagtt tcctgttttc atagcacctc atcttaacac tccaggctat	48360
tatatagaaa agaatcaaat gtggagaagg ctgtgggaga agggatgcct gtgccacaaa	48420
ggcctgcatt aggctgacct attgatgtca tatccaggac tcaaaagact agtctgtgga	48480
ttatgactgg tgaagttcaa aatgttctta ttcttagagt ggtatgagaa gtagaaagag	48540
agagaaacag agaaggggag gagaggggaa gagaggaaga tgagagaaaag gaaagagagg	48600
gggaaacacc tgttcttgac atacaggaat gattcaagac attttcttcc tcccctgatg	48660
tgtccctttc tcccctaacg cactatgcag catcctgcag aaaattcacc acctgaccct	48720
tttagaaacc ctgagtagta ggagcgccaa atgacccaat caagaattgc agtgagacag	48780
ttagttttga aaaatcagtt aaagcatgta taatcatttt aacaacaata catctattca	48840
ctaaacatat aattttaatg tcaaataattt acgtgtaaac atattgacca atctttcgat	48900
gtagttgggc ccaatacctt ttccaaaaat tgatcagtta atgggggttc tatgggggtt	48960
tcttttcttg ccattattca cacttatgtc acattagcta tgatttgcag ttttaatttc	49020
tttaaaattg agtagggact aaagacatct ccaaaaagcc tggatataga ctttttacia	49080
cttttccata gcttttatag ttgactcacc cagtatctac taaatacttc actttctcac	49140
gtatttccaa aggttttctt ccaccctcac aattttccat taatgtagta ctttaattaaa	49200
ttagatagtt aaattttcaa atgtgaattg ctaaacaggt gtggaaatac cattggctat	49260
aatcaagcat ataacacaac catttgagaa ggaaagtatg tggcaatatt agggaagagc	49320
cctttcctct caagcaattc agcatttagg aaccatcaga cagcaggacg atggagggaa	49380

cagagagggt taacatggca agttactgaa gaggacttct actgaatctt gttgaattcc	49440
ccacttaatc cagattgtat catatcttct ttcttttgta attctaccat atcatcttag	49500
tcaatgccaa gacttctgag ctcataacat ggtaacaaat accaaaggag ctttcagtat	49560
cgtttagaaa ggagagaagc aagtaacca gacaaacttg acaactgctt tcccctatcc	49620
aaccatgaag tacagtactt aggaaataaa agaaattgct tcactataat tcatcatttc	49680
acttctaata tctagaaaat gtcaaatgaa aatattatag ccatatttta gtggcaatag	49740
tagcacataa tatgatgcaa cttaaaatga taaaaatatt ttcagggaat aagattctgt	49800
gattctttcc ctaagaggta attttgataa tatgtacctg ttttgtaa atgtcaatagtc	49860
ttggggatac aggtgggtgt tggttacatg gaaaagttcc ttagtggtga tttctgagat	49920
tttagtgcac ccaataccca agcagtgtac actgtaccca atatgtagtc tttcatccct	49980
cgccccact cccaaccttc cccacaagt ctctaaagtc cattatatca ctcttatatc	50040
tttgcatact catagcttag ctcccactta tgagaacata tgatagttag tgctcaattc	50100
ctgagttact tcacttagaa taatggcctc cagctccacc caagttgctg caaaagacac	50160
tatttagttc ctttttatgg ctgagtagta ttacatgggt tatatatacc acattttatt	50220
tatccacttg ttgggtcaatg gacacttaac attagttcca tatctttgta atttcaagtt	50280
gtgctgctat aagcatgcat gagcctgtgt ctttttcata taattacttc ttttcctttg	50340
ggtagatacc cagcagtggg attgctggat caaatgatag ttctactttc agttctttat	50400
gttttccaca gtggtcatac taattttacat tcccatcaac agtgtaaagt gttccctttt	50460
catcacacc atgccaacac ctattgtttt ttgacttttt aattacggcc attcttgacg	50520
gagtaagggt gtatttcatt gtggttttta tttgcatttc cctgatgttg acaatattta	50580
actctttagt tatagattcc agctattatc aatttacacc tattgcattc ttctcatctt	50640
ttgttttctt gtgattctga tgcacaaata tcatgtgtgc aaccacttac tgttgaacat	50700
gtctgatgaa cacttactat tgaacatgtc tgatgaatga ataatgaaat aggaaaagg	50760
attaaaacta gcctttatta attgtttgct ataggccaga cttttttgga tgtactatca	50820
catttcatcc aaacaacaac ctaaaagaaa atactgtgat tatccccatt tcacatctaa	50880
ggaacctggt ctttaggaag attaagtcatt ttggccaaga tcacaagtag accacagaga	50940
ctagatttga atgcaagtct gtttgactcc aaaccttttt actatctgcc catgaccct	51000

gatcaccaac atctcaatgt atgaacatgt gctttcttag ctcacacaac tcactcctga	51060
ccccTTTTTT atattgcaag tgcatagtca ttagtaaaaa gaaggatttt tgatgatact	51120
gacctcatct tgaatttaat taggctcata tgacagaatt ccatagatgg aattgacatc	51180
ctaggtcata tagtccaagt ccttgTTTTat atttgatacc tagtgagatt aaaggacat	51240
taaaaagtaa agaaaggaaa gacctcatat ttcttacctt ccagtagaga aatctttcta	51300
tgaaatcaga ggaaagaatt agaggaccag aatttttcct aaaatcaact ttcatacatc	51360
ttttttcata taaaaggcat agctgcatac aatgctaaaa tattgtatta catttccttt	51420
atattgatgg gaggaagggg gtaaattgca gaaaacattg taaatttaga tatgcttggg	51480
cctctgacag tgcctagcaa atatcaggag atcaataatg aaataaatat tatcaaagag	51540
tagtcttctt gatgaacctt ctctgagtat cacaactgct ttaggaacct ctagattcaa	51600
ggtctagtaa ttgcaaacag tgagctgata agaaaaacag actgtatggg aaattacatg	51660
cttcctgcat gactgccttt tgttctccca cattttgata taaagtcaca ttaacagttc	51720
atgagtaa attcgataat gtgaacgtaa agtgttcaaa taatagagtg actaaaatgc	51780
ctgaaaacaa ataattttta attagaaact cataatcatt tattttctct tttccacat	51840
tatctcaagc tcacaaatta tattttattct ttcttatggc aaaatccatt ttgttaacac	51900
taattttgag tttacaaga agtgtactcc aaagtagcct aataatacta attataatgt	51960
ttcctgctat gttatcagtt tgaatttata tgaatcttta gacttgaggc ttctttttcc	52020
tagcatagtg atggctctggg ctttttctca atttttgcc gagctcagct ctactaatt	52080
agtttctttc tgcatagaaa aaagattttg cttcatcttt ttctttataa tagcagaaca	52140
aaaagaagaa tcagctgcat ccatgcta atttccctgtg acattttcaa acaggatttg	52200
atttctctat gcatgcctct ttctttctct tcatggTTTT tgaacatata caaaagctca	52260
tttaaacc aa ttaaataaaa ttgtttttta tctctttctc tagagtcaac ttcttgctta	52320
ctccaactct gtatctttga aggaagtata ggggtgtcta tgcctttttt ctcccagaat	52380
ctacacttga aaagacacat ttttccatgc aactataaaa tgttctcctc actcaacatt	52440
gaaattgtat agcagtgatt aagagagtga gctgtagagc caggttccct gggtttaaat	52500
cccacttggt agtatcatga agatgggcaa gttacttacc cttcctgtgt ttcagtttct	52560
tcatctgcaa aatggggaca ataatagaat gtccactata agattattgt gaggattaag	52620

ggaattaata caggtaaaac gtgtactgat gcaggtctgg tacacattaa gtgcctaata	52680
aatattcagt attatgatat aaagaaccct ataagtgtag actccttgag attaatagag	52740
tttaacgata agttttactt tatagctggg caagtttatt tcttctgaac taaaagaatc	52800
tatagagtct caatttctgg agcttcagag ggaaggagag aagcaatgta agcaacattc	52860
tacagaaata taaataatac tactaataat tagcatctta aaatttcaat tcaatgaaca	52920
tttatttagc gcctatgata tatgcaagac agtttgattt tagtcatctg atgtatagcc	52980
acatactaaa aaatactgat tttagtcatc tgatgtatag ccacatacta aaaaatactt	53040
cctccatcag ttccctcctc aggaagttca gttcccaatc ccaggctagt accttggttc	53100
cttatgtaaa taaacatcca ccaattacat gctatctgca aagcactctg ctaggccctg	53160
caaatggaaa aaaaaatgat aaaacatagt ccaggccctc aatgagctta cagtcaaata	53220
taatagagga gacaagaaca gagaggctca taatacaact agaataaaat gactgccgaa	53280
taaaaggaaa gatttatgca ggtgttcaaa tggaaagtga gataagtttg caggtttagtc	53340
tttgcagtct cataaaaaatc tttatggaga aaaggacaat ggtcataggg cttaaagagt	53400
aagtttataa tcctgaccag tggagatgaa agactagcat tgaaaaattgc atgacaagac	53460
aattccatta aactgaaaca tcaagtgtgt gtaggaaaag atgggggtta tgactggaaa	53520
cgtcacttgg actgcaatta tgaagggcct tgacaaacag gtcaagagtt taagaagcag	53580
tatagaaagt cttcgtcctg gatctagccc tcccagagtg tccatcagga ttataaagtc	53640
cttaaaatat tagtcaaaag gaacgacatc attagaaatg atagagaaac aataatgtga	53700
tgttttatta cttttctctg gattttatact ctgacctaata tattcaaaac tatcttaata	53760
acatgaactt ttggatcatag ttttaaaaca aaacagtgtt aaatataattt tttaaaacac	53820
agtaagtctt gtaagatctt ttctaacatg acattttgca gggcccatat tttccttctg	53880
aaatgggaaa aattcataaa agtagacacc aaactgggtt acttctagtc aagcgcatgg	53940
tacgcaaagg accagacaaa aagggcctgt gacatttctt cttccttttg tgttttttag	54000
gagaggcatg ctgcggaggt gcgcaggaac aaggaactcc aggttgaact gtctggctga	54060
agcaaggag ggtctggcac gccccaccaa tagtaaatcc ccctgcctat attataatgg	54120
atcatgcat atcaggatgg ggaatgtatg acatggttta aaaagaactc attataaaaa	54180
aaaaaaaaa aaaaaaatca aaaattaaaa aaaatcaatg cggctctctt gcagaatgtt	54240

ttgcttgatg tttaaaaaat accttggatc ttattttgta aatacttaca tttttgttaa	54300
aaaatacaag tattgcatta tgcaagttat ttcataatct tacatgtcct gtaacaggct	54360
tttgatgttg tgtctttcca ctcaaatgaa tttgctaggt ctgttctttt tgaagctccc	54420
catgtctaac tccattccaa aagaaaaatg aggtcagtag acagtctatg gtgctagaaa	54480
cccaccattg cctaatagacc tagaaggctt tgttgtctct gagcttgact aagaccatac	54540
ctagatcaca ggtattatga ctccacatga accttcacat ttgttcgctc ataacttact	54600
tactgcctaa aaactacaaa accaggctaa gaaataccac cagtcatagc atttacttct	54660
gcttctcctg gattatgtgc tacaaatgtg ctttggcttt agaaagggat ggatgagaag	54720
acagacctga gaccaatctg ggtagaagca aaaagttgaa ctttttaaag tgctgaacac	54780
aaatccaaat tcgaatgggt caagcagccg tgaaatcgct cttcataaag tgggcttaat	54840
tctctagttt aagttctttt gatggaatga attaattaat gtgtcagggt gcttatttgt	54900
ggatgccatg attgatgatg ttcattttta gctcttacct atagtacaag tacatgatgc	54960
tactgaatat ttttccactt ggaaactgtg agctggttgt tgcattaaaa cacacataca	55020
aacaaaatca aaaacactgc ggactttcac tcaagctggc ctttcttccc cagtgtgaagg	55080
caatcctgcc tactaacaac accaacaaca aaacactcca tctgtgaagc tgacgcagtt	55140
aagggggcta ggcagggcat ttgtgccaac taagaatcac cagataccca ccataagtac	55200
ctatcgcagt tttgaagtcg tttctcccca actcccaact cctgaagggt gctgcctgca	55260
tatttactct tcattagtgc tattttcctg tatgtcattg tgagcaagct gtgattaata	55320
aagaattgga gttctgtgaa ctaataaagg tttggtctgt t	55361

<210> 1392
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1392
 auccaauuaa gagagaguga ugg

23

<210> 1393
 <211> 23

<212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1393
 aauccaauua agagagagug aug 23

 <210> 1394
 <211> 23
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1394
 uccaauuaag agagagugau ggg 23

 <210> 1395
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1395
 uccaauuaag agagagugau g 21

 <210> 1396
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1396
 ccaauuaaga gagagugau 19

 <210> 1397
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1397
 aauccaauua agagagagug a 21

<210> 1398
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1398
 caauuaagag agagugaugg g 21

<210> 1399
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1399
 gaguccugca auaugaauau aa 23

<210> 1400
 <211> 23
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1400
 guccugcaau augaauauaa uuu 23

<210> 1401
 <211> 21
 <212> RNA
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1401

guccugcaau augaauauaa u

21

<210> 1402

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1402

gaguccugca auaugaauau a

21

<210> 1403

<211> 21

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1403

ccugcaauau gaauauaaau u

21

<210> 1404

<211> 19

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1404

gaguccugca auaugaaua

19

<210> 1405

<211> 19

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1405
ugcaauauga auauaauuu 19

<210> 1406
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1406
gucuucugcc gaguccugca aua 23

<210> 1407
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1407
aggucuucug ccgaguccug c 21

<210> 1408
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1408
cuucugccga guccugcaau a 21

<210> 1409
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1409

ucugccgagu ccugcaaua 19

<210> 1410
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1410
gcacacaugc ucacacagag agc 23

<210> 1411
<211> 23
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1411
acacaugcuc acacagagag cca 23

<210> 1412
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1412
acacaugcuc acacagagag c 21

<210> 1413
<211> 21
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1413
gcacacaugc ucacacagag a 21

<210> 1414
 <211> 21
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1414
 acaugcucac acagagagcc a 21

<210> 1415
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1415
 gcacacaugc ucacacaga 19

<210> 1416
 <211> 19
 <212> RNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1416
 augcucacac agagagcca 19

<210> 1417
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1417
 gagtcctgca atatgaatat aattt 25

<210> 1418

<211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1418
 ggtcctgca atatgaatat aattt 25

 <210> 1419
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1419
 aatccaatta agagagagtg atggg 25

 <210> 1420
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1420
 aatccaatta agagagagtg atggg 25

 <210> 1421
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 1421
 aggtcttctg ccgagtcctg caata 25

 <210> 1422
 <211> 25
 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1422

aggtcttctg ccgagtcctg caata

25

<210> 1423

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1423

gcacacatgc tcacacagag agcca

25

<210> 1424

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1424

gcacacatgc tcacacagag agcca

25

<210> 1425

<211> 25

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1425

gaguccugca auaugaauau aauiu

25

<210> 1426

<211> 25

<212> RNA

<213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1426
 gaguccugca auaugaauau aauiu 25

<210> 1427
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1427
 aauccaauua agagagagug auggg 25

<210> 1428
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1428
 aauccaauua agagagagug auggg 25

<210> 1429
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 1429
 aggucuucug ccgaguccug caaua 25

<210> 1430
 <211> 25
 <212> RNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic

oligonucleotide

<400> 1430
aggucuucug ccgaguccug caaua 25

<210> 1431
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1431
gcacacaugc ucacacagag agcca 25

<210> 1432
<211> 25
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 1432
gcacacaugc ucacacagag agcca 25

<210> 1433
<211> 564
<212> DNA
<213> Homo sapiens

<400> 1433
atggctaata cagcaatggc ctacaaggaa aaaatgaagg agctgtccat gctgtcactg 60
atctgctctt gctttttaccc ggaacctcgc aacatcaaca tctataactta cgatgatatg 120
gaagtgaagc aaatcaacaa acgtgcctct ggccaggcctt ttgagctgat cttgaagcca 180
ccatctccta tctcagaagc cccacgaact ttagcttctc caaagaagaa agacctgtcc 240
ctggaggaga tccagaagaa actggaggct gcagaggaaa gaagaaagtc tcaggaggcc 300
caggtgctga aacaattggc agagaagagg gaacacgagc gagaagtcct tcagaaggct 360
ttggaggaga acaacaactt cagcaagatg gcggaggaaa agctgatacct gaaaatggaa 420
caaattaagg aaaaccgtga ggctaattcta gctgctatta ttgaacgtct gcaggaaaag 480

ctggtcaagt ttatttcttc tgaactaaaa gaatctatag agtctcaatt tctggagctt 540

cagaggggaag gagagaagca atga 564

<210> 1434

<211> 187

<212> PRT

<213> Homo sapiens

<400> 1434

Met	Ala	Lys	Thr	Ala	Met	Ala	Tyr	Lys	Glu	Lys	Met	Lys	Glu	Leu	Ser
1				5					10					15	

Met	Leu	Ser	Leu	Ile	Cys	Ser	Cys	Phe	Tyr	Pro	Glu	Pro	Arg	Asn	Ile
			20					25					30		

Asn	Ile	Tyr	Thr	Tyr	Asp	Asp	Met	Glu	Val	Lys	Gln	Ile	Asn	Lys	Arg
		35					40					45			

Ala	Ser	Gly	Gln	Ala	Phe	Glu	Leu	Ile	Leu	Lys	Pro	Pro	Ser	Pro	Ile
	50					55					60				

Ser	Glu	Ala	Pro	Arg	Thr	Leu	Ala	Ser	Pro	Lys	Lys	Lys	Asp	Leu	Ser
65					70					75				80	

Leu	Glu	Glu	Ile	Gln	Lys	Lys	Leu	Glu	Ala	Ala	Glu	Glu	Arg	Arg	Lys
			85						90					95	

Ser	Gln	Glu	Ala	Gln	Val	Leu	Lys	Gln	Leu	Ala	Glu	Lys	Arg	Glu	His
			100					105					110		

Glu	Arg	Glu	Val	Leu	Gln	Lys	Ala	Leu	Glu	Glu	Asn	Asn	Asn	Phe	Ser
		115					120					125			

Lys	Met	Ala	Glu	Glu	Lys	Leu	Ile	Leu	Lys	Met	Glu	Gln	Ile	Lys	Glu
	130					135					140				

Asn	Arg	Glu	Ala	Asn	Leu	Ala	Ala	Ile	Ile	Glu	Arg	Leu	Gln	Glu	Lys
145					150					155					160

Leu	Val	Lys	Phe	Ile	Ser	Ser	Glu	Leu	Lys	Glu	Ser	Ile	Glu	Ser	Gln
				165					170					175	

Phe Leu Glu Leu Gln Arg Glu Gly Glu Lys Gln
180 185

<210> 1435
<211> 540
<212> DNA
<213> Homo sapiens

<400> 1435
atggcctaaaa cagcaatggc ctacaaggaa aaaatgaagg agctgtccat gctgtcactg 60
atctgctctt gcttttacct ggaacctcgc aacatcaaca tctatactta cgatgatatg 120
gaagtgaagc aaatcaacaa acgtgcctct ggccaggcct ttgagctgat cttgaagcca 180
ccatctccta tctcagaagc cccacgaact ttagcttctc caaagaagaa agacctgtcc 240
ctggaggaga tccagaagaa actggaggct gcagaggaaa gaagaaagtc tcaggaggcc 300
caggtgctga aacaattggc agagaagagg gaacacgagc gagaagtcct tcagaaggct 360
ttggaggaga acaacaactt cagcaagatg gcggaggaaa agctgacccg gaaaatggaa 420
caaattaagg aaaaccgtga ggctaattcta gctgctatta ttgaacgtct gcaggaaaag 480
gagaggcatg ctgcggaggt gcgcaggaac aaggaactcc aggttgaact gtctggctga 540

<210> 1436
<211> 179
<212> PRT
<213> Homo sapiens

<400> 1436
Met Ala Lys Thr Ala Met Ala Tyr Lys Glu Lys Met Lys Glu Leu Ser
1 5 10 15

Met Leu Ser Leu Ile Cys Ser Cys Phe Tyr Pro Glu Pro Arg Asn Ile
20 25 30

Asn Ile Tyr Thr Tyr Asp Asp Met Glu Val Lys Gln Ile Asn Lys Arg
35 40 45

Ala Ser Gly Gln Ala Phe Glu Leu Ile Leu Lys Pro Pro Ser Pro Ile
50 55 60

Ser Glu Ala Pro Arg Thr Leu Ala Ser Pro Lys Lys Lys Asp Leu Ser
65 70 75 80

Leu Glu Glu Ile Gln Lys Lys Leu Glu Ala Ala Glu Glu Arg Arg Lys
85 90 95

Ser Gln Glu Ala Gln Val Leu Lys Gln Leu Ala Glu Lys Arg Glu His
100 105 110

Glu Arg Glu Val Leu Gln Lys Ala Leu Glu Glu Asn Asn Asn Phe Ser
115 120 125

Lys Met Ala Glu Glu Lys Leu Ile Leu Lys Met Glu Gln Ile Lys Glu
130 135 140

Asn Arg Glu Ala Asn Leu Ala Ala Ile Ile Glu Arg Leu Gln Glu Lys
145 150 155 160

Glu Arg His Ala Ala Glu Val Arg Arg Asn Lys Glu Leu Gln Val Glu
165 170 175

Leu Ser Gly

<210> 1437
<211> 525
<212> DNA
<213> Homo sapiens

<400> 1437
atggcctaca aggaaaaaat gaaggagctg tccatgctgt cactgatctg ctcttgcttt 60
taccggaac ctcgcaacat caacatctat acttacgatg atatggaagt gaagcaaadc 120
aacaacgtg cctctggcca ggcttttgag ctgatcttga agccaccatc tcctatctca 180
gaagccccac gaacttttagc ttctccaaag aagaaagacc tgtccctgga ggagatccag 240
aagaaactgg aggctgcaga ggaaagaaga aagtctcagg aggcccagggt gctgaaacaa 300
ttggcagaga agagggaaca cgagcgagaa gtccttcaga aggctttgga ggagaacaac 360
aacttcagca agatggcgga ggaaaagctg atcctgaaaa tggaacaaat taaggaaaac 420
cgtgaggcta atctagctgc tattattgaa cgtctgcagg aaaaggagag gcatgctgcg 480
gaggtgcgca ggaacaagga actccaggtt gaactgtctg gctga 525

<210> 1438
<211> 174
<212> PRT
<213> Homo sapiens

<400> 1438
Met Ala Tyr Lys Glu Lys Met Lys Glu Leu Ser Met Leu Ser Leu Ile
1 5 10 15

Cys Ser Cys Phe Tyr Pro Glu Pro Arg Asn Ile Asn Ile Tyr Thr Tyr
20 25 30

Asp Asp Met Glu Val Lys Gln Ile Asn Lys Arg Ala Ser Gly Gln Ala
35 40 45

Phe Glu Leu Ile Leu Lys Pro Pro Ser Pro Ile Ser Glu Ala Pro Arg
50 55 60

Thr Leu Ala Ser Pro Lys Lys Lys Asp Leu Ser Leu Glu Glu Ile Gln
65 70 75 80

Lys Lys Leu Glu Ala Ala Glu Glu Arg Arg Lys Ser Gln Glu Ala Gln
85 90 95

Val Leu Lys Gln Leu Ala Glu Lys Arg Glu His Glu Arg Glu Val Leu
100 105 110

Gln Lys Ala Leu Glu Glu Asn Asn Asn Phe Ser Lys Met Ala Glu Glu
115 120 125

Lys Leu Ile Leu Lys Met Glu Gln Ile Lys Glu Asn Arg Glu Ala Asn
130 135 140

Leu Ala Ala Ile Ile Glu Arg Leu Gln Glu Lys Glu Arg His Ala Ala
145 150 155 160

Glu Val Arg Arg Asn Lys Glu Leu Gln Val Glu Leu Ser Gly
165 170

<210> 1439
<211> 19
<212> RNA

<213> Homo sapiens

 <400> 1439
 gcucaagcau ggauucuaa 19

<210> 1440
 <211> 19
 <212> RNA
 <213> Homo sapiens

 <400> 1440
 caaucaaggu aguaauaug 19

<210> 1441
 <211> 19
 <212> RNA
 <213> Homo sapiens

 <400> 1441
 gggcuucgcu acaggauc 19

<210> 1442
 <211> 19
 <212> RNA
 <213> Homo sapiens

 <400> 1442
 caggguaggau uugguaaua 19

<210> 1443
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <220>
 <223> Description of Combined DNA/RNA Molecule: Synthetic
 oligonucleotide

 <400> 1443
 aaggcttcac attgtacttt 20

<210> 1444
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic primer

 <400> 1444
 ctcagtcct tattcagtct tctc 24

 <210> 1445
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic primer

 <400> 1445
 tcttctgccg agtcccattt 20

 <210> 1446
 <211> 24
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic probe

 <400> 1446
 tcagcgtctg cacatcccta caat 24

 <210> 1447
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic primer

 <400> 1447
 ccacgaactt tagcttctcc a 21

 <210> 1448
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>

<223> Description of Artificial Sequence: Synthetic primer

<400> 1448

gccaatgtt tcagcacctg

20

<210> 1449

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 1449

actttcttct ttcctctgca gcctcc

26